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Patients must receive sufficient information about their medicines to be able to take 
them safely, to make informed choices, and to understand the benefits of adherence. 
Providing written information alongside verbal communication is best-practice to 
ensure comprehension and aid recall. However, leaflet provision is not mandatory in 
New Zealand.  
Automated provision of information in a digital format may support informing people 
about their medicines in practice. Internationally, digital tools have allowed self-
reporting of chemotherapy side-effects (Patient Reported Outcomes) to provide 
medicines information and self-management advice. However, such systems are not 
yet available in New Zealand and it is not known how they would be received.  
Aim 
To investigate how patients are provided with information about their medicines in 
New Zealand practice and explore potential solutions to optimise quality and 
provision.  
Methods 
This study was conducted in four stages:  
1. A description of patients’ views on what content should be included in medicine 
information leaflets and how they should be designed to improve usability and 
usefulness.  
2. Surveys to examine a) pharmacists’ and general practitioners’ (GPs’) medication 
counselling practices, b) their opinions and use of written information, and c) 
patients’ opinions and experiences of receiving written medicine information.  
3. Feasibility study to determine the viability of producing a medicines information 
tool (automatic leaflet-tailoring and prompting system) for GPs and pharmacists: a 
survey of vendors of prescribing and dispensing software in New Zealand. 
4. Focus groups and interviews with former oncology/haematology patients to 
determine their opinions regarding the information provided about their 
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chemotherapy, and their views of the possible use of an online digital tool to report 
side-effects and receive information.  
Main findings 
1. Both summary and comprehensive medicine information leaflets should be readily 
available. Leaflet content requirements were identified, including names of the 
medicine, dose, benefits of treatment, and potential harms of therapy. The 
guidance provided by the New Zealand regulatory agency about how to design 
written medicine information does not align with patients’ stated needs. 
2. Patients may not be receiving all the information they want or need to know 
about their medicines during verbal communication with GPs and pharmacists. 
3. GPs and pharmacists do not routinely provide written medicines information 
leaflets. Facilitators to encourage provision included having summary and tailored 
leaflets available, more time with patients, and automatic computer prompts. 
GPs, pharmacists, and patients believe it is important that leaflets are given with 
new medicines. 
4. At this time, it is not feasible to build an automatic leaflet-tailoring and prompting 
system within prescribing and dispensing management software used in New 
Zealand.  
5. Oncology/haematology patients consider the way they are given information 
about their treatment could be improved. Many thought having a digital system 
available to report side-effects and receive information about management would 
be beneficial. 
Conclusion 
We need to improve the way we give people information about their medicines in 
New Zealand. Providing verbal and written information is not mandatory at present 
and may sometimes result in suboptimal practice. 
Patients and health professionals thought digital technology could be used to help 
provide medicines information. Furthermore, online digital tools utilising Patient 
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Structure of thesis  
This thesis has seven chapters. The first chapter is the introduction, which describes 
the primary health care setting in New Zealand, the requirements for patient-centred 
care, the benefits of providing written communication, and the potential difficulties 
and limitations for achieving optimal communication with patients in practice. It also 
briefly touches on how information for patients could be improved. 
The second chapter is the narrative review outlining (i) what information patients 
want included in medicine information leaflets, (ii) how this information should be 
presented for optimal readability and understanding, and (iii) what legislative 
requirements are in place in New Zealand and internationally on how manufacturers 
should create this information. This chapter contains two published articles, one in 
section 2.3.1 (‘What patients’ want?’ Tailoring medicines information to patients’ 
needs) and one in section 2.4.1 (Regulatory agencies’ recommendations for medicine 
information leaflet: Are they in line with research findings?). These constitute the 
majority of this chapter. 
The third chapter presents cross-sectional surveys of general practitioners and 
pharmacists working in New Zealand primary health care. This chapter describes, from 
self-reports, what verbal communication these health professionals have with their 
patients, compared with the patients’ desired information described in chapter 2. This 
chapter contains one published article in section 3.3.1 (Do health professionals tell 
patients what they want to know about their medicines?). This chapter also describes 
the limitations of relying on self-reports for determining participants’ practices. 
The fourth chapter also presents cross-sectional surveys of general practitioners and 
pharmacists working in New Zealand primary health care, as well as one performed by 
patients. The focus of these surveys is (i) the delivery of medicines information leaflets 
to patients, (ii) health professionals’ and patients’ opinions of leaflets available, and 
(iii) the barriers and enablers to leaflet provision. This chapter contains three 
published articles, one in section 4.3.1 (Doctors and pharmacists provision and 
opinions of medicines information leaflets in New Zealand), one in section 4.4.1 
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(Patient-focused medicines information: General Practitioners’ and pharmacists’ views 
on websites and leaflets), and one in section 4.5.1 (General Practitioners’ medicine 
information leaflet provision: New Zealand patients’ views). These articles constitute 
the majority of this chapter. 
The fifth chapter describes a feasibility study of building a tool within patient 
management systems in GP and pharmacy software to automatically create 
personalised medicines information leaflets and counselling points for health 
professionals to use at point-of-care. This chapter presents a Use Case (a description 
of individuals’ to be involved and actions required to complete a task) and an example 
of a personalised medicine information leaflet to describe how the software could 
work. These were presented to the six vendors of prescribing and dispensing software 
in New Zealand who were asked to complete a survey to determine the feasibility of 
building a tool. In the last part of this chapter, the outcome of the feasibility study is 
discussed. 
The sixth chapter presents a qualitative study with focus groups and interviews with 
former oncology/haematology patients. This chapter describes (i) their opinions 
regarding the information provided about their chemotherapy medicines; and their 
views on (ii) receiving information about their treatment in a digital format and on (iii) 
the possible use of an online digital tool to report side-effects and receive 
management advice. 
Finally, chapter 7 is the discussion and conclusion, which summarises the findings of 
the investigations in this thesis, strengths and limitations of the project, 
recommendations for current practice and recommendations for future research. 
A pictorial overview of thesis structure can be seen in Figure 1 on the next page. An 




Figure 1: Structure of thesis
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Figure 2: Overview of objectives, research questions, and methods 
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Chapter 1: Introduction  
1.1 Background 
1.1.1 The informed patient 
Do patients need to be informed about their medicines?  
Historically the answer was “no”. Healthcare professionals took an authoritarian 
approach where patients were generally expected to do as they were directed without 
being given information about their treatment.1 And until relatively recent times, 
medicines were commonly given to patients without printed information.2  
Today’s answer is “yes”. Fortunately, there has been a shift in decision making within 
healthcare systems in New Zealand and other developed countries2, 3 with a drive 
toward patient-centred care and improved outcomes for patients. Approaches to this 
include patients and healthcare professionals sharing treatment decision-making and 
a focus on informed choice and patient empowerment.1 Adding fuel to this fire, is an 
increase in patient demand for information about their medicines and often a 
willingness to be involved in their own care.2, 4, 5 The gold-standard for decision-
making in healthcare now is achieving concordance between a patient and their 
healthcare provider, meaning that a patient is involved in the decision that the 
treatment is the right option for them.2, 3 We now acknowledge that the patient needs 
education about the medicine before it is dispensed and they take it home. 
In line with this trend, the New Zealand Ministry of Health has outlined a Roadmap of 
actions in the 2016 New Zealand Health Strategy.6 The first theme on the roadmap is 
‘people powered’ which encompasses the ideal of making services more people-
centred with a focus on better knowing people’s health needs and experiences. One of 
the 5-year aims is to ensure “People have access to reliable, clear information, 
including online, to find out about the choices they can make and how they can take 
greater responsibility for their own health”. 
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There is significant research about informing patients about their medicines. 
Literature reviews from the early 2000’s demonstrated that there is little information 
given to patients about their medicines in practice.7-9 Patients may also find it difficult 
to access their doctors to obtain sought-after information if they need to know more.2  
So it is possible that patients are not receiving the essential information to facilitate 
safe and optimal medicine use. Health professionals need to engage patients in 
discussion about their medicines and ensure that they understand what is being 
communicated with them. Unfortunately, in practice many real and perceived barriers 
may prevent this occurring. Further discussion about informing patients about their 
medicines is in chapter 3. 
1.1.2 The impact of poor health literacy 
Health literacy is commonly described as peoples’ capability to acquire and 
understand information about their basic health and health-services needed to make 
suitable health decisions in regards to their care.10 Poor health literacy seriously 
affects the ability of individuals to be actively involved in decision-making about their 
health and treatment.11 People with poor health literacy tend to know less about their 
medicines and disease, have difficulty managing their own health, have poor 
adherence to their medicines, and have disproportionately higher rates of chronic 
illnesses, health care costs, and increased mortality.11-13 For example, the National 
Academy for an Aging Society in America estimates that low health literacy resulted in 
$73 billion (in 1998 healthcare dollars) in unnecessary healthcare costs.14  
Poor health literacy may disproportionately affect certain groups of people. The report 
Kōrero Mārama: Health Literacy and Māori produced by the New Zealand Ministry of 
Health11 found that New Zealanders, particularly Māori, commonly suffer from poor 
health literacy. The review article by Sadowski15 also notes that older adults generally 
have poorer health literacy compared to the younger population. This is troubling as 
older age groups generally have increased healthcare needs and higher use of health 
services.11 Ensuring people with poor health literacy, particularly the groups at highest 
risk of poor literacy, are appropriately informed about their treatments is essential to 
improve their health outcomes and to decrease unnecessary healthcare costs. We 
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need to change focus in the way health professionals interact with people and make 
sure we are informing people about their medicine in an appropriate and culturally 
safe way.  
1.1.3 Improving safety  
Balanced and accurate medicine information for patients helps ensure that they take 
their medicines safely and will obtain as optimal benefit and outcome as possible. It is 
expected that all patients should at least know why a medicine is prescribed and how 
to take it. However, Jaye et al in a New Zealand study from 2001 showed that of 344 
patients, only 87% knew the indication of their medicines and that the dose was only 
correctly recalled 83% of the time.16 And a 2004 survey of a sample of 616 patients in 
a community setting in Boston USA, showed that 13.5% of patients could not recall 
the indications of all their medicines.17 It is possible that patients who cannot identify 
the purpose or dose of their medicine, may also be unaware of other important 
aspects of their therapy such as signs of toxicity or allergy. In another New Zealand 
study, Brounéus et al18 found that 47% of medicine-users could not recollect 
information about the safety of their medicines. Nevertheless, 84% of these patients 
were convinced they could use their medicines safely. This leads us to question 
whether patients are making informed decisions about their medicines. How can they 
do so if they do not know the harms and benefits of the medicines they are taking? 
Being able to recognise a reaction to a medicine can be crucial to prevent the 
escalation of an event. Hospitalisations and death have resulted from lack of 
comprehension on medicine use.19 In order to use a medicine safely, patients must at 
least know how to take the medicine, what could interact with that medicine, as well 
as the risk of side-effects and what action is necessary if they occur. This is particularly 
true for frail elderly patients who over-represent those admitted to hospital due to 
adverse events with their therapy.20 Hospitalisation due to adverse events results in 
an average of nine days of hospital admission,20 resulting in huge cost as well as 
possible physical and emotional trauma to the patient. In New Zealand there were 
4373 reports of suspected adverse reactions to medicines in 2018, of which 1473 were 
for vaccines and 57 for complimentary or alternative therapies.21 Twenty percent of 
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these reactions were considered to be serious. The ability to recognise an adverse 
reaction to a medicine will help patients identify side-effects sooner,18 allowing for 
prompt discontinuation and medical treatment if required. In order to be fully 
concordant, it is necessary that patients know and understand the harms of their 
therapy. 
1.1.4 Improving continuation of therapy 
The report Adherence to long-term therapies: Evidence for action produced by the 
World Health Organisation in 2003, citing two reviews, states that ‘adherence to long-
term therapy for chronic illnesses in developed countries averages 50% and in 
developing countries the rates are even lower’.22 This report also described the 
temporary effects of interventions that increase adherence, including leaflets and 
encouragement for use. These are only effective while the intervention is in place, and 
once it is removed, the benefits will decrease.  
There are also varying levels to which information can be shared, digested, and used. 
Whilst at the very basic level patients must be informed about their medicines, that is 
to be told, taking the time to educate medicine users may result in more deeper 
understanding and willingness to continue therapy.23 Educating a person is a more 
time-consuming commitment, but may result in improved shared decision-making, 
removal of health literacy barriers, and actual improved knowledge of concepts about 
their treatment.23 
It has also been demonstrated that educating patients about their therapy and why 
they need to take it can improve patients’ overall satisfaction, desire to take their 
medicine, and their adherence to treatment.9, 24 So is this education occurring in 
primary care? Many patients do not read accompanying written information supplied 
with repeat medicines when they collect them from a pharmacy25-28 so repeated 
discussions with patients about benefits and potential harms of treatment and the 
importance of adherence may be needed. This means an active conversation at every 
opportunity of repeat dispensing and prescribing. Further discussion about continued 
need for information on chronic therapy is discussed in chapter 3. 
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1.1.5 Some challenges faced in New Zealand’s primary 
health care setting  
Costs involved 
Primary healthcare in New Zealand is mostly funded from general taxation. This 
subsidises the cost of GP visits and prescription medicines to the patient.29, 30 The 
remaining cost is recuperated as fee-for-service payments from patients. Although 
these co-payments are a small charge compared to the full cost of treatment and 
service delivery, they can still drive inequity and result in an overextended health 
workforce. 
Because GP practices are privately owned, the cost of a GP visit is variable. Adults 
earning a low income with a community services card can visit their GP for 
approximately NZ$19.31 However, for other patients who do not qualify for this 
additional subsidy, it is reported that visits can cost up to NZ$60 per consultation32 
and this cost could impede accessibility of healthcare services. 
Prescription charges for each medicine depend on the medicines’ funding status, the 
age of the patient, who prescribes the medicine, and whether the patient has a 
community services card.30, 33 New Zealand’s Pharmaceutical Management Agency 
(PHARMAC) decides which prescription medicines the government will fund and the 
level of subsidy.34 For fully subsidised medicines the patient pays a co-payment of 
NZ$5 if prescribed by a GP (or NZ$15 if prescribed by a private specialist), or for 
partially subsidised medicine the charge is variable depending on the amount of 
subsidy provided.33 Although, there is some competition for customers between 
pharmacies, and some pharmacy businesses offer to supply medicines without the 
required co-payment. Furthermore, if a person, their partner, and dependent children 
together purchase over 20 prescriptions in one year from 1st February, for the 
remainder of the year they do not have to pay the co-payment for prescriptions.33, 35 
Nevertheless, some medicines are completely unsubsidised and require full payment 




Quality face-to-face contact time with health professionals can be variable. 
Consultations with GPs are typically 15 minutes,36 which can result in significant time-
pressure in complex circumstances e.g. if patients have multiple morbidity, language 
barriers, or cognitive impairment. Patients’ consultations with pharmacists about 
dispensed medicines are not funded, so, at busy periods their discussions may be 
short and lack the depth of information needed or not conducted at all. Pharmacists 
can receive additional funding for patient counselling if patients have long-term 
conditions,37 but this is mostly focused on patients’ medicine adherence rather than 
medicine knowledge. There is considerable information to tell patients in the short 
amount of contact time healthcare professionals have with them, let alone assess 
their understanding of what has been discussed. Although it is written into ethical 
standards that health providers must make people aware of the harms and benefits of 
treatment, it may not always be possible to reasonably do so in the current health 
model in New Zealand. 
Communication issues 
Adequately informing people about their medicines can be difficult. It would be 
challenging for a healthcare provider to inform every patient of all the required 
information about each medicine every time it is prescribed or dispensed. In addition 
to time pressures and lack of funding for services, other possible barriers include poor 
health literacy,12 lack of patient willingness to be counselled (a documented 
occurrence in pharmacies8), and concern from health professionals that if they provide 
information on side-effects their patients will refuse their medication.2 Furthermore, 
patients are often not able to recall all of the information given in one brief interaction 
and much of the information that has been discussed will be forgotten.9, 38, 39 This can 
worsen if the patient’s ability to comprehend what is being explained to them is 
affected at the time e.g. if the patient is anxious or stressed,15 or the information was 




The inability to remember or comprehend verbally provided information emphasises 
the importance of patients receiving easy-to-understand written medicine information 
that they can refer to at home, or ‘absorb over time’.2 However, it is not known 
whether suitable medicine information resources are commonly used at point-of-care 
in primary care in New Zealand. 
1.2 Improving how information is given  
Patients want to be given more information from their health provider.15, 40 In New 
Zealand it is mandatory that people are provided with relevant and appropriate 
information by their prescriber and pharmacist dispensing the treatment.41-43 Yet 
compared to some other countries, the format of how the information is provided is 
not regulated. European union and UK legislation requires that every medicine is 
dispensed with a patient information leaflet (PIL), also known as a consumer medicine 
information leaflet (CMI), usually inside the medicine packaging.2 In the UK, it is 
believed that the medicine information leaflet provided with the dispensed 
medicine/s may be the only information a patient receives.40 This legislation ensures 
that, although verbal communication about medicines may be lacking, people are still 
receiving information about their medicine. In the USA, there are a large number of 
medicines where provision of information leaflets are mandatory if they are 
considered to have a significant safety risk.44, 45 
In New Zealand and Australia2 there is no binding legislation on the provision of 
medicine information leaflets, and the ethical obligation to inform patients about their 
medicines does not demand the provision of medicine information leaflets. An 
Australian report26 identified that there is no widespread provision of CMI to patients 
and it is likely that New Zealand has the same variable provision practices. Therefore, 
it is likely that there are many occasions where patients are not given leaflets. 
Medsafe (the ‘New Zealand Medicines and Medical Devices Safety Authority’) 
recommends that medicine information leaflets are considered an adjunct to verbal 
counselling.46 The Medsafe website also lists the CMI for medicines where these are 
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available,47 but given that production of CMI is not currently a legal requirement, they 
are not available for all medicines. On the contrary, although Australia does not 
mandate the provision of leaflets, CMI have to be available for patients for all 
prescription and pharmacist-only medicines. Most CMI are made available on a central 
website to be downloaded and printed off as needed.48, 49  
1.2.1 How medicines information leaflets support the 
informed patient and enhance safety  
Patients’ value discussions with their healthcare professional about medicines they 
have been prescribed.2, 4, 18, 26 However, a combined approach of both verbal and 
written information is favourable to increase patient understanding of their therapy.9, 
15 Ideally, medicine information leaflets should be given in conjunction with any verbal 
communication. As well as a source of information about their medicines, patients can 
use these leaflets as a tool to help manage their illness, aid the decision to continue or 
stop therapy, and to explain their treatment or condition to others.2 Medsafe states 
that information leaflets should be used to ‘assist consumers to distinguish between 
the symptoms of their illness and any possible side-effects induced by the medicine’.3  
As mentioned earlier, patients frequently feel they are not getting enough information 
from health professionals with some people being unaware of why they are taking a 
medicine or their treatment options.2 Some health professionals only discuss 
information that they think is important, rather than finding out what is important to 
their patient.8, 15 Medicine information leaflets would ensure that all the information 
about a medicine is given to the patients. They may also give a patient confidence to 
raise concerns or queries with their healthcare provider where they would have felt 
unable to do so without a resource to justify their questions.2 Yet, there is evidence 
that medicine harms and side-effect information may be withheld by health 
professionals, even although this is often the most sought after information by 




1.2.2 Importance in an older population 
Written sources of information are necessary to give older people important guidance 
about how to take their medicines, as well as possible harms with treatment. People 
over 60 years of age consume approximately 50% of all prescription medicines even 
although they represent only 12% to 18% of the population.22 Older patients are more 
susceptible to side-effects due to alterations in pharmacokinetics and 
pharmacodynamics of medicines, cognitive decline, and frailty, which may result in 
poorer outcomes to treatment.22, 50, 51 Although older people experience more health 
problems resulting in more chronic use of medicines, they often have poor knowledge 
of their medicines.16 In one study, over 40% of elderly patients did not know the 
dosing instructions of a medicine after visiting their doctor.7 Giving written medicine 
information is essential for older adults. Teaching strategies for older adults promote 
provision of written material to reinforce the major points of teaching.13 Thus to 
ensure adequate education about new concepts and difficult to understand harm 
versusbenefit information, a leaflet about the information discussed should be 
provided to older adults at point-of-care. 
1.2.3 The information leaflets available in New Zealand 
In the US, leaflets have been required to accompany certain medicines since the 
1960s.52 The FDA began evaluating leaflets in the US in the 1970s.52 In the 1990s, the 
FDA approved a law requiring provision of CMI to people receiving new medicines 
(stating that by 2006 at least 95% of people must receive leaflets with new medicines). 
Similarly, a European Union Directive in the 1990’s made it compulsory that 
manufacturer-produced leaflets accompany all dispensed medicines.40, 48 At roughly 
the same time in Australia, new legislation required all new drugs to have patient 
information leaflets available—also written by the medicine manufacturer.48, 53 Since 
becoming prevalent, research into optimal design of patient information materials has 
been ongoing. However, regardless of this continued research and recommendations, 
improvement is still needed. 
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Many organisations create medicine information leaflets for patients in New Zealand, 
although these all differ in content and style. The different leaflets available are 
discussed in further detail in chapter 2. 
Medsafe encourages manufacturers and sponsors of medicines in New Zealand to 
make CMI leaflets available and publishes these on their website. These are 
sometimes included in boxes of dispensed medicines. However Medsafe does not 
review or approve the CMIs being created, instead they expect the sponsor of the 
medicine to self-assess the CMI they create against the requirements of the Medsafe 
Guideline and Template.54 Unlike the requirements for drug companies and sponsors 
from countries in the UK and European union, the use of the template is not 
mandatory when creating leaflets for patients.3  
The template recommended by Medsafe for the content of the leaflets (summarised 
in Table 1) is comprehensive, but may contain unnecessary and irrelevant information 
making leaflets needlessly lengthy. However, does the suggested content contain the 
medicine information that people most want to know about? The optimal content of 
medicine information leaflets is discussed further in chapter 2.  
Table 1: Summary of the Medsafe guideline and template for preparing Consumer 
Medicine Information for New Zealand consumers54 
Section title in leaflet Summary of template suggestions 
Trade name 
 Trade name and the international nomenclature (generic) 
name 
 Dose strength and form 
What is in this leaflet A small section of miscellaneous information, that does not 
inform the reader about what is in the leaflet, but states: 
 To read the leaflet before taking medicine 
 The leaflet does not include all the information (does not 
replace doctor or pharmacist) 
 The doctor has considered the risks and benefits of the 
medicine 
 To ask your doctor or pharmacist if any concerns 
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Section title in leaflet Summary of template suggestions 
 To keep the leaflet for future reference 
What [Trade name] 
used for 
 
 Details of the New Zealand-approved therapeutic indications 
 Simple description of how the medicine works, the pharmaco-
therapeutic group, or type of drug action 
 Warning of habit-forming potential 
Before you use [Trade 
name] 
 
When you must not use it 
 List of instances when medicine should be avoided (contra-
indications) 
Before you start to use it 
 List of precautions; if it can be used in pregnancy or breast-
feeding 
Taking other medicines 
 Instructions to tell the doctor if taking other medicines 
including non-prescription medicines and complementary or 
alternative therapies 
 List of medicines (including non-prescription), complementary 
and alternative therapies, food, or alcohol that interact with 
the medicine 
How to use [Trade 
name] 
How much to take 
 Usual instructions on ‘proper’ use of the medicine 
 The dose 
 Method and route of administration 
When to take it 
 Frequency and time of administration; food considerations 
How long to take it 
 Duration of treatment (including warning of withdrawal 
effects if necessary) 
If you forget to take it 
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Section title in leaflet Summary of template suggestions 
 Management strategy on what to do if missed a dose or more 
medicine is taken than prescribed; possible clinical 
consequences of missing a dose 
 What to do if the medicine does not work, if applicable 
While you are using 
[Trade name] 
 
Things you must do 
 Instructions to stop immediately and contact a doctor if 
pregnant, if applicable 
 Instructions to inform doctor or pharmacist about the 
medicine before a new one is initiated 
 Special warnings and monitoring requirements 
Things you must not do 
 Instructions to not give medicine to other people and warning 
to seek advice before stopping medicines that may cause 
withdrawal or side-effects 
Things to be careful of 
 Medicines effect on driving or operating machinery 
 Other potential hazardous effects 
 Alcohol avoidance if necessary 
In case of overdose 
 Contact details of National Poisons Centre 
 Brief description of signs/symptoms of overdose if applicable 
Side Effects 
 
 Instruction to inform doctor/pharmacist if feel unwell and to 
ask them questions 
 List side-effects that can occur and if urgent withdrawal and 
contacting the prescriber is required 
 List side-effects that are common, severe, or prolonged (only 
recognisable symptoms should be included) 
 Statement that other side-effects not listed may occur 
 Statement to not to be alarmed by side-effects listed because 
they may not occur 
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Section title in leaflet Summary of template suggestions 
After using [Trade 
name] 
 How to store the medicine 
 How to dispose of the medicine including those that are 
expired; possible signs of deterioration 
Product description What it looks like 
 Description of each dose form and strength, including pack 
sizes 
Ingredients 
 List of active and inactive ingredients (advice on common 
allergens) 
Sponsor Details The name, address and phone number of the medicine supplier in 
New Zealand 
Date of Preparation Date the leaflet was prepared or revised 
Despite having comprehensive suggestions for leaflet content, Medsafe has limited 
guidance on how to present the information for readability, and the little information 
given is also suggestive rather than mandatory.3 Without strict regulations, the 
medicine information leaflets available in New Zealand may have extremely variable 
designs and formats55 and thus variable readability and usefulness. In a New Zealand 
study of community-dwelling elderly people, 12% of participants had difficulty reading 
leaflets and 6% of participants had difficulty understanding them.56 However, there is 
also the risk that heavy legislative requirements for medicine information leaflets do 
not always correspond with expert opinion on user-friendly design57 resulting in sub-
optimal leaflets being created.58 The templates used for leaflets in the European 
Union are often criticised.59, 60 This demonstrates how important it is to get the style 
of the leaflet right, to ensure it is understandable to those who are going to be reading 
it. Any legislative requirements for document design must be strongly influenced by 
evidence for readability. How information leaflets should be styled for readability and 
usability is discussed further in chapter 2. 
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1.2.4 Providing leaflets at point-of-care 
It is important that patients are made aware of leaflets when they are receiving their 
prescribed medicines. In a New Zealand study, 66% of patients reported that they like 
to use medicine information leaflets as a source of drug safety information.18 
However, a UK study found that if leaflets are put in a bag with a person’s medicine 
and not discussed they may not be noticed and thrown away.27 Furthermore, as 
mentioned earlier, leaflet provision is not mandatory in New Zealand and so leaflets 
may not even be given to patients. A systematic review has shown that prescribers do 
not like leaflets and they do not encourage patients to read them.2 Furthermore, the 
reviewers found that some patients do not read leaflets because they trust and rely on 
their doctor to provide them with all the information they need2 and trust that they 
can recall the information given to them at time of consultation. In reality it is unlikely 
that people are provided with all of the harm versus benefit information about their 
medicine during a consultation with their doctor and even less likely they would be 
able to recall this information after the appointment.7, 9, 26, 28 Furthermore, providing 
medicine information leaflets alone without discussing them with the patient does not 
improve adherence to treatment instructions.2 In Australia, Aslani et al recommended 
holding CMI consumer awareness campaigns which would alert patients to their 
availability, and formal incorporation of CMI into healthcare professional workflow 
practices e.g. highlighting relevant sections for the patient.26 This change in practice 
would help with providing leaflets to every patient as well as highlighting the 
availability and usefulness of leaflets to patients. 
Many patients want leaflets to be used during discussions about medicines when they 
are prescribed.4, 26, 40, 61 Using leaflets during initial treatment discussions with patients 
is optimal because (i) it will expose the availability and content of the information 
leaflets to patients and (ii) it will remind the health professional of important medicine 
points to cover during consultation. This approach could also give the patient the 
ability to ask further questions to improve understanding and willingness to take their 
medicines and assist informed decision making.62 Patients should also have an 
opportunity for discussion about their medicines when they are dispensed. However, 
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pharmacists may not be widely seen as sources of medicine information by the 
public.16, 26 Studies show medication counselling practices can be variable. A 2009 
review of studies from the UK, Australia, USA, Netherlands, Finland, and Canada by 
Puspitasari et al63 found that pharmacist counselling rates ranged from 8–80% 
depending on the method used for data capture. Another more recent study 
conducted in 2014, investigating counselling practices in England using consumer self-
reports (obtained as soon as they left the pharmacy), found that unsolicited 
counselling occurred with dispensing of 41.9% of new prescriptions and 25.5% of 
repeat prescriptions.64 Promotion of pharmacists’ skillset and knowledge by active 
counselling with medicine information leaflets would help further strengthen their 
place in primary care in patient’s minds and endorse their capabilities as a source of 
information. 
The use of medicine information leaflets in primary care in New Zealand is further 
discussed in chapter 4. 
1.2.5 Updating the way information is provided about 
medicines  
So far, the usefulness of medicine information leaflets and verbal communication has 
been discussed, but there are limitations to the usefulness of these methods of 
communication. Apart from hesitancy from the health provider in giving leaflets to 
patients, some patients do not like reading them and can find them difficult to 
understand.65-67 Furthermore, leaflets can be very general and contain information 
that is not relevant to the person taking it, e.g. leaflets tend to contain pregnancy and 
breast-feeding advice which, obviously, is not relevant to male recipients. Some 
leaflets may contain numerous indications (see Figure 3), or conversely may contain 




Figure 3: List of indications from propranolol manufacturer-produced Consumer 
Medicines Information (CMI) leaflet68 
 
 
Figure 4: List of indications from propranolol leaflet produced by independent 
body69 
Full examples of these leaflets are available in Appendix 1. 
1.2.6 Personalising information 
It is obvious from Figure 3 that there is information included in manufacturer 
produced information leaflets that is not applicable to individual patients. However, is 
it more appropriate to simply not include this? Either option could lead to people 
questioning the relevance of the leaflet and undermine the integrity of the 
information given to them. For information to seem relevant to people it needs to be 
personalised, succinct, and contain what they want and need to know about a 
medicine to take it effectively. Unfortunately, there is no easy way to do this in 
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current practice. Yet, it may be possible to do this by utilising the personal information 
contained in digital health records. A software system could be used to extract 
relevant patient details and automatically personalise information for medicine 
counselling and information leaflets. Further discussion around the possibility of 
personalising information for patients is included in chapters 2, 4, and 5. 
1.2.7 Digital information 
In today’s technological society, some people might prefer an electronic source of 
medicines information. People are looking to the internet for health information70 and 
this could be seen as a suitable alternative to hard-copy leaflets. Furthermore, people 
expect to be given accurate and up-to-date information and this should be easier with 
a digital resource. Some people may prefer to access the internet to see the 
information about their medicine at a time that suits them rather than be given a 
printed leaflet that they have to then keep somewhere (and remember where it is 
kept) at home. Globally the use of digital applications (apps) has rocketed, and there 
has recently been development of an app (Mymeds) in New Zealand by the Ministry of 
Health that the public can download to access information leaflets about their 
medicines.71  
It is important to consider accessibility to technology when promoting the use of 
digital sources for information. Some groups may struggle to use the technology, may 
not be able to afford the technology, or have access to the internet. Governments and 
health providers should ensure equity in access to information by making it available 
in both hard-copy and digital formats.  
Further discussion about providing digital information to patients is provided in 
chapter 4, 5, and 6. 
1.2.8 Patient Reported Outcomes 
Patient Reported Outcomes (PROs) are patients’ reports on their health, ability to 
function, and well-being.72 In clinical practice, PROs data can be used to aid diagnosis 
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or management of a condition.73 However, PROs are not routinely used in primary 
care to gather information about how a patient is taking their medicine, their 
experiences with their treatment, or to determine what people want or need to know 
about their medicines. Using a digital tool to gather information from people about 
what they need or want to know about their medicines would allow a personalised 
and relevant web-based information source, detailing exactly the information they 
desire. Furthermore, if it could gather information about side-effects they are 
experiencing with their therapy, specific details about the management of that side-
effect could be given instantly; or they could be directed to seek immediate medical 
help if appropriate. Also if this is electronically linked to their National Health Index 
(NHI) number (a unique number allocated to healthcare users in New Zealand) the 
data could be automatically updated into their health record for: a) GP review and 
monitoring; and b) aggregation for population monitoring of drug safety. Using PROs 
for medicine information and safety could improve medicine management and 
adherence with treatment. The potential use of PROs in primary care in New Zealand 




The overall aim of this research is to investigate how patients are provided with 
information about their medicines in New Zealand practice and explore potential 
solutions to optimise quality and provision of medicines information for patients. 
Specific aims are presented in each chapter. 
Prior to commencing, medicines were defined as either low-risk (common medicines 
dispensed in primary care with limited side-effect potential) or high-risk (medicines 
associated with serious side-effects that require frequent monitoring).  
In order to achieve the aim, several areas for investigation were identified and the 
work was conducted in four stages:  
1. A description of what information people want to know about their medicines 
(i.e. the content of information delivered to them) and what good-design 
principles to follow  
2. A survey of current opinions and practice by New Zealand GPs, pharmacists, and 
patients about information provision for medicines in a community setting 
3. A feasibility study for the implementation of tailored medicine information 
software  
4. Interviews and focus group discussions to determine patients’ opinions on 
current provision of information about chemotherapy and ideas for 
improvement, and their perceptions of the possible use of Patient Reported 
Outcomes (PROs) for optimising information and medicine management.  
To achieve these aims the following objectives were identified: 
1. To determine, from a user’s perspective, the information that should be included 
in medicine information leaflets and how they should be designed to enable 
patients to easily find and comprehend information.  
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2. To examine pharmacists’ and general practitioners’ medication counselling 
practices and their opinions and use of written medicines information leaflets in 
their practice.  
3. To examine patients’ opinions and experiences of receiving written medicine 
information.  
4. Based on the findings from objectives 1 and 2, to determine the feasibility of 
creating a personalised medicines information tool (automatic leaflet-tailoring 
and prompting software) for GPs and pharmacists to promote the provision of 
verbal and written medicine information to patients.  
5. To determine, from a user’s perspective, the effectiveness and usefulness of 
information provided about high-risk medicines (chemotherapy), and their 
perspectives on the possible use of digital platforms that could provide clinically 
appropriate information about chemotherapy medicines and allow integrated 
patient reporting and feedback on chemotherapy-related side-effects.  
1.4 Hypotheses 
It is hypothesised that:  
1. Patient medication counselling performed by both general practitioners and 
pharmacists is of variable standard. 
2. Written medicines information resources for patients are of differing quality, are 
under-utilised, and are sometimes given without adequate verbal counselling. 
3. It is possible to digitally automate the creation and provision of personalised 
information about medicines at point-of-care. 
4. The provision of information about high-risk medicines is of variable standard and 
the use of digital technology to provide patients with personalised and relevant 
medicine information might be well-received.
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Chapter 2: Providing optimal information 
with medicines 
2.1 Synopsis 
This chapter examines the types of information patients want included in their 
medicine information leaflets and how this information should be presented to 
optimise understanding and ability to find information, and to increase people’s 
willingness to read it.  
In a narrative review (published as a commentary) we identified a number of items 
that patients would like included in leaflets. These included names of the medicine, 
dose, benefits of treatment, and potential harms of therapy. Additionally, a clear set 
of content and design principles were identified that should be followed when leaflets 
are being created. Regulatory agencies’ leaflet design requirements were also 
examined. Countries differed in their regulations on whether leaflets must be 
provided. Countries where provision is mandatory tended to have more 
comprehensive guidance provided by regulators as to how leaflets must be written 
compared to New Zealand, where leaflets are not mandatory. However the findings in 
this chapter show there are still improvements that could be made to leaflets and that 
there is no one leaflet suitable for all patients, concluding that a personalised 
approach would be beneficial. 
This chapter also examines whether informing patients about their medicines can be 
performed in a much smarter way. It explores the benefits of using digital technology 
to provide information about medicines and the use of Patient Reported Outcomes 
(PROs) to further enhance and personalise information for patients. 
Chapter structure 
This chapter has four distinct parts: 
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1. What patients want included in a medicines information leaflet and how they 
should be designed for optimal use. This section describes the clinical 
information a medicine information leaflet should include and briefly describes 
how leaflets should be designed for optimal communication with patients 
(manuscript 1). 
2. How medicine information leaflets should be designed compared to regulatory 
agencies’ recommendations. This section expands on the information from the 
first section about how leaflets should be designed, and compares content and 
good-design principles with what is recommended by regulatory agencies in New 
Zealand and some other countries (manuscript 2). 
3. Digital information about medicines, is there a need? This section explores the 
case for further development of digital information about medicines, and what 
benefit this would have for patients. 
4. Patient Reported Outcomes (PROs). This section describes PROs in healthcare 
resulting from taking/using medicines and outlines their place in practice, 
discussing the benefits and pitfalls of their use and their potential to improve 
patient management. 
2.2 Chapter aims  
Patients need to be informed in a way that suits their needs for them to be able to 
take their medicines safely and as recommended. This chapter aims to provide an up-
to-date commentary on what information about medicines should be provided to 
patients based on their requirements, how this information should be designed for 
optimal use, and possible issues with the provision of digital information. 
Specific aim 1: To identify what information patients want included in medicine 
information leaflets for them to be adequately informed about their medicine and 
encouraged to take their medicines appropriately. 
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Specific aim 2: To define how medicine information for patients should be designed to 
enable patients to find what they need, understand it sufficiently, and improve their 
willingness to read it. 
Specific aim 3: To determine the appropriateness, comprehensiveness, and 
consistency of countries’ published content principals and design requirements of 
medicine information for patients. 
Specific aim 4: To outline the benefits for the provision of information about 
medicines in a digital format and the issues with unregulated availability of digital 
information for patients. 
Specific aim 5: To discuss the advantages and disadvantages of Patient Reported 




2.3 What patients want included in medicines 
information leaflets and how they should be designed 
for optimal use 
Published Manuscript Entitled ‘What do patients want?’ Tailoring 
medicines information to meet patients' needs 
The manuscript entitled “‘What do patients want?’ Tailoring medicines information to 
meet patients' needs.” was published in the journal Res Social Adm Pharm 
2017;13(6):1186-90.  
The co-authors contributed to the manuscript as follows: Review and synthesis of the 
literature were performed by PhD candidate Amber Young, under the supervision of 
Dr Alesha Smith and Associate Professor June Tordoff. All the co-authors revised the 
content of the manuscript and approved the final version for publication. The PhD 
candidate Amber Young was the lead author in manuscript preparation and writing, 
and corresponding author. 
The manuscript is presented as accepted for publication; however, the numbering of 
the pages, figures, and tables has been adjusted in accordance with the style of this 
thesis. All references from the manuscript can be found in the section ‘References’ at 
the end of the thesis.  
The search strategy and inclusion/exclusion criteria for this narrative review are in 
Appendix 2. Only studies published from 2008 onwards were examined because prior 
to this large systematic reviews by Raynor et al., Aslani et al., and Shrank et al. 
investigated similar topics.2, 7, 26 The findings from Raynor et al’s review are discussed 
alongside the findings from this current work in section 2.4 of this chapter.  
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2.3.1 ‘What patients’ want?’ Tailoring medicines 
information to patients’ needs 
Amber Young*, June Tordoff, Alesha Smith 
New Zealand's National School of Pharmacy, University of Otago, Dunedin, New 
Zealand 
* Corresponding author. New Zealand's National School of Pharmacy, University of 
Otago, PO Box 56, Dunedin, 9054, New Zealand. 
E-mail addresses: Amber.young@otago.ac.nz (A. Young), June.tordoff@otago.ac.nz (J. 
Tordoff), Alesha.smith@otago.ac.nz (A. Smith). 
Abstract 
Medicines information leaflets can equip patients to be in control of their own 
healthcare and support the safe and effective use of medicines. The design and 
content of leaflets influences patients’ willingness to read them, and poor examples 
can cause patient confusion and anxiety. Researchers examined the literature over the 
past 8 years to determine the content and design of medicine information leaflets that 
patients prefer in order to read, understand, and use them effectively. It was found 
that existing leaflets do not meet patients’ needs and appear ineffective. Leaflets lack 
the information patients seek and may contain non-essential material, affecting 
patients’ perception of, and willingness to read them. Additionally, the acceptable 
leaflet length varies between patients. Application of good-design principles improves 
readability, comprehension, and ability to locate information. Medicine information 
leaflets must meet patients’ needs and be well designed. Tailoring information leaflets 
to patient characteristics and requirements would enhance effectiveness. Passive 
provision of pre-printed leaflets is outdated, unvalued, and ineffective. Using 
automated computer systems for leaflet tailoring with the ability to further adapt 
patients’ information might be the best way forward. 
Keywords medicine information, counselling, patient information leaflet, patient 




Medicine information leaflets are essential 
Patients’ expectations for information about their treatment and involvement in the 
decision making process has evolved remarkably within healthcare systems in 
developed countries in recent times.26  
Adherence to long-term therapy for chronic illnesses averages 50% (with even lower 
rates reported in developing countries), resulting in poorer health outcomes and 
escalating health costs.22 Patient education is a critical component of improving 
adherence to therapy and optimising medicine use.9, 74 Because medicine information 
leaflets improve patient knowledge, satisfaction, and adherence to therapy,26 they 
should be provided with dispensed medicines. Adherence might also be affected by a 
patients’ engagement in their healthcare decision making process.22 Effective 
medicine information leaflets equip patients to be in control of their own healthcare2 
and empower patients’ participation in decision-making3, 19, 40 thereby positively 
affecting their intention to adhere.  
Mandatory manufacturer-produced leaflet provision with dispensed medicines applies 
in Europe,40, 48 although there is no such binding legislation in many other countries. 
However, ethical standards usually apply requiring patients to be fully informed and 
provided with relevant and appropriate information.42, 75 Medicine information 
leaflets for patients support these standards and promote safe and effective medicine 
use by reinforcing verbal information and improving patients’ understanding of their 
treatment.9, 74 Unfortunately, where there is no legal requirement to give out written 
medicines information, rates of leaflet provision may be as little as 30%.26 
Medicines information leaflets need improving 
Giving leaflets as an adjunct to counselling should improve outcomes, yet patients do 
not always find them useful and often throw them away.4, 9 Extensive research on 
medicine leaflets over the last few decades resulted in some improvement, however 
patients still do not value or consider them useful.2, 61 Patients are often dissatisfied 
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with the information they receive,2, 9 perceiving leaflets to be poorly designed and 
complex.2 Furthermore current legislation, regulatory templates, and 
recommendations for patient leaflets support a ‘one size fits all’ approach where a 
single leaflet is expected to suit all patients taking a medicine. Leaflets need improving 
to satisfy individual patient needs. 
Poorly written leaflets can increase confusion76 and are often written to a higher 
readability level than recommended for the general population.9, 26, 55, 77 Patients who 
feel frightened and anxious after reading through the package insert may be less 
willing to continue with therapy and even stop their treatment.9 Poor readability is a 
major reason for older adults not using medicines information leaflets.15 Hence 
leaflets need to be written clearly, avoiding uncertainty and confusion for patients, 
and must include a balanced assessment of risks and benefits. Conversely patients’ 
confidence may be undermined by over-simplified leaflets that they perceive as dull, 
patronizing, or lacking in authority.9  
Providing well-written and useful medicines information leaflets and encouraging their 
use will improve their impact, and support safe and effective use of medicines. For this 
to be achieved, good-design principles should be followed and the patients’ 
requirements must be understood.  
This commentary provides an up-to-date review determining ‘what patients want’ 
regarding leaflet design and content i.e. for conveying information attractively and 
increasing its use; and for encouraging patients to take their medicines. Nineteen 
studies were reviewed from multiple countries, three focused on content, seven on 
design and nine on both content and design of the leaflet.
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What should an information leaflet contain? 
Focusing on content, studies explored the inclusion of different components. They 
found that people want leaflets tailored to their condition or disease, age, and 
gender,78 as well as explanations of how the medicine works, and a general benefits 
statement.79 However, concerns were raised that a benefit statement might create 
unrealistic treatment expectations. The same study also found that people had 
difficulty interpreting the Number Needed to Treat (NNT) so this should not be 
included.79 In another study, incorporating information presented prominently at the 
beginning of a leaflet that summarises key safety messages about a drug did not help 
users find or understand information but was well liked by patients.80 Another theme 
across the papers was that participants felt that current leaflets contain too much 
information, so actions to reduce the length would be desirable.78, 79 
Key findings 
 Many medicines information leaflets do not meet patients’ needs and will 
not be used 
 Medicine information leaflets should contain information on the medicine’s 
benefits 
 Information should be tailored, at least to disease or condition 
 Side effect information is often lengthy, confusing, and frightening to 
patients. This should be simplified, and the leaflet should state the action 
required if a side effect occurs 
 Applications of good design and simplified language improve perceptions, 
comprehension, ability to locate information, and leaflet readability 
 Preference of leaflet length is unclear – patients like one page formats in 
some studies, but in other studies they want more comprehensive 
information. Tailoring to requirements would be an advantage 
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What should the information leaflet look like? 
Focusing on design, three studies evaluated new prototypes, comparing the usual 
style of leaflet against two novel formats; a ‘bubble’ format and a new styled 
prototype25 or American ‘OTC’ style prototype.81, 82 All three studies limited the 
information to one page, optimised design, and applied plain language principles to 
the new formats. The new designs improved comprehension,81 decreased the time 
required to find information,25 and were preferred by patients.25, 82 One study found 
that the new leaflets did not improve the participants’ ability to apply the information 
to scenarios.81 
Five studies compared effects of optimisation against original leaflets26, 59, 83, 84 with 
one study focusing on shortening the leaflet84 and one focusing on differing font 
sizes.83 Two of the studies included were from the Investigating Consumer Medicines 
information (I-CMI) project by Aslani et al;26 the User testing: Evaluation of Alternative 
CMI Formats, and The CMI Pharmacy Trial. All used multiple optimisation techniques 
to improve leaflet design and readability. Some techniques were used in more than 
one study e.g. removal of repetition, jargon, or difficult words, and simplification of 
sentences. Optimal leaflet design increased the likelihood that patients would read 
and keep it for later use26 and improved ability to locate information.26, 59, 83, 84 Patient 
perceptions of the leaflet improved reducing the total number of words or ‘difficult’ 
words.84 Increasing medical terminology in a leaflet decreased participants’ 
confidence in using the medicine, made them feel less informed, and reduced 
comprehension.84 The ability to locate information was best with font sizes between 
nine and 12, any lower than nine and leaflets were less likely to be read.83 However 
optimising the leaflet (e.g., simplifying sentences and removing repetition and jargon) 
improved participants’ performance more than changing the size of the font. Two 
studies showed that comprehension was improved with the revised text,59, 83 however 
the User testing: Evaluation of Alternative CMI Formats study26 found that patient 
comprehension did not improve following optimisation.  
Lastly, removal of negations improves leaflet readability and patients’ comprehension 
(e.g., no, not, only, hardly, never, and prefixes such as ‘un’). Negations increased 
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perceived complexity which decreased the participants’ appreciation of the leaflets 
and intention to adhere.85 Furthermore, participants favoured additional optimisation 
of leaflets such as a clear table of contents, bold or italics used for important 
elements, improved comprehensibility, and the inclusion of more information (seen as 
more important than reducing information). 
Content AND design? 
Three of the studies found that current medicines information leaflets were not 
meeting patients’ needs26, 86, 87 and because of their current content and design, 
participants thought them alarming which might cause patients to discontinue their 
medicines.86, 87 The Needs Analysis26 showed that failing to determine patients’ needs 
and preferences leads to creating information leaflets that will not be used.  
Four studies evaluated the effects of leaflet optimisation.61, 88-90 All used multiple 
optimisation techniques to improve leaflet design and readability, often by simplifying 
the format and removing jargon. Two of the studies used specific tools for 
optimisation,61, 90 and compared the new leaflets against the original style. 
Optimisation improved readability61 and comprehension.61, 90 Two studies evaluated 
specially created leaflets, although these were not directly compared to existing 
leaflets.88, 89 These studies found that younger and more highly educated participants 
wanted more information about their medicines88 and that a simplified format ranked 
highly in regards to readability, and ability to locate information.89  
Two major trends for leaflet content were highlighted in this review. Firstly, patients 
want information tailored to their disease or condition and prefer no ‘unnecessary 
information’.7, 26, 61, 78, 90 Secondly, patients want to know how a medicine works for 
them and the benefits of taking the treatment;2, 7, 26, 40, 61, 79, 87, 89, 91 in particular, how 
and how much the medicine would assist them.79 Patients perceptions of leaflets and 
intention to take medicines will improve if leaflets include information on how quickly 
they will ‘feel better’ after taking the medicine,61 and a statement about the 
medicine’s benefits and how it will works.91 Furthermore for some patients, knowing 




Knowing the type of information patients want included in the leaflets ensures the 
information is i) more appropriate for their needs, ii) more likely to be used 
(particularly if less pertinent information is omitted), and is iii) more likely to help 
them take the medicines safely and effectively. 
Innovation is necessary 
A single one page document performs better for comprehension, ability to locate 
information, and in overall perception of leaflets.25, 81, 82, 84 Some patients want a short 
summary leaflet,2, 26, 78, 89 but others require more comprehensive information.2, 61, 79, 
85, 88 At the very least two versions should be available; a summary leaflet should be 
given with all medicines with access to more comprehensive information if desired.26 
But we could go even further and tailor leaflets for patients.  
Tailoring is an important and overlooked requirement for medicines information 
leaflets. Tailored interventions are associated with higher patient satisfaction and 
increased intention to change poor health behaviour.12 People only want information 
relevant to them, yet the leaflets can contain a number of confusing and irrelevant 
indications, doses, contra-indications, precautions, and side-effects. A young female 
patient prescribed salmeterol for asthma will need very different information 
compared to an elderly male prescribed the same medicine for chronic obstructive 
pulmonary disease, yet the same leaflet would be given to each patient. There are 
examples of patients being prescribed antidepressants for neuropathic pain who, on 
reading the accompanying information leaflet, have refused to take their medicine 
because they think it has been prescribed inappropriately.92 Furthermore, regimen 
and dosage strength are deemed important by patients;26, 87 however, if a patient’s 
dose is different to that stated in the leaflet, a particular problem for a legitimate but 
off-label use of a medicine, then there might be a risk of confusion and error.  
Adherence to chronic therapy can also be encouraged through tailored information 
leaflets. The majority of patients do not read medicine information leaflets if they 
have taken that medicine in the past.2, 25-28 This is understandable as patients could 
not be expected to read the same information month-by-month with each dispensing 
of their medicine. Moreover individuals at different stages of chronic disease will have 
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quite different information needs.12 Tailoring information for patients on chronic 
therapy would enable more appropriate information to be given to them with each 
medication review cycle, such as further advice on lifestyle and long-term possible 
side-effects (e.g. Cushing’s syndrome with corticosteroids),2, 26, 40, 78, 88, 89 and should 
encourage continued compliance.  
A computerised system could automatically tailor leaflets to patient characteristics 
and medical condition, providing the core elements in a short summarised easy-to-
read and understand information leaflet.25, 26, 81, 82, 84, 88-90 For patients requiring 
additional and more comprehensive information, the system could populate 
personalised leaflets, allowing healthcare practitioners and patients to choose what to 
include in the leaflet. This would allow optimal leaflet tailoring for all patients’ needs, 
and point-of-care use of the leaflet for patient counselling. The added benefit would 
be the patient’s engagement in the process, acknowledgement of leaflet importance, 
and increased willingness to read and use the information. Whilst there is 
considerable research on computerised tailored information for patients, this has not 
centred on medicines information but focused on pre-surgical education and 
preventative health measures e.g. dietary changes, smoking cessation, disease 
education, and safe sex practices.93, 94 Interactive Health Communication Applications 
(IHCA’s) such as those used by health insurance companies and other healthcare 
providers, tailor information according to data provided by the user and deliver digital 
health information, guidance, and support.94 They contain large volumes of 
information, but present it in small sections allowing users to select the information 
they want.95 IHCA’s are not intended for providing medicine information leaflets as 
they are not designed for direct face-to-face contact with patients. However, the 
concept of a program allowing this functionality would suit tailored and relevant 
medicines information for patients and following consultation, patients’ could 
continue to stylise their own information throughout their therapeutic journey.  
Having printable leaflets at point of care is also of benefit as patients prefer 
information presented in an A4 format,26, 61 making it easy to print from the internet 
33 
 
or computer programs and, as the electronic information can be edited as necessary, 
it would ensure that the most up-to-date information will be given to patients. 
Practice implications 
Current medicine information leaflets are not considered helpful by many patients and 
are infrequently used. Because of the varying needs of patients, a ‘one-size-fits-all’ 
version of a leaflet available for each medicine is not appropriate. Tailoring of 
information providing core 1–2 page information leaflets based on the content 
requirements (Box 1) to be given out alongside counselling from a healthcare provider 
is preferred. The ability to use automated computer systems for this process might be 
a desirable step forward. 
Box 1 Recommendations for content of medicine information leaflets 
Recommendation Comments 
Name of the medicine2, 7 The name people are most familiar with (i.e. the 
brand of the dispensed drug) should also be included. 
Tailored information7, 26, 61, 78 Tailored information to indication a definite 
requirement. Age and gender are less important to 
patients but worth considering if possible. 
How a medicine works and the 
benefits of treatment2, 7, 26, 40, 61, 79, 
87, 89, 91 
Include: 
 why it is important to treat the disease and what 
would happen without treatment 
 whether the medicine is curative, preventative, or 
provides symptomatic relief 
 how long treatment will be required for. 
Dose26, 87 This information should only be included if it can be 
tailored to the patients specific regimen – i.e. 
personalised. 89 
How to take the medicine2, 7, 26, 61, 89
  
Also include what to do if a dose is missed. 
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How long to take the medicine for2, 
7, 26 
For certain medicines also include what would 
happen if stop medicines e.g. withdrawal symptoms 
from antiepileptic medicines, return of infection for 
antibiotics etc. 
How to monitor the treatment’s 
effectiveness26 
Include when to return to the doctor if no benefit 
seen – i.e. antibiotics should start to see benefit 
within days compared to antidepressants which takes 
weeks. 
Comprehensive list of risks 
 
Important to include the action required if side-
effects are experienced. Duration of risk would be 
helpful to include.40 Note design of side effect list is 
mentioned below. 
Numeric description of side 
effects25, 26, 40, 59, 61, 81, 82, 89, 96 
As well as describing numerically, e.g. as natural 
frequencies (e.g., three in 100 people), side-effects 
should be categorised by how likely they are to occur 
and how serious they are with details of what action 
is required if a side-effect is experienced. Boxes or 
tables should be utilised for clarity with side-effects 
requiring immediate cessation of therapy or medical 
treatment listed first. 
Long-term effects2, 26 Where applicable e.g. corticosteroids, 
benzodiazepines (addictive). 
Monitoring requirements61 Such as blood monitoring and usual frequency. 
Interactions2, 26, 86  Focus should be on over-the-counter medicines and 
foodstuffs. 
Allergies and excipients26 Evidence-based cross-reactivity should be included as 
well as excipients and any particular allergy concern  
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How to store a medicine26, 61, 89 The general recommendation of keeping out of reach 
of children as well as specific requirements. Also 
should include how to dispose of medicines (e.g. 
fentanyl patches—ensure nobody can accidentally be 
exposed to remaining active ingredient). 
Lifestyle information and general 
health tips40, 88, 89 
Lifestyle information about medicine or disease 
effects including driving, drinking, sexual activity etc. 
General health tips cover how to best self-manage 
disease e.g. healthy diet and exercise in diabetes. 
Details for more information26, 40, 89 Where to see more detailed information leaflets, 
patient organisations, helpline numbers, and website 
addresses.  
Comparative information for 
alternative drug therapies and 
treatment options including non-
pharmacological and natural 
medicine2, 26 
This may be problematic as it could confuse some 
people and lead to anxiety in some cases. It would be 
necessary to tailor this information following 
discussion with patients and before treatment 
decisions are made to aid concordance. Information 
should be succinct and evidence-based only and may 
not be available for a number of medicines. 
Date61, 89 Date of last update of leaflet. 
Conclusion 
This review focused on the content and design of medicine information leaflets, two 
very different but equally important factors that affect patients’ ability to locate and 
comprehend medicines information, and their desire to use it. Generally, the findings 
are consistent with the conclusions of earlier systematic reviews,2, 7, 26, 97 although 
there is now more impetus driving the need for personalisation and innovation in 
leaflet generation. This is especially so, given that many countries have recently 
developed policies moving toward more patient-centred care alongside empowering 
patients to be actively involved in health decision-making. 
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This paper describes the types of information and presentation that improve patients’ 
ability to use their medicines safely and effectively. Furthermore, the review of other 
papers described here can be used for guidance on content and presentation; be used 
to help produce safe and effective patient-centred medicine information leaflets; and 
act as a template against which to assess those currently available. 
Conflicts of interest 
None. 
Role of the funding source 
This research was undertaken with the aid of a scholarship from the University of 
Otago, New Zealand. 
Acknowledgements 
We thank the School of Pharmacy, University of Otago for supporting this work, and 
the University of Otago for the doctoral scholarship.
37 
 
2.3.2 Limitations of commentary  
This commentary was designed to give an overview, from recent studies, of what 
patients want included in the information provided to them about their medicines; 
and how this information should be designed for optimal use.  
To undertake this narrative review, we carried out a search of published literature 
with a focus on patient information leaflets. The ‘design’ information was gathered 
from the results of the studies identified. Studies were only included if they included 
patient preferences or opinions, or provided data showing a design characteristic 
improved acceptability, comprehension, or usability of leaflets. We used the 
terminology ‘design’ when discussing concepts that covered both the design of the 
information (font style and size, use of bullets, line spacing, ways to emphasise text, 
and page layout etc.) as well some content-design principles (e.g. simplified language, 
tone, sentence length, phrasing, paragraph length, sequence of content 
(organisation), use of jargon, and repetition). Although this was done to separate the 
desired clinical information from how it should be written and presented, this may 
mean there is disparity between this study and other studies when describing design 
principles.  Furthermore, literature that investigated the use of imagery and 
pictograms were not included. It is understood that pictures help convey complex 
information to certain patient groups,98 but for the purposes of this project, papers 
that focused on the use of pictures and pictograms were excluded. Absence of 
discussion around the use of pictures in leaflets is not intended to downplay 
effectiveness of this technique for conveying information. 
The limitations of the studies included in this commentary may restrict the ability to 
generalise to the whole population. For example, none of the studies included 
children so conclusions can only be drawn for adults. Many studies in the commentary 
excluded participants who were not native speakers of the language of the country so 
it is not possible to generalise findings to those who do not speak the ‘leaflet’ 
language fluently. Some studies also excluded those with learning difficulties or who 
misused drugs, or were on the methadone programme. This may mean that findings 
38 
 
may not relate well to those who have impaired ability to understand complex 
information. 
Overall there is a consistent bias of participant self-selection among the studies 
included and this resulted in many of the studies having uneven representation of 
womenof higher education levels, and of particular age group. Three studies had 
purposeful sampling in adults over 50 years78, 79, 88; one study had purposeful sampling 
of children between 13 and 19 years and in adults over 50.83 Another study had 
younger participants with mean ages ranging from 22.2 to 32.9 in the differing 
participant groups in the study. 90 Most other studies had participants with a mean 
age over 45 years (often much higher). 25, 26, 59, 61, 80-82, 86, 89 Two studies had mean ages 
between 30 and 40 years of age 84, 85 and other reported age participant age ranges 
with half of the participants under 45 and half over 45 years of age.87 
Furthermore, many of the qualitative studies reviewed were of a limited sample size. 
Although this is characteristic of studies involving one-on-one interviews and focus 
groups, it means that the results may not necessarily be generalised to other 
population goups.. 
None of the studies focusing on content of information leaflets measured the literacy 
of participants and this variable may affect outcomes of participants. However, some 
of those with a focus on design did quantify literacy, although differing measures were 
used between each study; often education level was obtained as a proxy for literacy. 
For the studies investigating optimisation by design, many leaflets were enhanced in 
multiple ways in addition to the specific concept under scrutiny.25, 59, 80-84, 90 This may 
result in overestimation of benefits of the specific intervention being investigated or 
make it difficult to know what did and did not aid readability and understanding of 
leaflets.  
Lastly, the included studies’ measured outcomes and methodological heterogeneity 




2.4 How medicine information leaflets should be 
designed compared to regulatory agencies’ 
recommendations  
Published Manuscript Entitled Regulatory agencies’ recommendations for 
medicine information leaflet: Are they in line with research findings? 
The manuscript entitled “Regulatory agencies' recommendations for medicine 
information leaflets: Are they in line with research findings?” was published in the 
journal Res Social Adm Pharm 2018;14(2):196-202.  
The co-authors contributed to the manuscript as follows: Review and synthesis of the 
literature were performed by PhD candidate Amber Young, under the supervision of 
Dr Alesha Smith and Associate Professor June Tordoff. All the co-authors revised the 
content of the manuscript and approved the final version for publication. The PhD 
candidate Amber Young was the lead author in manuscript preparation and writing, 
and corresponding author.  
The manuscript is presented as accepted for publication; however, the numbering of 
the pages, figures, and tables has been adjusted in accordance with the style of this 
thesis. All references from the manuscript can be found in the section ‘References’ at 
the end of the thesis.  
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2.4.1 Regulatory agencies’ recommendations for 
medicine information leaflet: Are they in line with 
research findings? 
Amber Young*, June Tordoff, Alesha Smith 
New Zealand's National School of Pharmacy, University of Otago, Dunedin, New 
Zealand 
* Corresponding author. New Zealand's National School of Pharmacy, University of 
Otago, PO Box 56, Dunedin, 9054, New Zealand. 
E-mail addresses: Amber.young@otago.ac.nz (A. Young), June.tordoff@otago.ac.nz (J. 
Tordoff), Alesha.smith@otago.ac.nz (A. Smith). 
Abstract 
The design of medicine information leaflets can determine whether a leaflet will be 
read or discarded by patients. It may also influence patients’ ability to understand the 
information about their medicines within the leaflet. Researchers compared 
regulatory agencies’ recommendations for medicine information leaflet design from 
New Zealand, the United Kingdom, the European Union, and the United States against 
recommended good-design principles to determine the appropriateness, 
comprehensiveness, and consistency of their recommendations. Recommendations 
for medicine information leaflets varied between the regulatory agencies. There were 
some inconsistencies between the recommendations and some gaps were identified. 
There was little guidance given to creators of medicine information leaflets in New 
Zealand compared to other countries, and this could lead to manufacturer-produced 
information leaflets of a poorer quality. Up-to-date and enforceable guidance for 
creators of medicine information leaflets should be provided in all countries to ensure 
they are of an appropriate standard.  





The provision of medicine information leaflets 
Medicine information leaflets are expected to increase consumers’ knowledge of 
medicines, assist in distinguishing side-effects and recognising interactions, and 
improve consumers’ health management skills.3 In New Zealand there are ethical 
requirements that patients are fully informed about their prescribed medicines.41, 42 
However, in contrast to other countries (e.g. within Europe), there is no legal 
requirement for medicine information leaflets to be given, nor any binding official 
requirements for manufacturers to adhere to when creating leaflets. This has led to a 
system where there is no consistency in the provision of medicine leaflets at 
dispensing between pharmacies, or possibly between individual pharmacists within a 
pharmacy. One benefit of not having to legally provide the manufacturers information 
leaflet is that health professionals can choose which material to provide to patients. 
Some examples are those produced by independent providers such as Med+info (a 
subscriptive resource for pharmacists to print for patients),99 SafeRx (produced by the 
Waitemata District Health Board),100 Healthinfo (a Canterbury District Health Board 
initiative),101 Kidshealth (a joint initiative between the Paediatric Society of New 
Zealand and Starship Foundation),102 and Health Navigator New Zealand.103, 104 This 
allows scope for incorporating patient preference.  
Compulsory provision of medicine information leaflets is regarded as a positive step 
forward in patient education, yet there are some patient reservations around the 
trustworthiness of manufacturer provided information.2, 26 Furthermore, even 
although there are guidelines in place for manufacturers to use when producing 
information leaflets they may still be substandard.105 In the USA, private vendors 
create medicine information leaflets (named consumer medication information (CMI)) 
which are expected to be given with the first dispensing of all medicines. These 
leaflets, however, are of variable quality.105, 106 One important problem with this 
system is that some vendors include too much information in an attempt to ‘cover all 
the bases’ and prevent possible litigation. The outcome of this is that leaflets fail to 
meet their primary purpose in effectively educating patients.106 Medicines associated 
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with serious and significant public health concerns (decided by the FDA), or those 
containing oral contraceptives or estrogen, and some other prescription medicines 
(decided by FDA or manufacturer) have manufacturer-produced medication guides or 
patient package inserts. These are reviewed and approved by the FDA,107 although still 
fail to meet federal standards and patient requirements.45, 108 
Why leaflet design is so important 
Medicine information leaflets can be a useful tool for educating patients about their 
medicine, allowing patients to use their medicines safely and improve adherence.9, 26, 
74 This is of particular importance to patients with poor health literacy, who have 
reduced ability to obtain and comprehend basic health information and make 
informed and appropriate decisions about their health.11 These patients also tend to 
be the most vulnerable to illness and suffer worse health outcomes.11, 12  
A recent review looked at how information leaflets should be designed to convey 
information effectively and accurately.109 The key findings were that a well-designed 
leaflet with simple language improve patient perceptions of the leaflet, and improve 
patients’ ability to find and comprehend the information in the leaflet. However, as 
pointed out in the review, many patients find leaflets are poorly designed, complex, 
too long, and difficult to read2, 9, 26, 55, 77, 78, 84, 86, 87 so this reduces patients’ willingness 
to read the leaflet. Perceived complexity, perhaps due to leaflet length or use of 
jargon, decreases patients’ appreciation of the leaflet and probably the likelihood of 
following the recommendations.85 Patients have even reported stopping their 
medicine if the information in the leaflet is unclear.87  
This article provides an up-to-date comparison of government regulatory agencies’ 
recommendations from New Zealand, the United Kingdom, the European Union, and 
the United States with recommended good-design principles to determine the 




The investigators used their own “20 good-design principles” (20-GDP; Table 2) 
identified in a literature review109 to compare the recommendations made by Raynor 
et al,2 and made by medicines regulatory agencies in the EU,110, 111, New Zealand,3 the 
UK,40, 112 and the USA.113, 114 The regulatory agencies in the EU, New Zealand, and the 
UK provide advice to manufacturers and the USA to creators of CMI leaflets. UK 
recommendations were evaluated separately (but guidance provided by the EU is also 
relevant to the UK). These countries were chosen because their guidance was 
available freely online and in English. See Figure 5 for method diagram. 
 
Figure 5: Comparison of design principles between literature reviews and regulatory 
agencies 
All good-design principles identified in the reviews and the medicines regulatory 
agencies websites were tabulated for identification of similarities, inconsistencies, and 
gaps in guidance (see Table 2). 
Each resource was given a star rating for consistency with the identified “20 good-





The guidance published by medicines regulatory agencies varied considerably in 
quantity and alignment with the investigators “20 good-design principles” (20-GDP) 
derived from the literature (Table 2). Regulatory agencies guidance was published 
online from three (UK) to 20 (USA) years ago. However, the US guidance was updated 
in 2006. Some design aspects identified in our “20 good-design principles”, such as 
number of pages and minimising repetition was not included in any guidance from 
regulatory agencies. It is worth noting that in some instances, the regulatory agencies’ 
guidance went into greater detail than what was found in the 20-GDP. This included 
the type of paper to be used (not glossy, shiny, or too thin), specifics for line length of 
documents, and the spacing between lines.  
Generally speaking, the findings of this review are in line with the recommendations 
made by Raynor et al (see Table 2), suggesting that conclusions drawn around good-
design principles from the previous decade are still highly relevant. However, there 
are a few important new points that we discovered in our review, such as avoidance of 
repetition, type of paper to use (A4), and leaflet length. Minor inconsistencies were 
also uncovered such as optimal font style and size.
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Table 2: Summary of design principles for medicine information leaflets 
Design Principles 
Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Words and language  
User-friendly language. No 
medical terminology or 
semi-technical expressions 
(unless necessary and fully 
explained).  
No acronyms or 
abbreviations. 
Write to appropriate 
reading level— year 6 (11 
years of age). 
 
 
Easy to understand 
(everyday language 
with short familiar 
words). 
Minimise use of jargon 





must be in a 
language 
consumers find 






lay language. Simple 
words of few syllables. 
Complex language and 




Simple words with few 
syllables. Avoid 
abbreviation, acronyms 
(unless necessary and 
fully explained) and 
scientific symbols. 
Translate medical 
terms into lay terms 
(can follow lay term by 
medical term then use 
either). 
 
Use language a 
consumer feels most 
comfortable reading. 
Information should 
be clear and concise, 
avoiding complex 
terms.  
Short simple words 
used—i.e. 6-8th 
grade reading level. 
Tone, attitude, and 
meaning 
Instruct the patient not the 
healthcare professional, and 
conversational tone (‘you’ 









must be correct, 
clear, and 
unambiguous. 
   
 
Not discussed (but 




Do not repeat medicine 
name, instead say ‘your 




Use plain language 
and from the 





Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Tone, attitude, and 
meaning  [continued] 
Avoid being negative, 
patronizing, or emotive. 
Information should be 
direct, positive, and 
unambiguous. 
Tone should be 
conversational, using 
‘we’ or ‘you’ rather 
than ‘the patient’ and 
the name of the 
organisation. 
Ensure language alerts 
reader to relevant 
information and 
required actions. 
Voice and phrasing 
Important to use active or 
imperative voice. Use 
affirmations, not negations 
where possible and avoid 
non-quantifiable phrases. 
 
Active voice, and 
imperative voice for 
instructions. 






Not discussed (but 
covered in European 
Commission, 2009110). 
 
Active, not passive 
style. Actions should be 






Short sentences (15-20 
words), preferably one 





Punctuation should be 
simple. Short sentences, 









Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Font style 
Sans serif style fonts 
preferable.  
Avoid widespread use of 
capitals. 
All text horizontal. 
 
Conventional familiar 
typeface. Serif or sans 
serif equivocal – some 
recommend serif for 
headings and sans serif 
for body. 






Easy to read font. Serif 
typeface preferred for 
extensive text (PILs), 
sans serif fonts for 
signs. 
Avoid writing in capitals. 
All text horizontal. 
 
Easy to read font 
(letters and numbers 
distinguishable). 
Avoid widespread use 
of capitals (can be used 
for emphasis). Italics 
can be used for Latin 
terms. 
 
Do not use ornate 
typefaces and italics. 
Bolder type over a 
thin version. 
Opinions vary on 
using serif or sans 
serif font. Many 
experts recommend 
sans serif for 
headings and serif 
for text. Avoid 




letters, no more 
than -3 “kerning” 







Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Font size 
Font size 10–12 point. 
 





Use large as possible 
text size. Font size 14 
for headings and 12 for 
body of text. 
 
Large enough type size 
e.g. minimum 9 point 
Times New Roman. 
 
Use 10-point or 
larger type size (12 
point for materials 
intended for older 
persons). 
Colour and contrast 
Colour may be useful to 
emphasise important points 
or sections (not conclusive). 
 
Use sparingly. Do not 
use red type. Black on 






Sparing use of colour 
but ensure adequate 
contrast between text 
and background.  
Generally dark text on 
light background. 
Reverse type can be 
used for particular 
warnings (may require 
larger font or bold). 
 
Ensure adequate 
contrast between text 
and background. 
Colour can make 
headings or important 
information clear. 
Generally dark text on 
light background. 
Reverse type can be 
used for particular 
warnings (may require 




Select text colour 
and paper that give 
a strong contrast. 
Black, dark blue, or 
brown on white or 
pale yellow 
uncoated paper best 
contrast (avoid 





Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Line length and spacing 
Shorter lines preferable. 
Lines must be well-spaced. 
 
Both long and short 
lines impair reading. 
Aim for 40-70 
characters (8-12 
words). 





Line length 60-70 
characters, unless in 
columns. Spacing 
between lines 
important – generally 
1.5 times than between 
words. 
 
Spacing between lines 
important – generally 
1.5 times that between 
words (at least 3mm). 
 
 
In 10-point or 12-
point type, optimal 
line length is 
approximately 40 
letters and leading 
(space between 
lines) at least 2.2 
mm. 
Paragraph length and 
spacing 
Short paragraphs.  
Avoid listing information in 
a paragraph format. 


























Left justification of text. 
 





Align text to the left. 
 







Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Organisation of content 
Logical sequence of 
information. Treatment 
benefit, how the medicine 
works, and directions before 
risk. 
 
Logical structure – 
‘before’, ‘during’ and 
‘after’. 
 
          
Desirable for a 
standardised 
format. Sponsors 
encouraged to use 
the template. 
          
Important to consider 
how the information 
order and structure is 
set out (note that 
instructed in EMA 




          







format should make 
it easier to locate 
information. 
White space 
Page should not be 
cluttered. Plenty of white 
space. 
 













Table of contents 
Numbered table of contents 
with associated numbered 
headings in longer leaflets. 
 




          
Index important if a 
booklet format (note 
that contents required 
for all leaflets in EMA 
template111). 
         
Necessary for all 
leaflets. Prominently 
displayed reflecting 
main sections, with 







Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Headings 
Clear headings and 
subheadings necessary and 
must stand out from rest of 
text. The heading ‘before 
you take’ is ambiguous 
(people do not understand 
what information will be 
listed underneath it). 
 
Short and on a single 
line. Clear 
subheadings. 
Questions may not be 
useful. Section 
headings in reverse 







Must be visually 
prominent:  
•use of reversed text 
•larger and bold font  
•contrasting colour.  
Must accurately 
describe the contents of 
section and be concise. 
Sub-headings useful. 
Should be consistently 
placed with consistent 
font. Lines to separate 
text. 
 
Bold or different 
colour. Consistent font 
and spacing above and 
below. Lines to 
separate text. Caution 
with multiple levels 
(warranted for complex 
information). 
Adhere to section 
headings as per legal 
requirements. 
 
Space above and 
below headings. 
Bullet points 
Use of bullet points for lists 
rather than long 
paragraphs. 
 
Organise text into 
steps or points (instead 
of numbered lists as 
appropriate). 
Numbered lists useful 





Use of bullet points for 
lists rather than long 
paragraphs (maximum 
five or six points). 
 
Use of bullet points for 
lists rather than long 
paragraphs (maximum 
five or six points). 
 
Bullets should be 




Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 
aFDA USA, 1996113 
and 2006114 
Emphasising information 
Bold to highlight important 
text. Avoid over use as this 
reduces the emphasis. 
 
Use bold. Only use 





Do not use italics or 
underlining. Reverse 
type can be used for 
particular warnings 
(may require larger font 
or bold). 
 
Use different sizes for 
emphasis e.g. headings 
Capitals can be used 
for emphasis. Do not 




Use bold-face type 




than highlighting or 
underlining. 
Page layout and page break 
A4 page, portrait 
orientation, with 2 columns 
for information (3-column 
format makes lines too 
short). Sections should 
finish on the page. 
 
Avoid sections being 
broken between 









is kept together. 
 










Avoid repetition. All 
information on one topic 















Articles included in 
review,109 2008-201525, 26, 59, 
61, 78-90 
Other information sources 
Raynor et al, 20072 Medsafe New 
Zealand 20133  




and EMA, 2016111 









Avoid glossy, shiny 
paper, or paper that is 
too thin and allows 
show-through of text. 
 
Avoid glossy, shiny 
paper, or paper that is 
too thin and allows 
show-through of text. 
Folding must not affect 
readability. 
 
Material should be 
printed on uncoated 
paper. 
Number of pages 
Maximum 1–2 pages in 
length with clear instruction 












aThe more recent publication is not a comprehensive list of design principles, but refers to the earlier publication as a resource to be adhered to when 
creating medicine information for patients. The information included in both documents has been merged for the purposes of this table. 
bIt is a legal requirement that manufacturers’ medicine information leaflets also undergo consumer user-testing before they are approved for use. 
 Consistent with the 20 good-design principles (20-GDP) from the investigators review109 
 Somewhat consistent with the 20-GDP 
Not consistent with the 20-GDP or not discussed in recommendations 
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Discussion and conclusion 
Discussion 
In this commentary, the investigators compared regulatory agencies 
recommendations for medicine information leaflets for alignment with the design 
principles found in two sources. One source was the investigators recent review,109 
and the other recommendations made by Raynor et al in 2007.2 Each source had 
identified design principles that would facilitate leaflet use by patients, and maximise 
leaflet effectiveness. The recommendations examined were from agencies in the EU, 
New Zealand, the UK, and the USA (see Table 2).  
We found that the design recommendations for medicine information leaflets varied 
between the regulatory agencies. Understandably guidance published by the EU and 
the UK were very similar and those from the USA also contained many similarities to 
them both. However, there were some inconsistencies between the 
recommendations and the literature; and some gaps in guidance were identified. This 
may be because our literature review109 was completed many years after the guidance 
on the agencies websites were written or updated. This suggests that there is a lag in 
uptake of new information about textual style and design that becomes available from 
research. In New Zealand, there is little regulatory guidance given to the creators of 
medicine information leaflets compared to other countries, and this could lead to 
manufacturer-produced information leaflets of a poorer quality. New Zealand needs 
stronger regulatory guidance on the use of good-design principles for the creators of 
medicine information leaflets. Furthermore, in all countries, leaflets could be updated 
in line with research findings more rapidly, and there could be greater international 
collaboration by agencies when developing guidance.  
A leaflet’s appearance at first glance might attract or deter patients from reading it. 
Legislation in many countries concerning what must be contained in leaflets has led to 
them being long and cumbersome which does not encourage patients to read them.84 
In the USA, leaflets produced by different vendors for the same medicine may have 
more than 1000 word difference in length between them. The longer leaflets contain 
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all of the necessary information but because of the quantity presented, it is not read 
and retained.106 Involving patient groups when creating regulations or guidance, 
rather than the standard of ‘user-testing’ after the fact, would help agencies exclude 
the unimportant. This would make leaflets a more desirable length, and more patient-
centred. 
As well as emphasising the importance of the leaflet design, there should be more 
guidance on the final provision of the information. Patients prefer printed information 
presented in an A4 format,26, 61 making it easy to print from the internet or computer 
programs, and beneficial to both healthcare practitioners and patients who want to 
access it. However, it is important to note that leaflets presented on thin paper folded 
multiple times and inserted in a pack with dispensed medicines may not seem 
important enough to read.27 Likewise a leaflet folded and put into a dispensed bag of 
medicines, without discussion from a pharmacist, may go unnoticed or seem 
unimportant. Perhaps as well as updating recommendations on the design of 
medicines information leaflets, guidance should be provided on how printed 
information leaflets should be presented and discussed with patients. Furthermore, 
there has been no guidance for healthcare professionals on how to provide electronic 
medicines information, despite improved patient-access and preference for digital 
information alongside increasing use of smart phones. There are also new patient-
centred initiatives such as patient accessible electronic health records where patients 
can view their health information and contact their health care provider directly. 
Regulation of information provided to patients digitally is warranted; this should 
include when electronic medicines information should be provided and what that 
information should be.  
Practice implications 
Many countries have developed guidance on how to produce well-designed 
information leaflets about medicines but only a few have regulations that require the 
leaflets to be given to patients when medicines are supplied. Other countries, 
including New Zealand, have little or partially outdated information, and guidance 
requires a complete update. Also there has been no guidance for the provision of 
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medicines information electronically, which is surprising in a time where the use of 
smart phones and patient electronic health record access is commonplace. A change 
in practice is required to establish up-to-date and enforceable guidance for those 
creating medicine information leaflets so that leaflets are produced to an appropriate 
standard and in appropriate formats.  
Conclusion 
There has been considerable investigation in Australia, the USA, the UK, and other 
countries within the EU into the strengths and weaknesses of currently available 
medicine information leaflets, and what could be done to improve them. 
Recommendations from research and regulators are available yet these are not 
consistent or fully comprehensive. In some countries, these recommendations are not 
commonly incorporated into leaflet-writing practice, or the common templates used 
may not allow these principles to be followed. Medicines information for patients 
should be as direct and simple as possible—it is essential that instructions are clearly 
given so patients know when action is required, and what action should be taken. We 
have highlighted recommendations (20 good-design principles) for medicine 
information leaflet design based on our literature review findings. These can be used 
as a template for creating and assessing medicine information leaflets in use. 
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2.5 Digital information about medicines, is there a 
need?  
Many health professionals are continuing to rely on verbal discussion or, sometimes 
more often, printed leaflets. The Medicines and Healthcare Products Regulatory 
Agency UK report in 200540 stated that printed leaflets may be the only information 
many people receive about their medicines. Providing information about medicines 
digitally can allow even more information to be provided if necessary or desired by the 
patient, and can improve patient engagement compared to routine clinical 
appointments.115 Linking to more useful information such as instructional videos or 
further resources for reputable information about the disease or condition would also 
be useful for patients. 
As discussed earlier, patients have improved access to digital and personal health 
information yet there is no guidance about providing information about medicines or 
evidence-based treatment this way. Furthermore, people are increasingly looking to 
the internet for health information.70 Unfortunately, online information can be of 
variable standard and sometimes dangerously inaccurate.116, 117 Like other health 
information, information about medicines is already available in a digital format and is 
being consumed by patients. This suggests there should be more emphasis on the 
need for suitable digital information rather than the need for having information 
available in a digital format. The key need is for healthcare professionals to be able to 
direct patients towards accurate, reputable, and easy-to-read digital information.117 
For this to occur it is essential that the desired information is available digitally and 
easily for health providers to access and disseminate. 
2.5.1 Practicalities 
Digital information would need to be usable at point-of-care and accessible to the 
patient once they have left a consultation. Having the information available 
electronically rather than pre-printed may be seen as a natural evolution in a 
technology-rich society. It is important that patients can access information at a time 
that suits them and that it is available in a format suited to their requirements. Some 
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health providers no longer provide disease and treatment information in paper 
format, but instead send patients a reputable weblink via an SMS (text message).118 
However, these services may still require active health professional engagement for 
the patient to gain access to the content. This can be remedied by some automation 
of information provision following consultation.  
Digital information can be easily edited and disseminated which allows updates about 
the medicine to be available to patients straight away—possibly even alerting them to 
safety updates in real time. Digital information can also improve patient usability e.g. 
using in-built dictionaries to explain complex medical terms, allowing a change in font 
size on a mobile phone, or utilising a read-back function for audio versions of the text 
on the web page.119  
Nevertheless, it is important that digital medicine information is easy to access and 
does not lead to accidental access of incorrect information (e.g. patient searching for 
information about dextromethorphan accidentally reading information about 
dexamethasone). There are ways around these issues with links or codes being 
provided directly to patients rather than them searching for the information 
themselves. Examples of this are patients receiving email or an SMS (text message) 
with a direct web link, or a code (e.g. QR, quick response code) on medicine 
packaging.119 These could be electronically and automatically provided by the 
prescribers or dispensers of medicines. Text-based initiatives provided to patients via 
SMS have been shown to improve health outcomes in many situations including 
weight-loss, but there is not much information as to whether they are beneficial for 
providing medicine information and improving patient knowledge.115 It is likely that 
SMS would require links to applications or websites in order to be of benefit. 
2.5.2 Patient preference 
As discussed earlier, the presentation of the information can affect patients’ opinions 
of the resource. Poorly presented leaflets can be ignored.27 Digital information that is 
easily accessible can improve perception of the resource and patients willingness to 
read it. There is also a risk that patients may think the content is not important if not 
specifically provided by their health professional.115 It may be the role of the health 
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provider in the future to point patients in the direction of reputable digital information 
to minimise this assumption. 
The growth of information technology supports improved patient engagement in 
healthcare with information being accessible anywhere at any time. Disease-specific 
mobile applications help patients feel more in-control of their own healthcare.115 With 
the use of educational websites patients feel they have a better understanding of their 
condition, more satisfaction with doctor’s visits, and advocate wider use of patient 
education websites by other health professionals involved in their care. They are also 
likely to return to the website as needed in the future.120 Many patients would be 
happy to receive information about their medicines electronically, and it may allow 
them to quickly navigate and find the desired information without having to read the 
whole leaflet.119 However it may not be appropriate for all patients such as those less 
tech-savvy or some elderly patients who are not well practised at navigating digital 
information. In these patients there may be acceptance for electronic information, but 
they may also want to continue receiving printed information.119 User-friendly eHealth 
services must be in place along with simple to follow education programs to educate 
patients who lack the know-how of more digitally advanced patients. But in addition 
to this, the information available digitally must be “printer friendly” to ensure those 
without digital access still can read the information important to them if a health 
provider, family member, or friend is accessing the content on their behalf. 
Finally, if patients have access to information in a digital format it will be possible for 
them to tailor the information to their own requirements. For example, automatic 
personalisation could occur during consultation, with the healthcare professional 
providing a tailored short summarised leaflet, web link, or email with a link to access 
further information if required. In many cases, patients might find the summarised 
leaflet sufficient for their needs.2, 78 Yet some might prefer to receive comprehensive 
information and want to read as much as they can about their medicines. These 
patients would find the link to additional information useful and reassuring.2, 79, 85 For 
example, patients could either read the most common side-effects in the tailored 
information provided by their health professional, or they could link to more detailed 
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information about medicine harms . They might decide to look at pregnancy and 
breast-feeding information if appropriate; or look at alternative treatments or lifestyle 
factors that could help manage their condition more effectively if they were motivated 
to do so. For this to be of value to patients, the interface must be well designed, and 
the system must be user-friendly.  
2.6 Patient Reported Outcomes 
2.6.1 What are Patient Reported Outcomes? 
So far this chapter has discussed the passive flow of information from provider to 
patient or from resource to patient. This assessment does not allow viewpoints and 
direct involvement from individual patients about what information they should be 
receiving. Patient Reported Outcomes (PROs) are patients’ direct accounts about their 
treatment or health condition,121, 122 and enable representation and discussion about 
what is most important to them.73, 121  
The information collected by PROs can be either disease-specific (e.g. diabetes), 
condition-specific, or generic. This information can be attained by a number of 
different methods such as targeted patient interviews, self-completed questionnaires, 
or even patient diaries.121 Information can also be collected digitally using web-based 
forms on smart devices.121 PROs can be used for an almost infinite number of 
purposes and collected in a multitude of different ways for different applications: they 
can be collected during inpatient stays, outpatient visits, or during ambulatory care; 
for acutely presenting patients, for chronic patients, or for acute presenting chronic 
patients; at time of consultation, or between visits. The quantity of PROs collected is 
also for debate i.e. they can be a single report or recurrent reports; some PROs are 
collected on a daily basis.72 Because of the variation in type of information that can be 
collected, the way it is collected and when it is collected, PROs can be designed for 
almost any purpose and tailored to specific requirements. 
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PROs can be used to collect information from patients to help generate tailored 
information to be provided to them. For example, patients taking medicines 
associated with high-risk of harm (e.g. oncology medicines) can report the side-effects 
they are experiencing and depending on the responses they provide. Actionable side-
effect management advice could then be provided to them to suit their needs. 
Patients can report specific problems experienced through pre-determined 
questionnaires and their responses can generate self-management advice based on 
those responses (or other useful information). This is being investigated for oncology 
medicines,123-129 but could be extrapolated to other drugs where patients need 
symptoms reporting on a regular basis to prevent worsening toxicity e.g. 
breathlessness for methotrexate, skin complaints with lamotrigine and so forth. 
Information about the medicine and harms of treatment are the most likely things to 
be requested. 
2.6.2 Benefits of Patient Reported Outcomes 
Increasing the information available to health practitioners for use during a 
consultation by acquiring PROs could improve person-centred care by encouraging 
clinicians to focus on the patient’s concerns rather than patient’s disease.130 Most 
current healthcare models allow discussion about treatment benefits and side-effects. 
However, these may rely on clinician-led appointments to discuss patients’ concerns 
and can be short and unfocused. This process is also often impeded by cost and by 
both parties having limited time to adequately undertake true shared-decision 
making. PROs could facilitate communication between patients and their healthcare 
provider thus enabling shared-decision making and engaging patients in their own 
care.122, 130 PROs allow the flow of information from patients back to health 
professionals, facilitating adequate, up-to-date, and focused information to be 
discussed and reviewed during consultation, possibly without increasing consultation 
time.130 Furthermore, the information gathered by PROs assists early detection of 
health problems requiring urgent medical intervention, allows the application of 
standardised disease-progression measures, and enables evaluation of treatment 
impact on patients’ lives.122  
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There are many different tools available that allow documentation of PROs, assessing 
a multitude of different outcomes including symptoms of disease or side-effects from 
therapy, functional status, quality of life, and perceived well-being.121 For some 
methods, patients can report outcomes at any time in the comfort of their own home. 
This would be beneficial when early detection and management of certain clinical 
issues is essential, such as signs of early infection in patients having chemotherapy.131 
Furthermore if PROs are collected using digital mediums such as smart devices, there 
is potential for that data to be directly inputted into patients’ Electronic Health 
Records (EHR) and thus automatically alerting clinicians if urgent intervention is 
required.72  
It is well understood that health professionals may only provide patients with the 
information that they feel is important and may withhold information that some 
patients want including that on side-effects and potential harms  of treatment.2, 132 
This phenomenon may also occur when health practitioners are following up with 
chronic therapy and discussing treatment effects with their patients. It is also possible 
that some issues that may concern the patient could be forgotten and not discussed. 
The use of PROs would ensure that the problems patients find most important could 
be flagged to their health provider for discussion during consultation, particularly 
those that may be otherwise overlooked.72, 122 Furthermore, some side-effects are 
unable to be easily quantified and the resulting impact on patients may only be known 
to the patients themselves, such as fatigue and emotional pressures when undergoing 
chemotherapy; PROs are useful in capturing data on how patients are coping with 
their treatment.121 If PROs were used this way, patients could be directed to where 
they could find more information or support to help overcome these issues, for 
example tailored information leaflets or websites for support groups. This information 
for the patient could be sent to them in a digital format e.g. via email, text message, or 
through their patient portal. 
Collecting PROs would also allow effective documentation of patients’ improvement 
or deterioration over time. In doing so, this would benefit individual patients by 
enabling them to manage their disease or symptoms more effectively. There is also 
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benefit at a population level where collected data could be aggregated for further 
analysis to determine treatment outcomes for certain population groups and to assess 
treatment effectiveness or side-effects. This would also facilitate more effective and 
tailored patient education about expectations of treatment and the side-effects they 
may experience. The aggregated data could also help shape future treatment 
strategies for managing toxicities or disease progression. 
2.6.3 Disadvantages of Patient Reported Outcomes  
Collection of PROs must be appropriate for patients’ skills and be easy for patients to 
complete accurately. Some PROs might require a high degree of digital literacy or 
could be too time consuming for patients to complete.72, 122 It could also become 
burdensome for health professionals to teach patients how to use tools to capture 
PROs.  
There may also be disadvantages to health professionals depending on where PROs 
are collected. If collected in a clinic, private space to fill in a form may need to be 
made available. If collected by the patient at home there needs to be either IT 
management if digital applications are utilised or manual data entry if paper PRO 
forms are used. Either way there are costs involved.72, 130 Other disadvantages health 
professionals may be faced with include intensified workload due to increased 
information received, difficulty and extra time required to learn the systems for 
collecting and interpreting PROs, and the difficulty with fitting PRO explanation and 
discussion into their usual workflow.130 
A poorly designed instrument may not capture appropriate data, may not be sensitive 
enough to capture data to monitor change over time, and may miss outcomes 
important to patients.72 Involving patients in the early stages of developing tools for 
collecting PROs is essential to ensure the tools are user-friendly, understandable to 
patients, and effective enough to capture the outcomes to be measured.121 There is 
also a risk that PROs could cause anxiety to patients by overemphasizing problems 
that might not have concerned them.122 Alternatively, patients may receive ‘high 
scores’ but intervention may not be necessary because the problem may not be 
distressing to the patient, or the ‘high score’ may be due to something other than 
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what the PRO tool is intended to identify.73 Patients may also be averse to completing 
PROs due to worry that it may impact on their relationship with their clinician.130 
2.6.4 Use of Patient Reported Outcomes in practice 
Patients are often described as being in charge of their own care,133 yet their concerns 
may not be consistently addressed in practice. Modern healthcare aims to increase 
patients’ well-being and improve quality of life, yet PROs for use in practice are not 
standardised or regularly used.72 A review article by Greenhalgh73 outlines a variety of 
ways that PROs can be used in practice. In summary, PROs can be used: 
 During patient-clinician consultations for screening (e.g. for depression), 
monitoring (e.g. toxicities, treatment outcomes), and promoting patient-centred 
care such as supporting shared-decision making.  
 To facilitate communication within a multidisciplinary healthcare team. 
 To monitor health outcomes at a population level. 
Over time it is possible that PROs could be aggregated and fed back to patients to help 
shape their expectations for treatment side-effects and outcomes.134 However, the 
effectiveness of PROs for use in general practice has not yet been adequately 
demonstrated, partly due to the heterogeneous nature of the studies describing their 
use, the way they have been applied in practice, and the types of PROs investigated.73, 
122 For example there is clear evidence that the use of PROs for screening purposes 
promote the detection of problems patients’ experience (such as depression), 
although there is no evidence that this encourages treatment adjustment or improves 
patient outcomes.73 
Identifying specific conditions for outcome reporting may be more appropriate and 
allow for a more focused and actionable approach.72 There are a number of studies 
showing benefit of using PROs in those undergoing chemotherapy,123, 124, 135, 136 and 
also evidence for improving outcomes in psychotherapy patients predicted to have a 
poor treatment response.137 This may be because there is a defined set of criteria 
relating to treatment-failure with psychotherapy or toxicity of chemotherapy and that 
the outcomes of toxicity reports with chemotherapy are defined and targeted. 
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Therefore it is essential that if used, the PROs are targeted and focused where clear 
benefit might be obtained. It may be that on further investigation and refinement, 
PROs could be routinely reviewed alongside other reported information such as 
laboratory results.72 
2.7 Chapter conclusion 
This chapter described patients’ key requirements for the design and content of their 
medicine information leaflets, and compared regulatory agencies leaflet content 
principle and design recommendations against patients’ needs. Furthermore, the 
chapter discussed the need to provide appropriate digital information, and outlined 
the benefits and disadvantages of utilising Patient Reported Outcomes (PROs) for 
improving patient outcomes and involvement in their healthcare. 
Some patients want comprehensive medicines information and some only a short 
summary. Many patients wanted tailored information provided to them, with 
irrelevant information removed. Ideally, the information given needs to be 
personalised to individual requirements. The information also needs to be well 
designed and in language that is easy to understand. Many current medicine 
information leaflets available in New Zealand do not fully meet patient requirements 
and could be improved.  
Patients may not receive all of the information they require during consultations, and 
may experience difficulty in recalling what has been discussed with them. This is why 
providing additional readable information is so important. Unfortunately because 
providing medicine information leaflets in New Zealand is not mandatory (unlike the 
European Union), information leaflets are not available for all medicines. Furthermore, 
even if available, patients may/may not be receiving any printed or digital information 
with their medicines. This needs to be addressed at a regulatory level. 
Many countries, such as the UK and those in the European Union, give specific and 
comprehensive advice about how information leaflets need to be written. However, 
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some of this guidance is out-dated and does not follow the 20 good-design principles 
identified in the commentary (2.4.1). New Zealand has very limited advice on writing 
leaflets. Perhaps this is because providing medicine information leaflets is not 
mandatory, so comprehensive and directive advice is not considered necessary by 
Medsafe.  
Providing medicines information to patients has historically been through verbal 
communication, or more recently through the provision of medicine information 
leaflets in some shape or form. The rise of the internet has allowed wider access to all 
sorts of information and misinformation. Healthcare providers must embrace the 
digital provision of information as many patients appreciate information in this format 
and the importance that they be directed to a reputable information source cannot be 
overemphasized. Further to this, digital access gives flexibility to patients with regards 
to the type and quantity of information they can access. Digital sources also allow for 
supplementary media (e.g. instructional videos) being incorporated on websites to 
enhance understanding and engagement.120 
Patient Reported Outcomes (PROs) can be utilised to provide even more specialised 
personalised information to patients. Using aggregated data from collected PROs 
could enable calculation of specific harm-related risks for groups of patients and aid 
education on expected treatment outcomes.134 This information could also help to 
predict toxicity issues expected with certain treatments e.g. when expected side-
effects with chemotherapy regimens are likely to occur in the cycle. As well as 
facilitating more effective education of patients, this could help shape future 
treatment strategies for managing toxicities or disease progression. 
Further investigation into healthcare providers’ opinions and use of medicine 
information leaflets and the verbal information they give to patients during 
consultation will be conducted using surveys in chapters 3 and 4. 
Further investigation into the utilisation of digital technology and Patient Reported 
Outcomes for medicine management will be undertaken in chapters 5 and 6.
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Chapter 3: Verbal communication with 
patients about medicines 
3.1 Synopsis 
The gold-standard of care is considered to be verbal discussion accompanied by 
written information. This would support what has been discussed and provides 
information for the patient to refer to later. This chapter builds on the previous 
chapters’ descriptions of what patients want to know about their medicines to see if 
they are given this information verbally. Because it is not mandatory for GPs and 
pharmacists to provide information in a written format, we wanted to find out if the 
medicine information patients want to know is discussed during consultation.  
We determined from self-reports that GPs are more likely than pharmacists to talk to 
patients about their newly prescribed medicines (chapter 3). Less than half of the 
pharmacists reported that they discuss newly dispensed medicines all of the time. 
Similarly, GPs were more likely than pharmacists to report discussing most counselling 
points identified in chapter 2 all or most of the time. Although some counselling points 
are discussed all or most of the time by GPs or pharmacists, overall patients are not 
receiving all of the information they want following prescribing and dispensing of their 
medicines. Therefore, relying on verbal communication to relay all the necessary 





This chapter has three parts: 
1. What information is given verbally to patients about their medicines? 
Section 3.3 explores verbal communication with patients and examines what 
medicine information GPs and pharmacists are talking to patients about 
during consultations.  
2. Methods, further information. Section 3.4 describes the methodology of the 
study in more detail, including the rationale of approaches used. 
3. Limitations, further information. Section 3.5 describes the limitations around 
using self-reported data collection when describing participant behaviour. 
Further limitations of the studies are also described. 
3.2 Chapter aims  
GPs and pharmacists are legally and ethically required to appropriately inform patients 
about their medicines. This chapter aims to examine New Zealand GPs’ and 
pharmacists’ verbal communication with patients about their medicines, and to 
ascertain ways that provision of medicines information could be improved. 
A secondary aim of this chapter is to review the limitations of self-reporting when 
participants are completing health questionnaires and acknowledge the impact this 
has on the generalisability of the findings of this study. 
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3.3 What information is given verbally to patients about 
their medicines?  
Published Manuscript Entitled Do health professionals tell patients what 
they want to know about their medicines? 
The manuscript entitled “Do health professionals tell patients what they want to know 
about their medicines?” was published in the Health Educ J.2018;77(7):762-77.  
The co-authors contributed to the manuscript as follows: Survey creation, execution, 
analysis, and write-up was performed by PhD candidate Amber Young, under the 
supervision of Dr Alesha Smith and Associate Professor June Tordoff. Dr Sharon Leitch 
provided advice from a practicing general practitioner perspective. All the co-authors 
revised the content of the manuscript and approved the final version for publication. 
The PhD candidate Amber Young was the lead author in manuscript preparation and 
writing, and corresponding author. 
The manuscript is presented as accepted for publication; however, the numbering of 
the pages, figures, and tables has been adjusted in accordance with the style of this 
thesis. All references from the manuscript can be found in the section ‘References’ at 
the end of the thesis. Further details of the methods used and limitations of this study 
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aSchool of Pharmacy, University of Otago, Dunedin, New Zealand 
bDepartment of General Practice and Rural Health (DSM), University of Otago, 
Dunedin, New Zealand 
Corresponding author: 




Background: Discussing medicines with patients is the responsibility of prescribers and 
pharmacists. However, it is not well known if patients are given the information they 
want or if information provision continues when medicines are taken long-term. 
Objective: To determine how often general practitioners (GPs) and pharmacists 
provide verbal information to patients about their medicines, and compare the 
information given with what patients want to know. 
Design: Cross-sectional surveys. 
Setting: New Zealand primary health care. 
Method: Two questionnaires were developed and sent to a sample of pharmacists and 
GPs and chi-squared analysis was carried out. Open responses were analysed 
qualitatively to detect further ideas. 
Results: 119 pharmacists and 150 GPs responded. For new medicines, significantly 
more GPs than pharmacists reported giving verbal information all of the time. 
Significantly more GPs than pharmacists reported discussing most counselling points 
all or most of the time. Pharmacists were more likely than GPs to discuss counselling 
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points only when requested to by patients. For repeat medicines, significantly more 
GPs than pharmacists were likely to consider counselling points very important. 
Conclusion: Patients may not be receiving the information they want to know about 
their medicines, and there may be an overall lack of verbal communication about 
medicines with patients. Some information will only be discussed if the patient 
actively requests it; the likelihood of this increases with repeat medicines. The use of 
counselling aids and tools, such as a medicine information leaflet, could help 
healthcare providers provide patients with the information they need. 
Keywords medicine information, counselling, patient education, medicines education, 
verbal information, communication 
Introduction 
Optimal use of medications relies on the appropriate choice of drug and patient 
adherence.22, 138 Patient adherence can be diminished by poorly constructed and 
complicated verbal communication or lack of information.138, 139 Discussing medicines 
with patients is not the sole responsibility of a single health profession. The prescriber 
and pharmacist have a duty of care to ensure patients at least know what to take and 
how to take it. Although pharmacists provide information when dispensing 
medicines,140 in one New Zealand study, General Practitioners (GPs) or hospital-based 
doctors were considered the primary source of medicine information by 71.5% of 
patients, but pharmacists by only 0.5%.16 Another later survey of 316 people 75 years 
and over found that 93% would ask their doctors about medicine-related worries, and 
32% their pharmacist.56 This disinclination to discuss medicine-related queries with 
pharmacists has also been shown in Australia.16, 26 However, pharmacist medication 
counselling is important to ensure patients get their desired information, and can also 
help reduce adverse events and improve patient satisfaction.141  
Guidelines describe the information patients need about their medicines.42, 63 Many 
health professionals rely on verbal communication to relay this and do not provide 
written information such as a medicines information leaflet. 26, 140 Because of difficulty 
in recalling important information about medical treatment,63, 139 reiteration of 
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information is important, particularly if health professionals are relying on verbal 
communication to inform patients adequately about their medicines. It is unclear 
whether patients are being informed when they are prescribed new medicine and 
when they are prescribed repeated medicines for chronic conditions. Patients on 
chronic therapy have high rates of nonadherence22 and misunderstanding about their 
therapy,138 yet studies show that people collecting repeat medicines from pharmacies 
are less likely to undergo counselling than those picking up acute medicines.63, 140 It is 
unclear whether GPs or pharmacists in New Zealand consider ongoing medicine 
counselling for repeat medicines as important. However, ongoing discussion about 
medicines with patients is essential to encourage adherence and detect any issues 
with their treatment.22, 63, 142 
We know what patients want to know about their medicines. Some key information 
they require is: what the medicine is for, how it helps the condition, and how to take 
it, risks of taking the medicine (contra-indications, precautions, side-effects, 
interactions), and monitoring of treatment.109, 143 Unfortunately, some may not get 
enough information from their GPs and pharmacists at the point-of-care.7-9, 63, 144, 145 
Many studies have assessed pharmacists’ medication counselling performance. In a 
2009 review, the rates of pharmacist counselling for prescription medicines based on 
proportions of prescriptions in Finland, the UK, and USA ranged from 60% to 80%.63 
This review found that counselling rates differed depending on the research method 
used and were higher for self-reports than observation. Overall, 51–100% of 
pharmacists claimed to provide verbal counselling. Alarmingly, the rate of counselling 
in some observational studies reviewed was as low as 8%. In a 2009 US study with 
trained shoppers presenting new prescriptions, only 43 people (43%) received verbal 
counselling, and of these, 16 instances were prompted by the “patient”.146 Similar low 
rates of counselling from community pharmacies in Pakistan were observed in a 2011 
study where no counselling at all was given in 52.7% (n = 582) of the observed 
cases.147 Studies have also shown that observed discussions between GPs and patients 
about medicines may be inadequate.145, 148 Observational studies in New Zealand 
indicate that counselling times for prescription medicines appear to be short 74, 149 and 
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there is limited information about what information they give to people collecting 
prescription medicines.  
Furthermore, it is not well known what type of information patients are receiving at 
point-of-care in New Zealand compared to what patients want to know. The 2009 
review63 found that, in international studies, information on directions for use, dose, 
name of medicine, and indications were most commonly given. Medicine warnings 
such as precautions, side-effects, interactions, contra-indications were less likely to be 
given. A more recent Swedish observational study from 2014 found that pharmacists 
spent little or no time counselling patients about medicines with half of discourses 
about medical/pharmaceutical issues taking 10 seconds or less.150 A later study from 
the Netherlands showed not all necessary counselling points are covered adequately 
in pharmacy consultations.151 
Whilst many of these studies determined if specific points about medicines were 
covered, there is limited information on what verbal information is given to patients in 
New Zealand and no studies examining if the information that patients want to know 
is provided. The aim of this study was to determine from self-reports (i) how often GPs 
and pharmacists in New Zealand provide verbal information to patients about their 
medicines; (ii) compare the information given with findings from the authors’ recent 
review about what patients want to know about their medicines;109 and iii) make 
comparisons between the practices of both professions.  
Methods  
Questionnaire  
A questionnaire was developed (Appendix 3) based on previously validated 
questionnaires140 and the authors’ recent review investigating what details (or 
counselling points) patients’ want to know about their medicines.109 GPs and 
pharmacists were asked how often they gave verbal counselling about low-risk types 
of medicines (e.g. an asthma inhaler). Low-risk medicines (e.g. an asthma inhaler) 
were chosen because they are common in primary care and patients need adequate 
information to ensure appropriate and safe medicine-use. They were also asked how 
frequently they discussed specific counselling points about low-risk medicines and the 
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perceived importance of each point for repeat long-term medicines. This was to 
identify what counselling points were deemed important as a guide to see what may 
be discussed during a consultation with patients on chronic therapy. Mostly questions 
were designed for tick box selection of single responses and included the option of 
‘other’ where applicable. Where participants were asked to identify frequencies, most 
of the time was defined as more than half of the time, and some of the time was 
defined as less than half of the time. Three community pharmacists and three GPs 
were consulted during development by reading over and testing the questionnaires. 
Minor changes were made following this and the survey was piloted on a total of 10 
GPs and 10 pharmacists. The study was approved by University of Otago Human Ethics 
Committee (Reference number D16/298; Appendix 4).  
Recruitment 
A selection of GPs and pharmacists practising in New Zealand were invited to 
participate. Following a sample size calculation, it was estimated that 278 responses 
were required to detect a significant effect (α = 0.05 and 95% CI).152 To allow for low 
response rates153 600 GPs were selected for inclusion from a list obtained from the 
primary care advisory organisation bpacnz.154 Pharmacies were selected using the 
randomising function in Excel. Four hundred community pharmacies were identified 
for inclusion from a list created through publicly available records and other sources 
including the Pharmacy Guild, the School of Pharmacy, and Medsafe (the New Zealand 
medicines regulatory agency). Pharmacists were asked to participate through the 
selected community pharmacies and it was expected that 600 pharmacists would be 
reached. Invited participants were informed that survey participation implied 
informed consent. 
Data collection 
Questionnaires with a participant information sheet were emailed to potential 
participants in October 2016. Reminder emails were sent after one and six weeks. 
SurveyMonkey® was used to collect data from emailed contacts. Questionnaires and 
participant information sheets with a reply-paid envelope were posted to those 
pharmacies who did not have email addresses and those who did not respond to 
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email. To capture more responses, pharmacist questionnaires were linked to the 
Young Pharmacist group Facebook page in mid-October 2016 and reposted one week 
later. All participants had the option to enter into the draw to win a $100 or $50 
supermarket voucher as an incentive for participation. The survey was closed for 
analysis in January 2017. Demographic information was collected for each group 
including participant’s age, sex, and the location of their practice.  
Analysis 
The frequency of provision and the nature of verbal information given was analysed 
for new medicines, and also the perceived importance of the same information given 
to those taking long-term medicines. Quantitative data underwent descriptive 
statistical analysis using STATA 13.1. Responses from GPs’ and pharmacists’ were 
compared using post-hoc chi-squared (χ2(1)) analysis performed at the two-sided 0.05 
level. Fisher’s Exact test was undertaken when more than 20% of expected values 
were below 5. For the provision of verbal information analysis, the Likert scale was 
simplified by combining ‘never’ and ‘never, this is the role of the pharmacists/doctor’. 
For the analysis of counselling points for new medicines, the groups ‘all’ and ‘most of 
the time’ were combined, as were ‘never, the patient does not need to know this’ and 
‘never, this is the role of the pharmacists/doctor’. Missing data were reported as ‘no 
response’. 
Open responses were analysed by thematic analysis using an iterative approach by AY 
to detect further ideas.155 Qualitative data themes were identified and discussed 
amongst the research team. 
Results 
Demographics  
Responses from 119 pharmacists and 150 GPs were analysed and demographic 
characteristic are shown in Table 3. This gave a response rate of 19.8% for pharmacists 
and 25.0% for GPs. This included responses from 18 pharmacists through the 
Facebook page. Survey responses from 15 participants were removed from analysis 
because they had more than 20% missing data. 
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Table 3: Summary of participants 
Demographic GP group Pharmacist group  
Sex 
n (%) 
Male 58 (38.7%) 53 (44.5%) 
Female 83 (55.3%) 61 (51.3%) 
No response 9 (6.0%) 5 (4.2%) 
Age 
n (%) 
20-29 3 (2.0%) 27 (22.7%) 
30-39 32 (21.3%) 34 (28.6%) 
40-49 31 (20.7%) 18 (15.1%) 
50-59 50 (33.3%) 25 (21.0%) 
>60 25 (16.7%) 10 (8.4%) 
No response 9 (6.0%) 5 (4.2%) 
Location 
n (%) 
Major City (e.g. Auckland, Wellington, 
Christchurch) 
63 (42.0%) 59 (49.6%) 
Provincial City (urban area with a 
population over 30,000 people e.g. 
Hamilton, Dunedin, Nelson, New Plymouth, 
Napier, Gisborne) 
37 (24.7%) 30 (25.2%) 
Provincial Town (town with a population 
between 1,000 and 30,000 people e.g. 
Levin, Gore) 
28 (18.7%) 23 (19.3%) 
Rural (non-urban areas such as rural centres 
with population under 1,000 people) 
13 (8.7%) 2 (1.7%) 
No response 9 (6.0%) 5 (4.2%) 
Compared to the national population of GPs, respondents tended to be of a younger 
age group but similar distribution for gender.156 Pharmacist respondents were similar 
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ages, but less likely to be female than national representation.157 Geographical 
location was not analysed similarly in national surveys, so comparison was not 
possible. 
Providing verbal information  
For new medicines, significantly more GPs than pharmacists reported giving verbal 
information all of the time (75.3% vs 43.7% respectively, χ2(1) 28.0, p<0.001).  
For repeat medicines for chronic conditions only 5.3% GPs and 3.4% pharmacists 
stated they would give verbal information all of the time (Figure 6). For both 
professions, significantly more would advise patients only on request about their 
repeat medicines compared to a new medicine (GPs 13.3% vs 1.3% (χ2(1) 15.9, 
p<0.001)); pharmacists 37.8% vs 4.2% (χ2(1) 40.5, p<0.001)). 
 
Figure 6: Reported frequency for giving verbal information about new or repeated 
medicines
0% 10% 20% 30% 40% 50% 60% 70% 80%
GP: newly prescribed medicines
Pharmacist: newly prescribed medicines
GP: repeated medicines for chronic conditions
Pharmacist: repeated medicines for chronic conditions
All of the time Most of the time Some of the time Never Only on patient request
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Counselling points for new medicines  
GPs and pharmacists mostly agreed about how often they would discuss counselling 
points (Appendices 5 and 6), but their most common responses sometimes differed:  
 The generic and brand names of the medicine: GPs some of the time (56.7%), 
pharmacists all or most of the time (48.7%) 
 What to do if a dose is missed: GPs some of the time (54%), pharmacists only 
on patient request (52.9%) 
 How to monitor the treatment’s effectiveness (including when to come back if 
necessary): GPs all or most of the time (87.3%), pharmacists some of the time 
(37.0%) 
 Potential interactions: GPs all or most of the time (51.3%), pharmacists some 
of the time (43.2%) 
 General health tips that would improve treatment outcomes: GPs all or most 
of the time (70.7%), pharmacists some of the time (58.0%) 
 Storage and disposal of the medicine: GPs never (40.7%), pharmacists some of 
the time (44.5%) 
 Information about alternative therapies and treatment options: GPs some of 
the time (40.0%), pharmacists only on patient request (58.0%).  
All other counselling points were mostly discussed all or most of the time by both 
groups except ingredients in the medicine (e.g. lactose, sugar) and where patients can 
access further information about the medicine or condition were most likely to be 
discussed only on patient request. 
In response to an open question, a small number of pharmacists claimed to discuss 
technical issues such as funding or supply issues, stat dispensing, or repeat status. A 
few in each profession indicated they would discuss the use of a medicine information 
leaflet or website with their patients.  
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Types of information given all or most of the time 
Significantly more GPs than pharmacists reported giving most counselling points all or 
most of the time (p<0.05) (Table 4, and Appendices 5 and 6). More pharmacists than 
GPs reported counselling patients on some points (generic and brand name of the 
medicine and medicine storage and disposal) all or most of the time. No difference 
was seen between groups for how to take the medicine (administration instructions), 
missed doses, ingredients, and where patients can access further information about 
the medicine or condition. 
Table 4: Counselling points reported to be used all or most of the time for new, low-
risk medicines 








Significantly more GPs than pharmacists talk to patients about these points all or most of 
the time  




χ2(1)= 33.0, p<0.001 













χ2(1)= 16.3, p<0.001 
How to take the medicine: dose 





χ2(1)= 14.4, p<0.001 
How to monitor the treatment’s 
effectiveness (including when to 





χ2(1)= 109.1, p<0.001 
Monitoring requirements of the 





χ2(1)= 44.5, p<0.001 




χ2(1)= 5.9, p=0.015 
Side-effects and what to do if 





χ2(1)= 31.8, p<0.001 
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Significantly more GPs than pharmacists talk to patients about these points all or most of 
the time  
Lifestyle information (e.g. drug 
effect on driving, drinking, 





χ2(1)= 4.5, p= 0.03 
General health tips that would 





χ2(1)= 52.9, p<0.001 
Information about alternative 






χ2(1)= 7.0, p= 0.008 
Significantly more pharmacists than GPs talk to patients about these points all or most of 
the time  






χ2(1)= 14.9, p<0.001 






χ2(1)= 22.2, p<0.001 
No significant difference between GPs and pharmacists 






χ2(1)= 2.5, p=0.11 




χ2(1)= 0.2, p=0.63 






χ2(1)= 1.3, p=0.26 
Where patients can access 
further information about the 





χ2(1)= 0.3, p=0.59 
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Types of information given only on patient request 
Overall pharmacists were more likely than GPs to discuss counselling points when 
requested to do so by patients. Significantly more pharmacists than GPs claimed to 
discuss the following points only on patient request:  
 what the medicine is for (5.9% vs 0.7%, χ2(1) 6.3, p=0.012);  
 how the medicine helps the condition (26.9% vs 0.7%, χ2(1) 42.4, p<0.001);  
 contra-indications and precautions (21.8% vs 3.3%, χ2(1) 22.3, p<0.001);  
 how to take the medicine: dose and length of treatment (3.4% vs 0%, χ2 (1) 5.1, 
p=0.024);  
 what to do if a dose is missed (52.9% vs 24.7%, χ2(1) 5.6, p=0.018);  
 how to monitor the treatment’s effectiveness (including when to come back if 
necessary) (31.1% vs 0%, p<0.001, Fisher’s exact test);  
 monitoring requirements of the drug (if applicable) (25.2% vs 2.0%, χ2(1) 33.2, 
p<0.001);  
 potential interactions (19.3% vs 2.7%, χ2(1) 20.4, p<0.001); 
 side-effects and what to do if they are experienced (18.5% vs 0%, χ2(1) 30.2, 
p<0.001); 
 lifestyle information (e.g. drug effect on driving, drinking, sexual activity) (7.6% 
vs 0%, χ2(1) 11.7, p=0.001);  
 general health tips that would improve treatment outcomes (16.0% vs 2.7%, 
χ2(1) 15.0, p<0.001);  
 ingredients in the medicine (e.g. lactose, sugar) (80.7% vs 47.3%, χ2(1) 31.3, 
p<0.001).  
Other points did not have significant difference between professions although those 
more likely to be discussed by pharmacists only when requested were how to take the 
medicine: administration instructions, where patients can access further information 
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about the medicine or condition, and information about alternative therapies and 
treatment options. GPs were more likely to discuss storage and disposal of the 
medicine and the generic and brand names of the medicine only when requested, 
although no significant difference was found (see Appendices 5 and 6). 
Types of information given never discussed 
Significantly more GPs than pharmacists reported never counselling about:  
 storage and disposal of the medicine (40.7% vs 2.5%, p<0.001, Fisher’s exact 
test);  
 ingredients in the medicine (e.g. lactose, sugar) (39.3% vs 7.6%, χ2(1) 35.5, 
p<0.001);  
 where patients can access further information about the medicine or condition 
(7.3% vs 0.8%, χ2(1) 6.6, p=0.01); and  
 how to take the medicine: administration instructions (3.3% vs 0.0%, χ2(1) 4.04, 
p=0.04).  
Pharmacists reported never counselling significantly more than GPs about: how to 
monitor the treatment’s effectiveness (including when to come back if necessary) 
(7.6% vs 0.7%, χ2(1) 8.8, p=0.003) and monitoring requirements of the drug (if 
applicable) (8.4% vs 1.3% respectively, χ2(1) 7.8, p=0.005). Fewer than 10% of 
pharmacists stated they never counsel patients on any counselling point. 
Comparisons of the medicine information patients want to know with the information 
given by GPs and pharmacists can be seen in Table 5. 
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Table 5: Comparison of the medicine information most patients want to know with 
the information given by GPs and pharmacists 
Counselling points that most patients 
want to know 109 
GPs Pharmacists 




What the medicine is for 
 
 
How the medicine helps the condition 
 
 
Contra-indications and precautions 
 
 
How to take the medicine: dose and 
length of treatment 
 
 




What to do if a dose is missed  
 
 
How to monitor the treatment’s 
effectiveness (including when to come 
back if necessary)  
 
 




Potential interactions  
 
 






Counselling points that most patients 
want to know 109 
GPs Pharmacists 
Lifestyle information (e.g. drug effect 
on driving, drinking, sexual activity)  
 
 




Storage and disposal of the medicine 
 
 




Where patients can access further 




Information about alternative therapies 
and treatment options 
 
 
given all or most of the time by more than 75% of responders 
given all or most of the time by most, but less than 75%, of responders 
given all or most of the time by most, but less than 50%, of responders 
given some of the time by most responders 
given never, or only on patient request by most responders  
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Information for patients with repeat medicines 
GPs and pharmacists were asked to evaluate the importance of each counselling point 
for users of long-term medicines. Overall, significantly more GPs than pharmacists 
were likely to consider most counselling points very important and pharmacists were 
more likely to consider counselling points not important (Table 6, Figure 7, and Figure 
8). The three counselling points considered very important by most GPs were what the 
medicine is for, how to take the medicine: dose and length of treatment, and how to 
monitor the treatment effectiveness.  
Table 6: Counselling points viewed as very important for patients’ low-risk repeat 
medicines 








Significantly more GPs than pharmacists considered these points very important  






















How to monitor the treatment’s 
effectiveness (including when to come back 



































Significantly more GPs than pharmacists considered these points very important  







Where patients can access further 






Information about alternative therapies and 






Significantly more pharmacists than GPs considered these points very important 







No significant difference in views between GPs and pharmacists 












Lifestyle information (e.g. drug effect on 










χ2(1)=3.4, p= 0.06 










Figure 7: Counselling points considered very important for repeat medicines 
 
Figure 8: Counselling points considered not important for repeat medicines 
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In response to an open question a small number of pharmacists indicated that patient 
counselling in the current session depended on what was covered in a previous 
session. Likewise, a few in each profession indicated the key points covered would 
depend on patient need or type of medicine being taken.  
Discussion 
This study suggests some patients in New Zealand may not be receiving adequate 
information about their newly prescribed medicines. Ongoing communication and 
education about medicines appears even less likely when they are prescribed for 
chronic conditions. Furthermore our previous review investigated what information 
patients want to know about their prescribed medicines and determined that specific 
information is often desired.109 For this study, we labelled the specific information as 
“counselling points” (Tables 5 and 6) and determined if GPs and pharmacists discuss 
these points with their patients. The present study indicates that patients are often 
not given the specific information they desire. Self-reports suggest New Zealand GPs 
discuss most counselling points more frequently than pharmacists; pharmacists are 
more likely to discuss the medicine formulation and administration. Many counselling 
points are discussed only if requested by the patient. 
Significantly more GPs than pharmacists considered most counselling points very 
important for repeat medicines. Nevertheless, the results from this study suggests 
that counselling patients with repeat medicines is not regular practice for either 
profession.  
Providing verbal information  
The present study suggests GPs and pharmacists do not verbally inform patients about 
new medicines all of the time. Three quarters of GPs and less than half of the 
pharmacists reported doing this. This is in contrast to studies in Australia where 
pharmacists and consumers indicate information is given all of the time with new 
medicines.140 Though as discussed earlier the counselling rates varied hugely and was 
more positive in self-reports.63 Methods other than self-reports, including mystery 
shoppers and direct observations tend to have lower observed counselling rates.63, 146, 
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147 Informing patients about their medicines before they start treatment is written 
into New Zealand health professional standards.43, 75 The fact that many respondents 
indicated they do not orally communicate with patients all of the time highlights the 
difference between ideal practice and what can be achieved in the real world.  
For repeat medicines, the majority of participants said they would only give 
information some of the time. However compared to new medicines, more GPs and 
pharmacists would rely on patients requesting the information rather than giving it 
spontaneously, possibly because of an expectation that patients will remember what 
has been told to them previously.63 
It is worth noting that GPs report more frequent verbal counselling than pharmacists 
for new and long-term medicines. This may be because (i) GPs have a one-to-one 
counselling opportunity, (ii) the professionals perceive their roles differently and (iii) 
pharmacists could lack information (e.g. medicines indication) required to counsel 
effectively.158 Nevertheless, there is an opportunity for pharmacists to take a more 
proactive role in informing patients about their medicines. However, community 
pharmacies in New Zealand may struggle to engage in thorough clinical counselling for 
every patient with every visit, and the stresses of fitting in all the required counselling 
into the available time is a concern facing both professions. This is also a problem 
facing pharmacists internationally where pharmacy income is based on number of 
items dispensed or sold rather than patient counselling.150 Furthermore, lack of time is 
of international concern in community pharmacy practice and is often identified as a 
barrier to provision of services.159  
Given the above, healthcare providers should be encouraged to provide patients with 
an appropriate information leaflet about medicines. This will help ‘fill in the gaps’ 
around counselling points that are unable to be covered at the time. This would also 
be beneficial for patients who are unwilling to receive counselling at point-of-care.26, 
150 This is of particular importance in countries like New Zealand and Australia where 
providing information leaflets to patients is not mandatory as it is in the UK.26, 40, 160 
Less than a third of patients in Australia may receive leaflets.26  
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Counselling points for new medicines  
Most guidelines recommend that counselling about medicines should satisfy the 
needs of the patient.43, 63, 161 In the present study, only what the medicine is for, how 
the medicine helps the condition, and the dose and length of treatment are reportedly 
discussed all or most of the time by over 90% of GPs (see Appendix 6), which was 
much higher than reported by pharmacists. Furthermore, GPs appear to discuss other 
counselling points with patients more often than pharmacists. However, what 
happens in actual practice was not determined.  
Patients often feel they are not getting all the information they want.15, 40 The 
literature highlights the disparity between what health professionals consider patients 
should know, and what patients themselves want to know.8, 15, 63, 109 Health 
professionals more frequently discuss how to take the medicine and how the medicine 
will help the condition 63 to aid compliance and decision making.  
In the present study, almost all GPs and over half of pharmacists reported discussing 
this with patients all or most of the time. In comparison, most patients are more likely 
to be concerned about the risks of the medicines (including side-effects, potential 
interactions, and precautions).2, 26, 28, 162 Nevertheless, this information is sometimes 
intentionally withheld by prescribers.2, 63 In this study, GPs and pharmacists were less 
likely to discuss these risks all of the time or most of the time compared to discussing 
the possible benefits. Consistent with other studies, both professions frequently 
commented that giving side-effect information would increase patients’ anxiety and 
reduce compliance.2, 26, 63 A recent Swedish study demonstrated that community 
pharmacists spend very little, if any, time discussing clinical medicine information.150 
In this study, only the medicine name, ingredients, administration, storage and 
disposal instructions were predominantly provided by pharmacists (see Appendix 5). 
This was consistent with the Swedish study where pharmacists only discussed ‘non-
medical’ counselling points.150 In Australia, however, pharmacists reported frequently 
discussing a wide range of counselling points with prompting from a consumer 
medicine information leaflet.26 Possibly using counselling tools and medicine 
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information leaflets as prompts for discussion in practice could help improve the 
information being provided to patients by pharmacists.  
The counselling point General health tips that would improve treatment outcomes is 
an important addendum to medicine counselling to optimise treatment outcomes. 
Ideally this should be given with all prescriptions to optimise benefits. Over two-thirds 
of GPs in this study reported providing this information, but only about a quarter of 
pharmacists reported this. Counselling about lifestyle interventions (e.g. diet and 
exercise) is essential, particularly for conditions linked to the growing obesity epidemic 
where modifications can have huge benefits for patients’ morbidity.  
Counselling points appeared to be discussed by both professions to varying degrees. 
Many counselling points were frequently only discussed when requested by the 
patient. This indicates patients would not receive the information because many 
would not think to ask about these individual points. These findings emphasise the 
need for other methods of educating patients, such as providing information leaflets 
to patients for both new and repeat medicines, to ensure patients are receiving the 
required information if it is not given verbally. 
Information for patients with repeat medicines 
In the present study, GPs viewed counselling points as very important more frequently 
than pharmacists. However, most GPs claimed they only discussed repeat medicines 
some of the time (i.e. less than half of the time). This suggests possible discrepancies 
between aspirations and practice and it has been demonstrated that self-reports may 
show more positive outcomes than observational studies.63 
Less than half the pharmacists considered any particular counselling point very 
important. It has often been demonstrated that after the first dispensing, patients are 
less likely to be counselled about their medicines.63, 140 This may be due to time 
constraints,139 patients not wanting further information,26, 140 or the incorrect 
assumptions that patients remember what they have been told during initial 
discussions.138 Of note, slightly more GPs considered the positives (what the medicine 
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is for and how it helps the condition) than the negatives (risks of the medicine) very 
important which is a common opinion of health professionals.2  
Limitations 
Selection bias may have arisen due to the nature of recruitment, with participants 
interested in patient education possibly more likely to respond. Further bias could 
have resulted from participants incorrectly reporting practices; this was potentially 
mitigated with anonymity in survey responses.  
Busy health professionals may have low response rates to surveys.153 However, the 
response rate was lower than expected and although statistical differences between 
the groups were demonstrable, the results may lack substantive significance in 
practice.  
Because of the above, the findings are only indicators of what may be occurring in 
practice. Further research is necessary before drawing conclusions about medicine 
counselling more widely in New Zealand practice. The questions in the survey did not 
quantify the information given so it was not possible to know the extent or quality of 
information given. It was also not determined if respondents used counselling aids 
during consultation, such as medicine information leaflets, so complete methods of 
patient education used could not be elucidated. 
Conclusion 
Results from this study indicate that patients in New Zealand are likely to receive 
some verbal information with new medicines all or most of the time from GPs or 
pharmacists. With chronic therapy, continuing medicine counselling is less likely. The 
question remains if this is sufficient for their needs in these situations. Furthermore, 
the information provided by health professional groups may differ. General 
practitioners report they are more likely than pharmacists to discuss many counselling 
points including the clinical information (purpose of the medicine, how it might help 
the patient’s condition). Pharmacists are more likely than GPs to advise on practical 
aspects (how to administer the medicine, medicine formulation). Some information 
may only be provided if requested by the patient. Neither profession appear to 
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consistently cover all of the counselling points that the literature suggests patients in 
general want to know for both new and repeat medicines. Adequate verbal 
counselling about medicines may be difficult to achieve in practice. The use of 
counselling aids and tools such as medicine information leaflets should be 
encouraged, when leaflet provision is not mandatory, to ensure patients have access 
to information they need. 
3.4 Methods, further information for the GP and 
pharmacist studies 
Two surveys were created for this project, one investigating verbal counselling 
practices (as discussed in chapter 3), and one investigating the use of, and opinions 
on, medicine information leaflets (discussed in chapter 4, sections 4.3 and 4.4). These 
surveys were sent to both GPs and pharmacists in New Zealand. In the interest of 
brevity, the additional methods described below relate to both of these surveys. 
Figure 2 (xxviii) shows how the research questions map to the research objectives of 
the thesis. 
Rationale of methods chosen 
Quantitative questions 
A quantitative method was chosen to statistically analyse responses and compare 
findings to similar international research, as well as comparing practice between 
pharmacists and doctors. A survey with quantitative questions could also potentially 
obtain a larger sample of people than a qualitative study and be more able to assure 
generalisability of the findings. 
Scales were used in parts of the surveys to gather quantitative data. Due to limits on 
individual cognitive processing and ability to recall, we used scales as estimation 
strategies, as is typical practice. We based our scales on similar studies;140 However, 
we thought if we used short scales (Yes/No/Do not know) we might miss some high 
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quality data, so to allow for more discriminating data we had more options for 
response.  
Qualitative questions 
Where we felt that further strength and depth could be added to the research 
findings, we included some qualitative questions for analysis. These were included 
where we wanted information about participants’ perceptions and we wanted to 
understand the reality of practice, and participants to explain in their own words ‘why’ 
they acted as they did in practice. 
Questionnaire validity  
The questionnaires were developed based on previously validated questionnaires.140 
Questions added were extensions of the concepts investigated in this larger Australian 
study.  
In the present study, a research team consisting of academics, pharmacists and a GP 
were consulted and provided feedback on the validity of the questions. Face and 
content validity were determined from having the research team involved in 
questionnaire creation to ensure suitability and comprehensibility to target groups. 
The research team focused on these three concepts:163 
1. Content standards (will questions determine what we want to know?) 
2. Cognitive standards (are questions able to be understood and responded to 
appropriately and consistently?)  
3. Usability standards (can the survey instrument be easily completed as intended?). 
The research team assessed whether the content of the questions is measuring the 
intended concepts and whether other aspects were missed and needed addressing, 
and whether the questions met the cognitive and usability standards (i.e. checked that 
questions were clear and unambiguous). Concurrent validity was assured by 
comparing responses to other validated surveys140 with many comparative results 
being obtained. Construct validity was considered by reviewing whether based on 
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relevant existing knowledge, and the questions included were relevant to measure 
what was intended by the research team. 
Following the creation of the questionnaire and expert review, the questionnaires 
were pilot tested in a small subset of the intended population (20 GPs and 
pharmacists) using the same modes of data collection as proposed for the study. This 
was to assess readability and understanding. When piloted, we included three extra 
questions: 
1. Did you have trouble understanding the questions? 
2. How did you find the length of the survey?  
3. Did you feel you could answer the questions truthfully?  
Responses to the first question identified an error in the web-based survey program 
that needed amending, and a clarification needed around one question in the survey 
(we changed ‘on patient request’ to ‘only on patient request’ in the verbal counselling 
questionnaire). One respondent thought the survey too long, but others thought it 
was fine so no change was made to the length. All who contributed responded that 
they could answer truthfully. 
The verbal counselling questionnaire was estimated to take 10 minutes to complete 
and the use of, and opinions on, medicine information leaflets survey was estimated 
to take 15 minutes to complete. 
Survey dissemination 
We determined the sample size needed for each group to be 278,152  based on the 
estimation that there are approximately 1000 GP practices and over 900 community 
pharmacies in New Zealand. We chose a 95% confidence interval with a significance 
level set at 0.05. (α = 0.05 and 95% CI). To allow for low response rates,153 we aimed 
to recruit 600 GPs and 600 pharmacists for participation.  
Email was chosen as the most appropriate method of reaching large numbers of 
health professionals as it is a rapid method of communicating. In addition, we could 
send a direct link to an electronic survey with easy-to-use software. We also had 
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access to email lists so we felt that this would be a convenient and suitable means of 
sending a survey. We wanted to be cautious with the reminders, to avoid annoying 
potential participants. Both groups are busy health professionals and are often 
contacted by universities to complete surveys. Therefore, we decided that we would 
send out the initial reminder after one week. This seemed appropriate for those who 
might have intended to complete the survey later, but lost it in their emails. We 
considered that another attempt at the six-week mark might perhaps capture those 
who had not wanted to complete it at the time but who were now more willing to do 
so. We thought that two reminders would be sufficient and further attempts might 
cause annoyance. 
We mailed out a paper copy of the surveys to pharmacies without known email 
addresses. Additionally, it became apparent that we were not receiving the numbers 
of responses we were aiming for from pharmacy, so we posted paper copies on 18 
November 2016 to encourage those who had not responded to the email request for 
participation. (This was two days after their second email reminder and just over six 
weeks after their original email). For the verbal counselling practice survey (chapter 3) 
we received 48 responses from pharmacists by post (out of a total 119) and for the 
use of, and opinions on medicine information leaflets survey (chapter 4) we received 
51 responses from pharmacists by post (out of a total 126). 
The pharmacist surveys were also posted on Facebook after low completion rates 
were identified in the pharmacist group. The Facebook page used was the “New 
Zealand Young pharmacists” group. This is a private group set up on Facebook for 
young practitioners in New Zealand. We decided that it could also provide useful data 
from pharmacists who are from a younger demographic than pharmacy owners, who 
may be the people with access to post and email and be more likely to receive the 
other surveys sent by post or email. However, the impact on responses was small. 
There were only 18 further respondents in the verbal counselling practice survey 
(chapter 3) and 16 respondents in the use of, and opinions on, medicine information 
leaflets survey (chapter 4). 
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3.5 Limitations, further information 
The limitations in this section describe the limitations of the studies in chapter 3 and 
chapter 4 of this thesis. 
General limitations of the studies 
Questionnaire 
Whilst validity was determined for the survey, there was no statistical investigation 
into the reliability of the instrument. This lack of statistical analysis on reliability is a 
limitation of this and other questionnaires used in this thesis.  
Recruitment 
The databases of GPs and pharmacies used to recruit from were substantial but not 
exhaustive for all GPs and pharmacies in New Zealand. We acknowledge that we may 
not have captured all the possible ones in New Zealand by using our list. The GP 
database included a large proportion of the GP workforce, however, it did not list 
every practising GP, and there were some who contacted us stating they no longer 
practised. Because we had originally contacted many more than required by the 
sample size calculation, we did not add any more to our email list for inclusion.  
The limitations of using the pharmacy database was that the email or letter only went 
to the pharmacy, not individual pharmacists. Thus only one person might have 
responded out of a possible multiple number of pharmacists. We tried to counteract 
this with using the Facebook group and also by encouraging those participants in 
pharmacies to ask their colleagues to complete the survey and/or be willing to be sent 
the other survey investigating the other topic. The limitation of using the Facebook 
group for recruitment was that we could not estimate the sample size we were trying 
to recruit from. The group currently (as of 2021) has 1255 members but we could not 
adequately determine the number of users who saw the post. This affects the 
response rate; however, we had very few responses from Facebook (18 in the verbal 
counselling practices survey (out of a total 119) and 16 in the use of, and opinions on, 
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medicine information leaflets survey (out of a total 126)) and it can be considered the 
overall the impact from this group is minimal. 
Furthermore, a two-pronged approach to survey dissemination, the print and posted 
and web-based survey, was utilised to recruit for the pharmacy group. Web-based 
surveys are less costly and were our intention, but we did not have email contact 
details for all pharmacies whereas the postal addresses were all publicly available. A 
mixed-mode strategy (mail and web-based survey delivery) may minimise non-
response so that is a benefit of undertaking this strategy.164 However, there is a risk 
that different visual layouts for questions may produce different responses from 
participants165 and this phenomenon was not explored as differences between web-
based responses and mailed responses were not evaluated. 
Response rate and participants 
The questionnaire investigating use of, and opinions on, medicine information leaflets 
took approximately 5 minutes longer to complete than the verbal counselling 
questionnaire and there were more participants who had more than 20% of responses 
missing (29 removed compared to 15). The questionnaire may have been too long for 
busy professionals to complete.  
The low number of responses to both studies has an impact on the power of the 
findings. Therefore we cannot reject the null hypothesis to say there is a difference 
between the groups (all GPs compared to all community pharmacists). The low 
response rate also prevented us from performing more in-depth statistical analysis 
with the data. We can only say there was a difference between our groups of 
respondents, but this may not be able to be extrapolated to whole population of GPs 
and pharmacists. Whilst disappointing that we could not achieve our aim for 
recruitment we felt that the results do provide an estimate of what is happening in 
practice and we were still able to get valuable information from individual GPs and 
pharmacists about their opinions and experience. 
The demographics of respondents in both surveys differed slightly to the population of 
GPs and pharmacists in New Zealand. Compared to the national population of GPs, 
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respondents tended to be of a younger age group.156 With regard to informing 
patients about medicines, younger GPs’ experiences, attitudes, and techniques may 
differ from those of older GPs. Arguably capturing their attitudes and opinions is very 
important as the younger ones are the future of general practice, which is a known 
aging workforce with a large population due to retire within the next 10 years.156 
Therefore, weighted capturing of the younger groups opinions may be pertinent to 
understand what will be happening in the future. The pharmacist participants had a 
similar age distribution to the national cohort, but more males participated in the 
research compared to national cohort of male to female ratio.157 Despite this, there 
were still more female than male respondents in the pharmacy group for both 
surveys. It has been suggested that  female pharmacist can have increased job 
satisfaction through increased interactions with patients compared to males.166 
However, conclusions for this difference could not be drawn because comparison in 
responses between genders was not undertaken. 
Limitations of self-reports 
Bias in any form will impact the generalisability of findings in research. A common bias 
that may have resulted in the recruitment process of these studies is selection bias. 
Selection bias can result in people choosing to participate in a study because they 
have a strong opinion about the concept investigated. However, the responses 
displayed diverse opinions, with a wide variety of thoughts expressed. Because of the 
wide spectrum of data gathered it could be assumed that selection bias for or against 
a concept was not an issue in these investigations.  
This section will briefly describe another such bias commonly introduced when using 
questionnaires to describe participant behaviour and the actions taken to minimise 
risk.  
These studies utilised a questionnaire for GPs and pharmacists to complete, with a 
focus on how they inform patients about their medicines. A limitation of this method 
is the reliance on true-reporting from the participant. It has long been recognised that 
some participants feel a social desirability to report attitudes or activities that present 
them more favourably to the research team. Inaccuracy in self-reporting can arise 
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from intentionally responding incorrectly to questions, or through ‘self-deception’ 
where participants believe the incorrect information they are reporting to be true.167, 
168 This phenomenon is called social desirability bias (SDB) and has been concerning 
for those undertaking survey-based research for many decades.168, 169 
There are several methods for estimating potential social desirability bias in surveys, 
varying in complexity and degree of validation.169 However, health care professionals 
response to surveys can be low153 and inclusion of a social desirability scale section of 
the questionnaire would have negatively impacted response rate due to question-
overload. In view of this, the research team identified ways to minimise SDB within 
the questionnaire responses. These included using a questionnaire format, rather than 
an interview or focus group;167 ensuring that participant anonymity is upheld;168 and 
basing the surveys on previously validated questionnaires.140 Furthermore, when the 
questionnaires were piloted, we asked participants if they felt they could answer the 
questions truthfully and all of the pilot participants responded yes to this question. 
However, we acknowledge that the risk of SDB is high even if responses are 
anonymous when there is both patient and fellow health professional expectations 
about certain professional standards of care that participants should conform to.167 
This was also potentially mitigated by having two differing questionnaires sent to 
different health professionals; one for verbal counselling and one investigating use of 
written communication for counselling (see chapter 4). This split was purposeful 
because although informing patients about medicines in New Zealand is mandatory, 
guidelines do not specify what format this must be in. Thus some practitioners may 
prefer verbal discussion and not provide information leaflets and others may prefer 
leaflets and be less inclined to provide patients with a full verbal description of their 
medicines. This split was successful because responses by participants did not display 
overly favourable results for either profession and proved that improvement in both 
practices is still required. In the future, when investigating the current delivery of 
health information practices, adopting a validated technique to determine the 
potential social desirability bias when respondents are participating in questionnaires 
would be useful. 
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3.5 Chapter conclusion 
This chapter described what GPs’ and pharmacists’ discuss with their patients about 
their new and repeated medicines through self-reports. The study examined the 
frequency of provision of certain counselling points (i.e. those identified in chapter 2) 
and the perceived importance of these for patients being prescribed repeat medicines 
for chronic conditions.  
In general, GPs reported they discuss patients’ medicines with them more often than 
pharmacists when they are prescribing new medicine. However, it is apparent that 
patients could be prescribed and dispensed a new medicine without receiving 
adequate verbal information from their GP or pharmacist. Some patients may not 
think to ask for specific information when talking to their GP or pharmacist at point-of-
care, and so may miss useful information about their treatment or need to look 
elsewhere for information.  
Both health professions reported they are more likely to only discuss repeat medicines 
with patients some of the time or if requested by the patient. This is an 
understandable finding since the information may have already been covered and 
some therapies may have been safely taken for a number of months or years. Knowing 
that patients struggle to remember what they have been told about their medicines 
and in some cases may have been given inadequate information in the first place it 
would seem prudent to continue to discuss the medicine with the patient as 
treatment continues—perhaps it could be incorporated in an annual medicine review. 
The type of medicine investigated in this study was low-risk type of medicine (though 
no medicine is considered risk-free from causing harm) so it could be assumed that for 
high-risk medicines these health professions may have more stringent verbal 
counselling practices. In saying this, it is a requirement that all patients must be fully 
informed about their medicines, not just those receiving high-risk medicines. 
The findings from this self-reporting survey leads to the unmistakeable conclusion that 
verbal communication cannot be relied upon in practice because it is not adequately 
accomplished by GPs or pharmacists for every patient given new medicines. Even 
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when verbal communication about medicines is undertaken at point-of-care, not all 
information that patients want to know is discussed with them. Although improving 
verbal communication with patients is important, it is an unrealistic goal to discuss 
every aspect of information about medicines at point-of-care. Patients must be 
provided with other forms of information such as medicine information leaflets or 
links to reputable websites to ensure they know about the medicines they are taking. 
We examine this further in chapters 4 and 6. 
The limitations of this research include social desirability bias and the small number of 
participants. Although some measures were taken to minimise bias, a larger study is 
needed to make comprehensive and certain recommendations for a change in clinical 
practice. 
Examination of New Zealand GPs and pharmacists opinions about medicine 
information leaflets, the delivery of leaflets to their patients, and discussion about 
ways in which provision of written information could be improved is reported in 
chapter 4.       
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Chapter 4: Leaflet provision in New 
Zealand 
4.1 Synopsis 
The previous chapter identified that patients are not receiving all of the medicine 
information they want to know via discussions with their GPs and pharmacists. 
Verbally discussing information with supplementary written communication is ideal. 
However, if verbal communication is not up to the appropriate standard, routine 
provision of an information leaflet should then be considered as a minimal 
requirement for ensuring patients are knowledgeable of their treatment benefit and 
potential harms. We wanted to determine if patients are receiving medicine 
information leaflets to fill the gaps in verbal communications from their GP or 
pharmacist. 
This chapter analyses self-reports and opinions given in two studies. The first study 
involved GPs and pharmacists (sections 4.3 and 4.4), investigating their provision and 
opinions of medicines information leaflets. We ascertained from self-reports that GPs 
and pharmacists are not giving medicine information leaflets to their patients all of 
the time, however most GPs and pharmacists agreed that leaflets should be provided 
to patients when they are given a new medicine. There are many reasons that GPs and 
pharmacists liked and disliked the leaflets available to them, which could influence 
their provision. Having summary and/or tailored leaflets available, more time with 
patients, and automatic prompting in software at point-of-care could improve leaflet 
delivery.  
The second study involved patients (section 4.5), investigating how they are provided 
with medicine information leaflets from their GPs and their opinions of these. We 
found that in the last six months most patients had not received a leaflet from their 
GP, although the majority of participants thought it was important, particularly with 
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newly prescribed medicines. Most patients who received leaflets liked them, and 
found them easy to read and understand.  
These studies show that patient information leaflets about medicines are considered 
important by health professionals and their patients, however the provision of leaflets 
could be improved in practice. 
Chapter structure 
This chapter has three distinct parts: 
1. Provision of medicines information leaflets and how they are perceived by 
health professionals. Section 4.3 describes the findings from a study investigating 
whether New Zealand general practitioners (GPs) or pharmacists give medicine 
information leaflets to their patients, where they source these leaflets from, how 
they provide leaflets to their patients, and what they like and dislike about the 
leaflets that are available. This section includes a published manuscript. 
2. Using websites for medicine information and improving provision of leaflets 
Section 4.4 expands on the information from the first section, investigating 
whether GPs and pharmacists recommend websites to patients to read about 
their medicines. It also investigates what GPs and pharmacists think would 
facilitate the provision of leaflets in their practice. This section includes a 
published manuscript. 
3. Patients’ opinions on medicines information leaflet provision and usefulness. 
Section 4.5 describes the findings from a study investigating, from a patient’s 
perspective, GPs’ provision of medicine information leaflets. It also determines if 
patients like the leaflets given to them, how they use them, and if they want 
leaflets to be provided by their GPs. This section includes a published manuscript. 
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4.2 Chapter aims  
Providing patients with written information along with verbal communication 
optimises their ability to understand and recall information about their medicine. This 
chapter aims to examine New Zealand GPs’ and pharmacists’ opinions about medicine 
information leaflets, their delivery of leaflets to their patients, and determine ways in 
which provision of written information could be improved. 
Specific aim 1: To examine self-reported provision of medicine information leaflets by 
New Zealand GPs and pharmacists. 
Specific aim 2: To examine what GPs and pharmacists like and dislike about the 
leaflets currently used in practice, and to determine whether they support tailoring of 
information leaflets to patients’ needs. 
Specific aim 3: To determine how often GPs and pharmacists recommend websites to 
patients to read information about their medicines.  
Specific aim 4: To understand why GPs and pharmacists do not use medicine 
information leaflets and to explore factors that might improve written medicine 
information provision to patients. 
Specific aim 5: To examine patients’ estimations of receiving leaflets from their GP and 
their opinions and uses of the leaflets that they have been given. 
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4.3 Provision of medicines information leaflets and how 
they are perceived by health professionals 
Published Manuscript Entitled Doctors and pharmacists provision and 
opinions of medicines information leaflets in New Zealand 
The manuscript entitled “Doctors and pharmacists provision and opinions of 
medicines information leaflets in New Zealand” was published in the Int J Clin Pharm 
2018;40(3):676-85.  
The co-authors contributed to the manuscript as follows: Survey creation, execution, 
analysis, and write-up was performed by PhD candidate Amber Young, under the 
supervision of Dr Alesha Smith and Associate Professor June Tordoff. Dr Sharon Leitch 
provided advice from a practicing general practitioner perspective. All the co-authors 
revised the content of the manuscript and approved the final version for publication. 
The PhD candidate Amber Young was the lead author in manuscript preparation and 
writing, and corresponding author. 
The manuscript is presented as accepted for publication; however, the numbering of 
the pages, figures, and tables has been adjusted in accordance with the style of this 
thesis. All references from the manuscript can be found in the section ‘References’ at 
the end of the thesis. Further details of the methods used and limitations of this study 
are described in section 3.4 Methods, further information and section 3.5 Limitations, 
further information.  
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4.3.1 Doctors and pharmacists provision and opinions of 
medicines information leaflets in New Zealand. 
Amber Young*, June Tordoff, Sharon Leitch, Alesha Smith 
* Amber.young@postgrad.otago.ac.nz  
Abstract 
Background: Providing verbal medicines information to patients may be insufficient. 
Medicine information leaflets could benefit provision, however New Zealand health 
professionals’ opinions or use of leaflets is unknown.  
Objective: To examine self-reported provision and health professionals’ views about 
medicine information leaflets and to determine their support for tailoring patient 
leaflets.  
Setting: A cross-sectional survey of general practitioners (GPs) and community 
pharmacists in New Zealand primary care. 
Method: GPs and pharmacists completed validated questionnaires. Data was collected 
using SurveyMonkey® and where applicable, chi-squared analysis was carried out. 
Main outcome measures: Frequency of leaflet provision, how leaflets are used in 
practice and why, likes and dislikes of available leaflets, and opinions on providing 
tailored information.  
Results: 143 GPs and 126 pharmacists responded. For new medicines, significantly 
more pharmacists than GPs reported providing leaflets all or most of the time. For 
repeat medicines, leaflets were more likely to be given only on request. Leaflets were 
given to ensure patients are well-informed. Most GPs and pharmacists report 
discussing sections of leaflets with patients. The likes and dislikes of leaflets were 
mostly about design and content. Both professions support tailoring leaflets to meet 
individual’s requirements. 
Conclusions: Provision of medicines information needs to be re-evaluated. Relying on 
verbal communication is inadequate and leaflet provision appears to be suboptimal. 
Making leaflets more patient-centred and accessible could improve health 
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professionals’ perceptions and use of them. Automated creation and provision of 
tailored summary leaflets would be beneficial. Further advantage could be gained by 
digital patient access. 
Keywords medicine information; counselling; patient information leaflet; patient 
education; tailored information; New Zealand 
Impact Statements: 
 GPs and pharmacists should consider using medicine information leaflets 
regularly as a counselling tool. 
 The provision of medicine information leaflets for repeat long-term medicines 
should be encouraged. 
 Access to suitable medicine information leaflets needs to be improved for use 
at point-of-care. 
Introduction 
Patients receive variable amounts of verbal medicine information from health 
professionals7-9, 63 and leaflets may be a key source of medicine information.40 Recall 
of verbal information given at point-of-care is known to be low,7, 9, 26, 28 particularly if 
the patient is anxious.15 Providing verbal and written information helps ensure 
patients learn important issues about their medicines.13, 15, 26 Leaflets can reinforce 
information from a consultation,3, 9, 63 allow involvement in treatment decisions,2, 3, 7, 9, 
66 and improve treatment adherence.170-172 Using a leaflet during 
consultation/counselling can emphasise important issues, such as how to recognise 
side-effects and other risks of treatment.3, 143 Leaflets are also useful resources for 
patients to refer to later.2  
In many countries, prescription medicines are legally required to be supplied with a 
medicine information leaflet.110, 112 However, where this is not compulsory, as in New 
Zealand, leaflets may be given infrequently by GPs or pharmacists or only if 
requested,26, 173 and leaflets for all medicines may not be available. Although leaflet 
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provision in New Zealand is not mandatory, ensuring patients are fully informed about 
their treatment is a legal and ethical obligation.3, 42, 75 A New Zealand survey in 2001 
(n=344) found only 2.1% of patients reported a leaflet being their primary source of 
information about prescription medicines.16 In New Zealand there are numerous 
available medicine leaflets including the manufacturer provided information (known 
as Consumer Medicines Information (CMI) in New Zealand and Australia or 
internationally as Patient Information Leaflets (PILs)), as well as others written by 
various health bodies.160 Unfortunately, the regulatory guidance for those creating 
leaflets for New Zealand consumers is not as robust as countries where there is 
legislation surrounding this and leaflets may not be written according to good-design 
principles.160  
All-purpose information leaflets are often disliked by patients and healthcare 
providers and are not used (particularly manufacturers’ versions), because they are 
too lengthy, difficult to navigate, and contain complex terminology.4, 40, 48, 65, 66, 173 
When health professionals do not like leaflets, there is little likelihood they will 
encourage patients to read them, as has been described internationally.2 Improving 
health professionals’ views on information leaflets may change the way they give 
them to patients e.g. discuss them with their patients rather than not acknowledging 
their availability. Tailoring information to patients’ characteristics and needs might 
produce a more useful resource for patients4, 78, 109 and improve health professionals’ 
perceptions and provision of leaflets. However there is little research on this topic in 
New Zealand. Because patients’ perception and use of the information of leaflets can 
be influenced by their health professional, investigating health professional opinions 
of leaflets could improve their utilisation of them in New Zealand and internationally. 
Aim 
The aim of this study was to i) examine self-reported provision of medicine 
information leaflets by New Zealand General Practitioners (GPs) and pharmacists; ii) 
examine their views on available leaflets; and iii) determine whether they support 








Structured questionnaires were developed by the research team (AY), from previously 
validated questionnaires (Appendix 7).140, 173 One questionnaire was written for GPs 
and one for community pharmacists with input from GPs and pharmacists for validity 
to New Zealand practice. The survey was piloted with 20 GPs and pharmacists in total 
and minimal changes made. For frequencies, most of the time was defined as more 
than half of the time, and some of the time defined as less than half of the time. 
Questions were asked about low-risk types of medicines (e.g. an asthma inhaler) 
because these are commonly given and, although low risk, still require adequate 
information provision to ensure appropriate use.  
Health professionals indicating they use information leaflets with patients were 
entered in to a subgroup with additional questions to determine how and why they 
use medicine information leaflets, and what they like and do not like about the 
leaflets they use. 
Data collection 
Sample size calculations estimated 278 responses were required to detect significance 
at a level of p<0.05 with 95% confidence.152 A list of GPs was obtained from Best 
Practice Advocacy Centre New Zealand,154 and 600 were randomly selected and were 
invited to participate. A list of New Zealand pharmacies created from a variety of 
sources (including the Pharmacy Guild, School of Pharmacy, Medsafe and publicly 
available records), was used to select 400 pharmacies where 600 pharmacists were 
expected to be reached. 
In October 2016, the questionnaires and a participation information sheet were sent 
via email to the selected participants using electronic survey software 
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SurveyMonkey®. A reminder email follow-up was sent to those who had not 
responded after one and six weeks. Pharmacies without a known email address were 
mailed a hard-copy survey and participation information sheet. Following low initial 
responses, a paper copy was sent in November 2016 to pharmacists who did not 
respond. Paper responses were manually entered into SurveyMonkey®. The 
questionnaires were also posted to the Young Pharmacist Facebook group in mid-
October 2016, and reposted after one week.  
Demographic information was collected for each group including age, sex, and 
location of practice.  
Analysis 
Quantitative data were evaluated with statistical software. GPs’ and pharmacists’ 
responses were compared with Chi-squared analysis using STATA 13.1. Significance 
was set at p=0.05. Responses with more than 20% missing data were removed from 
analysis.152 
Qualitative data themes were identified155 by AY where data were analysed by reading 
responses several times using an immersion–crystallization iterative approach. 
Thematic grouping was undertaken after coding of individual responses and was 
discussed amongst the research team before the final analysis. Opinions of 
pharmacists and GPs were similar and have been analysed together. 
Results 
Demographics 
In total 143 GPs and 126 pharmacists responded (Table 7). This gave a response rate 
of 21.0% for pharmacists and 23.8% for GPs. Sixteen pharmacists responded through 
the Facebook page. Twenty-nine survey responses with more than 20% missing data 
were removed from analysis. GPs (n=75, 52.4%) and pharmacists (n=65, 51.6%) were 
mostly female and from major city practices (GPs n=62, 43.4%; pharmacists n=54, 
42.9%). GPs were mostly 50-59 years-old (n=54, 37.8%) and pharmacists were mostly 
20-29 (n=31, 24.6%) and 30-39 years-old (n=32, 25.4%). 
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Table 7: Summary of participants 




Male 58 (40.6%) 54 (42.9%) 
Female 75 (52.4%) 65 (51.6%) 




20-29 3 (2.1%) 31 (24.6%) 
30-39 26 (18.2%) 32 (25.4%) 
40-49 35 (24.5%) 18 (14.3%) 
50-59 54 (37.8%) 23 (18.3%) 
>60 15 (10.5%) 15 (11.9%) 




Major City (e.g. Auckland, 
Wellington, Christchurch) 
62 (43.4%) 54 (42.9%) 
Provincial City (urban area 
with a population over 30,000 
people e.g. Hamilton, 
Dunedin, Nelson, New 
Plymouth, Napier, Gisborne) 
37 (25.9%) 31 (24.6%) 
Provincial Town (town with a 
population between 1,000 
and 30,000 people e.g. Levin, 
Gore) 
20 (14.0%) 27 (21.4%) 
Rural (non-urban areas such 
as rural centres with 
population under 1,000 
people) 
14 (9.8%) 7 (5.6%) 
No response 10 (7.0%) 7 (5.6%) 
Self-reported provision of medicine information leaflets  
For new medicines, most GPs (n=68, 47.6%) and pharmacists (n=51, 40.5%) reported 
giving leaflets some of the time (less than half the time). Significantly more 
pharmacists than GPs (n=16, 12.7% vs n=3, 2.1%, p=0.001) reported providing leaflets 
all of the time and most of the time (n=35, 27.8% vs n=16, 11.2%, p=0.001) (Figure 9 




Figure 9: How often General Practitioners (GPs, n=143) and pharmacists (n=126) 
provide patients with medicines information leaflets 
For repeat medicines significantly more participants reported they never give a leaflet 
for a repeat medicine compared to a new medicine (GPs n=49, 34.3% vs n=28, 19.6% 
(p=0.001); pharmacists n=11, 8.7% vs n=0 (p=0.001)) or would give it only on request 
(GPs n=67, 46.9% vs n=28, 19.6% (p<0.001); pharmacists n=93, 73.8% vs n=24, 19.0% 
(p<0.001)) (Figure 8 and Appendix 8).  
When medicine information leaflets should be provided 
Significantly more pharmacists (n=89, 70.6%) than GPs (n=81, 56.6%) thought leaflets 
should be provided with new medicines (p=0.0018), (Figure 10). Significantly more GPs 
(n=51, 35.7%) than pharmacists (n=26, 20.6%) thought leaflets should be provided 
before medicines are prescribed so patients’ can review potential risks and benefits of 
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GP: an information leaflet for new medicines
Pharmacist: an information leaflet for new
medicines
GP: an information leaflet for repeat medicines
Pharmacist: an information leaflet for repeat
medicines




Figure 10: When General Practitioners (GPs, n=143) and pharmacists (n=126) would 
like patients to receive leaflets 
How and why medicine information leaflets are provided 
A subgroup indicated using leaflets (n=89 GPs and n=94 pharmacists) and reported 
how and why they used leaflets. 
The majority of these GPs (n=73, 82.0%) and pharmacists (n=76, 80.9%) reported they 
discuss chosen leaflet sections with patients. See Appendix 8 for other ways leaflets 
are provided to patients.  
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Before prescribing (to think about treatment
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When they are prescribed a new medicine
When they are prescribed a repeat medicine
Every 6-12 months for repeat medicines
When there is a brand change
When new information becomes available
When prescribed a medicine associated with
serious side-effects




Table 8: Why General Practitioners (GPs) and pharmacists would provide medicine 
information leaflets 












I want the patient to make an informed choice about 




















I want to check that I did not forget to provide any 






I want to reinforce the benefits of the medicine and 













Likes and dislikes of leaflets  
There were 239 free-text responses about leaflet preferences and 226 about leaflet 
dislikes (Appendix 9).  
Qualitative analysis indicated five themes about leaflets: i) design; ii) content; iii) 
accessibility; iv) perceived quality; and v) usefulness and usability.  
i) Leaflet design 
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More than half of responses were about design. The majority of participants preferred 
simple, clear, and easy-to-read and understand leaflets. Some thought patients might 
misinterpret complex leaflets.  
Over a third preferred concise leaflets whereas under a tenth preferred 
comprehensive ones. Over a third also thought leaflets have too much information or 
unnecessary detail. Some preferences were “easy to understand. Short and clear 
format”, “Short, to the point, good language that don't overwhelm”. Some dislikes 
were “Some have much too much information and are scary for the patient. Others are 
far too generic and don't contain any useful information”, “Often too much 
information and not individually tailored, Not always useful for those with limited 
literacy”. 
Some liked leaflets with a consistent format, designed with the patient in mind. Three 
participants thought leaflets were poorly formatted, difficult to navigate, and not 
user-friendly. Participants favoured A4-format, large-print leaflets with photos or 
pictures and disliked those considered confusing or hard to understand (including 
difficult for those with low literacy). 
ii) Leaflet content 
A fifth of responses related to content. Many more participants disliked than liked 
leaflet side-effect profiles. Participants who liked the side-effect section favoured 
easy-to-read leaflets with a selection of side-effects listed and valued leaflets advising 
what to do if side-effects occurred. Those who disliked this section thought a plethora 
of side-effects might stop patients taking their medicine, particularly when no 
frequency of effects was listed.  
Six participants liked the inclusion of directions for taking the medicine and indications 
or benefits were mentioned by three. Ten participants were concerned if information 
was missing e.g. medicine benefits, dose, directions for use, or storage information. 
Several participants worried about the all-purpose nature of the leaflets, and over a 
quarter of negative comments were about leaflets containing incorrect indications, or 
not being tailored to patients’ needs.  
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iii) Leaflet accessibility 
A tenth of responses commented on accessibility. Most preferred easy-to-access 
leaflets, perhaps from a patient management system. Five of those concerned with 
accessibility disliked printing leaflets and thought digital provision would be useful. 
Two GPs felt there were too many options available. 
iv) Perceived quality 
Quality was mentioned in less than a tenth of responses. A few participants favoured 
leaflets from a known reliable source, others prioritised them being accurate and up 
to date. A few believed manufacturer’s leaflets more reliable, whilst others disagreed. 
Two participants disliked seeing advertising within leaflets. 
v) Usefulness and usability 
Usefulness and usability was mentioned in over a tenth of responses. Many GPs and 
pharmacists thought leaflets useful, informative and beneficial for patients because 
they provided more information than could be covered during consultation. However, 
nine participants were concerned that leaflets cause anxiety for patients, or were 
sometimes irrelevant.  
Half the responses describing leaflets as useful was because they reinforce verbal 
information and give patients information to read when it suits them. Leaflets could 
help educate patients, allowing informed choice and be a guide for discussion. 
Conversely, over a third who commented negatively felt they would need to explain 
the leaflet to patients, and would lack time for this. 
Some commented that leaflets were not useful because they were only available in 
English. A few commented that leaflets rely on patients’ wanting to read them and 
find the desired information. 
Support for tailoring leaflets  
Overall, GPs and pharmacists had similar views on each leaflet option proposed (Table 
9). However, more pharmacists (n=80, 63.5%) than GPs (n=71, 49.7%) thought a 
tailored leaflet would be most useful to patients (p=0.02). Most popular were the 
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summary leaflets with instructions to access more information. Of these options, 
significantly more GPs and pharmacists preferred the personalised/tailored compared 
to the general leaflet (n=56, 39.2% vs n=39, 27.3% GPs, p= 0.03; n=63, 50.0% vs n=22, 
17.5% pharmacists, p<0.001). The least preferred option was the comprehensive 
leaflet (manufacturer’s CMI or PIL). 
Table 9: Which type of medicine information leaflet General Practitioners (GPs) and 
pharmacists thought most useful to provide to patients 







A comprehensive leaflet (e.g. manufacturer CMI) 






A personalised summary leaflet printed from 
prescribing or dispensing software tailored to the 






A personalised summary leaflet printed from 
prescribing or dispensing software tailored to the 
patient’s characteristics, with instructions on how to 
access more comprehensive information if the patient 













A general summary leaflet printed from prescribing or 
dispensing software with instructions on how to access 




















Providing verbal medicines information during consultations may be variable so a 
medicine information leaflet should accompany all dispensed medicines.13, 15, 26 The 
present study found that New Zealand pharmacists and GPs do not often provide such 
leaflets and prefer them to be given for new rather than repeat medicines. GPs and 
pharmacists give leaflets to reinforce treatment benefits and inform of side-effects, 
thereby enabling patient participation in decision-making. Both professions also 
acknowledged leaflets’ importance as a reference tool and additional information 
source for patients. 
Participants preferred a well-designed leaflet, a clear description of side-effects, and 
information about what to do if a side-effect was experienced. Informing patients of 
treatment benefits and accessibility of the leaflet was also considered important.  
Some leaflets were described as too long and difficult to understand. Ideally, patients 
should receive tailored information.109 In the present study GPs and pharmacists 
supported the provision of tailored medicine information leaflets.  
Self-reported provision of medicine information leaflets  
It is not compulsory in New Zealand to provide medicine information leaflets to 
patients and the present study found that leaflet provision is low. From self-reports, 
pharmacists appeared more likely to provide leaflets than GPs. Furthermore, the 
likelihood for patients on long-term therapy to receive leaflets was even smaller, so 
patients would probably need to request one (Figure 9). In one Australian study,26, 173 
pharmacists reportedly provide leaflets more frequently with 48% giving leaflets all of 
the time, and 43% giving them most of the time (12.7%, 27.8% respectively in New 
Zealand). Consistent with New Zealand findings, 13% of Australian doctors would 
never give a CMI with a new medicine,26 although more would provide a leaflet all or 
most of the time.26, 173 Medicines information leaflet provision should be increased 
because verbal communication appears extremely variable.7-9, 63 Solely relying on 
verbal interactions is not considered good practice.7, 9, 12, 15, 26, 28 Internationally, 
medicine information leaflets are provided more often because they are compulsory 
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with dispensed medicines.110, 112 Ideally leaflets should also be given with every 
medicine in countries where provision is not mandatory.2, 3, 40 
In New Zealand and Australia,26, 173 specific leaflet sections are discussed with patients 
in order to cover important issues and encourage leaflet use by patients.27, 173 In 
Australia, GPs and pharmacists were more likely to rely on the patient to read the 
leaflets themselves and return with questions if needed.26, 173 Earlier consumer studies 
in Australia and the UK have shown patients report receiving leaflets without 
additional instruction.65, 66, 143 However, in this current study and the most recent 
Australian study, few GPs and pharmacists would now give a leaflet without any 
advice, which is a positive step forward in information provision.  
In Australia most GPs and pharmacists claim to provide leaflets on patient request.26, 
173 In New Zealand, most provide leaflets to educate and inform patients which is in 
accordance with regulatory agency recommendations and ethical standards.3, 41, 42 
Leaflets are being used in practice to reinforce verbal communication, provide 
information that cannot be given during consultation, ensure salient points are 
covered, and for patients to refer to later.  
Leaflets should be seen as a useful tool for consultations and should not be a burden 
to the healthcare provider. However, many participants in the present study reported 
not having the time required to explain leaflets sufficiently.  
Likes and dislikes of leaflets  
Information leaflets were often described as lengthy, complex, and confusing in this 
and other studies.2, 26, 40, 48 Most participants preferred simple, clear, and easy-to-read 
and understand leaflets which is similar to international outcomes.2 Well-designed 
leaflets help patients find and comprehend information.2, 7, 109 Improvement in leaflet 
design and readability could encourage leaflet use. 
Risks, particularly side-effects, were the most popular and contentious leaflet 
component mentioned in the present study. Consistent with GPs’ and pharmacists’ 
views, patients’ want clear information about side-effects, including understandable 
information about the frequency of occurrence and instructions on how to manage 
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them.2, 4, 26, 40, 61 This information is often not provided in available leaflets and can be 
presented in an alarming manner.9, 40 Treatment benefits are also important to both 
professions in the present study and to patients.40, 61 Reasons for leaflet disapproval 
such as containing irrelevant information, inappropriate length, and generic nature 
could be improved by tailoring leaflets to individual patient requirements.2, 4, 109 
Accessibility is an important issue for busy health professionals. Time pressure is of 
considerable concern and leaflets that are difficult to obtain will be easily dismissed or 
forgotten. Five GPs mentioned that they would prefer to not print leaflets, but instead 
provide them digitally. However sending patient’s medicine information digitally is not 
seamlessly integrated within patient management systems in New Zealand. However, 
with increasing uptake of patient portals in New Zealand (where patients access their 
health information online) and with further innovation within patient management 
systems, digital provision of medicine information could soon be the preferred option.  
Support for tailoring leaflets  
New Zealand GPs and pharmacists support the use of tailored leaflets. Of all options in 
the present study, a tailored summary leaflet was most preferred. Tailored summary 
leaflets could improve health professionals’ opinions of leaflets and possibly 
encourage them to actively discuss them with patients. There is potential for patient 
management systems in community practice to analyse patients’ Electronic Health 
Record in order to tailor leaflets to their gender, medical conditions, and age. 
However there is no system in place to enable the creation of individually-tailored 
medicine information leaflets.  
Patients also want tailored and relevant information about medicines.2, 12, 61, 78, 109 All-
purpose and inappropriate leaflets can appear unsuited and lower patients opinion of 
them.78 New Zealand GPs and pharmacists concur the CMI is the least preferred leaflet 
option, agreeing with other studies that they are too long, difficult to understand,2, 15, 
40, 48, 78 too detailed,2, 26 and not patient-centred.4, 26, 40, 78, 109 Despite this, CMIs may be 
the only medicine information resource that patients receive because they are often 




Whilst New Zealand regulations about provision and creation of leaflets differ from 
other countries,160 the present study’s findings are well in line with the international 
research focusing on the provision of leaflets and why health professionals do not like 
them.2, 26 International research indicates leaflets across the globe are inadequate and 
that improving them will benefit patients.39, 40 Furthermore, many countries provide 
the generic manufacturer-created information for patients160 which this study has 
shown is the least-preferred option by health professionals. This study discusses 
health professionals’ opinions of leaflets and their accessibility, and gives examples of 
where health professionals feel improvement is needed. Improving leaflets by 
incorporating health professionals’ opinions should improve their provision of leaflets 
where it is not mandatory, and encourage active use of them with patients in New 
Zealand and overseas. These improvements could be made to leaflets and their 
accessibility worldwide.  
Future studies in this area should focus on the ability to create accurately tailored 
information to patients and its impact on patient knowledge and adherence as well as 
leaflet provision. This would be useful in international practice where generic 
information is still the mainstay of medicine information leaflet provision. 
There are some limitations to this study. Participants with an interest in leaflets and 
patient education were more likely to respond, possibly resulting in selection bias. 
Alternatively, selection bias may occur from those with a strong dislike of available 
leaflets wanting to put their opinion forward. Furthermore, the study relied on 
reported practices, so participants may have given a socially desirable response to 
impress researchers. This was potentially mitigated by allowing anonymity. The survey 
had a lower-than-expected response rate which affects generalisability of the results, 
but analysis was considered appropriate as the sample was over 20% for each group, 
statistical differences between the groups were detectable, and surveys among health 
professionals may show low response rates.153 Generalisability to international 
practice is affected due to the nature of leaflet provision in New Zealand and Australia 
compared to other countries where provision is mandatory, but other aspects of this 
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study such as the likes and dislikes of leaflets and how leaflets are provided are 
relevant to international practice. 
Conclusion 
Most GPs and pharmacists give information leaflets to ensure patients are informed 
about their medicines. This is in line with professional obligations in New Zealand.41, 42 
However, healthcare providers need to re-evaluate methods for providing medicine 
information. Provision of information leaflets in New Zealand appears to be 
suboptimal with most GPs and pharmacists only giving leaflets to patients less than 
half the time they prescribe or dispense a new medicine. Many do not give leaflets for 
repeat medicines. Opportunities to give verbal advice vary, so providing an 
appropriate easy-to-read medicines leaflet containing all the patient wants to know 
would help ensure their information needs are met. Understandably, when leaflets 
were provided, GPs and pharmacists mostly discussed particular sections of the leaflet 
with patients. This would highlight the importance of the leaflet with patients and 
draw attention to important information. Because it is not mandatory to provide 
leaflets to patients in New Zealand, health professionals’ opinions of them will affect 
whether they are used. Overall, GPs and pharmacists preferred well-designed, patient-
centred, concise leaflets, containing useful information and written in a way that 
avoids patient anxiety. Many GPs and pharmacists struggled with leaflet accessibility 
in their busy practice so improving this would help improve perceptions and usability 
of them as resources.  
Both GPs and pharmacists preferred the concept of summary leaflets, and of these the 
tailored versions were most popular. For healthcare professionals to give leaflets that 
are of real benefit, leaflets should be tailored to meet their patients’ needs. At a click 
of a button it should be possible to provide or even create an appropriate leaflet. 
Furthermore, it should be possible to create leaflets that could be sent in a digital 
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4.4 Using websites for medicine information and 
improving provision of leaflets  
Published Manuscript Entitled Patient-focused medicines information: 
General Practitioners’ and pharmacists’ views on websites and leaflets 
The manuscript entitled “Patient-focused medicines information: General 
Practitioners’ and pharmacists’ views on websites and leaflets” was published in the 
Health Educ J 2018;78(3):340-51.  
The co-authors contributed to the manuscript as follows: Survey creation, execution, 
analysis, and write-up was performed by PhD candidate Amber Young, under the 
supervision of Dr Alesha Smith and Associate Professor June Tordoff. Dr Sharon Leitch 
provided advice from a practicing general practitioner perspective. All the co-authors 
revised the content of the manuscript and approved the final version for publication. 
The PhD candidate Amber Young was the lead author in manuscript preparation and 
writing, and was corresponding author. 
The manuscript is presented as accepted for publication; however, the numbering of 
the pages, figures, and tables has been adjusted in accordance with the style of this 
thesis. All references from the manuscript can be found in the section ‘References’ at 
the end of the thesis. Further details of the methods used and limitations of this study 
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Objectives: To determine how often general practitioners (GPs) and pharmacists 
recommend patients obtain information about their medicines via websites and to 
explore factors that might improve delivery of written information about medicines to 
patients. 
Design: Cross-sectional surveys. 
Setting: General practitioners and community pharmacists in New Zealand primary 
care. 
Method: Questionnaires were developed and sent to a sample of pharmacists and 
GPs. Data was collected using SurveyMonkey® and analysed to examine views on 
websites and leaflets for informing patients about medicines. 
Results: In total, 143 GPs and 126 pharmacists responded. GPs and pharmacists did 
not routinely direct patients to medicine information websites. Most commonly, GPs 
did not provide medicine information leaflets due to time constraints and concerns 
about possibly confusing information. Both professions thought leaflets might cause 
patients to worry about side-effects. Pharmacists mainly withheld leaflets because the 
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medicine was taken previously, or because leaflet indications differed to prescribed 
use. A summary leaflet, if available, would be the preferred option for improving 
leaflet provision. 
Conclusion: Providing digital medicine information is uncommon in New Zealand. 
Summarised, relevant information tailored to patient requirements might facilitate 
provision of medicines information at point-of-care. 
Keywords medicine information; patient information leaflets; consumer information; 
patient education; tailored information; New Zealand 
Introduction 
Adequate verbal counselling about medicines may not fulfil patients’ needs and be 
difficult to achieve in practice.132 Providing medicines information leaflets in addition 
to verbal counselling could increase patients’ understanding of their medicines,9 
however some health professionals do not value leaflets or recommend them to their 
patients.2 Furthermore, when leaflet provision is not mandatory, some providers may 
purposefully withhold leaflets due to concerns that leaflets are confusing or could 
reduce adherence.2, 173, 174 Although many health professionals do give leaflets with 
newly prescribed medicines, they typically do not provide leaflets with repeat 
medicines.26, 174 Providing leaflets for repeat medicines benefits patients by continuing 
and reinforcing patient education,4, 62 supporting and encouraging compliance,22 and 
by enabling healthcare professionals to assess patient understanding which is maybe 
overlooked in practice.8 Ongoing provision could also remind patients’ that leaflets are 
a useful resource if problems with therapy occur.2 It has been shown that summary 
leaflets are preferred by health professionals for new medications,62, 174 but it is 
unknown if a summary leaflet would encourage leaflet provision for repeat medicines. 
There are few alternatives for the patients if they are not provided with leaflets. 
Patients increasingly seek information from the Internet70 because of the 
convenience, coverage and anonymity of digital information.175 This is not ideal when 
not provided by a health professional because many websites contain incorrect and 
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poorly written information.4, 116, 117, 175 Health professionals can guide patients to 
reputable user-friendly information online, but it is not known whether this occurs in 
New Zealand. Furthermore, some patients may be reluctant to seek information from 
sources other than their health professional for fear that this could be inferred as 
undermining professional opinion.2 This anxiety would be abated if the health 
professional provides further reading resources for patients to peruse at their leisure.  
Internationally, many countries have made the provision of information leaflets 
mandatory with dispensed medicines in recent years.2, 26, 107 In New Zealand and 
Australia there is no such legal requirement.160 Our previous research found that 
leaflets are infrequently given with prescription medicines (see section 4.4.1).174 This 
paper reports on further findings from that study by examining whether GPs and 
pharmacists recommend patients obtain medicines information from websites, and 
factors that might discourage or encourage medicines information leaflet provision 
when provision is not mandatory.  
Aim of the study 
The aims of the present study were to i) determine how often GPs and pharmacists 
recommend patients obtain information about their medicines via websites; and ii) 
explore factors that might improve delivery of written medicine information to 
patients.  
Method 
The present study examined findings from a larger project (see section 4.3.1)174 
involving a survey of GPs and pharmacists in New Zealand on medicine counselling 
practices and medicines leaflet provision. Structured data collection instruments were 
developed from previously validated questionnaires140, 173 that utilised a combination 
of multi-choice questions, Likert scales and open-ended responses. Two surveys were 
prepared: one for GPs and one for community pharmacists with input from GPs and 
pharmacists for validity. The surveys were piloted on 20 GPs and pharmacists 
requiring minimal changes. The following questions were asked: For medicines 
considered low-risk (e.g. an asthma inhaler), are GPs and pharmacists recommending 
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websites as a source of medicine information for their patients; if medicine 
information leaflets are used (as determined in the larger project findings174), what is 
the preferred source of leaflets; why would GPs and pharmacists not provide leaflets 
to their patients; what might help GPs and pharmacists provide leaflets; and for 
medicines that could be regarded as high-risk and low-risk1, how they think leaflets 
should be provided (see Appendix 10). 
A sample size of 278 responses were required to detect significance (p<0.05 with 95% 
confidence).174 A sample of 600 GPs and 400 pharmacies (expecting to reach 600 
community pharmacists) were selected for participation.174  
Questionnaires and patient information sheets were distributed via SurveyMonkey® in 
October 2016, with reminders sent at one and six weeks for those who had not 
responded. Paper copies of the surveys were sent to pharmacies when email 
addresses were not obtained and to those who did not respond to the emailed survey. 
Mailed responses were manually entered into SurveyMonkey®. In mid-October 2016, 
the questionnaires were also posted to the NZ Young Pharmacist Facebook group.  
Quantitative data were evaluated using STATA 13.1 to determine GPs and pharmacists 
views on websites and leaflets for informing patients about medicines. Comparisons 
were made between GP and pharmacists responses using Chi-squared analysis with 
significance set at p=0.05. If responses had more than 20% of data missing, they were 
removed from analysis.152 
Ethics approval 
The University of Otago Human Ethics Committee (D16/298; Appendix 4) gave its 
approval for the study. 
                                                     
1 This was to determine if the perceived risk of the medicine would alter how health professionals 
believe leaflets should be provided; high-risk medicines are those at particular risk of side-effects and 





In total there were 269 responses (143 GPs and 126 pharmacists) giving a response 
rate of 21.0% for pharmacists and 23.8% for GPs. The majority of respondents were 
female (GPs n=75, 52.4%; pharmacists n=65, 51.6%) and most commonly resided in a 
major city (GPs n=62, 43.4%; pharmacists n=54, 42.9%). Most pharmacists were aged 
20-29 years (n=31, 24.6%) or 30-39 years (n=32, 25.4%), and most GPs were aged 40-
49 (n=35, 24.5%) or 50-59 years (n=54, 37.8%). Further demographic information is 
reported elsewhere (see  section 4.3.1).174 
The use of websites to give medicines information 
Significantly more GPs reported giving web addresses to patients some of the time 
(GPs n=67, 46.9% GPs vs pharmacists n=43, 34.1% (p=0.034)). Significantly more 
pharmacists reported giving web addresses only on patient request (pharmacists n=62, 
49.2% vs GPs n=22, 15.4% (p<0.001)). No GP reported recommending a website all of 
the time and only 4.9% of GPs reported recommending a website most of the time. 
None of the pharmacists reported recommending a website all of the time or most of 
the time.  
The top three websites from which GPs and pharmacists obtained leaflets were:  
 Medsafe (New Zealand medicines regulatory agency)47 (20.6% pharmacists, 
15.4% GPs)  
 New Zealand Medicines Formulary176 (15.4% GPs, 12.7% pharmacists)  
 the ‘Patient’ website177 (8.4% GPs, 7.1% pharmacists). 
Reasons why medicine information leaflets are not being used 
GPs and pharmacists had different reasons for not giving an information leaflet (see 
Appendix 11). However they had a level of agreement on the following reasons: the 
patient has difficulty with understanding or reading the medicine information leaflets 
(pharmacists n=65, 51.6% vs GPs n=70, 49.0%); the leaflet is too long to print off 
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(pharmacists n=36, 28.6% vs GPs n=55, 38.5%); and the leaflet is not available in other 
languages (pharmacists n=53, 42.1% vs GPs n=49, 34.3%).  
The top three reasons selected significantly more by pharmacists compared to GPs 
were the patient has taken the medicine previously (pharmacists n=81, 64.3% vs GPs 
n=54, 37.8% (p<0.001)); the medicine is being used for a purpose other than indicated 
(including ‘off-label’ use) (pharmacists n=73, 57.9% vs GPs n=27, 18.9% (p<0.001)); and 
I am concerned the patient will worry about the possible side-effects and not take the 
medicine (pharmacists n=70, 55.6% vs GPs n=62, 43.4% (p=0.046)). Around half of GPs 
and pharmacists would not provide leaflets because they believed patients are not 
interested in receiving medicine information leaflets (pharmacists n=68, 54.0% vs GPs 
n=60, 42.0% (p=0.049)). 
The top three reasons selected significantly more by GPs than pharmacists were I do 
not always have time to spend discussing a medicine information leaflet with the 
patient (GPs n=32, 52.4% vs pharmacists n=75, 25.4% (p<0.001)); I do not think to use 
them when talking with patients (GPs n=6, 30.1% vs pharmacists n=43, 4.8% 
(p<0.001)); and it is the (other professions’) role (i.e. pharmacist or GP as appropriate) 
to provide medicine information leaflets (GPs n=32, 22.4% vs pharmacists n=0, 0% 
(p<0.001)).  
In free-text responses, sixteen participants reiterated time limitations. Seventeen 
participants would not supply leaflets that they considered too difficult to understand 
and could be misinterpreted, leading to anxiety. Nine participants thought that the 
available leaflets were too long with unnecessary detail, a further eight would not 
supply leaflets because of concerns with the side-effect information listed. Thirteen 
participants would not use leaflets because they give the information verbally and 
seven participants acknowledged patients’ preference for digital or internet 
information. Nine GPs reiterated that they did not give them because patients did not 
want them and nine also stated they would not give them because the pharmacist 
supplies them. Other reasons for non-use were poor accessibility (e.g. not available 
through patient management systems); and leaflets were not considered useful 
(including leaflets were too generic and not personalised or relevant). 
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What might help GPs and pharmacists provide leaflets to patients 
Most participants believed that having a summary leaflet (covering important points 
about a medicine) would encourage them to provide leaflets (GPs n=102, 71.3% and 
pharmacists n=81, 64.3%), as well as having more time to provide and explain leaflets 
(GPs n=67, 46.9% and pharmacists n= 68, 54.0%).  
Significantly more GPs than pharmacists thought that automatic prompting to provide 
leaflets and recording when leaflets are given in the Patient Management System 
would help (GPs n=75, 52.4% vs pharmacists n=49, 38.9% (p=0.026)); and significantly 
more pharmacists than GPs thought that reimbursement for providing leaflets would 
help (pharmacists n=71, 56.3% vs GPs n=26, 18.2% (p<0.001)). There was much 
agreement on other measures to enhance provision: personalised leaflets tailored to 
patients’ characteristics, disease, or condition (GPs n=61, 42.7% and pharmacists n=54, 
42.9%); specific counselling appointments to discuss a patient’s medicines (GPs n=58, 
40.6% and pharmacists n=52, 41.3%); having leaflets available in different languages 
(GPs n=56, 39.2% and pharmacists n=59, 46.8%); and more frequent requests from 
patients for information leaflets (GPs n=53, 37.1% and pharmacists n=59, 46.8%). 
Six GPs in free-text responses thought they would be more inclined to provide leaflets 
if they were improved. Seven pharmacists discussed how payment would help with 
their provision of leaflets. A few participants suggested other ways of improving 
leaflet provision such as having leaflets available in all medicine packages as they are 
in other countries, employing a system to send leaflets digitally, and improving access 
to available leaflets.  
When and how a personalised summary leaflet could be provided  
Participants were asked if a personalised summary leaflet was available, which 
profession should provide these leaflets, and when for new (Figure 11) and repeated 
medicines for chronic conditions (Figure 12).  
New medicines 
For new low-risk medicines, significantly more GPs and pharmacists believed that 
pharmacists could provide personalised summary leaflets all of the time compared to 
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the numbers who believed GPs could provide them (GPs: believed pharmacists could 
provide them n=80, 55.9% vs GPs could provide them n=51, 35.7% (p=0.001); 
pharmacists: believed pharmacists could provide them n=80, 63.5% rather than GPs 
n=44, 34.9% (p<0.001)). For new high-risk medicines, significantly more pharmacists 
thought they could be the ones to provide these all of the time (pharmacists could 
give n=105, 83.3% vs GPs could give n=88, 69.8% p=0.008) whereas GPs believed the 
leaflets could be provided by either health professional (pharmacists could give n=108, 




Figure 11: New medicines: General Practitioners’ (GP; n=143) and pharmacists’ 
(n=126) opinions about who could provide personalised summary leaflets 
Repeat medicines 
Overall, both professions thought leaflets were less essential for repeat medicines. For 
low-risk repeat medicines, very few participants thought summary leaflets could be 
given all of the time. However, for high-risk repeat medicines, more GPs (18.9%) than 
pharmacists (7.9%) thought leaflets could be given by GPs (p=0.009) (Figure 12). 
Similar proportions of professions thought neither GPs nor pharmacists could give 
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proportions of GPs and pharmacists were again similar, but smaller than those for low-
risk medicines.  
 
Figure 12: Repeat medicines: General Practitioners’ (GPs; n=143) and pharmacists’ 
(n=126) opinions about who could provide personalised summary leaflets 
Most GPs (81.8% for low-risk medicines, 85.3% for high-risk medicines) and 
pharmacists (77.8% for low-risk medicines, 74.6% for high-risk medicines) agreed that 
leaflets could be given if patients asked for them for repeat medication. 
Discussion  
Informed and knowledgeable patients have improved satisfaction with their therapy, 
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study was to explore factors that might improve delivery of medicines information to 
patients in a country where written information provision is not mandatory.160 This 
research provides important background information that may help develop targeted 
initiatives to improve on current low levels of medicine information leaflet provision174 
in New Zealand and other countries such as Australia that do not regulate provision of 
non-verbal information.  
This study found that providing patients with web-based information is not a regular 
practice among New Zealand health professionals. It is known that leaflet provision in 
New Zealand may also be sub-optimal,174 possibly because health professionals are 
concerned about the economic implications of providing them: GPs state they do not 
have the time to discuss them with their patients, while pharmacists are concerned 
with funding for this service. Often it is also thought that patients do not want leaflets 
or that leaflets are not suited to patients’ needs. Many GPs and pharmacists were 
concerned that side-effect information would cause anxiety and affect medication 
adherence. 
Having a short, well-written, personalised summary leaflet is likely to encourage GPs 
and pharmacists to use leaflets during consultation. However, these summaries must 
be readily accessible at point-of-care. Neither profession felt that summary leaflets 
should be given with repeat medicines all of the time, although GPs were more 
inclined to think they should be routinely provided to patients.  
The use of websites to provide medicines information 
Patients search for health information online,70 but the sources available are of 
variable readability and quality.116, 117 GPs and pharmacists using online resources tend 
to recommend government funded websites who publish leaflets (Medsafe, New 
Zealand Formulary, Canterbury District Health Board). However, it is not well known if 
health professionals also inform patients about how to find this information on their 
own or educate them about the risks of searching for health information online.  
Web based applications can improve patient knowledge120 and user-friendly 
applications have been developed that link to the manufacturer’s information 
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enabling patients to find leaflets more easily (e.g. MedSearch179). However these types 
of services are not yet available in New Zealand (at the time of publishing this article). 
Other digital initiatives such as text messaging patients with links to online 
information leaflets have been developed118 but are not widely used. Increasingly 
digital-savvy patients expect to be able to conduct their own research and read up 
about their medicines online. However, the current study showed that most 
pharmacists and GPs do not regularly provide links to websites for medicine 
information leaving many patients without knowledge about what sources would be 
best to access.  
Reasons why medicine information leaflets are not being used 
Our study showed that many GPs and pharmacists do not give leaflets to patients who 
have taken the medicine before. Other New Zealand and Australian studies show 
health professionals agree that leaflets should be provided when a patient is given a 
new medicine, but not necessarily for repeat medicines. 26, 174 Ongoing discussion and 
reinforcement of treatment benefits may however improve adherence to chronic 
therapy, which is as little as 50% in developed countries.22 While patients may not 
read leaflets following repeat dispensing,25, 26, 28 some information may have been 
forgotten or changed, so continuing leaflet provision and discussion is still important.  
Time constraints 
In the present study, GPs and pharmacists reported time constraints as obstacles to 
providing and discussing leaflets with patients. This appears a greater barrier in New 
Zealand than Australia, and greater for GPs than pharmacists (52.4% New Zealand GPs 
vs 39.4% Australian GPs; and 25.4% New Zealand pharmacists vs 8.3% Australian 
pharmacists).26 Given time constraints, it might be more efficient to provide leaflets to 
patients and encourage them to return with any concerns. For patients who prefer not 
to receive this information at the time of prescribing or dispensing this allows them to 
read the information in their own time. Time constraints are also a problem in 
countries where leaflet provision is mandatory because they limit health 
professionals’ ability to actively discuss leaflets with patients and encourage patients 
to read them at home.  
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Not wanted by patients 
It was commonly reported in the present study that participants did not provide 
leaflets because they believed that patients did not want them. Believing patients do 
not want further information is a common misconception internationally.2, 26 In an 
Australian study, 88% of 607 patients stated they had never refused a leaflet about 
their medicine,26 suggesting although not perfect, leaflets are still of use.  
Not fit for purpose? 
Medsafe (the New Zealand medicines regulatory body) states that to make informed 
choices, consumers need to know the benefits and risks of medicines and feel able to 
compare these with information about other treatment options or ‘no treatment’.46 In 
this study, and in Australia,26 GPs and pharmacists felt that leaflets were unsuitable for 
patients because side-effect information could cause anxiety, reduce adherence, and 
undermine healthcare professional recommendations. In contrast, other studies found 
patients value being informed about side-effects4, 180 and that providing such 
information does not cause the issues mentioned.26, 162, 171, 181 Furthermore, informed 
patients are more likely to avoid interactions, cope better with predictable side-
effects, and recognise possible reactions sooner18 and giving leaflets would help fulfil 
the requirements to fully inform patients.  
Around half of GPs and pharmacists in the present study do not provide leaflets 
because they view them as difficult for patients to understand. This is a valid concern 
because confusing or unclear information can affect adherence.86, 87 Many participants 
felt leaflets were poorly written, unsuitable, and not patient-centred which is often 
how manufacturer provided information is described internationally.2, 26 There is still 
much work to be done to improve manufacturer provided information on a global 
scale in order for health professionals to find them suitable to use in practice. If 
leaflets were consistently presented in a clear format with understandable and 




What might help GPs and pharmacists provide leaflets to patients 
In New Zealand, GPs and pharmacists commonly prefer to provide patients with 
summary leaflets.26, 174 Unfortunately summary leaflets may not be readily in use and 
in many countries the leaflets provided are produced by the manufacturer and are 
often lengthy. Perhaps to promote active provision of written information, health 
authorities should promote summary leaflets to be made available for patients.  
As mentioned above, improving leaflet quality may increase their provision by GPs and 
pharmacists, particularly because there is little time to explain confusing poorly 
written information. Given stakeholder agreement, perhaps independent 
organisations outside of industry should take control of leaflet writing and provide 
easy-to-read leaflets. 
Many GPs in the present study did not think to use leaflets when talking with patients 
and said they could not or did not know how to access them. More than half the GPs 
said that integrating leaflet provision into Patient Management Systems (PMS) would 
help them provide leaflets. Pharmacists did not have this problem, perhaps because 
automatic provision of leaflets is already integrated into dispensing software in many 
pharmacies. Although available in some GPs’ PMS, widespread availability is needed. 
Including an option to print an appropriate leaflet within the workflow would prompt 
GPs to consider using leaflets while providing easy and direct access to the leaflet.  
When and how a personalised summary leaflet could be provided  
Ideally, information should be personalised to the patient’s requirements, including 
the condition being treated (even if the medication is used ‘off-label’) and in their own 
language. Personalised summary leaflets were considered more important for new 
medicines than for repeat medicines. Whilst there was no definitive answer about 
who could provide personalised summary medicines leaflets for patients and when, 
overall GPs and pharmacists felt that both professions could be involved, particularly 
for high-risk medicines. Pharmacists appeared to be the preferred provider which is 
consistent with current practice, although many patients prefer to receive leaflets 
from their GP or from both their GP and pharmacist.26, 62, 66 Providing personalised 
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leaflets should be adopted with every prescribing or dispensing of medicine by 
enhancing Patient Management Systems to create and print leaflets automatically and 
streamlining the process with current practice.  
Limitations 
Participant recruitment could have resulted in selection bias with those being more 
interested in leaflet provision possibly more likely to respond. Furthermore, the study 
involved self-report rather than observation so results may differ from actual practice. 
The small sample size of the study could affect generalisability of results, however 
statistical difference between groups was demonstrable. Additionally, participants 
were not asked if they were familiar with all websites that leaflets can be obtained 
from, and so it could not be determined whether their recommended sources were 
their personal preferences or one of only a few resources known to themselves. 
Conclusion 
Based on the findings of this New Zealand study, there are three main reasons why 
leaflets are not being used in practice. Firstly, GPs and pharmacists are unwilling to 
give leaflets to patients if they think the leaflets are difficult for patients to 
understand. Secondly, many leaflets currently available are not considered fit-for-
purpose, and there is concern that side-effect information may cause patient anxiety. 
Summarised, relevant information tailored to patient requirements might overcome 
some GPs’ and pharmacists’ reluctance to provide leaflets, and could benefit patients. 
Thirdly, funding limitations (i.e. limited funded time to provide and discuss leaflets or 
lack of reimbursement) also prevents leaflets being used at the point-of-care. Time is 
short for verbal discussion, but this should not be a barrier to leaflet delivery. 
Incorporating leaflet provision into usual practice workflow through patient 
management software would improve leaflet delivery.  
Digital resources appear to be underutilised by GPs and pharmacists as a source of 
medicines information for patients. Informing patients about where to find accurate, 
reputable, and up-to-date digital information needs to be encouraged. Development 
and provision of appropriate medicines information leaflets or digital resources may 
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help improve patients’ decision-making about medicine use. They could also help 
patients avoid interactions, cope better with predictable side-effects, and recognise 
possible reactions sooner. 
Moving forwards, New Zealand’s medicines regulatory agency should advocate 
mandatory leaflet or digital medicine information provision with patients’ medicines. 
This would be consistent with international practice, by providing consumers with high 
quality, accessible health information to facilitate greater patient engagement, reduce 
costs, improve the utilisation of appropriate treatment, and strengthen informed 
choice.175  
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4.5 Patients’ opinions on medicines information leaflet 
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Introduction: Giving patients medicine information leaflets with oral information 
could help improve patient understanding about their medicines. Some health 
professionals believe patients do not want to receive leaflets or find them too difficult 
to understand so do not provide them.  
Aim: To investigate Dunedin general practitioners’ (GPs) provision of medicine 
information leaflets from patients’ reports and to examine patients’ views about the 
leaflets provided. 
Methods: Patients collecting prescriptions from community pharmacies in Dunedin, 
New Zealand, between December 2016 and February 2017 were asked to complete a 
survey. Responses were entered into SurveyMonkey and data were exported into 
Excel for analysis 
Results: Of the 151 survey respondents, over three-quarters (79%) did not receive a 
medicine information leaflet from their GP in the last 6 months, although most 
believed it important to receive one. Many participants felt that leaflets improved 
their knowledge and helped them take their medication correctly. Most participants 
liked the leaflets they received, although over half (60%) would like a short summary 




Discussion: Some patients may not seek further information about their medicines 
other than during consultation. Although rarely given, most participants who received 
leaflets from their GP appreciated them. Most participants read and understood 
leaflets they were provided, although ready access to a one- to two-page summary 
leaflet may be preferable. Technology could enable GPs to easily provide leaflets to 
patients in their care. 
Keywords medicine information leaflet; patient communication; patient education; 
general practitioner 
What gap this fills 
What is already known  
In New Zealand, it is not mandatory to provide patients with written information 
about their medicines. Although patients should ideally be given written and oral 
information about their medicines, many health professionals believe patients do not 
want to receive medicine information leaflets. 
What this research adds 
Patients in Dunedin are not often provided with medicine information leaflets by their 
general practitioners, but do wish to receive them. Most patients read leaflets when 
they are provided and think that leaflets improve their medicine knowledge and help 
them take their medicines correctly. 
Introduction 
Patients require information about their medicines to ensure they are used safely and 
effectively.109 Patients have access to health information from a number of sources, 
although some patients prefer to receive drug safety information from their GP.18 
However, discussions with patients about their medicines may be limited in practice7 
and access to GPs for medicine information following an appointment may be difficult 
or costly.2 Furthermore, patients struggle to remember information that has been 
discussed at point-of-care7, 9, 26, 28, 38, 39 and they may not understand orally 
communicated drug information.12, 182 This is a common problem internationally, with 
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studies showing that patients often feel they are not adequately informed and may 
not even understand why a medicine is prescribed.2  
Ideally, oral information should be supported by a medicines information leaflet183 
because they can increase patients’ understanding of their medicines.9 Provision of 
information leaflets is mandatory in many countries160 and usually the manufacturer-
produced consumer medicine information leaflet is provided with dispensed 
medicines. In New Zealand, provision is not mandatory and leaflets in use are either 
those produced by a drug manufacturer or an independent organisation.160 In 
Australia, leaflet provision is also not mandatory and research shows that they are 
often forgotten or deliberately withheld.26, 173 Similarly, research in New Zealand 
identified that general practitioners (GPs) rarely provide patients with medicine 
information leaflets.174 The reasons that GPs may withhold leaflets include their 
perception that leaflets are too long or confusing and difficult for patients to 
understand, or their concern that patients will worry about possible side-effects and 
not take the medicine.184 However, it is not known if these concerns are reciprocated 
by their patients.  
The aim of this study was to investigate Dunedin GPs’ provision of medicine 
information leaflets from patient reports, and to examine patient views on the leaflets 
provided.  
Methods  
A survey was developed based on previously validated questionnaires (for health 
professionals)174 and then pilot tested on 10 members of the public to ensure validity 
for this group. Minor changes for clarification were made (final questionnaire in 
Appendix 12). A sample size of 150-200 participants was intended, based on studies 
using similar sample sizes to investigate medicine information in primary care (ranging 
from 80 – 143 participants).174, 185, 186  
S. Moore administered the survey in community pharmacies in Dunedin, New Zealand 
between December 2016 and February 2017. Patients 18 years or older attending the 
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pharmacy with a prescription were invited to complete the survey. As an incentive, 
participants could enter a draw to win one of two NZ$50 supermarket vouchers.  
All responses were entered into SurveyMonkey® by participants, or on behalf of 
participants by S. Moore. Data were extracted and analysed in Microsoft Excel 
(Microsoft Corporation, Redmond, WA, USA). Basic descriptive analysis of data was 
undertaken. Sub analysis was performed on those who had received leaflets to 
investigate how it was provided to them, their preferences and opinions of the leaflets 
they were given, and whether they read the leaflet. Analysis on all groups was then 
undertaken to asses when they would like to receive leaflets, and how they prefer 
leaflets to be given (paper copy/digital version or full text/short summary). The 
University of Otago Ethics Committee approved the study (D17/007; Appendix 13).  
Results 
There were 151 respondents to the survey. Most were female (70%), spoke English as 
their first language (99%), and all eligible age groups were represented (Table 10). 
Highest qualifications gained was lower than that of the general population187 with 
over half only educated to secondary-school level (54%). 
Table 10: Demographics of participants 
Characteristics 
Total n = 151 
n (%) 
Gender 
 Female 105 (69.5) 
 Male 46 (30.5) 
Highest completed qualification 
 No qualifications 7 (4.6) 
 Secondary school 82 (54.3) 
 Postgraduate diploma 29 (19.2) 
 Bachelor’s degree 18 (11.9) 




Total n = 151 
n (%) 
Age (years) 
 18–19 7 (4.6) 
 20–29 16 (10.6) 
 30–39 20 (13.2) 
 40–49 39 (25.8) 
 50–59 25 (16.6) 
 60–69 22 (14.6) 
 >70 22 (14.6) 
First spoken language 
 English 149 (98.7) 
 Bengali 1 (0.7) 
 Chinese 1 (0.7) 
Receiving medicine information leaflets 
Most participants (n=119, 79%) had not received a medicine information leaflet from 
their GP in the last six months. Almost two-thirds (n=93, 62%) believed it was very 
important to receive a leaflet about new medicines. For repeat medicines, fewer 
participants (n=33, 22%) thought it was very important to receive a leaflet.  
Of the respondents who had received a leaflet (n=32, 21%), over half had either 
discussed the leaflet with their GP or their GP had drawn attention to specific sections 
(n=9, 28% and n=8, 25% respectively). Most participants who received leaflets felt that 
it had improved their knowledge (n=23, 72%), and half (n=16, 50%) believed it had 
helped them take their medication correctly. One third (n=11, 34%) thought the 
leaflets encouraged them to take their medication as instructed. 
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Opinions on provided leaflets  
Overall, 97% (n=31) liked the leaflet they received. Over half liked its appearance 
(n=19, 59%) and 75% (n=24,) believed it contained relevant and findable information. 
Most agreed they could read and understand it (n=23, 72%), but 9% (n=3) thought it 
was too long. Two-thirds of participants had read the full leaflet (n=21, 66%) and 10 
(31%) had partially read it. Only one participant (3%) had not read the leaflet. Over 
half said they had not kept the leaflet (n=18, 56%) but 43% (n=14) had kept it.  
When and how patients want information  
Most participants (n=116, 77%) would like to receive a leaflet from their GP when 
prescribed a new medicine, while 5% (n=8) preferred not to be given one at all. 
Approximately half of participants wanted to receive a leaflet when new information 
becomes available (n=82, 54%), when the medicine is associated with serious side-
effects (n=80, 53%), or when there is a change in the brand (n=72, 48%). 
Most respondents (n=120, 80%) would prefer a paper leaflet to a digital alternative. 
Over half (n=90, 60%) preferred a one– to two-page summarised version of a leaflet 
(summary leaflet) rather than a comprehensive leaflet, or a summary leaflet with the 
option of receiving more information.  
Participants mostly never sought further information (n=50, 33%), or sought more 
information less than half the time (n=47, 31%).  
Discussion 
Patients are usually given information orally, but written information should also be 
provided to ensure patients are fully informed, and to remind them of information 
and instructions for use.109 Most participants in this and other studies consider it 
important to receive medicine information leaflets from their GP.26 However, when 
providing leaflets with medicines is not a legal requirement (as is the case in New 
Zealand)160 they are often not given.173, 174  
In New Zealand, previous research has shown that GPs avoid providing leaflets 
because of concern that patients cannot understand them, patient’s previous 
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medicines, assumed patient indifference and belief that pharmacists provide 
leaflets.184 Yet almost all participants who had received a leaflet from their GP 
appreciated it and had no difficulty in understanding the information it contained. 
Some participants did have difficulty understanding the content, and other research 
indicates that manufacturer-produced leaflets may be poorly suited to patients’ 
requirements in style and readability.9, 55, 160 However, participants in this study with 
qualifications higher than secondary school were underrepresented, indicating that 
those with potentially lower literacy still appreciate leaflets being provided to them.  
Previous New Zealand-based research found that GPs provided leaflets to inform 
patients, aid medicines adherence, prompt discussion, and to reinforce instructions 
and benefits of medicines.174 Most participants who received a leaflet in this study 
read it fully and agreed that leaflets improved their knowledge and helped them take 
their medicines correctly, showing this achieves their GPs’ intended purposes.  
Discussing leaflets could benefit those patients who have difficulty understanding 
them but time-pressures can affect information provision. System technological 
improvements might facilitate this process by alerts suggesting leaflet provision and 
automated leaflet printing within GP prescribing software. Further investigation is 
needed to establish whether automatic provision would alleviate time restraints at 
point-of-care. 
There is evidence to suggest patients are increasingly searching for information 
digitally,70, 175 but most participants in our study preferred a paper leaflet rather than a 
digital alternative. Perhaps further encouragement and support from healthcare 
providers about reputable web-based information would help patient engagement. 
Most participants preferred the idea of a one- two-page summary and health 
professionals prefer to provide summary leaflets so this format may be more suitable 
than lengthy manufacturer-produced leaflets. Actively providing summary leaflets to 
patients is not common practice.174 Action by governments and health professional 
bodies may be needed to ensure patients have access to tailored information leaflets 
that suit their needs.78, 109 
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Some patients may want more information about their medicines than GPs’ currently 
provide, yet two-thirds of participants in this study did not look for further medicines 
information from other sources.173, 188, 189. Patients may need encouragement to be 
proactive and ask for more information from their GPs. 
Limitations 
As this was a small study, there are limitations to what can be gleaned from the data. 
Results may not represent other patients in Dunedin or in other more ethnically and 
age-diverse parts of New Zealand. Most participants spoke English as their first 
language and understanding written communication may differ for people who did 
not originally speak English. 
We did not collect information on the medicines patients were prescribed, so no 
conclusions can be drawn as to the types of medicines more likely to prompt leaflet 
provision, although earlier research indicates leaflets are more likely to be provided 
with higher-risk medicines.174 This study did not confirm the type of leaflets 
participants received, so differences between manufacturer-produced leaflets and 
leaflets from independent organisations were not explored. 
There is a risk of recall bias with participants being asked to remember the previous 6-
month period. Participants may also not remember exactly who provided them with 
leaflets, with the questionnaire being administered in a pharmacy. Attempts were 
made to mitigate this risk by orally explaining to participants that the focus was on GP 
provision of leaflets before they completed the questionnaire, as well as in the 
questionnaire. Some participants may have still been confused and inadvertently 
answered about pharmacist provision of leaflets. 
So far, there is no consensus on who should provide information leaflets. Both 
pharmacists and GPs are required to ensure patients are fully informed about their 
medicines. Further research is required to determine who should provide what 
information, at what time, and in what format. This could contribute to clearer 




Patients value having leaflets provided to them with new medicines, but this may not 
commonly occur in practice because it is not a mandatory requirement in New 
Zealand. Patients should be encouraged to ask and look for information about their 
medicines from reputable sources. Ensuring they receive leaflets along with oral 
discussion about their medicines could help them take their medicines safely and 
improve their knowledge. Further research is required to determine patient 
preferences of the different leaflets available and the perceptions of patients from a 
larger sample of the population. 
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4.5.2 Methods, further information  
Rationale of methods chosen 
A quantitative method was chosen to statistically analyse responses and compare 
findings to similar international research. A survey instrument with quantitative 
questions would take less time to administer in a busy pharmacy and potentially 
obtain a larger sample of people than a qualitative study and be more able to assure 
generalisability of the findings. 
Questionnaire validity  
The questionnaires validity was determined using the same methods described in 
section 3.4 (i.e. same methods used for the GP and pharmacist surveys).  Following 
this validity testing, the questionnaires were pilot tested in 10 members of the public 
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using the same modes of data collection as proposed for the study. This was to assess 
readability and understanding. Any necessary modifications were implemented after 
careful assessment by the research team. Minor changes to wording were required, 
e.g. ‘verbally’ changed to ‘discussed with you’, ‘monitor the treatment’s effectiveness’ 
to ‘tell if the medicine is working’. 
The questionnaire was estimated to take eight minutes to complete. 
Recruitment 
The research team identified eight possible pharmacies, when considering location in 
Dunedin, New Zealand, their customer/population profile, and suitability of their 
premises for data collection and privacy. The first five of these pharmacies 
approached agreed to take part and the survey was administered in those locations.  
People 18 years and older were approached in a pharmacy as they waited for their 
prescription. Participants were required to be able to read and understand English and 
currently taking a prescription medicine. Pharmacy staff invited patients who had 
submitted a prescription to be filled to speak to a researcher based in the pharmacy. 
The researcher would describe a survey he was carrying out and ask if the patient 
would like to complete this while waiting for their prescription to be filled. This ‘arm’s 
length’ approach was to ensure that patients who were potentially under 18 years old, 
distressed or vulnerable were not directly approached by the researcher.  
Those who indicated that they were interested in participating were provided with a 
paper Patient Information Sheet (PIS) to read and could ask the researcher questions if 
needed. Completing the survey was regarded as implying consent.  
The questionnaire was entered into SurveyMonkey (electronic survey software) and 
presented to the participant via a tablet computer. Participants could complete the 
survey themselves, or if they preferred, the researcher could ask them the questions 
and enter responses on their behalf. If they preferred electronic access to the PIS and 
survey, participants could have provided the researcher with their email address and 
we would email them the PIS and a survey link. Alternatively, we could have provided 
them with a hardcopy of the survey weblink to complete the survey in their own time.  
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Because recruitment was being undertaken by busy pharmacy staff, data on 
recruitment rate was not collected. Instead, we had a target participation rate of 150–
200 participants and continued recruiting until this target was attained. 
4.6 Chapter conclusion 
This chapter described provision of medicine information leaflets to patients with new 
and repeat medicines, GPs’ and pharmacists’ opinions on leaflets available and their 
reasons why they would and would not provide leaflets. The use of websites and 
provision of personalised information was also discussed.  
We ascertained from self-reports that GPs and pharmacists are not giving medicine 
information leaflets to their patients all of the time. Most GPs and pharmacists give 
their patients medicine information leaflets some of the time (i.e. less than half of the 
time). Additionally very few GPs or pharmacists provide leaflets with repeated 
medicines. Most GPs and pharmacists agreed that leaflets should be given with new 
medicines and that they provide leaflets because they believe patients should be fully 
informed about the medicines they are taking. Our study also revealed that GPs and 
pharmacists do not usually guide patients to websites for reputable and accurate 
information about their medicines. This is concerning because, in chapter 3 it was 
discussed that patients may not be adequately receiving enough verbally provided 
information to take their medicines safely. Furthermore, as mentioned previously, 
there are limitations to purely relying on verbal communication for reasons such as 
patients’ limited capacity for remembering and understanding information at time of 
consultation. This study added to the information provision picture in New Zealand 
primary care by showing that patients may also not be receiving printed or digital 
medicine information they need. 
To try to understand why leaflets may or may not be given to patients, we asked what 
GPs and pharmacists liked and disliked about the leaflets currently used. The reasons 
that both groups liked and disliked leaflets were similar and fell into the same 
categories: i) leaflet design; ii) content of the leaflet; iii) accessibility of leaflets at 
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point-of-care; iv) perceived quality; and v) usefulness and usability. With positive and 
negative comments given in each category (see Section 4.3.1). Tailoring leaflets would 
improve the content, complexity, and usefulness of leaflets and the GPs and 
pharmacists in the study support the creation of tailored summary leaflets for their 
patients. 
So why else are leaflets not being provided? There are many reasons given by GPs and 
pharmacists. More pharmacists avoided giving leaflets because the patient had taken 
the medicine before and the medicine was being used for an indication that was not 
on the leaflet. Alarmingly many from both groups responded that they do not want to 
worry the patient with information about side-effects because this could cause anxiety 
and reduce adherence to treatment. This has been disproven in the literature, with 
some consensus that if potential harms are well explained to patients it does not 
discourage them from taking their medicines.26, 190 Furthermore, this also takes away 
patient informed choice, where the choice to take no medicine should also be left up 
to the patient if they feel the risk of harms outweigh the potential benefits of their 
treatment.2  
Other reasons that leaflets are not provided or liked by GPs and pharmacists include 
the lack of time available to discuss them, difficulty in accessing them, forgetting their 
availability, and the perceived lack of appropriateness for patients. System changes 
and the use of technology to support health professionals at point-of-care could help 
address these challenges. Improving accessibility and instilling their provision in the 
usual work-flow of GPs and pharmacists would encourage their use simply by making 
it easier for them to print off. This would require a change in the software currently in 
use e.g. for the incorporation of a ‘print medicine information leaflet’ button to be 
simply clicked at the end of the prescribing and dispensing process. Additionally, 
improving the design and content of leaflets currently available would be beneficial to 
GPs, pharmacists, and patients, with all groups disliking the length and complexity of 
the manufacturer-written CMIs. Across the board, a summary one- to two-page leaflet 
is the most preferred option, possibly improved further with the ability to personalise 
the information to the patient requirements. The combination of improvements in the 
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software and the production of appropriate summary leaflets would both work 
together to improve the time necessary to print and discuss leaflets with patients, 
which is a large barrier for current provision.  
Unfortunately this technology is not yet available in clinical practice and it is unknown 
if software vendors are able to incorporate this functionality into current prescribing 
and dispensing systems. Further investigation into the feasibility of creating a digital 
system to provide personalised summary medicine information leaflets to patients will 
be discussed in chapter 5. 
GPs and pharmacists often thought that patients did not want leaflets and so would 
not provide them. However this is an unsubstantiated assumption, as the small study 
asking patients’ views (section 4.5.1) showed a positive response to leaflets when 
received, with most patients feeling that the additional information aided their 
understanding and their ability to take their medicines properly. Over three-quarters 
of patients prescribed a new medicine would like to receive leaflets from their GP and 
most patients who had received leaflets liked them and found them easy to read. 
Other reasons a leaflet may be desired was when new information arises, when a 
medicine is associated with serious side-effects, or when there is a change in the 
brand. However, similarly to health professionals’ views, less than a quarter thought it 
was important to be given leaflets with medicines that they had taken before (when 
no new information available). 
This study also found that most patients had not received a leaflet recently from their 
GP and patients tended to not look for further information about their medicines. 
However, there is an international trend that more and more patients are looking to 
the internet to provide them with information about their health, including 
information about their medicine.70 Patients may need encouragement to seek further 
information about their medicines to increase engagement in their health 
management. 
With patients not receiving enough verbal information about their medicines, it is 
possible they may begin to search for information on the internet. Whilst this could be 
beneficial to patients’ autonomy, it may be concerning due to the general lack of 
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know-how on critical analysis of web-content for accuracy. Health professionals have a 
role in providing accurate and useful information about medicines or, at the very least, 
guiding their patients to reputable websites for medicines information.  
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Chapter 5: Feasibility of creating 
personalised medicine information  
5.1 Synopsis 
Previous chapters have discussed the pitfalls of providing patients with medicines 
information in current practice including the type of material given, the way it is 
provided, and the opinions of health professionals on the information available to 
impart to patients. This chapter is an investigation into the possibility of providing 
personalised medicine leaflets and counselling points for GPs and pharmacists to use 
at point-of-care using software built into existing practice systems in New Zealand.  
A Use Case and mock-up example of personalised information resources was created, 
and a feasibility study was undertaken. For the feasibility study, the Use Case and 
mock-up example were sent to vendors of GP prescribing systems and pharmacy 
dispensing systems along with a questionnaire to determine vendors’ requirements to 
build the system and their opinions of market worth and practicality of the project. 
Informal telephone and email correspondence was also undertaken with those who 
were willing to discuss their thoughts on the project further. 
From vendors’ responses, we determined that it is not feasible to build this system 
within the current prescribing and dispensing management software used in New 
Zealand. The reasons for this include its: low perceived value by the vendors, 
potentially prohibitive costs, and possible lack of consistent use of patient coding by 
GPs. In addition, the pharmacy vendors’ thought that such a system might not work 
because pharmacists may not always be performing the role of prescription-data entry 
in the dispensary work flow and be unable to control leaflet and counselling-point 
production; this role is often performed by pharmacy technicians. 
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An alternative method is needed to provide patients with personalised and relevant 
medicine information. Use of Patient Reported Outcomes (PROs) might allow for 
personalisation and specific information provision.  
Chapter structure 
This chapter has two parts: 
1. A Use Case for providing personalised medicines information in primary care. 
Section 5.3 outlines a Use Case and mock-up example of automated personalised 
medicine information for patients at point-of-care for primary care prescribing 
and dispensing systems. 
2. Feasibility study for providing personalised medicines information in primary 
care. Section 5.4 uses the resources generated in the first section and 
undertakes a feasibility study on the viability of the proposed Use Case.  
5.2 Chapter aims  
There are a number of difficulties that health practitioners are faced with during a 
consultation. There is often little time for lengthy discussions about treatments and 
sometimes remembering to provide patients with in-depth information falls by the 
wayside when faced with the other tasks required for diagnosing, prescribing, and 
dispensing medicines. This chapter aims to describe and determine the feasibility of 
building software that would integrate into existing systems to automatically provide 
personalised information at point-of-care in New Zealand practice.  
Specific aim 1: To create a Use Case and mock-up example for GP prescribing systems 
and pharmacy dispensing systems to provide personalised medicines information at 
point-of-care for health care professionals to use during consultation.  
Specific aim 2: With the help of New Zealand’s vendors of prescribing and dispensing 
software, determine the feasibility of building a system to provide automatic 




5.3 A Use Case for providing personalised medicines 
information in primary care  
5.3.1 Introduction 
The findings in chapters 2, 3, and 4 indicate that there is room for improvements to be 
made in the way that information is provided to patients about their medicines. The 
narrative review in chapter 2 described what patients want to know about their 
medicines to support adherence and safe medicine-taking, and if presented in a 
written format, how this is best designed to attract their attention and encourage 
them to read it. Chapter 3 discussed the current prevalence and consistency of 
verbally imparting information about medicines to patients. Chapter 4 outlined the 
utilisation of medicines information leaflets in practice and GPs’ and pharmacists’ 
opinions on those currently available in New Zealand. Overall, these chapters painted 
a picture of inadequate and inconsistent information provision to patients with a 
strong need for a universal change in practice. Due to time and other constraints of 
health professionals in practice, we need to use technological advancements to 
facilitate change. One solution is for software to automatically provide counselling 
points and medicine information leaflets for GPs and pharmacists to discuss with 
patients at point-of-care. 
With this solution in mind, preliminary discussions were undertaken with a vendor of 
GP prescribing systems in New Zealand about what would need to be provided to 
software developers. A Use Case was requested by the vendor in order to “clearly 
articulate [our] approach & outcome, thus allowing the feasibility to be revealed i.e. 
effort vs benefit”.  
A Use Case is a standard requirement in the software development process and 
defines what steps are required to achieve the desired goal and who is involved in 
each stage of the process (see Table 11).191, 192 A Use Case can be adapted for project 
requirements but will generally contain the same basic components. 
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Table 11: Common components of a Use Case with descriptions191 with an example 
Component Description Example from daily life 
Description  A brief description of the Use Case. A customer decides to 
purchase a specific item 
from a shop and goes to the 
shop to make the purchase. 
Level Description of what level in the 
system the steps described in the 
Use Case occur. These are typically 
either user goal (achieves the 
desired goal for user), summary 
(broader context often with a set of 
user goal Use Cases; typically over 
hours, days, weeks, or longer), or 
sub function (isolated part of user 
goal moved into a separate Use 
Case).192 
User goal – a single person 
achieves their desired 
outcome by buying an item. 
Trigger The event that causes the Use Case 
to occur. 
Customer requests to buy 
an item from a shop. 
Primary Actor The main individual whose goal is 
satisfied on completion of the Use 
Case. 





Other individuals who are also 
involved in the Use case. 
Salesperson. 
Stakeholders  Those who are not directly involved 
in the Use Case, but have an 
interest in the outcome. 
Business manager. 




Preconditions The list of conditions that must be 
true for the Use Case to be able to 
run. 
Customer has funds to 
purchase item. 
The shop sells the required 
item. 
Technology available to 
complete purchase. 




The simplest steps required to 
result in accomplishing the goal. 
This should describe the actions 
and responses by the actors and 
system in the Use Case that ends 
with a successful completion of the 
process. 
Customer requests an item 
for purchase. Salesperson 
finds and scans item and 
requests payment. 
Customer pays for item and 
takes it away. 
Extensions Alternative routes and exceptions 
to the main success scenario. These 
are numbered according to what 
step of the success scenario that 
this alternate path occurred. 
Customer has insufficient 
funds in chosen payment 
method (e.g. in their bank 
account) and pays by 
alternative method (e.g. 
with cash). 
Business does not accept 
chosen payment method 
(e.g. credit card) and 
customer must pay another 
way (e.g. with cash). 
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Desired item not in stock 
and needs to be ordered in 
to shop. 
Customer returns goods and 










1. Successful outcome of the Use 
Case (primary actor’s goal is 
satisfied). 
2. The assurance provided to all 
actors and stakeholders that their 
interests will be protected 
regardless of the outcome of the 
Use Case. 
3. What the resulting outcome is if 
the Use Case fails. 
1. Customer successfully 
buys an item. 
2. The customer can change 
their mind at any time. 
Customer’s personal 
information is not collected 
unless for a specific purpose 
(e.g. for contact after 
ordering in item). The item 
remains in the shop if not 
paid for. 
3. The customer leaves the 
shop without making a 
purchase. 
Frequency How often the Use Case is 
expected to occur (to determine 
capacity requirements). 
Transactions occur in this 
shop 45 times per hour. 
Special 
Requirements 
Additional factors that could 
impact the Use Case e.g. 
performance, privacy, usability, 
accessibility. 
Good customer service is 
provided.  




Suitable payment methods 
are available. 
Shop is well-stocked. 
Shop must comply with the 
New Zealand Consumer 
Guarantees Act. 
Issues Any issues that require clarification 
or follow-up work required before 
development can begin.  
Items to keep in stock. 
Language requirements for 
area shop located. 
Use Cases are often displayed as a diagram to allow visualisation of how actors 
interact with the system. Summary Use Case diagrams can include multiple user goal 
Use Cases to show higher-level relationships between them. In the diagram actors are 
included as figures and Use Cases as ellipses. Lines are drawn that indicate the 
relationships, or communications between actors and Use Cases.192 Extensions to the 
Main Success Scenario (i.e. alternative route) can also be included. An extension is 
drawn using a dashed arrow between the extension to the Main Success Scenario (e.g. 
in the example in Table 11, an extension is not having the item in stock so ordering it 
in for the customer).192 
The vendor also requested an example of personalised information to understand 
how a “personalised leaflet [will] differ to what is already available? which includes a 
generalised leaflet coupled with the medication label.” Therefore, to present the 
solution to vendors of prescribing and dispensing software in New Zealand and to 





A Use Case template was found191 that was suitable for the purposes of presentation 
of the proposal to vendors of prescribing and dispensing systems used in New 
Zealand. The template was adapted slightly to fit the purposes of this particular 
project e.g. justification and expected benefits were included to describe to vendors 
why the proposal is a good idea and how it could benefit GPs and pharmacists. Two 
Use Cases, one for GP prescribing systems and one for pharmacy dispensing systems, 
were created. A summary Use Case diagram was also created to help show where the 
Use Case would sit in the prescriber- or pharmacist-patient encounter. 
An example of a potential personalised counselling point pop-up box and medicine 
information leaflet were also created. The content of these were adapted using the 
New Zealand Formulary,176 the British National Formulary,193 the manufacturers Data 
Sheets available on the Medsafe website47 which are commonly used in New Zealand 
primary care, and Medicines for Children UK194 (a leaflet used in paediatrics 
internationally).  
The Use Cases, the medicine counselling points and information leaflet were created 
by AY with input from project supervisors AS and JT, and from GP advisor Dr Sharon 
Leitch. 
5.3.3 Results 
Two Use Cases were created, one for GP prescribing systems and one for pharmacy 
dispensing systems, and these are presented in Appendices 14 and 15. Summary Use 
Case diagrams to visually model the functionality of the Use Case systems were 
created and are presented below. The examples created for the personalised 




Summary Use Case diagrams for functionality of integrated 
personalised medicine information tool  
 




Figure 14: Dispensing systems summary Use Case diagram  
Example of potential personalised information 
Example of key practice points 
An example created for display in prescribing or dispensing systems is presented on 
the next page, with some key features explained. The example is key practice points 
for a fictional 70-year-old female prescribed amitriptyline for neuropathic pain. 
Examples of information for omission include pregnancy and breast-feeding advice, 
contraception information, other indications and doses of amitriptyline, and child-




Figure 15: The prototype for key practice points to be presented in the Prescribing or 
dispensing system 
From this window it would be possible to automatically create a personalised 
information leaflet, by selecting ‘Medicine leaflet’. This would then form a 
personalised medicine information leaflet in the software to be printed by the 
prescriber or dispenser. An example of a personalised information sheet for the same 
hypothetical patient is presented on the next page. This is adapted from Medicines 




Example of medicines information leaflet 
Amitriptyline 
for neuropathic pain 
Medicine information for Theresa May 
 29.11.1947 
This leaflet is about the use of amitriptyline 
for the treatment of neuropathic pain (pain 
caused by nerve damage). 
Name of your medicine 
Amitriptyline (sometimes known as amitriptyline 
hydrochloride) 
Brands available include Arrow-Amitriptyline 
and Amirol 
What you have been prescribed 
10 mg tablets 
What amitriptyline will do for you  
Amitriptyline will help you to feel less pain. The pain 
may be described as having a burning, shooting or 
scalding sensation.  
How to take your amitriptyline 
1 tablet at night for 7 days. This may increase over 
time, see the label on your medicine for more 
information. Tablets should be swallowed with a 
glass of water, milk or juice. 
Follow your prescriber’s instructions about 
how much to take. 
Amitriptyline must be taken regularly every day 
and, depending on the cause of your neuropathic 
pain, may need to be continued indefinitely. 
Do not change the dose without talking to your 
prescriber first. Stopping suddenly may make you 
feel unwell. You will usually reduce the dose in 
small steps over time.  
When the medicine should start working 
Pain caused by nerve damage can be difficult to 
treat. It may take many weeks for amitriptyline to 
work properly. Continue to take the medicine as 
you have been told to. If amitriptyline does not 
seem to be helping your pain after four weeks, 
contact your prescriber for advice. 
If you miss a dose or are sick 
 If you forget to take amitriptyline, you can take 
the missed dose as long as this is 12 hours before 
the next dose is due. However, if amitriptyline 
makes you feel sleepy, it is better to skip the 
missed dose and take the next dose when it is 
normally due. 
 If you are sick (vomit) less than 30 minutes after 
having a dose of amitriptyline, take the same 
dose again. If you are sick more than 30 minutes 
after having a dose of amitriptyline, you do not 
need to take another dose. Have the next dose 
when it is normally due. 
Do not take a double dose of amitriptyline. 
Monitoring 
Your doctor may do a heart test (ECG) before you 
start and while you are taking amitriptyline. 
Possible side-effects 
Side-effects to see your doctor about straight away  
 Up to 1 in 10 people may have an irregular heart 
beat e.g. your heart may feel like it is racing or 
have a fluttery feeling in your chest. 
 Up to 1 in 1,000 people may get symptoms of 
jaundice like yellowing of their eyes or skin, dark 
urine (wee) or light-coloured poo. This could be a 
sign that you liver has been affected.  
 Up to 1 in 1,000 people may bruise or bleed 
easier, or have a persistent sore throat or fever. 
This could be a sign that your bone marrow is 
affected. 
 Up to 1 in 10,000 people have problems with 
their eyesight (e.g. blurred or double vision).  
Other side-effects you need to know about 
 More than 1 in 10 people feel sleepy for a few 
hours after having a dose of amitriptyline. This is 
why you should take amitriptyline in the evening. 
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 More than 1 in 10 people get a dry mouth. 
Taking sips of water or chewing sugar-free gum 
between meals may help. There are 
preparations that may help to moisten your 
mouth including sprays or lozenges, talk to 
your pharmacist or dentist. Make sure you 
brush and floss your teeth at least twice daily 
to prevent tooth decay. 
 More than 1 in 10 people, when first start 
taking amitriptyline, feel sweaty, feel sick 
(nausea), have constipation (difficulty doing a 
poo) or find it difficult to pass urine (do a wee). 
These symptoms should settle down after a 
week or so. 
If you still have any of these symptoms after 2 
weeks, or you are worried, contact your doctor. 
There may, sometimes, be other side-effects that 
are not listed above. If you notice anything unusual 
and are concerned, contact your doctor.  
Taking other medicines with 
amitriptyline 
You can take medicines that contain paracetamol or 
ibuprofen, unless your doctor has told you not to. 
Amitriptyline should not be taken with some 
common drugs that you get on prescription.  
Tell your doctor and pharmacist about any 
medicines you are taking before starting 
amitriptyline. 
Some other common medicines you can buy 
yourself from a pharmacy or supermarket may be 
harmful when taken with amitriptyline. These 
include antihistamines (in anti-allergy, anti-nausea 
and cough/cold medicines), cough/cold medicines 
containing dextromethorphan, St John’s Wort, and 
recreational drugs (e.g. ecstasy). 
Check with your doctor or pharmacist before 
taking any other medicines. This includes 
herbal or complementary medicines.                                                     
Storing your medicine 
 Keep the medicine in a cupboard in the 
container it came in, away from heat and direct 
sunlight. It does not need to be kept in the 
fridge. 
 Make sure that children cannot see or reach 
the medicine. 
 All unwanted medicines should be returned to 
your pharmacy for disposal. 
Lifestyle information  
 Amitriptyline may make you dizzy or sleepy. If 
this happens, do not drive or use tools or 
machines. Limit alcohol intake because it can 
increase these effects.  
 Up to 1 in 10 people experience a lower sex 
drive. If you are concerned about this, talk to 
your doctor. 
General health tips for neuropathic pain 
 It is important that you get enough sleep at night 
time. Avoid watching television or using 
electronic devices in the bedroom. Avoid 
stimulants or diuretics, including coffee, tea, and 
alcohol close to bed-time. For more information, 
see Tips to improve your sleeping habits, Health 
Navigator New Zealand, 
https://www.healthnavigator.org.nz/healthy-
living/sleep/sleep-tips/. 
 Exercise improves strength and balance and 
should be continued if possible. If your pain or 
medicine is stopping you from being able to 
exercise, talk to your doctor; an occupational 
therapist, physiotherapist or counsellor may be 
helpful. 
Alternative therapies and treatment 
options 
There are other treatment options available if 
amitriptyline does not work for you, such as 
nortriptyline or gabapentin. Other treatments can 
help neuropathic pain, such as acupuncture or 
transcutaneous electrical nerve stimulation (TENS). 
Your doctor will discuss different options with you.  
Who to contact for more information 
Your doctor, pharmacist or nurse will be able to give 
you more information about amitriptyline and about 
other treatments for neuropathic pain. 
Further advice and information is available from: 
 Health Navigator New Zealand, Nerve pain: 
https://www.healthnavigator.org.nz/health-
a-z/n/nerve-pain/  
 Arthritis New Zealand: 
www.arthritis.org.nz/information/treatment
-management/living-a-healthy-life/  
 The Pain Toolkit, pain self-management 
tools: www.paintoolkit.org/tools  
 New Zealand Pain Society: www.nzps.org.nz  
The information in this leaflet was created by XXXX. 




Upon creation of the Use Case and higher-level diagram it is clear that the processes 
involved are complicated and require many systems (Use Cases) working together to 
successfully provide patients with personalised information. From an academic 
perspective, the benefits of achieving the outcomes described in chapter 2 (narrative 
review) would likely outweigh the work required to achieve them. Furthermore, 
chapter 4 showed that health professionals generally approved of the idea of 
providing personalised summary leaflets to patients. Yet we must acknowledge there 
are already generalised medicine information leaflets available to patients and that 
those who develop and maintain dispensing and prescribing system software 
may/may not agree that the benefits of our proposed new system would outweigh the 
work and costs involved.  
5.3.5 Conclusion 
A Use Case is an important first step in software design and project management. It 
outlines the roles and requirements for the process and examines what would occur if 
the ideal scenario is not accomplished. A Use Case, a summary Use Case diagram and 
a mock-up example of personalised information were created to present to vendors of 
GP prescribing systems and pharmacy dispensing systems in New Zealand. This was 
the first step in determining the feasibility of building this application into software 
currently in use in New Zealand practice.  
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5.4 Feasibility study for providing personalised 
medicines information in primary care 
5.4.1 Introduction 
A Use Case was described in section 5.3, outlining the requirements for a system to be 
able to build personalised information for patients within prescribing or dispensing 
systems. Moving forward we need to determine if this can be built and at what cost. 
The best way to do this is to undertake a business feasibility study. 
A feasibility study determines the viability of a project and identifies potential 
problems that could occur.197 The common determinants in a business feasibility study 
are in Table 12. 
Table 12: Common components in a business feasibility study197 
Component What this is for 
Market Feasibility To describe how the project fits in with the current 
market and what future market potential is anticipated. 
Technical Feasibility To outline what would be necessary to implement the 
project (e.g. staff and resources required). 
Financial Feasibility To know what the start-up costs of the project would be 
(i.e. how much investment is required). 
Organisational Feasibility To describe how the project will work within the current 
organisation and if it would be disruptive to current 
workflows. 
Conclusions To explain how the project would improve the current 
business and enable it to work towards company 
philosophy or goals.  
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Using the identified components of a business feasibility study, the aim of this section 
is to: 
a) ask vendors their opinions about building personalised information for patients 
within prescribing or dispensing systems;  
b) determine the feasibility of producing the software from the vendors’ 
perspective; 
c) ask vendors their opinions about whether this project would benefit users of 
their systems.  
5.4.2 Methods 
Questionnaire 
Two questionnaires were created, one each for vendors of prescribing and dispensing 
systems (see Appendices 16 and 17), using the components of information required 
for a business feasibility study to determine opinions and estimations on the market, 
technical, financial, and organisational feasibility of the project. This was to identify 
the feasibility of the project from a business perspective.197 We also wanted to know 
vendors’ opinions on the project so we added an additional section in our survey of 
‘possible benefits to users’. 
Questions were about business case elements that would directly enable completion 
of the business case criteria. Each question was mapped against one of the required 
points for the business case. The requirements of the business case were section 
headings for the survey: benefit to users, market feasibility, technical requirements, 
financial requirements, scheduling feasibility, and barriers. The questions were 
designed as a combination of tick box selection and as open responses for estimations 
of required costs and timeframes. Further qualitative data could be captured with 
room for further comment after the questions. 
Face and content validity was assured by having the research team involved in review 
of the questionnaire and mapping this to the business case criteria identified. Concept 
validity was determined by the mapping of questions to the requirements for the 
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business case. Further peer review independent of the research team was also 
undertaken. 
The study was approved by University of Otago Human Ethics Committee (reference 
number D18/285). See Appendix 18 for copy of approval letter. 
Recruitment 
A list of all current vendors of software for primary care in New Zealand practice was 
collated, using information from the internet and local knowledge from GPs and 
pharmacists. This practical approach was taken because there are few software 
vendors in use in the primary care setting in New Zealand and the research team have 
extensive contacts working in pharmacy and general practice. Six vendors were 
identified through internet searching and local knowledge, four for prescribing 
systems, and two for dispensing systems, see Table 13. Contact details were found 
through an internet search. 
Table 13: Current vendors of prescribing and dispensing systems in New Zealand 







All identified vendors were invited to participate in the study via email and were sent 
the Use Case, the summary Use Case diagram, and the mock-up example of 
personalised medicine information to look over before answering the questionnaire. 





An introductory phone call was made to vendors in October 2018 with request for 
most appropriate email address, for which to send the correspondence, participant 
information sheets, and questionnaire. Data from emailed contacts was collected 
using SurveyMonkey®. A follow up email was sent in one month, and in another three 
months later. A further phone call follow up was made after five months of the 
original call, then the survey was closed for analysis in March 2019. Responses were 
grouped for discussion and interpretation. Documentation of conversations was also 
undertaken for those who had expressed reluctance to complete the questionnaire 
but were willing to informally participate via phone and email correspondence. 
Permission to record telephone conversations was not obtained. Instead, quotes from 
the telephone dialogue were transcribed during conversation and repeated back to 
the interviewee for confirmation and approval. This correspondence underwent 
thematic analysis (AY) using an iterative approach to examine other constructive 
feedback for the project and identify barriers in regards to feasibility.155  
5.4.3 Results 
Only two of the six vendors were willing to participate in the formal questionnaire. 
Two vendors, one for dispensing software and one for prescribing software, were 
willing to have informal discussions about the project, one via telephone and one by 
email correspondence to provide further comment around feasibility and their 
opinions.  
Survey findings 
Possible benefits to users 
Both respondents felt there is some need for a tool providing personalised medicines 
information for patients. One respondent also commented, “Provided they are 
accompanied by counselling they would help to improve patient outcomes”. They also 
commented, “My concern would be that pharmacists are already very constrained by 
time – (so) would they use them?”. Both respondents agreed or strongly agreed that 
patients would like to be given personalised information as described in the Use Case. 
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Respondents thought that all (n=1) or most (n=1) health providers would use the tool 
if it was available. One respondent provided further comment, “Somewhere between 
some and most pharmacists would use the tool. If experience in Australia is anything 
to go by, encouraging pharmacists to go through the leaflet with the patient could be a 
problem”. 
Both respondents’ current software allows users (healthcare professionals) to print 
medicines information leaflets for patients. The leaflets are currently available from 
standardised software/ information available in New Zealand, e.g. Med+Info99 and 
MIMS,198 and the New Zealand Formulary176 is to be integrated at some stage. They 
did not know if this functionality is used at point-of-care. One respondent commented 
that, “….89% of [users] have access to some form of paid patient information. 100% of 
[users] have access to the CMI, but generally speaking these are too long. We don't 
know how many [users] actually use these on a regular basis. The integrations are able 
to prompt [them] to print these for patients receiving new medicines”. One respondent 
estimated that, “….over half of [users] (maybe 70-80% even) …. use either MIMS or 
Med+Info”. 
Market Feasibility 
Both respondents anticipated this project (the ability to produce personalised 
medicines information sheets) has future market potential. One respondent added the 
proviso, “If provided free of charge”. Neither respondent anticipated the addition of 
the medicine information tool would influence potential buyers of the software. 
When asked if the software were to be either provided in the current package or 
available as a subscription, respondents answered, “It would depend on the funding 
model” and, “It depends on how much work we're required to do and who pays for 
that - it could be a sub or a one-off fee”. Neither respondents thought the addition of 
the medicine information tool would increase sales of their product. One commented, 
“It would certainly be seen as beneficial but I don't think it would increase our sales”. 
Nor did they think it would give them a market advantage over their competitors.  
176 
 
When asked about features of their system that set them apart from their 
competitors, vendor one mentioned a single unique feature and vendor two 
mentioned several unique features. 
Technical requirements 
Only one respondent answered the question about the additional materials or 
resources required to undertake this project (and expected number) and identified 
they would need additional servers (1), computer hardware and software (2), 
additional office space for employee(s) (2), and telephone with answering system (1). 
They further commented, “Content is the key. Who is creating the content and serving 
it up? Ideally [we] wouldn't be holding or serving up the content, just making the 
content available….”. The other respondent thought it too difficult to estimate 
technical requirements at this stage and commented, “It is difficult to estimate this 
without a full and exact specification of what we need to do. If we receive a file of MILs 
(Medicine information leaflets) specific for indications eg Amitriptyline for Neuropathic 
pain then we would find that easier to produce a personalised version….”. 
The number of current or additional employees that would be required to undertake 
this project (not including the clinical information within leaflets) were identified in 
Table 14. Responses were similar and combined into ranges where they differed. All 
are one-off costs except ‘on-going support and maintenance’. 
Table 14: Estimated employees and time of employment required 
Type of employee Number of Full Time 
Equivalents (FTEs, 1 
FTE = 40 hours/week) 
(mean response/ 
range) 
Time employee to be 
dedicated to project (e.g. 
in weeks or months) 
(mean response/ range) 
Senior Management 1 n/a 
Project Management 1 2–4 weeks 
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Type of employee Number of Full Time 
Equivalents (FTEs, 1 
FTE = 40 hours/week) 
(mean response/ 
range) 
Time employee to be 
dedicated to project (e.g. 
in weeks or months) 
(mean response/ range) 
Software Developer 1-2 4–8 weeks 
Additional clinical support 1 1–3 weeks 
Testing (Quality assurance) [Not specified] 2–4 weeks 
Deployment [Not specified] 1 week 
Setup support and on-going 
support and maintenance 
[Not specified] on-going 
One respondent further commented about these requirements that, “These are very 
rough estimates”.  
When asked whether there are other technology requirements not previously 
mentioned, needed to undertake this project, one respondent commented, “Time and 
priorities. There are already many other projects we are undertaking”. 
Financial requirements 
Only one respondent was willing to estimate the total start-up cost of this project, and 
they roughly estimated it would cost NZ$100,000. Both respondents stated that 
external investment would be required for the project, and only one of the 
respondents stated that their company currently sets aside funding for new projects. 





Both respondents felt it would take 3–6 months to create the software for this project 
and one respondent thought it would be disruptive to their current work schedules. 
Barriers 
Aside from the time and cost, other barriers to this project identified were on-going 
maintenance and updating of clinical information and taking the focus off the current 
schedule of development. 
One respondent could foresee concerns about data protection with the 
implementation of this project and commented that, “With the customisation, the 
printed information actually shows who is taking the medicine, whereas the current 
ones are generic and do not need to be securely destroyed”. 
Final thoughts 
Only one respondent thought that this project is one that would be worth pursuing. 
However, both respondents thought this project would help their company meet their 
philosophy or goal although the philosophy and/or goals identified by the 
respondents’ companies were, “Professionally satisfying, financially successful” and 
“To ensure the smooth running of [the business]…..” and not clinically focused. In 
conclusion, one respondent commented, “It would be a ‘nice to have’ and if delivered 
to us in a format that can be consumed easily would be beneficial”. 
Further comments made via telephone and email conversation 
Two vendors were willing to provide informal feedback to the project. The feedback 
has been grouped into Positives, Negatives, and Other possible beneficial suggestions. 
Positives 




i) The digital theme comprised of two ideas, one was that the option of a digital leaflet 
may be better for consumers. The other idea was that including leaflet prompting and 
printing functionality would require minimal work from the software vendor. 
ii) With respect to cost, the project would reduce costs to the users of the software for 
not having to print a leaflet if a digital one was provided. Also one vendor commented 
that there is, “Definitely space for a better free alternative but need funding to make 
this happen”. 
iii) The positive patient-centred theme included how beneficial personalisation of 
information would be, “Some drugs are used for multiple purposes and your approach 
allows just that condition to be presented on the leaflet removing unnecessary clutter. 
This could be easily highlighted by comparing an existing leaflet against a customised 
leaflet which will obviously [be] smaller in content because it is targeted to the 
individual”. A further benefit would be how information could be specific to that 
patient rather than for other family/whānau on the same medicines for which the 
information is not appropriate, “You should consider ALL data elements which are 
necessary for example PATIENT NAME, I would expect to be contained within the 
leaflet so it is identified as personalised for a specific patient rather than be shared 
among whānau [extended family] who are on the same medication and details may 
not be applicable to them. And in light of this a generic disclaimer may be prudent. 
Perhaps even NHI number & DoB for greater uniqueness”. The last identified patient-
centred benefit would be to enable more comprehensive documentation in patients’ 
clinical records, “The patient’s current condition list could be displayed for selection or 
another condition searched and once selected also adds to the patients condition list 
automatically”. 
Negatives 
The overwhelming majority of the feedback was critical of the project and there were 
many negative themes identified. The themes identified were i) cost, ii) workload, iii) 
risk of clinical harm, and iv) privacy. 
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i) The cost theme was about prohibitive costs to the software vendor, “Not 
commercially viable by itself, need funding to create and maintain it”, and to the user 
of the software “Costs – not everyone would want to pay”. 
ii) The workload theme also covered workload to the software vendors, “Would be 
considerable work customising it” and the health professionals having to use the 
system, “Having the [health professional] include or remove information would be 
tricky and they may not want to take the time”. Workload for health professionals was 
further emphasised with the comment, “This is just talking about the prescribing 
process, I would be shocked if a prescriber would create a customised leaflet for every 
consultation/medicine. And yes they may see four patients per hour but it may 
typically involve prescribing more than one medication per patient. Long term 
conditions such as diabetes may involve easily six medications/products. Is there any 
awareness of drugs that need targeting? If so this could allow volumes to be 
extrapolated”. 
Workload issues could arise due to the dispensing processes in community 
pharmacies, particularly if the prompt would appear when using the dispensing 
software. This is because a pharmacy technician may be responsible for prescription 
entry in the dispensing software (and hence leaflet and counselling point production) 
and a pharmacist may not be involved in this process. This process would not work if 
technicians rather than pharmacists are performing that task, which is often the case, 
so clinical judgement of what to include in the leaflets could not be given. Expecting 
pharmacists to oversee this process could cause significant disruption and may be 
impossible in small, busy community pharmacies. 
iii) Risk of clinical harm could occur in numerous ways: 
1. Inaccurate or inappropriate information being included by prescribers or 
pharmacists. For example, 
a. if free-type is an option.  
“you must decide could the information in the leaflet be relevant to other 
HCP’s involved in the patient’s care including Emergency HCP’s. If there is 
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relevance, which you cannot judge if you allow [them] to enter free-text as 
they could say anything and in a worst case scenario the contents may 
contradict the medication Label instructions AND may explain why they 
have shown up in Emergency. Going to the extreme if a patient should die 
then naturally the coroner will also require this access to see if this 
information may have contributed”.  
b. Or if the medicine has numerous uses.  
“a SINGLE medication could treat multiple conditions, now more so as 
medications are being combined into one tablet for patient convenience”. 
2. Important information being excluded.  
“How to avoid not including important information. This is probably the largest 
risk, which I mentioned above, that must somehow be addressed. Obviously it 
could be clinically dangerous if important patient information was omitted”. 
3. Information was confusing to patients.  
“Be careful about the use of abbreviations such as OTC, ‘much’ of the 
population may not know what this means”. 
4. I Inconsistency with medicine labels.  
“I am assuming the patient DOSE information may be auto-populated in the 
leaflet, if so it should be highlighted this information is unmodifiable in the 
leaflet as it must not differ to the medication label instructions. Reference to 
such an aspect highlights you have considered patient safety in regards to two 
separated pieces of information which MUST remain consistent”. 
Furthermore, there was a feeling that including dose ranges could allow 
patients to alter their medicines without prescriber involvement.  
“Knowing the patient’s age allows the presentation of typical dosage ranges, 
but these facts are maybe best left to the prescribers as it could allow patients 
to alter dosage”. 
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5. Information being outdated. One vendor commented that. “Dosages/Strengths 
can of course change, so there would be some hesitancy to include this, as the 
leaflet could become outdated”. 
iv) The theme of privacy was about how including identifiable patient information in 
the leaflets could be problematic.  
“Sorry I cannot see value in including the Name on the leaflet apart from increasing the 
risk to privacy. Obviously the patient would know the information is for them, so 
what’s the point. But if someone else sees it, it reveals their condition which would 
impact privacy”. 
Other possible beneficial suggestions 
Despite the critical comments about the project, there were useful suggestions for 
further improvement and considerations that could be included. The themes 
identified were i) architecture/software and ii) leaflet content. 
i) The architecture of the project could be remodelled completely and one vendor 
suggested that a different approach would be easier to maintain and roll out to 
multiple vendors. This was to have a central database of information that the vendors’ 
software can interact with to pull the required information out to provide leaflets. This 
centralised model would require the architecture to work with multiple systems. 
 “The other aspect which springs out is that potentially this solution would be best 
deployed via a centralised model rather than distributed across some or all [prescribing 
or dispensing] systems”.  
“A centralised model, which publishes an API [Application Programming Interface] 
which allows receiving the necessary parameters (Age, condition, current dosage?, 
name?) to it and then outputs the ‘customised leaflet’ for either printing or emailing. 
Conceptually it could even allow patients to generate their own directly”. 
Another software solution was the possibility for GPs and pharmacists to have ‘go to’ 
templates that they prefer to use with their patients. The thought was that this would 
make the system more appealing to users.  
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“If software can help a prescriber and help repeat processes then it becomes more 
attractive, hence reference to allow the prescriber to construct a personalised leaflet 
AND save it as a template for use for other patients and yes I realise this goes against a 
key principle but many patients will fit into the same category hence the advice should 
be consistent and not have to manually customise every time”. 
The final architecture/software solution was about having a web-page framework to 
allow patients to search for appropriate information online or for somewhere for GPs 
and pharmacists to refer patients to.  
“Historically Dr’s are always hesitant to listen to patients who have done searches as 
the information may not be accurate or trustworthy. In light of this there may be value 
to constructing a web-page framework which displays ‘trusted data sources’. Which 
could be considered a trusted source of information and avoids the commercially 
weighted ordered returns Google provides. Trouble is the means to endorse the data 
source is necessary and it would need to be maintained. If this did exist the means for a 
doctor to easily pass these links to a patient portal allowing the patient to access later 
if necessary”.  
The other benefit of a web-based system is that it is easily updated. 
“Web-based ‘content’ is a better model as it allows updates to be published 
immediately, without a system upgrade”. 
ii) There were two suggestions for including additional information in leaflet content. 
These were a photo or picture of the medicine the patient is taking, and having the 
ability to have multi-lingual leaflets.  
 “One other obvious gap is support for multiple languages particularly as NZ’s ethnic 
diversity is expanding….While the Treaty of Waitangi encourages the continued use of 
Māori, there is no legal obligations for other languages however obviously there is a 
clinical need to ensure the patient fully understands relevant details…. From a user’s 
perspective it would be nice to easily translate any information or even auto translate 




It is widely recognised that people benefit from information that is tailored to their 
needs.78, 109, 199 The possibility of automating the tailoring of leaflet creation and 
counselling points was investigated in the light of the time constraints and other 
limitations on counselling methods found in practice, in earlier studies in this thesis.132, 
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The aims of the feasibility study were to a) ask vendors their opinions about building 
personalised information for patients within prescribing or dispensing systems; b) 
determine the feasibility of producing the software from the vendors’ perspective; 
and c) ask vendors their opinions about whether this project would benefit users of 
their systems. The Use Case, summary Use Case diagram, mock-up example of 
tailoring information to patient characteristics and condition/disease, and a 
questionnaire were provided to vendors of prescribing and dispensing systems in New 
Zealand. 
Feasibility of the project 
The overall outcome of this study was that vendors considered that the project is not 
feasible to pursue. The reasons for this include large cost to the vendors, time 
required to complete the project, and the risk of hindering the development of 
vendors’ current projects in progress. Some patients may also have a negative 
response to receiving automated personalised information. In a UK-Australian study 
from 2013, researchers gave an example of a tailored leaflet to participants (people 
who take medicines) and found they had some similar reservations of being providing 
with tailored information, such as the feasibility and costs required to achieve it.78 
In the present study there was also little perceived value by the vendors, so it is 
unlikely this project would be successful. Additionally, it was thought that the ability to 
create personalised medicine information for counselling/providing leaflets would not 
influence potential buyers of the software. However, this could be because there are 
few vendors operating in New Zealand resulting in less competition for business.  
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Perhaps manual personalisation of information during consultation is still the best 
approach, particularly for certain groups who may have difficulties understanding the 
generic information provided.199 This is possible for certain medicines where there are 
numerous leaflets available. However, it may be necessary for different patient groups 
to be involved to help decide what should be included in the information they are 
receiving, e.g. those using inhalers may need more in-depth information about inhaler 
technique.200  
There are calls for more adaptable and flexible information provision to suit patient 
needs199, 200 and this could be accomplished with digital information presented to 
people on a smart platform. This could also allow people to ‘self-tailor’ their 
information as they see fit, which may be preferred by some people.78 However, this 
will not be appropriate for every patient. Individuals’ requirements for mode of 
information delivery need to be considered.199 
Another constraint to ability to provide leaflets identified in this study was how health 
professionals use their current software. There is lack of consistent use of patient 
coding by GPs, and limited access to determine indications for medicines by 
pharmacists. Furthermore, there is the limited/lack of involvement of pharmacists in 
the prescription-data entry processing in the dispensary work flow (and hence in 
leaflet and counselling point production). 
Vendors expressed concern about keeping the information up-to-date. This was 
understandable because a clear pathway for the ongoing updating of clinical content 
and the costs were unknown. Perhaps also deciding what information is to be 
included, how it should be written, and what is considered ‘tailorable’ would be a 
monumental and time-consuming task and would require significant clinician and 
patient involvement before completion. It may be more practical to start with a 
smaller group of medicines or medicines for specific conditions before attempting to 
create information for all medicines available in New Zealand. 
The vendors mentioned a number of potential clinical harmwith the project including 
the possible inclusion of inappropriate information in leaflets, the risk of missing out 
important information from the leaflets, and the risk of contradictory information 
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being present between the medicine labels and the information leaflet. Similar 
reservations were described in the UK-Australian patient study where concerns about 
patient safety (e.g. wrong information given to the wrong patient) and the quality of 
information (e.g. robust processes of content creation) were raised.78 These issues 
would need resolution before further work could be undertaken. 
The vendors thought the project might be more feasible if the architecture was 
changed to a central repository with coded information that could be pulled out by 
dispensing and prescribing systems rather than full integration within these systems. 
This would require less outlay from vendors and the possibility for multiple patient 
management systems being able to work with the central repository if an API was 
employed. However, there would still be some requirement for vendors to adapt their 
current systems to include the functionality to prompt GPs and pharmacists to use this 
resource and a change in clinical practice. 
Strengths and limitations 
This study was unique in that it was investigating the feasibility of a project 
(developing a medicine information tailoring tool) with vendors and their opinions on 
its worthwhileness. This is a strength of the study, as until now the practicality of 
automatically tailoring information within patient management software has not 
gained insight from the vendors of the software about the pros, cons, and barriers to 
its implementation.  
All vendors prescribing and dispensing software in New Zealand primary care were 
contacted for their opinions about this project. However, only two vendor 
representatives completed the questionnaire, which may limit generalisability to all 
vendor software developers in New Zealand. Most did not respond to repeated 
requests for participation; however, those who responded and declined to participate 
indicated they were unwilling to complete the survey as they felt it was asking for 
commercially sensitive information. The nature of gathering data from these disparate 
methods (by email and telephone conversation) makes the data and themes identified 
not readily generalizable to the vendor group as a whole. Nevertheless, the 
discussions held with two vendors gave further insight into concerns and suggestions 
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for project improvement, and allowed more exploration of ideas than gained from 
questionnaire responses. Furthermore, because all participants thought that the 
proposal was not practicable at this time, it could be concluded that this project is not 
feasible in New Zealand at present.  
Because of the small number of possible participants, statistical measurements on 
survey repeatability such as test-retest reliability were not possible. We invited a 
potential participant to read the questionnaire and assess for readability, however 
statistical analysis of users repeat responses was not possible.   
Generalisability for an international audience may be further limited because 
provision of medical services can vary significantly between countries. Nevertheless, 
the findings from this study may be somewhat relatable to countries with similar 
primary care medicine provision services where information provision is either a 
mandatory and/or an ethical requirement. 
5.4.5 Conclusion 
Creating personalised medicine information leaflets from within prescribing and 
dispensing systems, as described in the Use Case, does not currently appear to be a 
feasible option for software vendors in New Zealand. Vendors highlighted the 
following barriers: time and cost; on-going maintenance; current developmental 
obligations; data protection; and practicality for end-users. Vendors’ suggestion that 
using a central model with an API for the different software systems to interact with 
might be a more appropriate method for providing information available for the 
different software in use in practice.  
However, the research team acknowledges the clinical scope is too broad for 
implementation of such a system for all medicines. There are numerous risks to 
patient safety involved, notwithstanding the initial requirements for clinical 
adaptation and ongoing maintenance. To move forward in this area, it may be better 
to focus on certain conditions or groups of medicines. This system could then be 




To narrow the scope from ‘all medicine information’, a focus on high-risk medicines, 
e.g. chemotherapy for cancer patients, might be best. An emerging idea with an 
emphasis on patient-centred care is the use of Patient Reported Outcomes (PROs) to 
generate side-effect management information. As well as adapting general 
information to individual requirements, using PROs to provide personalised 
information to patients about how to manage their side-effects in a digital platform 
might be an innovative and achievable prospect for New Zealand practice. The use of 
PROs to provide tailored side-effect management information is discussed further in 
section 5.5 and chapter 6. 
5.5 Chapter conclusion 
This chapter is an investigation into the possibility of automatically providing 
personalised medicine information within prescribing and dispensing systems 
currently in use in New Zealand. Previous chapters have discussed the information 
that patients want to be provided with and suggested ways that the delivery and 
content of leaflets can be improved. This chapter described the a) creation of a Use 
Case, a summary Use Case diagram, and mock-up example for prescribing and 
dispensing systems to provide personalised medicines information at point-of-care; 
and b) the feasibility of the proposed Use Case from a business perspective with the 
help of New Zealand’s vendors of prescribing and dispensing software.  
A Use Case, a summary Use Case diagram and mock-up examples of personalised 
information were created as resources in order to effectively describe the proposal to 
vendors and explain how it is expected to work at point-of-care. These resources 
outlined a proposal that would provide GPs and pharmacists with personalised 
counselling points to be discussed with patients at the time of prescribing or 
dispensing, and also provide personalised information leaflets for printing off or digital 
delivery to patients. Unfortunately, the proposal was not deemed feasible by vendors 
of prescribing and dispensing systems for reasons such as prohibitive costs, time, 
resources, and potential clinical and privacy risks to patients. Furthermore, although 
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there was some potential benefit seen by vendors, there was little to gain and overall 
feedback was unenthusiastic. 
It was decided that this project is not viable because of the outcomes of the feasibility 
study and the broad scope for medicine information required. It was therefore 
determined that a narrower focus should be undertaken. Specifically, high-risk groups 
of medicines should be a primary focus where patient education and adherence is 
particularly important. A priority area is side-effects for oncology medicines that, if not 
managed appropriately and in a timely manner, may result in serious consequences.  
An alternative option to investigate 
An emerging idea of using PROs to generate tailored side-effect management 
information might have the potential to benefit patients immensely, particularly those 
taking high-risk medicines such as chemotherapy (see chapter 6). 
Nearly all patients taking chemotherapy medicines will experience negative outcomes 
such as side-effects (e.g. vomiting) during their treatment. If not appropriately 
managed, these side-effects can worsen, resulting in severe toxicity or fatality. On 
chemotherapy initiation, a large amount of information is communicated to cancer 
patients, with a strong focus on how to manage side-effects and when to seek further 
help. As mentioned in chapter 3, patients have difficulty remembering the information 
provided to them during consultation,63, 139 particularly when they are anxious. 
Therefore, improving the method of informing cancer patients about their treatment 
could help improve patient safety, satisfaction, and potentially even outcomes. 
The use of PROs to aid medicine management works well in cancer therapy, where 
there are detailed validated algorithms on side-effect management in New Zealand 
(personal communication with L Dagg, Associate Charge Nurse Manager 
Oncology/Haematology Outpatients (SDHB, March 2018)) and internationally.201 
Currently in New Zealand, if patients receiving chemotherapy experience side-effects, 
they can contact a designated oncology nurse at the DHB’s oncology unit, or the 
oncology ward (L Dagg, pers. comm. March 2018). A paper-based triage algorithm is 
commonly used to guide their nurses’ recommendations, e.g. attend the hospital 
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urgently, undergo monitoring, or provide home-based self-care management.201 The 
paper-based triage algorithms in use can be easily adapted into a digital questionnaire 
for patients to use at home, with their responses being captured in the hospital 
patient management record. The questionnaire could also be provided on a digital 
platform that contains useful medicine information for patients (including how to 
take, what side-effects to expect, and what you must avoid while taking the 
medicines) to provide a complete information and medicine management interface. 
This digital platform could help cancer patients manage their own health and provide 
them with additional information whenever they want to access it. Using digital 
platforms to collect Patient Reported Outcomes with medicines has been trialled in 
the UK, Europe, and Australia,124, 126, 129, 134 although it is novel in New Zealand. 
Adapting systems under trial internationally with a focus on the New Zealand cultural 
environment including Māori and Pasifika health could be a sensible first step to 
providing truly personalised information to New Zealand patients. The next chapter 
will discuss the use of PROs for information provision in oncology/haematology. It will 
examine views of those who have undergone chemotherapy to investigate their 
information needs and determine if a web-based PROs tool might be well-received for 
use in secondary care in New Zealand.
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Chapter 6:  Patients’ opinions about the 
delivery of information about high-risk 
medicines and their perceptions on use of 
Patient Reported Outcomes (PROs) for 
personalising information in practice  
6.1 Synopsis 
Chapter 5 examined the feasibility of building a personalised medicine information 
leaflet system into the current prescribing and dispensing management software used 
in primary care. The investigation found predominantly negative views: little perceived 
value by the vendors, prohibitive costs, lack of consistent use of patient coding by GPs, 
and that the pharmacist is often not involved in the patient data entry process in the 
dispensing management software and so would not be prompted to raise counselling 
points or print leaflets.  
In secondary care, where drugs associated with a higher risk of side-effects are 
prescribed (high-risk medicines), there may be an even greater need for adequate 
information to be provided. There is abundant patient information available in New 
Zealand about cancer treatments from a variety of sources such as the Cancer Society 
of New Zealand,202 the Breast Cancer Foundation NZ,203 Leukaemia & Blood Cancer 
New Zealand204, eviQ,205 as well as locally produced patient information.206 In 
meetings with S Pointer Oncology/Haematology MOSAIQ Specialist (Southern District 
Health Board (SDHB), December 2017) and L Dagg Associate Charge Nurse Manager 
Oncology/Haematology Outpatients (SDHB, March 2018) the processes for providing 
chemotherapy patients with information were discussed. At SDHB a designated nurse 
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is available via the telephone to answer side-effect related queries and recommend 
either self-management options or attendance at the hospital. However, this service 
may be underutilised if people are hesitant to telephone the hospital for advice. 
Furthermore, Pointer and Dagg clarified that the way information is provided and how 
side-effect management information is delivered to chemotherapy patients differs in 
other DHBs around the country. To investigate the delivery of information about high-
risk medicines, focus group discussions and interviews with patients who had 
undergone chemotherapy were undertaken. This was to understand their experiences 
of receiving information about their chemotherapy medicines and to identify any need 
for improvement.  
Another avenue investigated was patients’ perceptions of using a digital platform or 
web-based tool for personalised and relevant information about their medicines. This 
chapter further describes the possibility of using PROs in New Zealand practice for 
reporting side-effects into a web-based tool which can then be used to generate 
information about managing side-effects and provide other desired information to 
patients e.g. if, or when, further intervention is necessary.  
Chapter structure 
This chapter has three parts: 
1. Patients’ experiences with medicine information about their chemotherapy. 
Section 6.3 examines patients’ views on how they received information about 
their chemotherapy medicines. It investigates how New Zealand patients who 
have undergone chemotherapy treatment feel about the way they receive 
information about their chemotherapy, and whether they think that this process 
works well or could be improved. 
2. Patients’ views on the use of PROs for generating personalised information 
with high-risk medicines. Section 6.4 examines patients’ views about the 
possible use of a digital tool utilising PROs. It describes findings from the second 
part of the above study about a) whether chemotherapy patients would like to 
use a digital tool to receive medicines information about their chemotherapy 
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and b) their opinions about reporting adverse treatment outcomes through a 
digital tool that would generate advice about how to manage the side-effects 
they experience. 
3. Strengths and Limitations. Section 6.5 discusses the strengths and limitations 
of this study. 
Section 6.3 and 6.4 are two parts of a single study that cover two distinct research 
aims—see 6.2, below.  
6.2 Chapter aims  
Patients receiving high-risk medicines need to be well-informed of the potential harm 
of treatment. The deluge of information provided for some medicines, e.g. 
chemotherapy, could be daunting for patients to receive—particularly because it is 
given during a stressful and emotionally-charged time in peoples’ lives.207, 208 For 
information to best meet patients’ needs, it should be personalised and specific for 
their requirements. This chapter aims to investigate patients’ perceptions of the 
adequacy of the information provided to them about their medicines and their views 
of the possible use of web-based PROs to optimise their use of high-risk medicines.  
Specific aim 1: To explore the opinions of New Zealand patients who have undergone 
chemotherapy cancer treatment about the information provided to them.  
Specific aim 2: To determine the views of New Zealand patients about how possible 
web-based PRO tools could be utilised in future practice to improve medicine-related 
outcomes, and patients’ ideas on how this platform could be used.
194 
 
6.3 Patient experiences with medicine information 
about their chemotherapy  
6.3.1 Introduction 
In New Zealand, more than 20,000 patients are diagnosed with cancer each year.209 
Receiving a diagnosis of cancer will cause people to experience anxiety and distress207, 
208 and, as discussed earlier, this may result in them having difficulty comprehending 
and remembering information they receive at this time.15 Furthermore, chemotherapy 
medicines can be complex and associated with multiple serious side-effects210-212 so 
the type and quantity of information people receive about their treatment may be 
overwhelming.  
Provision of chemotherapy medicines in primary care is increasing in New Zealand. In 
2014 over 52,000 people received their chemotherapy or immunosuppressing 
treatment in primary care.213 Because of the aforementioned complications with 
conveying necessary information to people receiving chemotherapy at the time they 
are originally prescribed these medicines, it is imperative they are provided with 
adequate counselling and written resources to refer back to.214  
Provision of information  
In informal meetings with S Pointer, Oncology/Haematology MOSAIQ Specialist (SDHB, 
December 2017) and L Dagg, Associate Charge Nurse Manager Oncology/Haematology 
Outpatients (SDHB, March 2018) the provision of information about chemotherapy 
medicines in SDHB were discussed. In the SDHB, people who are about to undergo 
chemotherapy have an intensive one-on-one session with a nurse to discuss their 
chemotherapy medicines and are given printed information to take away. In informal 
discussions with A Jamieson, Clinical Pharmacist (BPharm, July 2020), a pharmacist 
who worked in oncology at Nelson Marlborough DHB, it was clarified that the type of 
information provided to people about their treatment can vary depending on what 
DHB they reside in, what type of cancer they have, and what treatment they are 
receiving. The resources used were also discussed in an informal meeting with A 
Jamieson (informal pers. comm. July 2020) and there are various sources available to 
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be provided to patients, including booklets created in individual DHBs206, 215 and 
written resources provided by regional cancer networks.216 The Australian eviQ 
patient information resources created by the Cancer Institute New South Wales205 are 
also widely used in New Zealand. The Australian NSW state government-funded eviQ 
web content is written by specialists and is also used in 170 other countries globally.217 
These are well-regarded resources and are easily available at point-of-care (S Pointer, 
informal pers. comm. December 2017, L Dagg, informal pers. comm. March 2018, A 
Jamieson, informal pers. comm. July 2020). In New Zealand, national resources are 
also available for children who are receiving chemotherapy, and their families.218 
Many other reputable sources of information about cancer types and treatments are 
available for people diagnosed with cancer in New Zealand. These can be easily found 
through web searches and include those produced by the Cancer society of New 
Zealand,202 and more specific information according to cancer type produced by 
organisations such as Breast Cancer Foundation New Zealand,203 Leukaemia and blood 
cancer New Zealand,204 and Bowel Cancer New Zealand.219 
Providing information about side-effects with chemotherapy 
medicines 
Side-effects of chemotherapy range from those that have less serious consequences, 
such as hair loss, to those that are potentially fatal such as febrile neutropenia and 
rash.210, 212 Furthermore, not all reactions are experienced to the same degree. Some 
side-effects, e.g. diarrhoea, may be minor for some patients and require only advice 
for home management, whereas other patients may experience the side-effect so 
severely they require hospitalisation. Although, it is possible to foresee side-effects 
that relate to the chemotherapy regimen and cancer type, the extent of severity of 
side-effects cannot always be predicted.210 If appropriately handled in the early stages 
some side-effects can be managed at home. However, if not managed early, some 
side-effects can worsen resulting in severe toxicity.125, 129  
The United Kingdom Oncology Nurse Society (UKONS) (http://www.ukons.org) has 
created an oncology/haematology triage tool with a traffic-light system risk-
assessment algorithm containing management advice for common and serious 
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chemotherapy side-effects.201 The tool is used in many countries worldwide, and its 
use in New Zealand was discussed in the meeting with L Dagg (SDHB, March 2018); 
similar to use in the UK, it helps the oncology staff decide what advice to give, e.g. 
advise patient to attend the emergency department at the hospital urgently, to attend 
the oncology ward for a review at a scheduled time, or to provide home-based self-
care management advice. The benefit of using this tool is that it enables the provision 
of standardised and evidence-based advice to people suffering from side-effects 
associated with their chemotherapy. 
In informal meetings with S Pointer (SDHB, December 2017) and L Dagg (SDHB, March 
2018), the system of patients’ reporting side-effects to the hospital was discussed. In 
the SDHB, patients receiving chemotherapy are told they can contact a nurse at the 
DHB’s oncology unit if they experience side-effects via an exclusive phone line.220 
During working hours this phone line is staffed by a dedicated oncology nurse and 
during out-of-hours the calls are answered by oncology ward nursing staff. The nurses 
use the UKONS triage algorithm to determine the action required. This system, with a 
dedicated oncology nurse for side-effect management, has been shown to reduce cost 
due to reduced admissions for toxicity management and reduce patient presentation 
at emergency departments. However its use is not widespread in New Zealand and 
DHBs around the country have differing approaches to monitoring and advising those 
requiring side-effect management.  
Aims of this research 
It is not clear whether the current practices of providing information about 
chemotherapy medicines are optimal for patients. The aims of this study are to 
explore the views of people who have had chemotherapy about (i) how they were 
given the information about their chemotherapy, (ii) whether they understood this 
and could act on the information given, and (iii) whether they think this could be 
improved.  
This study was approved by the University of Otago Human Ethics Committee 
(reference number H19/144). The study protocol is in Appendix 19. The ethics 





Plans for Participation  
We planned to hold focus groups sessions with 6–8 people in each group. In order to 
participate, people needed to meet the following selection criteria: 
 Be 18 years of age and over 
 Have previously had chemotherapy and are in remission 
 Can read and speak English. 
Those who were under 18 years of age, currently using chemotherapy medicines, or 
cannot read or speak English were excluded from participating.  
The first focus group would be a group from the general population from the Dunedin 
area. The second would be Māori participants from the Dunedin area. The third would 
be Māori participants from a rural part of North Island, New Zealand. The fourth 
would be a general population group from a more rural/remote location (to be 
recruited in Southland). 
Food/kai would be provided during the focus group sessions. Upon completion of the 
survey, participants would receive a $20 supermarket voucher.  
Participation in the study 
Our original intention was to only hold focus groups and not to have interviews. The 
benefit of focus groups is that conversation can be encouraged, and more ideas can 
arise than in a one on one interview.221, 222 Involving a diverse population to discuss 
concepts should lead to an enrichment of responses. If people have a different mind-
set on the concept it will allow discussion from all angles giving more detailed 
discussion on each topic.222, 223 Furthermore, focus groups may give more confidence 
to individuals to give their honest opinion if supported by others in the group. There is 




In early February 2020 we were advised that there might be recruitment difficulties in 
some localities/population groups (e.g. rural areas, Māori), so we extended our study 
protocol to allow face-to-face or online interviews of individuals who met the 
recruitment criteria. Recruitment, focus group meetings, and interviews began soon 
after this. 
Interviews may have some benefits over focus groups. They may allow more time for 
individuals to speak and individuals may speak longer on average to express their 
opinion.221 An interview guide is used and interviewers do not need to act as a 
moderator to control some of the conversation (as may be necessary in a focus 
group). Interviews are useful in giving respondents opportunities to express their 
attitudes without personal embarrassment from several other individuals being 
present.221, 222 Generally, interviews are easier to organise and it is easier to recruit 
hard to reach groups (e.g. Māori participants). Moreover, the interviewer can adjust 
their interviewing style to fit people’s needs and participants do not have to worry 
about group dynamics.222  
At 11:59 pm, 25 March 2020 New Zealand went into ‘lockdown’, prohibiting all but 
essential services and cancelling all unnecessary travel, events, and 
meetings/gatherings during the Coronavirus disease (COVID-19) pandemic.224 These 
restrictions meant we were unable to hold group or face-to-face meetings for the 
foreseeable future. The research team initially thought that meetings and interviews 
in a digital space might result in potential bias toward those who have high digital 
literacy (an area of focus for this study), so we suspended recruitment for further 
focus group meetings or interviews at that point. 
On Monday 8th June, New Zealand moved to alert level one225 meaning that meetings 
with people outside of direct family were now allowed. However, it was uncertain 
how long this alert level would be in place due to differences in international abilities 
to control spread of infection. The University of Otago Human ethics committee 
therefore continued to advise against holding face-to-face interviews and 
recommended videoconference or telephone options for data collection.226 Early 
analysis of the general population data already collected demonstrated we were close 
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to data saturation from this particular group. Because of this, we decided to continue 
recruiting participants from this population in the Dunedin area to ensure that data 
saturation occurred, offering telephone or videoconference methods. This would 
strengthen the findings of this study for applicability to the Pākehā (non-Māori) New 
Zealand population. Because of continued inability to meet face-to-face with Māori to 
foster relationships for recruitment and participation in this study, the research team 
agreed it was not possible to sufficiently align with Kaupapa Māori research 
methods227, 228 for data capture and recruitment. Therefore, we decided to abandon 
attempts to recruit Māori at present. The implications of this are addressed in the 
study limitations.  
Recruitment methods 
Study participants were recruited through local organisations/support groups. For the 
first focus group undertaken in Dunedin (pre-COVID-19 lockdown) we used the Otago-
Southland division of the Cancer Society, EXPINKTTM (the University of Otago Physical 
Education School’s exercise programme for women who have had breast cancer 
surgery), the Dunedin branch of the Leukaemia and Blood Cancer New Zealand, Breast 
Cancer Foundation, Bowel Cancer New Zealand, and Ripple. We asked the leaders of 
these organisations to advertise the project to their members/patients through 
posters and/or email (if appropriate). Members could contact the research team if 
they were interested in participating. They were provided with a participant 
information sheet either by direct handout, post, or by email (according to their 
preference). The participant information sheet has the contact details for the study 
team to allow participants to ask questions about the project before deciding whether 
to participate (see Appendix 21).  
Consultation with Māori advisors was undertaken about recruitment for this study and 
for support with understanding Kaupapa Māori research theory. Through this 
consultation we were given valuable contacts to aid our recruitment process 
(however, we could not proceed because of the COVID-19 lockdown restriction 
mentioned previously).  
200 
 
Focus group and interview outline  
The focus group meeting and individual interviews consisted of four parts: i) an 
individual questionnaire; ii) a discussion about items from the questionnaire; iii) an 
introduction to the online tool (capturing Patient Reported Outcomes (PROs); and iv) 
questions seeking participants’ thoughts on the online tool for capturing PROs (see 
Appendix 19). Parts three and four are reported in section 6.4 of this chapter. 
The informed consent form for participation and the recording of the focus group or 
interview was completed at the start of each session. 
Questionnaire and discussion guide development  
A questionnaire and focus group discussion guide were developed to understand 
people’s experiences with receiving information during chemotherapy and their 
typical use of digital technology and the internet (see Appendix 19). These were 
developed based on relevant literature,123, 229 clinical experience, and US government 
guidance on digital usability questionnaire templates.230-232 The questionnaires validity 
was determined using the same methods described in section 3.4 (i.e. following 
extensive research team and expert oncology review).  Expert oncology review led to  
adaptation of the questions: removing the question asking if people were 
‘comfortable’ with the information and instead asking if they liked it and understood 
it; removing the questions based on what people did if they experienced a side effect 
and changing focus to the information they had and how they had received it; making 
questions more focused and mapped closer to objectives by removing unnecessary 
questions (e.g. do you live alone). Expert advice on questionnaire validity was also 
received from a Māori advisor and changes following consultation were applied across 
all the questionnaires to make them identical. Specific changes were minor:  removing 
education level achievement as knowledge and health literacy not necessarily bound 
to academic merit and Māori students as a group spend less time in the education 
system than non-Māori (the focus was changed to digital literacy instead); asking 
participants about cultural appropriateness of information received; removing 
questions on gender; re-arrangement of focus group discussion. 
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Following this validity testing, the questionnaires were pilot tested in three former 
oncology patients. This was to assess readability and understanding. No necessary 
modifications were implemented after careful assessment by the research team.  
The questionnaire was designed to gather data and enable participants to recall their 
experiences ready for further discussion in the focus group or interview. 
Consultation with Māori advisors was undertaken regarding the content of the 
questionnaire and discussion guide. Following their review, adjustments were made to 
improve cultural appropriateness.  
Part one: Individual questionnaire  
The first part of the meeting/interview consisted of a questionnaire. The focus group 
participants were asked to complete the questionnaire on their own in the first 5–10 
minutes of the meeting. The individuals interviewed separately were sent the 
questionnaire 2–5 days beforehand so it could be completed prior to their interview. 
The questionnaire responses were collected by the interviewer. 
Part two: Focus group discussion about items from questionnaire 
The second part of the meeting consisted of a group discussion of the questionnaire 
facilitated by Amber Young and Dr Alesha Smith. This involved a wider discussion of 
the topics covered in the questionnaire in part one. 
In this part we discussed what the participants think might be good for improving the 
medicine information services for oncology patients. 
a. How were they given the information about their treatment and the 
possible side-effects (e.g. verbal only, written, web addresses)? 
b. Could this process of receiving information have been easier? 
c. Do participants think the information and how it is given is appropriate 
for someone from their culture? E.g. Māori or other culture  
d. Do they feel this could be improved in any way? 
We also discussed 




f. What they did if they experienced a side-effect and needed help  
g. If they looked for information themselves from other sources? 
Analysis of data 
The data from the questionnaire were entered into Microsoft Excel155and basic 
descriptive analysis was undertaken. 
The focus group discussion and interviews were recorded and AY transcribed these 
verbatim. AY then double-checked the transcriptions against the recordings and read 
through them again multiple times. JT and AS read through the final transcriptions. AY 
carried out semantic inductive analysis of the transcriptions, i.e. she reviewed the 
explicit content of the data and allowed themes to conceptualise from the 
conversations of people’s experiences. AY organised themes into a framework matrix 
in Microsoft Excel.155 The thematic coding and framework were reviewed by AS and JT. 
The analysis of this study met Lincoln and Guba’s criteria for trustworthiness.233  
Credibility (i.e. how well the context, participants, and methods examine the intended 
concept) was assured by implementation of an appropriate research and advisory 
team and by thorough review of transcripts and framework matrix by AS and JT. 
Furthermore, many quotes were used to show representation within the matrix.  
Dependability (i.e. reliability of data collection over time) was assured through an 
open dialogue within the research team and review of transcripts and framework over 
time. Transferability (i.e. extent that findings can be transferred to another 
group/setting) was assured by clearly describing the participants, data collection, and 
the full presentation of findings with numerous quotations to represent themes. 
Variability in participants leads to richer data gathering and different views being 
discovered. 
6.3.3 Results 
Eleven individuals participated in the study. Seven participated in the focus group 
meeting (five females F1, F2, F3, F4, F5 and two males M6, M7; the focus group 
discussion lasted for one hour) on 11th March 2020 and four others were interviewed 
individually in separate face-to-face interviews. Two interviews were performed on 
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20th March 2020 (F8; interview time 23 minutes and M9; interview time 15 minutes) 
before New Zealand went into alert level four (see section 6.3.3). Two further 
interviews occurred following lifting of restrictions, one on 24th June 2020 (F10; 
interview time 21 minutes) and 30th June 2020 (F11; interview time 21 minutes). Only 
one interview was performed in person (with M9), the others were performed via 
videoconference (with F8 because of personal preference, and with F10 and F11 
because of ethical restrictions required by the university—see section6.3.3). All lived 
in the Dunedin area. Most of the participants were in the age group 51–80 years (n=6, 
55%), three (27%) were aged 21–40 years and two (18%) did not disclose their age. 
The demographics of participants are in Table 15. 
Table 15: Demographics of Dunedin Participants 














New Zealand European 10 





 Participants (n) 
 
Lymphoma 3 
Breast cancer 3 
Myeloma 1 
Saturation of ideas was considered to be achieved following the first interview on 20th 
March 2020, three further interviews were held to confirm saturation achieved within 
this group of participants from the Dunedin area. No further focus groups or 
interviews were possible in the timeframe because of the aforementioned COVID-19 
meeting restrictions. Therefore, contacts in oncology organisations in rural areas, 
Northland, and local Māori contacts were not followed up for recruitment (see 
Strengths and limitations). 
Data analysis is described in two parts, firstly the analysis of the individual 
questionnaire responses using simple descriptive grouping analysis. Secondly the 
thematic analysis of the interview and focus group content is described.  
Part one: Individual questionnaire responses relating to information about 
chemotherapy 
Verbal information received 
Most participants thought that the verbal information they received was easy to 
understand (n=7, 64%) and just over half agreed the way it was given to them helped 
them to understand it (n=6, 55%). However, participants had mixed views on whether 
the amount of information provided was too much (n=5, 45%) or too little (n=6, 55%). 
There were also mixed views about the statement I was told how to get more 
information if I wanted it (disagree n=2 (18%); neutral n=4 (36%); agree n=4 (36%).  
One participant provided further comment that in some situations, copious 
information is not appropriate, “appearing in hospital with extreme sickness there isn't 
much time to deliberate over what type of treatment you receive and why.” [M6] 
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Another felt they had reached their limit of information-saturation, “They gave me all 
the information that I could take in.” [M9] 
One participant indicated that the amount of information received is inconsistent, 
“I've had 3 lots of chemo over 16 years and every time [it] was different.” [F1] 
Another participant thought that the quantity of information on differing topics was 
inconsistent, “The information regarding side-effects was abundant but information 
regarding what chemo was and how it was delivered was lacking.” [F3] 
One participant who felt the information was not given in a way they could 
understand it commented, “Information was all provided in written format and a lack 
of personal explanation noting that I was not in a fit state to take in all of the 
information. I sought information from family members.” [F10]  
Similarly, another participant further commented, “I remember this part of the 
appointment was very stressful as I had a lot of information given to me at once and I 
struggled to absorb it all.” [F11]  
Written information to take away  
Eight of the participants (73%) confirmed that they were given useful information to 
take away with them about management of side-effects, and one participant was 
given information to take away but did not consider it useful. The other two 
participants responded that they were not given useful information to take away. 
Just over half of participants (n=6, 55%) thought that the information was easy to 
understand. However, opinions differed about the quantity of take away information; 
four people (36%) strongly agreed and four (36%) disagreed that there was too much 
information given, one participant was neutral and two did not respond to this 
question. Most participants read the information at home (n=7, 64%) and found it 
useful to read at a later time (n=7, 64%). One participant (9%) who found the 
information difficult to understand commented, “[I] was handed lengthy pieces of 
paper which to someone with little to no medical experience wasn't helpful.” [F5]  
Another participant thought the information could be improved, “It would have been 
useful to have someone highlight the key pieces of information...I didn’t realise what 
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was going to be important until I was in the midst of it and by then my brain wasn’t 
that functional and I was quite distressed.” [F8] 
All participants shared information with other people such as their partner or family, 
and two shared it with their community pharmacist. One participant, who shared it 
with their pharmacist needed help to understand the information, “My daughter even 
had to go to the local chemist to try to understand some of the information relating to 
the medication and the side-effects as it was not clear on the multiple pieces of paper 
that I had accumulated.” [F10] 
Following the Information given 
Most participants (n=6, 55%) followed the advice provided if they experienced a side-
effect. Two participants stated that they only sometimes followed the advice and one 
participant stated they did not follow the advice (two participants did not respond to 
this question). The participant who did not follow the information given to them, 
contacted their family for help instead. 
The reasons given for not always following the official advice were because some 
participants deliberately ignored their symptoms to avoid going to hospital, and 
similarly because they did not have the energy or resilience to deal with, “another 
medical person poking and prodding me.” [F8]  
Other reasons for not following the information given to them were they could not 
remember the information, the information provided was not relevant to their 
symptoms, they found the information too difficult to understand, or they could not 
find the information they were looking for, “[I] can’t remember the information and 
what I did have was spread over [the] document.” [F10]  
All but one of the participants indicated they felt prepared about what to do if they 
experienced a side-effect. 
Part two: Qualitative analysis about chemotherapy medicine 
information 
Data analysis of the focus group and interview discussions revealed four main themes, 
and 12 sub-themes:  
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1) Gathering and use of information, with subthemes of 
a. Avoiding the information provided 
b. Information as a future reference  
c. Importance of family involvement 
d. Communication with HCP 
2) Problems identified 
a. General concerns about information received  
b. Problems with information about the side-effects that were experienced 
c. Communication difficulties and barriers identified 
d. Inability to process information  
3) Other opportunities used to aid understanding 
a. Help from fellow patients/support groups 
b. Other sources of information  
4) Improving information provision 
a. How information provision could be improved 
b. Personalised information needed 
Theme one: Gathering and use of information  
All participants received information at the beginning of their chemotherapy 
treatment, with large quantities provided as pamphlets or information sheets and 
sometimes links to websites were provided. In most cases verbal and written 
information was given.  
“Everything was written down for me as well...I also had, ah, websites I could go to, 
um they said a lot of stuff verbally as well.” [F5] 
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“There was lots of good information um about the drugs for the stem cell transplant 
you know and I’ve got the whole range of these, these things [information leaflets].” 
[F1] 
“So the way I got information was much like that, just sort of like, all in pamphlet 
form.” [F2] 
Because of the large amount of information, not all of this could be covered during a 
conversation. One commented, “I think there was some bits they went um, they went 
through with me but often it was, yeah ‘here’s, here’s the information, take it away 
and read it at home’.” [F8] 
Another one said, “They also talk to you a wee bit about it, but you know they can only 
give you so much information, you know.” [M9] 
One participant also indicated that the verbal information provided by their health 
professional was a comfort to them, “They explain things to you, what was going to 
happen, when it was going to happen, um, what to expect and you know like that…a 
lot of information to give you, you know? And that which takes the scariness out of it. 
You know? So it’s very good.” [M9] 
Not all participants received information about websites to visit. “They don’t, don’t 
really put you on to websites. They, it’s mainly books and then pamphlets and then 
information like that.” [M9] 
“No, nothing like that, no.” [F10] 
One participant indicated that while they did not remember the specifics of the 
information given to them, the side-effects they experienced with their treatment 
were not unexpected. “I don’t think I was really surprised about any of the side-effects 
I experienced while I was having chemo so that indicates to me that I knew. Like when I 
think back I don’t think that there was anything that really I was like ‘ooh I wasn’t 
expecting that’.” [F11] 
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a. Avoiding the information provided 
Six of the participants indicated that they avoided reading information about their 
treatment. The reasons for this varied—some were not interested in knowing or 
avoided information as a strategy to carry on with normal daily life, willing to wait and 
see what would happen. One participant said, “I didn’t really want to know too much 
either. Just get on with it... Didn’t really get into that side of it too much. Just let it 
happen. Trust the doctors.” [M7] 
Another participant agreed, “Didn’t want to know. Pretend it’s not there, you know?” 
[F2] 
Additionally, one commented, “Not actually delving too deep into it, I sort of at that 
time didn’t really care, didn’t really want to know.” [M6] 
One participant worried that if they knew the side-effects, they would start expecting 
them to occur. “Sometimes I think you don’t want to know... My kind of thought was, 
if I look at it and I know, I’m going to like expect it or be looking for it.” Or started to 
experience a nocebo effect from their treatment “I didn’t want to put it in my head, 
otherwise I’m going to end up with everything.” [F3] 
Two participants indicated that they did not want to read the information because of 
the quantity that was provided or the way it was presented.  
“I did a bit of reading on it, but then I was just kinda ... turned off, I just didn’t want to 
know. I was just like, you know, I’m just going to get through it the way that I have to. I 
don’t want to read anything ... anything else. So yeah. It was easier to just sort of you 
know, keep it simple.” [F5]  
“She fidgeted with all the pamphlets, poking them into this…and it was just really 
incredibly painful watching her do it. I was just like ‘oh, I hate that folder, I don’t even 
want to look at it’.” [F11] 
Two participants found the information available on the internet was concerning.  
“I never went online ‘cause you know going online is just scary as f***. I did at the 
start and I scared the sh** out of myself and I’m like I ain’t doing that again.” [F5] 
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And one participant indicated that their spouse didn’t want them to find out 
information that may frighten them. “Well my daughter went on the computer, and 
my husband said ‘get outta here! We don’t want to know the stuff off the computer’.” 
[F4] 
b. Information as a future reference  
One of the ways that the information was used, was to be referred to later when they 
are experiencing a problem. “Yeah it’s a good reference. It’s good reference material 
to go back if you need to, you know, check on something.” [F3] 
Some participants liked to have the information for their support people to use when 
a problem arose.  
“Mum had that as, like, her bible she used to call it. So if any of the drugs if I have 
anything...she used to go back and look.” [F2] 
“You’ve really got to be given the information at the beginning and then hopefully if 
things happen, someone else, you know, one of your support people, you know, may 
look at this.” [F1] 
c. Importance of family involvement 
Family or support people were perceived as vital information gatherers and seen as an 
essential part of visits with the oncology or haematology team.  
“I think it’s something that pretty well everyone has said that it’s essential to take a 
support person with you.” [F1]  
“They [her children] dug it [the information] all out and that’s where I got my help 
from. But in saying that, my heart bleeds for Joe Bloggs who doesn’t have that back up 
support.” [F10] 
One reason for this was because of the difficulty remembering what is discussed 
during a consultation. 
“My husband, especially this last time writing things down, um, and because you know 
the, you’re not going to remember everything that’s said to you.” [F4] 
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 “Luckily I had, you know, our daughter with us and, and she you know, brought all this 
stuff home, and later on if I had something I was going back and checking it.” [F3] 
Even although some people avoided information, it was often the support person who 
read and kept the information about treatment.  
“They might have looked at them [information leaflets], but I didn’t.” [M6] 
“But my partner, she researched it on the internet as well as reading all the 
pamphlets...yeah, I’ve just, let her, let my partner deal with them all.” [M7] 
One participant’s mother had just been through cancer so could provide some helpful 
support and tips for navigating the system. “My mum had cancer right before me and 
she gave me this notebook and this went with me everywhere I went and whoever was 
there with me would write down the notes of the questions that I would ask.” [F11] 
Two participants also revealed that their family members were often the driving force 
behind them reporting their side-effects to the nurses at the hospital.  
“You don’t want to go into the hospital ‘cause you don’t want to, you know, stuff 
them. So, that’s when your partner comes in and she says ‘no you’re going to have to 
go to hospital’, and then they help you.” [M9] 
“Waiting it out in bed and Mum’s like ‘have you got a temperature?’ and I’m ‘nah I 
don’t have a temperature’ and Mum’s like ‘I want to take your temperature, let me 
take your temperature’ ‘why do you need to take my temperature?’ and it’s like ‘your 
over the limit’.” [M6] 
One participant used their children, rather than the hospital, for help with managing 
side-effects. This participant was in a fortunate position of having health professionals 
in the family and in some instances were better at recognising medicine effects and 
how to manage these than the specialist team involved in their care. “When I was 
taking myself off morphine…such bad diarrhoea, and the hospital thought I might have 
eaten something but my haematologist son said ‘no that’s what happens when you 
come off morphine…have you ever seen the movie Trainspotting?’” [F10] 
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This participant was only able to stop the morphine, which was no longer needed, 
because of family support. “He’d said to me ‘you need to get off morphine Mum’ and 
he and his wife, they were here, and they just gradually got me off it.” [F10]  
Discontinuation of morphine was important to this participant because it allowed their 
life to resume normality, and they appreciated the support of their family as integral 
to this process. “I just don’t know, I just don’t know how I would have coped at sort of 
being able to get back to a normal life without my kids’ support.” [F10] 
d. Communication with Healthcare Professionals 
Participants often described their direct communication with the oncology and 
haematology team at the hospital as favourable. “Nurses in Dunedin, ah, they’re great, 
the cancer nurses...so empathetic and so, just gives you the information and 
fantastic.... I’ve got a good haematologist, she’s fantastic, and the nurses who were 
great.” [M9] 
 Their ability to communicate was also well-received.  
“They are very easy to communicate with. Yeah very good.” [M9] 
“I felt like they were explaining, I felt like all of the team that I saw were really good at 
explaining things at a very basic level”. [F11] 
The specialist nurses who provide the information about treatment were also highly 
thought of. “Specialist nurses...were invaluable.” [F3] 
One participant also described having positive communication with a cardiology 
specialist following a long-term side-effect associated with her doxorubicin. “…and I 
had um lovely attention from the um cardiologists who explained everything well, how 
he was going to balance, you know heart drugs and everything like that... so I felt the 
treatment was much more personal um and that I had enough information.” [F1] 
Another, who attended a different hospital for a stem cell transplant, valued 
communications with the ward pharmacist. “It was the pharmacist who you know, 
explained your drugs. Went through why you were taking it, side-effects and all that. I 
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couldn’t believe it, and gave you little sheets of paper that were yours, specially made 
out for you.” [F10] 
The ability to speedily contact a designated nurse at the hospital for information when 
a side-effect occurred was appreciated by many participants.  
“You could send a text at any time or phone up and you know talk to, to them and 
they’d pass a message on to one of the cardiologist or the, the, um doctor” and “they 
did give me a number for the hospital, for, um, up in the oncology ward for a nurse 
there and she was great.” [F1] 
“So, you’re, you’re advised what to do and they’re very um, they’re very strong on 
saying ‘look, if you really need help, go in. Don’t, don’t hesitate’.” [M9] 
“I was very happy to ring because they were really clear with that, keeping that 
communication line open...I felt like a VIP customer in a way, like I felt like they knew, 
they took an interest?…You get to know the nurses on a first name basis.” [F11] 
“They were very good because they’ve got a green card that you get with an 0800 
number that takes you straight to help. So I’ve got no complaints about that. That was 
really well done. That was done through the oncology day unit. Yes I knew exactly 
what to do, yeah and I felt very comfortable doing it.” [F10] 
However, one participant thought it would have been improved if you had more of a 
connection with this contact before you had problems with your treatment. “It would 
have been really useful to have either been rung by her or been encouraged to ring her 
before I started treatment... just so I felt like there was a bit of a connection already...I 
was only ever going to ring her when I was at a point where I was going ‘I don’t know 
what to do now’.” [F8] 
Two participants also stated that they did not know about the medicines they were 
receiving but were happy to put their full trust in the oncologists and haematologists.  
“I didn’t get involved in, um, what the chemicals were they were putting in to me. I 




“Got to trust the oncologist or haematologist and, um, you know, the specialist that 
they’re not deliberately giving you a poison you know...so I wouldn’t really read into 
the treatment that much.” [M6] 
“It’s not as if you get options it’s just that nobody asks what you want and you have to 
trust the specialists that it’s the right drug, this is the right drug.” [M6] 
Theme two: Problems identified  
Most participants (n=10)described problems with the way they were provided with 
information, or how they had difficulty understanding what they had been told. Some 
examples were given where there was a lack of communication and strained 
relationships resulting from communication difficulties. Participants also described 
how the cancer diagnosis affected their ability to understand the information provided 
to them by their doctors. 
a. General concerns about information received  
One participant felt they did not receive adequate verbal communication about their 
chemotherapy, which had a negative impact on their perceptions of the service. “I 
wasn’t really spoken [to] about it. I am very sceptical about all this [information about] 
treatment and I have to tell you, um I’ve got very negative thoughts about it.” [F10] 
The reason for lack of verbal discussion was thought to being put on a different ward 
due to lack of space on the oncology/haematology ward. “The ward that I should have 
been on was full and I was put into a ward with dementia patients. So I sort of feel, 
perhaps if I had been on the correct ward I may have had more interactions…they 
could have come in and explained it more.” [F10] 
Other participants described being given copious written information and the quantity 
of leaflets or pamphlets provided was sometimes overwhelming.  
“They can only give you a small amount of oral…and then they gave the 
pamphlets…and I got it home and I went bloody hell, you know? I just couldn’t believe 
it because the side-effects were huge and then you look at that, and it scared the sh** 
out of me”. [M9] 
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“It was information overload at that time, so I don’t think I actually looked up any of 
those things until maybe later on when I was thinking ‘oh do I have to, what should I 
check about that’ if I was wondering about something.” [F11] 
There was also concern that with the quantity of information provided and the way 
that it was given could limit comprehension, cause anxiety, or prevent you from 
finding what you were searching for. 
“The way that the information was given to me was incredibly stressful”. [F11] 
“It is just quite overwhelming. It’s overwhelming and it, the more they give you can 
confuse you.” [M9] 
“With one particular folder there was a lot of information in there and .... I remember 
it getting a bit mixed up and it took me quite a while, um, a couple of visits to the 
hospital to work out ‘oh actually I needed to read this piece of paper’.” [F8] 
Two participants further described their anxiety in how side-effects in particular were 
communicated to them.  
“When I got all of the information on the side-effects I really nearly, you know I, I just 
got blown away to put it nicely, you know. Because it’s scary.” [M9] 
“She gave me all of this, all these handouts just to reiterate the key side-effects and 
everything I was going to experience. And um, it was just information overload, like it 
was really stressful.” [F11] 
Another participant found it confusing the way the names of the regimens are 
provided, compared to the names of the drugs. For example “Doxorubicin 
hydrochloride” is also called “hydroxydaunorubicin”: “One thing about the drugs that 
would be helpful, um, is that so many of these drugs are known by about six different 
names and just sort of having a kind of list” going on to say “the doxorubicin, well you 
think in RCHOP there’s no D, you know...just sort of listing the things so that you know 
that the H refers to doxorubicin.” [F1] 
One participant used a notebook to document information about their ongoing 
treatment from all the different people involved, because each health professional 
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was providing separate information and it was difficult to remember everything being 
told to them. 
“I had that book and I had to record everything in it because I saw that many people, 
and I had that, like I had a lot of information that related to all of my treatment, 
beyond just the chemo aspect.” [F11] 
b. Problems with information about the side-effects that were experienced 
Five participants commented that they experienced a rare side-effect, and four of 
these struggled to get information about it from their specialists. One problem 
identified by many participants was the paucity of information about the rarer side-
effects experienced. “It was good to a certain point and then it was kind of like the 
information kind of stopped and it was almost like you know you kind of had to force it 
out of them.” [F5]  
Or they perceived the healthcare team did not know about it, as described by one 
participant who was asked if they found it easy to get information about a side-effect 
experienced; “Nup ‘cause they didn’t really know what the problem was.” [F2] 
Another participant, who had experienced a rare side-effect, struggled with knowing 
what side-effects to pay attention to in the information provided to them. “So then I 
was thinking about how you pay attention to what’s written down here, you know all 
these things are here so look at that, oh yeah, yep uncommon, and then rare...and I 
thought, well I really didn’t have common...so I think probably at the time I didn’t take 
much attention to what was rare.” [F1] 
Some (n=4) struggled to get information about rarer side-effects when they were 
experienced.  
“I didn’t know what was going wrong every time. I knew something was wrong, but 
nobody ever explained.” [F4] 
“Every time I came up to them and I wanted more information and stuff where I said 
‘I’m getting this side-effect is it normal?’ and they were just like ‘mmhmm mmhmm’ 




One participant believed that if information about less common side-effect was more 
comprehensive, it could have avoided a visit to the ED, “I ended up there [in ED] a 
couple of times, um which yeah, again, it was like, that could have been avoided with a 
bit better information.” [F8] 
Although people were encouraged to report their side-effects, they did not feel 
supported when rarer side-effects occurred, “But they gave me a diary to write all my 
symptoms in, um, to keep an eye on them and stuff like that, and I brought it in and 
showed the doctors but they sort of didn’t give me any info about it, they were just like 
‘oh yeah no that’s fine that’s okay’, hmm okay I guess I’ll just struggle on then.” [F5] 
This left some participants feeling like they had been fobbed off.  
“I knew something was wrong, but nobody ever explained.” [F4] 
“One of the side-effects I had was a lot of pain and that was not covered at all in my, in 
the information I got given and in the various meetings I had with the oncologist and 
the nurse. I was quite gobsmacked. Especially when I did find out that pain is not an 
uncommon side-effect.” [F8] 
“When I went to them and went ‘I had this weird breathing thing’...and they were like 
‘oh well that’s not one of the side-effects...we don’t know...if it keeps bothering you, go 
to your GP’. The GP’s like ‘I don’t know what it is’.” [F5] 
One participant also felt this lack of communication also occurred when they 
experienced severe side-effects. “The first time [I was admitted to ED] they just put me 
in to rest, they didn’t tell you anything, or what was going on with anything.” [F4]  
c. Communication difficulties and barriers identified 
Some participants (n=3) experienced communication difficulties with their specialists, 
and this led to problems with their ability to receive information. “I feel like the, the, 
information is given as if we were, you know, these rational beings, ah, which we’re 
not at the best of times, and we’re certainly not at that time.” [F8] 
In one instance, a relationship breakdown with their specialist occurred from poor 
communication. “The doctor, she says to me ‘oh you had it in your stomach as well’ I 
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says ‘no I didn’t’ she said ‘yes you did’. Now I’d never been told and my husband had 
never been told that, that I’d actually had it in my stomach as well...Nobody ever told 
me that. You know so… and I, we, sort of argued with them.” [F4] 
And in another instance, there was no communication about their treatment being 
initiated. “I can remember the day someone came in and they pulled my curtains and 
somebody came in, in PPE gear, and gave me a jab in the belly…they never told me 
what it was, I didn’t know what was happening. No idea. Nobody said ‘well this is the 
start of your chemotherapy’ nothing like that was mentioned.” [F10]  
Another participant was still wondering about why procedures were undertaken. “Like 
I went and got the stem cell thing done and I didn’t know what I was going for, it was 
just this appointment ‘here, go and do this’, you know you’re not explained to you 
what you are going for... I still don’t know why. Why did I have that done?” [F4] 
One participant admitted that they struggled to comprehend information because of a 
strained relationship with their specialist. “My interactions got quite complex... 
because of that, um, I was probably coming into some of those conversations...with 
less than, a less open mind than possibly I could have.” They then acknowledged, “I 
was probably maybe not as open to the information or as calm and, um ah, as I 
needed, as I could have been to collect the information, yeah.” [F8]  
Three participants were getting treatment at more than one location and felt that the 
communication received from these differing locations was not consistent.  
“It was like bouncing between everywhere...they were all trying to, like, work together 
and it didn’t really work.” [F2] 
One also felt that some areas had different knowledge about side-effects. “But when I 
was talking to one of the ladies in Christchurch, she actually told me about symptoms 
that Dunedin didn’t know about on my chemo.” [F5] 
One participant also felt that an attempt to empower them with decision-making left 
them feeling unsupported. “A lot of frustration around that, well ‘I’ve given you the 
information and you can make a decision’. Um, I, I remember saying quite a few times 
‘well just let me hit the pause button while I go off and get my medical training and get 
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20 years of experience and then I’ll come back to you with that decision’.” They went 
on to say, “I did want to be given the options, that’s for sure, and I wanted to be able 
to talk through all of the options, but then I also wanted some clear recommendations 
from that.” [F8] 
Some participants (n=3) also felt that it was the basic information that was lacking in 
what they were told. For example, a simple explanation of how the treatment works 
was not understood. “No one explained to me what chemo was. Like they would say 
‘and you have six rounds’ – what the hell does that mean? And so that’s where I feel it 
was really lacking ‘cause I didn’t know what that meant. ‘Six rounds’, and you try to 
look it up online and it just talks about rounds, but it doesn’t tell you what that 
means.” [F3] 
And one participant felt they didn’t receive adequate explanation about their type of 
cancer. “I mean, you know I hadn’t heard of the word myeloma before, I didn’t know 
until one of the kids explained that it was cancer of the plasma cells.” [F10] 
Another participant agreed with the lack of information saying, “Just little things that 
they don’t… they know it all. But they don’t tell you. They don’t explain everything. The 
logical things they don’t explain to you, you know?” [F4] 
One participant thought this could be because the staff are so used to the 
terminology, they forget that it may not be suitable for patients. “Certain people get 
into their lingo...They just expect you to know that. But you might not know that. It’s 
sort of because they are stuck in an environment, they say that all the time, so, with 
their different colleagues, so they know what that is. Sometimes the...things that they 
think are really simple... are the things that actually go over your head.” [M6]  
Conversely, one participant wanted to be provided with more in-depth information. 
“It was actually a bit too basic, I wanted to know a little bit more so I always had 
questions.” [F11] 
d. Inability to process information  
Participants found that their understating of the information given to them was 
impeded by their psychological reaction to their diagnosis. “I don’t know how other 
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people reacted, but with me, when they sat down and was explaining and giving me all 
the stuff, I was still in the ‘holy sh** I have cancer’ so I didn’t hear any of it.” [F3] 
Following this statement there was general agreement in the focus group, with others 
going on to say;  
“I just feel like you hear that word cancer and you sort of, you lose it, yeah you do lose 
it.” [F4] 
“I was like that too, you sort of, you put a wall up.” [M7] 
One participant also struggled with understanding information because they were 
taking morphine for cancer-related pain, and this left them unable to comprehend all 
the information provided to them. “The myeloma had attacked my back and I was on 
morphine and there was no way I could take anything in.” [F10] 
Another found that it was the chemotherapy that made them struggle to remember 
information. “Over that time the effect on my brain was quite significant so I would 
forget things” and “I was struggling to remember everything because of chemo.” [F11] 
Theme three: Other opportunities used to aid understanding 
Participants often searched for information from other sources to find what they were 
looking for. Many participants (n=6) found talking about side-effects with those who 
had been through treatment before very valuable for information gathering and for 
support. 
a. Help from fellow patients/support groups 
Participants agreed that communication with other people who had been through 
chemotherapy was invaluable for understanding treatment and side-effects. As 
mentioned above, many participants commented that the basic information about 
chemotherapy was not adequately conveyed to them, or they had difficulty 
comprehending the information because of the overwhelming diagnosis or medicines 
that affected their cognitive ability.  
One participant described how not understanding left her anxious and unable to cope. 
“And it was me having a breakdown in the oncology department and some lovely lady 
221 
 
going ‘what are you scared of?’ and so she sat and you know, I was like ‘I don’t know 
what this means’ and she sat and explained ‘cause she was going through it and then 
it was like ‘oh, okay!’.” [F3] This participant described being in “hysterics” and went on 
to say, “It was another patient explaining it versus anybody else” that helped them 
through that moment.  
Similarly, another participant felt receiving information from a former patient helped 
them cope with side-effects experienced. “There was a lot of side-effects I had that 
weren’t on the sheets, but the other girl had had as well, and she made me feel more 
normal than the doctors did when I had them. I was like ‘oh okay that’s normal, I can 
get over that’.” [F5] 
Other participants felt it especially helpful to talk to people who had been through a 
similar experience and were now recovered.  
“Women that were going through treatment as well as women who had been through 
and out the other side for quite a period...it was great to talk to them...when you’re in 
the midst of it, it’s all just overwhelming.” [F8] 
“I joined an online support group and relied heavily on the people there who’d had the 
same treatment regime as me because…it was really helpful to be able to rely on those 
people who had recently been through it because they could remember really well.” 
[F11] 
“I mean there’s not that many internet sources that talk about the specific treatment 
that you’re on. Whereas I knew I was on FEC-D and anyone who had that would 
understand that course of drugs and the side-effects and how they played out and the 
different timing.” [F11] 
One participant described how they struggled to get adequate information about a 
side-effect they experienced from their specialist but found help through a former 
patient. “I actually ended up going to, um, somebody else that had been through what 
I had been through and she was the one that confirmed that’s what my side-effects 
were and that she had them too and stuff like that.” They went on to say, “So it was 
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easier to actually go to someone that had actually done it, than go to the doctors for 
information.” [F5] 
This participant suggested that new patients should be put in touch with people who 
had been through similar treatment before. “I think it would be easier if they gave you 
information on people who had actually been through it as well. So, you’ve got info 
there from, like, people who probably have the same side-effects as you as well.” [F5] 
Many participants (n=5) described how much they appreciated the information and 
support received from patient support groups they went to. “Actually, it’s great when 
you go to a group if you can mix with people...you get to talk to people with different 
types of leukaemia and, um, you get to know, yeah, learn a lot more about it. And it is 
also good you support each other. I think the group is fantastic.” [M9] 
Participants continued to find them useful years after they have finished their 
treatment. “I still go to the blood and leukaemia meetings, and, I mean it’s been six or 
seven years, but they say keep coming, you know, because they can see it’s the 
survivors, you know, so we trot along every month or so in to it, you know, it’s quite 
good and I have learnt a lot.” [F4] 
And that the ability to share information with other people is useful. “you know, 
‘cause my muscles are sore you know, ‘my muscles, oh I have that too’ sharing, as you 
say, sharing information with other people is really cool.” [F4] 
Participants appreciated the encouragement for communication that these groups 
provided. “They [the Breast Cancer Foundation] encourage everybody who has been 
diagnosed with it to get on there [the smart application] and you can talk to other 
people who have the same stage or is going through the same.” [F3] 
One participant had a family member previously go through chemotherapy and used 
them as a source of information as this was perceived to be more relatable than other 
possible sources. “I’d had a family member who’d had been through chemo as well 
and she was really helpful with giving me tips so I would ask her questions and she 
would know, and I found that to be easier than kind of reading through the internet at 
the risk of finding something that didn’t relate to you.” [F11] 
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One participant also found that support groups were very useful for their support 
person. “And it [the support group] is also good for your support person. If ever your 
support person give a, gives a chance for them to talk, um and yeah, yeah it’s great, 
yes.” [M9] 
b. Other sources of information  
Six of the participants described how they obtained information from other sources. 
Many of these participants received information from a patient support group, two of 
whom received information from the Leukaemia and Blood Cancer New Zealand.  
“I got the information from Leukaemia and Blood foundation, that booklet and um and 
then there was you know lots of other, other things.” [F1] 
 “I think it was all leukaemia and blood foundation also had their website that I could 
go to and stuff.” [F5] 
Another participant valued the information and services provided by the Breast 
Cancer Foundation New Zealand. “Well I think that’s where the breast care service 
here is really good...they give you a heap of information, like, they gave me a journal 
and websites to go to and, you know, the app to go to, and just all this stuff.” [F3] 
The ‘app’ is a smart application provided by the Breast Cancer Foundation New 
Zealand that patients can use to contact a dedicated nurse for information. “So breast 
cancer services was really good as far as all that, and they assign you a nurse and that 
nurse… if you have any questions, so that part’s good.” [F3] 
The Breast Cancer Foundation New Zealand encourages all people with breast cancer 
to sign up, and as well as resources and a specialist nurse, it provides an avenue for 
contact with fellow patients. “They encourage everybody who has been diagnosed 
with it to get on there and you can talk to other people who have the same stage or is 
going through the same.” [F3] 
Other participants went to look for information independently of official organisations 
or recommendations from their specialists via the local library. “I did go to the, um, 
library as well and get books and things like that.” [F8] 
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Or by browsing the internet. “On my phone, um, I’d quite often go into CML and look 
up information um, but I try and make sure I go into good sites you know? And I would 
go in and look up to see what side-effects there are and things like that.” [M9] The 
information found on the internet could then be used for understanding when 
consulting with their specialists. “It gives you an idea of what’s coming, when it comes 
and it, so when the doc, when the specialist talks to you, you’ve got an idea of what 
they are talking about. You know?” [M9] 
One participant described how they wish they had thought of relying on their general 
practitioner (GP) for support and information and did not appreciate at the time the 
role they could have played in their treatment. “In hindsight...I should have made 
much better use of my GP in terms of an advocate and a sounding board...that that’s 
sort of what I learned out of that whole process, is that my GP is my best point of 
contact and my best advocate. And I’m very fortunate that I have a very good 
relationship with my GP.” [F8] 
Theme four: Improving information provision 
Some participants (n=4) had ideas about how information provision could be 
improved which would have helped them when they went through chemotherapy.  
a. How information provision could be improved 
Two participants felt that restructuring or reordering of the current information would 
be useful.  
One said, “You can only take so much information in and sometimes it’s probably 
better to give you the main facts, condense it, you know, rather than give you tons. 
‘Cause I find when you go in there you don’t actually remember everything.” [M9] 
Another participant suggested improving the findability and discoverability of the 
information could be achieved by separating content into different sections. “It would 
have been great to sort of, I don’t, where they had another pocket, two pockets in the 
folder, and, and the stuff in this pocket is the really critical stuff, and here’s the more 
background stuff.” [F8] 
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Three participants discussed the use of digital technology and how this could improve 
the provision of information to chemotherapy patients either via websites or smart 
applications.  
“I think it could be done online....especially when you are going to and from hospitals if 
you’re taking it, you know, stuff gets lost and if you’ve got a login then that just makes 
it a lot easier.” [F2] 
“Having like an online resource library would have been a much better way of giving 
me that information. Instead of giving me 12 different printouts or photocopies with 
various different websites like a one-stop online shop would have really helped me. 
Because that would have also saved me from delving into Dr Google unnecessarily 
which I tried to avoid.” [F11] 
“It could be done on, like, an app...it could list all the stuff that’s on paper and you 
could go in and type in side-effects and then see if it’s actually related to the drug you 
are taking.” [F2] 
“So that [breast cancer society digital tools] would be something good to have for 
other types of cancer…something set up that was specific to the different types that 
people that have that can go on and ask questions of other people or have the 
information or look up side-effects.” [F3] 
There was general agreement in the focus group discussion with these comments 
[participants F1, F2, F3, F4, F5, M6, M7]. 
b. Personalised information needed 
Three participants mentioned that personalisation of information provided to them 
would help. Two participants described how everybody reacts to treatment and 
disease differently.  




“There’s a huge amount [of side-effect information], yeah. And the thing is everyone’s 
different. And how it effects one person to another person ... it can affect other people 
differently so yeah.” [M9]  
One of these participants went on to describe a conversation with their specialist 
about differences in peoples’ reactions to side-effects. “She’d go ‘you know, some 
people have, um, this much problems [holds hands wide apart] but it’s only this [holds 
up thumb and forefinger apart] other people have that [holds up thumb and forefinger 
apart] and it’s really this [holds hands wide apart]’.” [M9] 
Two participants who had a preference for smart applications felt that these could be 
usefully personalised.  
“The doctors could you know, load on what, exactly what chemo’s you’re on and then 
it could list all the stuff that’s on paper.” [F2] 
“Stuff like that would be good if it was, you know, something set up that was specific 
to the different types [of chemotherapy].” [F3] 
6.3.4 Discussion 
This study explored the views of people who have had chemotherapy about the 
information they received about their treatment, and whether this could be improved. 
Overall, the majority of participants thought that the information could be improved. 
However, most participants knew what to do and who to contact if they needed help 
or information about their treatment. Some participants liked the information more 
than others, and some suggested ways to improve the information being given e.g. by 
reordering the information, providing the information in a digital format, and by 
tailoring the information to personal requirements.   
Being provided with information 
In order to attain maximum comprehension of information, the gold standard is to 
give patients both verbal and written medicine information,13, 15, 26, 214, 234, 235 and this 
appears to be what happens for those who are starting on chemotherapy at SDHB. 
Chemotherapy uses high-risk medicines that can cause many serious side-effects129, 
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210, 212, 213, 236 The risk and types of side-effects vary between regimens, but most 
people having chemotherapy will likely experience some.212 However, most individuals 
are willing to accept the toxicity that comes with chemotherapy to extend their life 
expectancy.237 To mitigate potential harm and prevent hospitalisation and fatalities, 
people need to be well informed.234 Furthermore, adequate provision of information 
about oral anticancer therapies can improve patients’ quality of life, satisfaction with 
treatment, and concordance.236, 238, 239  
It has been shown that much of the verbal information provided to cancer patients 
will be forgotten following a consultation.214, 236 Receiving a cancer diagnosis and the 
information about chemotherapy will cause anxiety and negatively affect people’s 
ability to understand and remember the important information needed.15, 214, 236 Most 
of the information provided by the oncology/haematology team in the present study 
was in written form, with some recommendations of reputable websites for further 
information. The quantity of information provided is large and although many 
participants in our study said they understood the information, their opinions differed 
about whether they were provided with too much or too little information. Some 
studies show people want to receive plenty of information, whilst others show  
patients prefer to receive little information,236 highlighting the importance of tailoring 
information to patient requirements. 
Written information 
Information about chemotherapy is complex and frightening and it is given to people 
at a vulnerable time of their lives. It is important that people feel they can understand 
the information being provided to them and act on it. In this study, just over half of 
the participants felt that the information given to them was easy to understand and 
the way it was provided aided their understanding. Yet, several participants believed 
its format and provision could still be improved. Furthermore, one participant, 
thought the terminology and language used in written information was difficult to 
understand. The use of a digital platform may improve comprehension,240 and could 
explain complex terminology and provide both in-depth and basic descriptions of 
complex terms.  
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Many participants did not find the information given them to take away ‘too much’, 
possibly because, as shown elsewhere,234, 236 they could read this at their leisure if 
they wanted to. Consistent with a Dutch hospital study of 208 cancer patients, some 
liked to receive an abundance of information because it made them feel reassured.238  
Conversely, some participants were alarmed and felt overwhelmed by the abundant 
information provided to them and deferred reading it. This has also been described in 
other studies with lower-risk community-prescribed medicines,4, 40, 48, 65, 66, 173 and 
smaller quantities of information. One participant found the information difficult to 
navigate and described being unable to find the information they needed amongst all 
that was given to them. This highlights a problem and suggests the information 
provided was not fit-for-purpose. Consistent with other studies, some participants 
would prefer to receive information that summarised the main points and pointed to 
further information if required, rather than a plethora of material.109 
The findings of this study reinforce the need to tailor information to patients’ 
requirements.109, 238 Therefore, the type of information and how it is given must be 
suitable for their personal requirements to encourage them to read it and enable 
them to find what they need to know in a timely manner. 
Digital information 
Earlier studies have shown that people having chemotherapy like to receive 
information about their medicines via the internet .236, 240 The present study found 
that participants would appreciate digital resources that contain the information 
provided by the hospital as an alternative source, with some commenting that they 
would like a special app provided. Some participants thought it would be easier to find 
information online, it might reduce the quantity of printed information given, and 
allow some tailoring of information e.g. to their own chemotherapy regimen. Other 
studies have shown that information about chemotherapy read on the internet is 
generally well-received.240 However, it is recommended that patients are directed to 
high-quality websites to prevent acquisition of inappropriate information.237, 240 
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Information about side-effects 
Having information available for later reference is vital for patients to access and find 
important information to help them through situations that may arise. Previous 
research demonstrates that people might not be receiving adequate information 
about chemotherapy side-effects.238, 239 In this study, two participants felt scared by 
what they found when they sought further information themselves. This could be 
prevented if information was vetted and presented by their specialist team with 
opportunity to discuss concerns.235 In the present study, all participants shared 
information they were given with their family or support people, even if they were 
unwilling to read the information themselves at the time, so even if the side-effect 
information taken home is not used by the patient themselves, it will still be an 
important tool for someone supporting and caring for the patient. 
Research demonstrates that withholding information, deliberately or otherwise, from 
cancer patients will increase fear, anxiety, and confusion.235 It can also create future 
difficulties for the patients and the health professionals involved in their care, i.e. 
causing communication breakdown. This will negatively impact patient experiences.237 
It is essential that the oncology/haematology team ascertain patient preferences 
rather than postulate what information patients want or need to know and that they 
deliver information, particularly upsetting information, appropriately.235 This would 
support open and frank discussions of difficult topics and ensure understanding. 
Other information 
Participants also expressed the desire for contextual types of information being 
available and that its absence resulted in anxiety. This has been demonstrated in other 
studies with cancer patients,236 and been described in palliative care.235 One 
participant needed information about the terminology (‘chemotherapy rounds’) and 
how the treatment would be given. Lacking this, they felt lost and extremely anxious. 
This example highlights patients’ different needs—it was not the risk of side-effects 
nor the diagnosis making it difficult for the patient to cope, but the lack of information 
about the medical procedure they were having to undergo. It is possible the individual 
was given this information, but was unable to recollect it later, as described 
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previously. Some participants postulated that the experts may forget that patients 
new to this setting are unfamiliar with the jargon used and be unaware that more 
explanation is necessary. Regardless of whether the information was given, it 
emphasises the point that ongoing access to information about treatment that a 
patient wants to know is important. Moreover, it highlights that digital sources might 
enable the organisation of information into ‘type’ i.e. description of the chemotherapy 
and how it is given, side-effects, monitoring required etc. This would make it easier for 
users to find what they need at a time that suits them. In addition, having a 
standardised platform of information that could be personalised should ensure there 
was no information missed. 
However, individuals’ information needs may change during an illness,236 so there is a 
need for an adaptable system to accommodate different patient needs at different 
times.  
Seeking information 
Overall there was high praise given to the oncology/haematology teams at the 
hospital. The designated nurses at the hospital that answer queries on side-effects and 
management were described as a valuable resource and much trust was put in the 
hospital team. Yet some participants in the present study spoke about communication 
problems they experienced perhaps from a relationship breakdown due to earlier 
miscommunication; perceived withholding of information by the specialists; 
miscommunication between hospital teams; and a lack of support in decision making. 
A cancer diagnosis and its treatment is a stressful time in a person’s life and can make 
people react in different ways. Regardless of their ability to have a constructive 
relationship with their specialist team, patients need to be able to receive, 
understand, and act upon information given to them with their treatment. It is 
essential that they understand the benefits and potential harms of their treatment, 
personalised to their requirements and in the context of their life expectancy.237 
Reluctance to contact healthcare professionals because of a relationship breakdown 
should not cause reputable and accurate information to become unavailable. Having 
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information accessible, without having to contact the team, may be crucial for those 
who feel unsupported or out of touch with their specialists. 
The common side-effects for chemotherapy regimens are well documented and 
readily accessible, but there appears to be a need for those considered less common. 
Most patients want to receive as much information as possible from their doctor.235, 
236 Yet many participants described being blindsided by the rare side-effects they 
experienced that they were not counselled about. They felt they were not provided 
with adequate information and were left unsupported. This made them look for other 
sources of information about these side-effects. 
Information from fellow cancer patients 
The perceived lack of support about management of ‘rarer’ side-effects was deeply 
felt by participants, with some resorting to finding out information themselves 
through others who had experienced the treatment before them. Earlier studies also 
show that some people prefer fellow or former patients as providers of 
information.241 
Having access to other people who have been through treatment before was 
described as invaluable. For some, discussing their treatment and concerns with 
former chemotherapy patients improved their understanding and ability to cope with 
the side-effects they experienced. It was thought that those who had previously 
experienced side-effects could provide more useful information than what they were 
receiving from their specialists about what measures to take to manage their 
symptoms. Particularly, reassurance that the side-effects being experienced were 
‘normal’ was a comfort. Access to support groups was also useful for discussing 
treatment, being provided with useful information, and finding answers. An Italian 
study also demonstrated that a large proportion of patients preferred to receive 
information about their chemotherapy from other patients (32.5%) or use other 
patients as educational aids (27.8%).241 This is a viable option for many people in New 
Zealand with the large number or support groups available.203, 204, 219, 242, 243 
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One participant felt that everyone who is receiving chemotherapy should be given a 
person to contact for support and to provide them with information. Furthermore, 
other studies have found patient appreciation of fellow/former cancer patients as a 
source of information.236, 241 There are several initiatives in New Zealand for 
connecting online with fellow patients for example via the Breast Cancer Foundation 
app and the Ripple app. The latter is for all patients with cancer and was borne from a 
cancer survivor’s desire to connect with people in a similar position who are able to 
share their experience, or to ask questions, as stated on their website ‘often questions 
not even a doctor could answer’.243 The recent development of these apps indicates a 
nation-wide need for connecting people. The Cancer Society of New Zealand also 
offers an information service and helpline242 and other cancer-specific societies have 
other platforms such as closed Facebook groups that allow communication with other 
people going through treatment. Unfortunately, determining if participants in this 
study accessed these services and apps, and their experiences of using them, did not 
occur, although some did mention that they had used them. 
Seeking information online 
Some participants in the present study searched for additional information on the 
internet, whereas others deliberately avoided it, or were discouraged from looking by 
support people or family members. Other studies have demonstrated aversion to 
information on the internet because it was ‘overwhelming’ and ‘too confronting’ 
about the course of disease.236 Yet, as described above, cancer patients are willing to 
receive information digitally. More needs to be done to direct patients to look for 
information on reputable websites to ensure people access accurate advice.240 This 
could prevent people becoming overly alarmed or misled by online misinformation. 
Taking the necessary action  
Two participants could not always remember what to do if they experienced a side-
effect, and presumably they could not find the instructions previously given. It is 
essential that people who are experiencing side-effects with their chemotherapy know 
when and how to act in order to prevent worsening of their condition.125, 129 Most of 
our study participants claimed they followed the information provided to them when 
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they experienced a side-effect, whether it was self-management or a requirement to 
visit the hospital.  
Similar to other studies, some participants avoided contacting the hospital 
immediately 129, 211 because they did not want to be a burden. Others avoided seeking 
help because they did not want to undergo testing and wait around in the hospital, or 
be admitted for a lengthy stay. Other studies have also shown that for some cancer 
patients, the time in hospital or time taken travelling there was the worst aspects of 
their illness, even more so than the side-effects experienced.237 
Further communication and education is required for people who actively avoid 
contacting the hospital. Perhaps there is room for improving community support for 
those who are wanting to stay home as they may put themselves at risk in their desire 
to remain out of hospital. Moreover, systems must be put in place to avoid people 
being unable to seek help because they do not know how. Standardised information 
about how to manage side-effects and when to seek help should be provided in a way 
that guarantees patients know where to find the information easily at a later time.  
Using family and friends for support with side-effects 
Cancer patients often use their family and friends as information sources and depend 
on them for help with recalling the information given during consultation.237, 241 In the 
present study, some participants relied on their family or support people to access the 
information they needed about their chemotherapy side-effects. Some participants 
described their support person taking control and becoming responsible for contacting 
the hospital for help with side-effect management. This highlights the necessity for 
family or support people to know what to do when problems arise. Thus, it is essential 
that information given to people about how to manage side-effects can also be used 
by family or support people so they can know what to do if side-effects occur. 
6.3.5 Conclusion 
Undergoing chemotherapy can be an emotional and stressful time in a person’s life. 
Being provided with information to understand the side-effects and know what to 
look out for is vital as some side-effects can result in severe morbidity and mortality. 
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However, the quantity of information currently given to people can either put them 
off reading it or can result in feelings of anxiety. Information given to patients about 
their treatment needs to be provided in a way that suits them. Although some people 
in this study decided to not read all of the information given to them, most used it 
later as a reference source. Therefore, the information provided must be user-friendly 
and well organised in order for them to find the information they want, when they 
need it. Some people would like to be given a short summary of the information about 
their treatment with the option to delve deeper and find more content on a given 
topic if they desire it. There was also some preference for being given information 
digitally and this will be further discussed in section 6.4. 
Because everyone has different needs in regards to the extent of information they 
want, how they react to their treatment, and their experience of side-effects, 
information needs to be provided in a personalised way. The current system may be 
limited in capacity to provide personalisation of information for each patient, but this 
could be supported through the use of digital technology. 
The strengths and limitations of this investigations are discussed in section 6.5.
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6.4 Patient views on the use of Patient Reported 
Outcomes (PROs) for generating personalised 
information in a digital tool for chemotherapy 
medicines  
6.4.1 Introduction 
As mentioned in section 6.3, it is imperative that side-effects experienced with 
chemotherapy are managed quickly and appropriately.125, 128, 129 Patients undergoing 
chemotherapy are able to contact health professionals for advice if they are 
experiencing problems with their treatment (S Pointer, informal pers. comm. 
December 2017 and L Dagg, informal pers. comm. March 2018). However, relying on 
patients to phone for side-effect management advice might have some disadvantages. 
Hesitancy in reporting may result in progression of symptom severity, requiring more 
intense clinician intervention (i.e. patients cannot manage the side-effects at 
home).129, 211 Patients may also have difficulty understanding and remembering verbal 
information given to them,214, 236 relying instead on friends and family for support. This 
means that side-effects are not always reported or proper advice not sought or 
understood, possibly resulting in sicker patients and more hospitalisations. 
PROs for chemotherapy side-effect management 
Chapter 2, section 2.6 of this thesis discussed the advantages and disadvantages of 
PROs and outlined how they could be used in practice. In this chapter, we are focusing 
on the possible use of PROs to report patients’ experiences with chemotherapy 
medicines.  
There are a number of prototypes that have been developed internationally for web-
based collection of PROs from chemotherapy patients,123-129 and those systems 
undergoing trials show positive results (e.g. improved management of side-effects) 
and patient approval.124, 128 These studies use validated algorithms for collection of 
side-effect information, similar to the information collected using the UKONs tool,201 
focusing on common side-effects experienced with chemotherapy medicines including 
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constipation, cough, diarrhoea, dyspnoea, dysuria, fatigue, nausea, pain, neuropathy, 
and vomiting. These programs use web-based questionnaires for patients to self-
report side-effects and to generate self-management advice to send back to patients 
or alerts in real time when they need to see the hospital staff.125, 126, 129  
Some prototypes allow hospital staff to view the patient-reported side-effects in the 
hospital record and send urgent email notifications when severe side-effects are 
reported to ensure proper management is initiated.126, 129 Others send email 
notifications or messages via pager-type systems to nursing staff responsible for 
symptom management.123, 128 One system from the UK was adapted for use across 
Europe and successfully implemented in five European countries.244  
There has been a range of studies internationally determining chemotherapy patients 
opinions on using these systems. In an Australian study124 17 chemotherapy patients 
completed semi-structured interviews about their experiences of using the system. 
Qualitative analysis showed that the PRO system gave them reassurance, improved 
ability to discuss and manage side effects, and improved empowerment and health 
awareness. The system was perceived to be easy to use and have a positive impact on 
care.  A study in the UK245 also used semi-structured interviews with chemotherapy 
patients (n=12) to determine their experiences of using their online side-effect 
reporting system. Similarly, this study found their system increased patient knowledge 
and confidence to manage their own symptoms, gave them reassurance, and reduced 
anxiety.  A larger study in the UK128 had patients who had used their advanced 
symptom management system perform questionnaires (n=36) or semi-structured 
interviews (n=12). The overall response to the questionnaires was that people liked 
using the system and most (91%) felt it had helped them manage their symptoms. 
Similar to other studies, participants in the semi-structured interviews felt reassured 
that their symptoms were being reported to their healthcare team.  
Some problems were identified with functionality of the systems such as trouble 
answering questions or sending their symptom questionnaires128, trouble inputting 
data because of previous disability, and lack of confidence in using the full 
functionality of the system.124 Problems were identified with the content of the 
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systems, such as: side-effects being experienced by participants that were not 
included in the system (thus could not be reported);124, 245 advice provided was too 
generic; the scales to identify severity of side-effects were too limited (and hence 
inaccurate reporting was done);124 and inappropriate question framing in the system 
meaning that historical symptoms were reported.245 
Because of the nature of the questionnaires used for collecting PROs, and the 
similarities to tools in current use in New Zealand, it should be possible to adapt these 
digital systems to our national requirements. The use of web-based reporting systems 
in New Zealand could be beneficial for patients, and may help overcome problems 
experienced with current systems of managing side-effects with treatment. However, 
it is necessary to investigate whether there are cultural differences that would prevent 
easy adaptation for use in New Zealand, and whether New Zealand patients would be 
able to, or want to, use electronic devices to receive targeted information about the 
management of chemotherapy medicines. 
Aims of this research 
It is uncertain whether the web-based PRO systems set up in other countries would be 
well-received in New Zealand or if they would be appropriate for our population. The 
aim of this investigation is to find out whether former chemotherapy patients would 
like to use a web-based PRO tool to receive information about their medicines and 
help them manage the side-effects experienced with their treatment.  
6.4.2 Method 
The methods described in this part are a continuation of those outlined in section 6.3 
of this chapter, specifically about part three and four of the focus group/interview 
outline. Participants, recruitment methods, and structure of the focus group session 
are also discussed in section 6.3. 
Focus group and interview outline  
The focus group meeting and interviews contained four parts: i) an individual 
questionnaire; ii) a discussion about items from questionnaire; iii) an introduction of 
the online tool (capturing Patient Reported Outcomes (PROs); and iv) participants’ 
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thoughts on the online tool for capturing PROs (see Appendix 19). Parts one and two 
of this study protocol are covered in section 6.3 of this chapter. 
Questionnaire and discussion guide development is discussed in section 6.3 of this 
chapter. Questions about what digital technology was used by participants were 
adapted from U.S. government guidance on digital usability questionnaire templates 
to measure digital media use.230-232 
Part three: Capturing Patient Reported Outcomes (PROs) using an online 
tool 
In the third part of this study, participants were introduced to the concept of using an 
online tool to capture PROs and how this could electronically provide cancer patients 
with personalised medicine-management advice online. A brief summary of 
international studies was given. The participants were provided with the information 
on a separate standalone document (this information is also in Appendix 19).  
Part four: Participants’ thoughts on the online tool for capturing Patient 
Reported Outcomes (PROs)  
The fourth part was an open discussion about the possibility of using an online tool for 
capturing PROs to determine participants’ ideas about the use of this tool and 
participants’ thoughts about the advantages/disadvantages of using this for people 
undergoing chemotherapy. 
The following discussion points were used: 
a. Do you think this online tool that we discussed would be something you 
would be able to use or like to use? 
b. What would you like about using the tool for a side-effect you 
experience?  
c. Would you also like to use this to look for other information about your 
treatment? 
d. What concerns would you have about using the tool to report a side-
effect or to receive information?  
e. What would be useful about using this tool?  
f. Would you prefer to use the tool or to telephone the hospital?  
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Analysis of data 
The data from the questionnaire (in Appendix 19) that related to the use of digital 
technology and the internet was entered into data management software and basic 
descriptive analysis was undertaken. The focus group session discussion and 
interviews were audio-recorded and then transcribed verbatim by AY. AY double-
checked the transcriptions against the recordings and read through them again 
multiple times. JT and AS read through the final transcriptions. AY carried out 
semantic inductive analysis of the transcriptions and organised them into a thematic 
framework matrix in Microsoft Excel.155  
Semantic inductive analysis of focus group discussions and interviews identified 
repetitive themes, illustrating patient attitudes and perceptions on use of an online 
tool for capturing PROs and for providing information about their treatment. Thematic 
coding and framework were reviewed by AS and JT. 
6.4.3 Results 
The same eleven participants completed this investigation as the one reported in 6.3. 
Their demographic characteristics and other results relating to data capture are 
described in section 6.3 of this chapter. 
Part one: Individual questionnaire responses relating to use of 
digital technology 
All participants indicated they use the internet on a computer and/or smart device 
often, or on a daily basis. All participants engage in a wide range of activities on these 
devices, see Table 16.
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Table 16: Activities undertaken on computers or smart devices by participants 
Typical activity undertaken on smart 
device 
Number of participants who undertake 
the activity 
n (%) 
Buy or make a reservation for travel 7 (64%) 
Email or instant messaging/chat 10 (91%) 
Look up a recipe 10 (91%) 
Look for health/medical info 8 (73%) 
Look for info on a hobby or interest 8 (73%) 
Read the news/weather/sports/blog 8 (73%) 
Online banking or bill paying 9 (82%) 
Shopping 8 (73%) 
Web searches 9 (82%) 
Playing games 4 (36%) 
Watch videos 6 (55%) 
When asked directly if they have accessed a website to locate health information in 
the last year, one (9%) participant never had, five (45%) participants had a couple of 
times, three (27%) participants had about once or twice a month, and one (9%) about 
once or twice a week. One participant did not respond to this question. 
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Part four: Qualitative analysis about personalised information in 
a digital tool for chemotherapy medicines  
The analysis of the focus group and interview data revealed four main themes (and 
three sub-themes of theme one):  
1) Prefer the proposed digital tool over the current system 
 a. Prefer it because they dislike the current system 
 b. Prefer it because it would be easier than current system 
 c. Prefer it because it would help them manage and understand their side-
effects 
2) Inputting information and how it is used 
3) Concerns about using the tool 
4) Prefer to use both current system and a digital tool 
Theme one: Prefer the proposed digital tool over the current system 
Some participants (n=5, 45%) liked the idea of the digital tool to report side-effects 
because they did not like some aspects of the current processes involved in reporting 
side-effects and the information received. Many (n=6, 55%) also thought that the 
system would help them better manage their side-effects. 
a. Prefer it because they dislike the current system 
Three participants talked about how they did not like to phone the hospital. “Yeah, I 
hated ringing in.” [F5] 
Their reasons varied with some not liking how it made them feel.  
“Yeah you felt horrible. You felt stupid.” [F2] 
 “I just, just didn’t feel comfortable ringing in.” [F5] 
One felt that ringing in gave them anxiety. “‘Cause it was always sort of like, I guess a 
little bit of anxiety ringing in and then them being like ‘ok you’re going to have to come 
in’ and then it makes it sound more serious than what it is.” [F5] 
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Another participant also felt anxious and even now they are affected by the feelings 
they experienced at the time. “There was a couple of times it was, just, I don’t, I can’t 
deal with any more poking and prodding. I can’t deal with being asked questions, the 
waiting, the whole environment, um it was, you know, I still get, I still get breathless 
when I go to the hospital.” [F8] 
One participant felt uncomfortable because of being asked about symptoms they 
were not experiencing making them worry unnecessarily.  
“I didn’t like some of the questions they asked me. I know they had a 
certain set of questions that they always had to ask you. So, it’s like, you 
know, ‘have you had shortness of breath? Blah blah blah blah blah’. But I 
felt that every time they asked me, I felt like I started thinking about it too 
much. Like that’s another symptom I could have. So, I didn’t like them 
asking me continuously. But I knew it was their job to go through a list on a 
piece of paper and say ‘have you had this? Do you feel like this? Have you 
had this?’ And sitting there going ‘no, no, no, no’ and then they’re like ‘ok 
so what’s your symptom?’ at the end of the bl**** list. And I’m just like 
‘you know what? I have probably got all of that now, because I am a 
hypochondriac now’…I just felt really uncomfortable ringing in and talking 
to them about it.” [F5] 
Two participants commented on the nurses’ expectations that they phone about every 
side-effect experienced and how this was not always practical. One participant was 
informed by the nurses, “‘you need to ring up every time you have a side-effect, you 
know, that you are worried about or need to talk about. You need to tell us every side-
effect you’re getting so we can write it down and have it on your file’.” [F5] 
If they did not ring straight away they felt they could be reprimanded. “I got told off 
when I rang up to talk to one of the nurses, she gave me an earful over the phone, um, 
because I didn’t ring up and tell her about [diarrhoea]…she pretty much told me off for 
not ringing in the day it happened.” [F5] 
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Another participant agreed but then said, “But then you’re calling for every little 
thing.” [F3] 
One participant also admitted that their reluctance in phoning the hospital may have 
resulted in an escalation of their symptoms. “The couple of times I ended up in ED I 
knew I should have rung earlier in the day but it was just like ‘this is alright, this is 
alright, this is better than going and getting poked and prodded’.” [F8] 
Whereas another described how they dealt with their symptoms themselves. 
“Sometimes I just didn’t [ring the hospital]...I just got through it.” [F5] 
Similarly, other participants avoided ringing because they preferred to stay at home, 
“Because it was always ‘come to the hospital’.” [F3] 
One participant had a long way to travel to the hospital and being told to attend 
sometimes resulted in an unnecessary journey. “It was a long way for us to come to 
the hospital, you know, and then you get there and they say ‘oh no, you have to go 
home again’.” [F4] 
b. Prefer it because it would be easier than current system 
Two participants thought an online reporting system would be easier to use than the 
current phone-in system, with one stating, “getting on to a computer is not quite as 
demanding.” [F8] 
One reason was because of how unwell they felt at the time. “I know there were a 
couple of times I just felt so bad I couldn’t even pick up the phone. That was too hard.” 
[F8] 
Another suggested it would make dealing with minor problems simpler. “I would 
rather it just be like ‘oh no that’s fine’. Just take an extra pill for it, you know or 
something like that. And it’s like ‘ok I can stay at home and relax’.” [F5] 
Rather than spending time having a lengthy discussion with a nurse, “I would rather 
just go online and have something where I can just type it in and then it just tells me 
straight away…[if] I can manage it myself, I don’t need to go in and see anybody. Um, 
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rather than have to ring in and they’re like ‘oh yeah, that’s fine’ and I’m like ‘oh well 
that was a waste of time ringing’.” [F5] 
Participants also thought it would make the decision to go to hospital simpler and 
more straightforward. “I think it would just be easier [than phoning] because you’re 
just like ‘oh it’s telling me to go, I had better go. I’d better jump in the drive’.” [F5] 
One participant thought it would be simple because their computer is always in use. 
“[the online tool] would be your first port of call. You know, because I don’t really close 
my computer down much, so it’s there, readily available. I have used it when I want to 
know side-effects of new drugs that I go on. [F10] 
c. Prefer it because it would help them manage and understand their side-
effects 
Six participants thought that an online tool would help them understand their side-
effects better. For example, it could help to further understand side-effect 
frequencies. “If they had two boxes, like one’s common and one’s uncommon, so you 
could see [you] might not get it.” [F5] 
Or help them remember their side-effects experienced with a previous round of 
treatment. “I think it would be useful if you could rationalise the side-effects you are 
experiencing over time as well…Every time I had a treatment, and I had six of them, I 
would have some consistent symptoms or side-effects, and then some things appeared 
over time...I would think ‘is this normal for me? or was I having that at the beginning?’ 
because I couldn’t remember, my brain was so foggy I couldn’t remember... knowing 
what your normal is.” [F11] 
Or better understand what treatment they will need. “I could go into a site that’s legit 
and look at what’s happening and um find out what’s going on you know? From a 
reliable site, what the next lot of treatment would be.” [M9] 
One thought it would be better because it would be easier to find the information 
they need. “Yes, yes it would be [easier to navigate than booklets]. I wasn’t very 
impressed with the booklets.” [F10] 
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Many participants (n=5) felt that having the online tool would help them make that 
decision about when to seek treatment.  
“It would help me make that decision…is this something I need to be worried about…is 
this just normal? Is this the way I should be feeling? Or is this something I should be 
worried about? So, any tool I think that could help with that um understanding would 
be great.” [F8] 
“Yeah probably just knowing whether or not you need to be concerned in relation to 
your own specific situation about something.” [F11] 
Another participant said, “you always brush things off you know…But with this you’d, 
um, you’d be putting down ticking boxes and you’d be making someone else aware of 
what the problems are and then they can make a better decision...alert you and 
confirm um that there is a problem.” [M9] 
This could have been particularly beneficial when they preferred to not contact the 
hospital. “…that would help, ah, would help make that decision ‘is this normal or is this 
something I need to be worried about? And if this is something I need to be worried 
about then either I need to get over this being too hard or I need to get my partner to 
call’.” [F8] 
Similarly another participant wanted to use it to know if they should be worried about 
a side-effect experienced when they would usually have avoided contacting the 
hospital by phone. “If I had something like that, you’d kind of tick things and it 
would’ve yeah, yeah, it would have alerted me, which sounds silly doesn’t it.” [M9] 
The system would also help their family or support person when they could see that 
someone needed help, but they refused to seek professional advice. “She can see 
things but she’s fighting me ‘cause I didn’t want to go into hospital and be a burden. So 
this would actually kind of just alert, even myself, or someone else.” [M9] 
In addition, this would help their support person to determine when to seek help for 
symptoms, reducing the anxiety around whether to push them to contact the hospital. 
“It would have alerted it, you know? And it would have taken a lot of worry away from 
my partner.” [M9] 
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Two participants felt that having a system like this would help explain side-effects to 
their family, with both going on to describe how their family did not understand what 
they were experiencing.  
“I wish my family knew what fatigue was. I just don’t think a lot of people know what it 
is. They just think you are being lazy or you’re tired. But they don’t actually realise.” 
[F5] 
 “I would say…’would you get me some wood and put it on the fire’ and he said ‘get it 
yourself, don’t be so bl**** lazy’. I just couldn’t physically get up.” [F4] 
Theme two: Inputting information and how it is used 
There was some discussion about how the information would be recorded and used. 
Many (n=6) participants agreed that they preferred their responses to be logged in the 
hospital record. 
“I’d rather it be logged into the system.” [F5] 
“Yeah I think it’s a good thing. Yeah, I think they need to know what’s going on.” [F4] 
“And if you’re not calling in, then how else would they know?” [F3] 
Another participant thought it was essential to ensure dangerous side-effects could be 
picked up. “There might be something that I’m putting in there that they’re going 
‘that’s a red flag that we need to be aware of’.” [F8] 
She explained that responses from nurses telling them they do not need to visit the 
hospital would be comforting, “having that confidence and assurance that, um yeah, 
there is somebody checking that and whether that’s a return email saying ‘hey with, 
um, thanks for uploading that, we’ve had a look at it um, yeah, if you’re happy to 
follow whatever’s been suggested then that all looks good’.” [F8] 
Furthermore, for those who would avoid contacting the hospital, having it 
automatically logged into the system without having to phone in was considered a 
good option. “I’d just write it in and at least they know it’s happening.” [F5] 
247 
 
Two participants in the focus group felt that they would want to use the tool for 
information finding, so would like the ability to go through different scenarios without 
these being logged into the system.  
“If they had an option of where could like ‘opt in’ to have it on your log, and then ‘opt 
out’ if you didn’t want it on your log.” [F2] 
“Then you could have a button that says like, say you are looking up some of the side-
effects, just because you are looking them up and wanna know. But if you are actually 
having them and you want it recorded you hit a button and it records them on the 
side.” [F3] 
There was general agreement among other focus group participants with this 
discussion [F1, F4, F5, M6, M7]. 
One participant suggested that a comment box for inputting free text would be useful, 
“You could have a comment box in, just saying, you know....I feel that my, I’ve got pins 
and needles in my body today or something.” [M6] 
Theme three: Concerns about using the tool 
Six participants raised specific concerns they had with having an online tool to report 
side-effects and receive information. 
One participant stated, “I’d just ignore it” going on to say “I think I would be more 
likely just to ignore the tool ‘cause I’d always ignore it myself, if I get a temperature of 
38[°C], I’d just be like ‘I’m staying home’.” [M6] 
This participant would avoid contacting the hospital when they were experiencing 
side-effects with their treatment, so would also avoid reporting side-effects with an 
online reporting system. “If it was getting into the amber and the red I’d still be like, ‘I 
just want to stay at home’.” [M6] 
They also felt the tool would not benefit them because they already knew what action 
was necessary when side-effects were experienced. “I already knew what I was 
supposed to do, take some antiemetic drugs, you know in case. Um, I don’t know if…it 
would help me too much.” [M6] 
248 
 
Another concern raised was that health professionals may be lulled into thinking 
someone was not having problems because they were not reporting problems via the 
tool. “They have a patient that’s sitting there and ‘don’t need to know that stuff…I’m 
not going to report my diarrhoea, I’m not going to report my vomiting to someone’, so 
then they might get complacent and think that that patient’s fine when they’re not.” 
[M6] 
And that if specialists relied on the system, they might think they do not need to go 
over these side-effects during consultation. “They’re not asking, going to ask those 
questions anymore that they always do. Because they got the, they get the feeling well 
you’ve got the app, you’re already doing it yourself, so why should I ask you this again? 
Some people, some people wouldn’t go over.” [M6] 
Conversely, they were concerned that constant use of the online tool could be 
irritating to healthcare staff being reported to. “But you might get some that might 
just turn off the doctors, that they find some patients that just constantly rambling. A 
doctor being like ‘oh for god sakes, she’s on again, what are they on about? Constantly 
writing down stuff and fretting over every single thing’.” [M6]  
Two participants were concerned with what happens to the information once it has 
been inputted by a patient and wanted to make sure it was reaching the right people 
at the right time. “I just ah, thinking the confidence that that data goes somewhere 
and someone’s looking at it...having that confidence and assurance that, um yeah, 
there is somebody checking that.” [F8] 
One concern was if the tool was using a system like email, and not alerting the health 
staff via direct means and in real-time then it could cause issues. “It’s not direct 
enough. No one replies to an email ever. So, this would be essentially an email tool to 
someone. And no one ever replies to an email. So, you’d send it and no one would reply 
to you really.” [M6] 
Three participants raised concerns with access to the internet, “Depending on access 
to internet and stuff.” [M7] 
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And other access barriers, “You don’t have to go far out of the city and, um, online 
becomes an issue or, an, or far out of, um you know of anyone of socioeconomic um, 
where you are. Yeah, so a lot of people just don’t have access to online things.” [F8] 
Two participants were concerned with peoples’ abilities to use the tool or to 
understand the terminology used. 
“I’m kind of basic on a computer, I can email, I can find things on the internet, um but 
there’s people a bit older than me or even the same age as me, um, who can’t.” [M9] 
“Interpretation of medical jargon could be difficult because everybody’s got a different 
understanding of what the scale of something means. Like plain English versus medical 
speak.” [F11] 
Two participants raised the concern about security.  
“It would be all um, safe wouldn’t it, yeah?” [M7] 
“I understand from what you are saying that it would be totally secure?” [F10] 
Theme four: Prefer to use both current system and a digital tool 
All of the participants preferred to keep both systems if an online tool became 
available. One preferred paper for finding information, “I’m still of that generation 
who likes to look at paper. I need to have paper so that I can refer backwards and 
forwards and relook at things and, and sometimes, you know, if its online…stuff is 
great but sometimes you can’t find stuff again.” [F8] 
Some (n=4) liked to have contact with people and would like this to continue.  
“I like people contact you know..., I’d rather look somebody in the eye and talk to 
someone.” [M9] 
“When you pick up the phone and you’ve got a human voice at the other end it can be 
quite reassuring. And you get an instant reply.” [F10] 
And would not like this to be taken away (n=2).  
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“I would be nervous if I was told that the tool was the only option I had because then 
there are times when you do just need to talk to a person.” [F8] 
“I still don’t think you can bypass that personal face-to-face talk with somebody. When 
you ask questions and you get answers, and you can discuss…But would hope that it 
[the online tool] would not take the place of regular interactions face-to-face, asking 
questions, discussion.” [F10] 
Two participants could see the online tool as part of the whole process.  
“But this could be um, maybe something before you um went into the hospital and 
took their time up, you know?” [M9] 
“So yeah, the tool sounds good, I certainly wouldn’t rubbish it at all. And probably that 
might be a first, or a start.” [F10] 
Two participants [F2, F5] specified (“yeah”) that they would like the paper information 
provided by the hospital also to be included in the tool. 
6.4.4 Discussion 
In the previous section (6.3), participants described how they appreciated contacting 
the nurses at the hospital when they had a problem with a side-effect. In this second 
half of the study, we investigated their preference for an alternative system—the 
possible use of an online tool for recording and advising on side-effects.  
This study investigated the views of people who had undergone chemotherapy about 
whether they would like to use a web-based PRO tool to receive information about 
their medicines and help them manage side-effects experienced with their treatment.  
All participants in this study frequently used the internet for various functions and so 
it could be assumed they were digitally literate and internet savvy. Ten participants 
used a device for emailing or chatting and so have experience with inputting varied 
information and most find health information on the internet too. The present study 
found that participants would like to use an online system for reporting side-effects 
and receiving information about their treatment.  
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Further support for receiving information digitally  
Take away materials are necessary to ‘process’ information after appointments214, 236 
but large quantities of complex information may prevent people from reading it at a 
later time.2 Cancer patients like to receive information in a digital format236, 240 and 
some participants in the present study expressed their desire for provision of digital 
information before this phase of the study was begun, as discussed in section 6.3.  
Having information available in a digital tool may prevent the visual overload of the 
paperwork provided by obtaining all of the same information tidied away in an easy to 
follow package. It would also enable the supply of even more information if wanted, 
with links to reputable websites for additional reading without further overwhelming 
patients with more printed material.  
Personalising information 
Tailoring information to personal requirements could improve patient acceptance of 
written material.4, 78, 109 It has been demonstrated that information should be tailored 
to requirements for cancer patients because their information needs depend on the 
individual or where they are in the cancer-treatment cycle.234 Digital tools could 
enable provision of targeted information personalised for different regimens in order 
to outline the most common side-effects expected for that patient. These tools could 
also provide other information such as long-term effects depending at what stage of 
treatment the patients are at. Furthermore, with the ability to target information for 
specific requirements, a digital tool could provide more in-depth information about 
the less well-known side-effects that could occur that are frequently not discussed. 
This was important for participants in our study as many experienced rare side-effects 
and faced difficulty when asking for help from their specialist oncology/haematology 
team (see section 6.3). A digital tool would have the capacity to provide in-depth 
information on a wider range of effects experienced by patients, not just the 
commonly discussed ones, without needing to manually search through an 
overwhelming amount of paperwork.120  
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Other benefits of receiving information digitally 
Other reasons that participants supported digital provision of information were 
described in the investigation in 6.3. These included improved ability to find 
information when using it as a reference source and perhaps the ability to be put in 
contact with former chemotherapy patients to give personal support and information. 
Many people valued the ability to talk to others about the rarer side-effects they 
experienced. There are ways for current patients to talk to those who have been 
through treatment previously, but this may be limited and dependant on cancer type 
and services available to that patient. There is currently an opportunity to undertake 
this communication and support more extensively using technology that is already 
available, for example the Ripple app developed in New Zealand.243 
Participants expressed frustration and sadness when describing their family’s 
reactions to side-effects they were experiencing. Improving information provision to 
cancer patients can help improve their family members understanding of the cancer 
and the treatment.246, 247  So having a digital tool available may support family 
members to have a better understanding of what the patient is experiencing. 
Participants agreed that the digital tool could help with explaining side-effects to their 
family and would be useful when needing to communicate with them.  
Support for digitally reporting side-effects and receiving 
management advice  
The current system at SDHB of having a designated nurse for side-effect management 
advice was generally well-regarded. However, many participants in the study also liked 
the idea of a digital tool to report side-effects and to receive information. There were 
many benefits identified by participants that could improve the way they receive 
information and how they feedback treatment side-effects to their 
oncology/haematology specialists. 
Improving patient empowerment 
Hesitancy in contacting the hospital may result in worsening of symptoms and is a 
limitation of current systems in New Zealand and internationally, where people may 
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‘put off’ contacting the hospital in a timely manner.129, 211 Hesitancy in phoning the 
nurses was also demonstrated in this study. The reasons why people avoid seeking 
help previously included not wanting to burden the nurses, wanting to avoid having to 
go into the hospital, and one participant also found that ringing and talking to a nurse 
would worsen their anxiety. Unfortunately, avoiding seeking help for side-effects 
experienced can result in a worsening of symptoms125, 129 and this was experienced by 
one participant in this study.  
One driving factor in development of digital symptom reporting tools internationally 
was to allow the capturing of real-time information about side-effects experienced to 
improve patient outcomes and reduce costs.248 A digital tool with access to reputable 
information and ability to provide side-effect management advice would be beneficial 
because it would provide both the reporting requirements and the required 
information to be given to people undergoing chemotherapy, bypassing their 
hesitancy in contacting the hospital.  
Participants were in agreement that being able to search for information 
independently and find out how to manage symptoms themselves would reduce 
feelings of anxiety, sense of burden, and apprehension. Furthermore, one participant 
thought it would help them view the side-effects they experienced over time, so they 
could see what they usually experience and what is new. This would be useful for 
those who struggle with impaired cognitive function during treatment and would 
provide an ongoing record of their ‘normal’ responses to refer to. 
There was general agreement in this study that having a digital tool to supply 
information about symptom severity and requirements for hospital treatment would 
be useful in a variety of ways. It would take away the anxiety over knowing whether a 
side-effect was something they should be worried about and confirm when they need 
to go to the hospital. Particularly because many people preferred home-management 
and it was important for them and their support person to know if this was 
appropriate for the symptoms experienced. This would be particularly useful for those 
support people who have to persuade patients to contact the hospital and who often 
feel stressed and anxious about a patient’s wellbeing. 
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Improving practicality of receiving information 
Besides personal feelings of preference, there were discussions around why being able 
to report symptoms digitally may be more practical. Participants thought the digital 
system sounded simpler and easier to use than phoning the hospital. In studies 
investigating peoples’ experiences in the UK, participants in that study felt the system 
was easy to use and approved of it.128 Some participants in the present study 
described that occasionally they felt too sick to actually go through the process of 
ringing the hospital and that in these situations, using a digital system would be easier. 
Furthermore, participants described feeling unwell so often it was not practical to 
phone a nurse for advice every time illness occurred. Inputting data into a digital tool 
would be quicker and more straightforward than discussing symptoms with staff 
which, as described above, could result in feelings of anxiety. However, it would only 
be easier for people who had sufficient computer literacy to use the system without 
difficulty. Similarly, the system in use would need to be created with a high degree of 
user satisfaction and have no room for user error. Studies in the UK using such tools 
have been shown to have a high level of user satisfaction,128 so this suggests it may be 
similar for the New Zealand population. Systems overseas have also undergone 
rigorous user testing with oncology/haematology specialists and consumers.128, 248 
Comprehensive testing with our population and specialists would be necessary for a 
system to be accepted for use in New Zealand.  
A digital tool may also lessen unnecessary travel from more rural areas. One 
participant, who had a 45 minute drive to the hospital, was instructed to visit the 
hospital when they phoned for advice, only to be told to return home once they got 
there; this occurred on more than one occasion. A digital reporting tool may help 
prevent unnecessary travel for those who live on the outskirts of main centres or in 
rural locations and must travel large distances to see a health professional. However, 




Inputting information and how it is used 
Participants were generally happy for their side-effect information to be logged into 
the hospital system to alert the staff. However, participants would also like the ability 
to use the system to search for information without it resulting in alerts being created. 
They wanted to be able to go through the questionnaire algorithm just to find out 
what information is given and would like an option of doing this without their 
responses being logged. Therefore, when a system is created, it would suit patients to 
be able to search for information with the ability to log in for information/alert 
production separately if needed. 
The preference for patients’ side-effects being logged in the system was interesting 
considering the discussion about not wanting to be a burden or not wanting to go into 
the hospital. Yet people overwhelmingly agreed that symptoms must be recorded in 
the hospital system to keep the oncology/haematology team informed about what 
side-effects were experienced at home. This indicates that although people may want 
to avoid visiting the hospital, they are keen to have their information made available 
to their oncology/haematology team and follow the recommendations given, even if 
those are saying to ‘go to the hospital’. 
Furthermore, in a UK study,128 participants using a similar electronic tool, wanted to 
make sure that someone was looking at the information they inputted. They wanted a 
quick response and assurance that if they followed the advice provided they (i) do not 
need to visit the hospital, or (ii) would only have to if the symptoms escalated. This 
suggests that providing feedback to patients is essential. Perhaps any new tool 
developed could incorporate a pop up message to inform patients when their 
information is logged in the system, and, if they input a serious or severe side-effect, a 
note confirming that a nurse will be reviewing the information shortly and to expect a 
phone call. This would allay concerns about information disappearing into an abyss 
never to be seen again.  
Nevertheless, some participants raised concerns about inundating their healthcare 
team with too much information by logging every side-effect experienced. Perhaps 
this could be reduced by the specialist team advising their patients about what is 
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expected to be logged in the system before giving them access to the system, and 
reassuring patients that logging symptoms was necessary and required by the 
healthcare team.  
Furthermore, one participant was concerned their worsening health might be missed 
if they chose not to report symptoms via the tool. Perhaps this could be addressed by 
adapting the format of consultation with patients to ensure that both the side-effects 
that were documented in the system and others not yet documented (for whatever 
reason) were acknowledged.  
Concerns with using the system 
Logging of information in the system would still depend on the patient, as would 
acting on advice. For example, one participant was adamant they would even ignore 
the advice of the tool and stay at home if it was recommended that they go to the 
hospital. They admitted they avoided phoning the hospital for advice, although they 
had a very high temperature and were at risk of febrile neutropenia. Knowing the 
consequences (being contacted by the oncology/haematology team for review) may 
prevent them from using the tool. Because of this, they may only use a digital 
reporting tool as an information source rather than a tool to log their symptoms in a 
hospital record.  
Most of the population in New Zealand has access to the internet.249, 250 However, 
some participants expressed concern about widespread internet access, particularly in 
more remote areas of the country. Official New Zealand data shows that internet 
access in rural areas is still poorer than that in urban areas, but is improving.249 Other 
concerns raised were poor digital literacy and risk of inequity. New Zealand continues 
to have some problems with inequity and literacy,11 so measures would need to be 
put in place to ensure any system used would not worsen inequity and health 
outcomes for those most at risk, and that adequate support is provided.  
Almost all participants wanted to have the current system in place as well has having a 
digital tool. This would be necessary for those who do not have reliable internet 
access, a device, or adequate knowledge of how to use the system. Also, the 
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participants highlighted that they sometimes prefer to talk to a person rather than use 
a questionnaire. So, any digital system adopted would be in addition to those already 
existing. This may make it harder to persuade those controlling the budgets to invest 
in a digital tool if savings cannot be made elsewhere in the system. Therefore, a 
feasibility study would be needed to discover if the tool would improve outcomes and 
save money for the health system. 
6.4.5 Conclusion 
This small study found that a digital tool to report side-effects, which logs these into 
patients’ hospital record and provides side-effect management advice online, would 
likely be well-received by oncology and haematology patients in New Zealand. Overall, 
it could benefit people undergoing chemotherapy by helping them understand their 
treatment and improve side-effect reporting and management. The tool could be used 
alongside current systems e.g. a nurse-staffed telephone helpline. Further work is 
needed to understand the views of Māori and ethnic minority groups and in those 
who are less frequent users of digital technology to ensure whether a digital tool is 
appropriate for all oncology and haematology patients in New Zealand society. 
Furthermore, if an international system is introduced into New Zealand it would 
require adaptation to New Zealand cultural and health system requirements, and 




6.5 Strengths and limitations 
There are a number of possible strengths and limitations to the investigations in 6.3 
and 6.4.The strengths were that we had eleven participants who contributed well to 
their focus group or individual interview and who provided a rich source of data for 
analysis. Saturation of ideas was reached within the number recruited; no new themes 
arose in the last three interviews. Participants in the focus group contributed equally 
to the discussions and no individual appeared to dominate the discussion. It is 
acknowledged that the latter factor can sometimes be a limitation among focus 
groups. This study met Lincoln and Guba’s criteria for trustworthiness .233 Analysis 
‘credibility’ was attained by the iterative approach to transcribing data and repetitive 
re-reading of transcriptions by AY. Coding and interpretation ‘dependability’ and 
‘confirmability’ was achieved through review of framework by JT and AS. 
‘Transferability’ was attained through inclusion of rich data and inclusion of context to 
the analysis and commentary of the article.233 A limitation of the survey instrument 
used was statistical reliability tests (e.g. test-retest reliability) were not undertaken. 
This was because the questionnaire was designed to gather some data, but largely to 
‘set the scene’ for individuals and to open conversation. Because of difficulty 
recruiting previous chemotherapy patients, we did not allocate time to perform test-
retest reliability and other methods for statistical analysis on questions. This may limit 
the generalisability and reliability of findings from the survey instrument. 
Focus groups were the initial chosen method for gathering qualitative data. The 
limitations of using focus groups is that some people may over talk others and have a 
disproportionate contribution. Focus groups also tend to have lower average speaking 
time per person. This means that people may not be able to delve into a topic as deep 
as they could in an interview.221 Moderator bias may be hard to prevent, but we tried 
to mitigate this by using the same topic guide as we did with the interviews. 
Another potential problem is that on sensitive topics,221 some people may be unwilling 
to share.222 However, in our focus group we recruited people who no longer had 
cancer (in remission) and were well-used to using support groups and discussing the 
personal effects of their treatment with others. We found people openly shared 
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problems with understanding information and other issues readily, as well as praise 
for the teams that looked after them.  
Focus groups may also be more difficult to organise – the logistics of getting everyone 
in one place can cause problems. It took a while to organise ours initially but some of 
the people who could not make the focus group could do a one-on-one interview at a 
later date.  
Interviews were utilised because we were advised this may be necessary to gather 
data from hard-to-reach groups. The implications of using different methods to gather 
qualitative data are that different types of responses may have been collected, with 
different possible bias involved. The interviews may not have raised as many different 
points, but may have yielded more in-depth information to be gathered.221 
Furthermore, there are different limitations to performing interviews compared to 
focus groups. There is a lack of a positive influence from others in a group that would 
facilitate deeper discussions. There may also be a risk of social desirability bias in 
interviews as people may be more inclined to tell the interviewer what they think the 
interviewer wants to hear. 
Because the research was being conducted by health professionals, there was risk of 
bias from participants providing ‘socially desirable responses’. There was also a 
possibility of selection bias. The manner of recruitment for these investigations may 
have resulted in this, as those who had negative opinions about how they received 
information about their treatment may have been more willing to participate. 
However, there were a range of views articulated, and some participants liked the 
current system and most expressed their desire for it to remain in place regardless of 
possible digital solutions. This indicates that both positive and negative views were 
obtained.  
Due to the COVID-19 pandemic and the recruitment difficulties outlined earlier, the 
final number of participants and focus groups was lower than originally planned. This 
may have limited the number of themes that could be explored. Furthermore, the 
findings would not be generalisable to all populations in New Zealand as participants 
were only able to be recruited from one DHB. It is unknown if patients opinions at 
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other DHBs would follow similar themes or be very different. As the study only took 
place in one country, New Zealand, the findings may not be generalisable to other 
countries. 
There was a lack of ethnic diversity amongst participants in this study. This was partly 
due to the national lockdown from the COVID-19 pandemic limiting recruitment to the 
Dunedin area, and to online or telephone interviews. There were no participants who 
identified as Māori nor participants from other ethnicities and this means that 
opinions of non-Pākehā ethnic groups were not explored. Therefore, conclusions 
about their views on information provision cannot be drawn from this study.  
It is disappointing that we were unable to obtain the views of a more diverse 
population. Māori, in particular, experience many health and social inequities.251, 252 
Initially we had planned to incorporate Māori world views and have true Māori-
centred focus and outcomes from this research. To do this we had tried to align our 
recruitment and data collection with Kaupapa Māori research methodologies.228 As 
non-Māori researchers, we sought guidance from Māori advisors from the University 
of Otago. They advised that we perform one-on-one face-to-face interviews with 
Māori participants as we may have difficulty in recruiting Māori participants for focus 
group meetings. This aligns with principle of āta227 and forming of respectful 
relationships and we agreed with this approach to recruitment.  
The qualitative nature of the study would not be adversely affected by this differing 
data-gathering format so, we amended our study protocol with agreement from the 
University of Otago Human Ethics committee to allow recruitment of participants for 
interviews. Unfortunately, we were unable to recruit Māori for interviews in the few 
weeks prior to the COVID-19 pandemic lockdown and the Human Ethics Committee 
advised to only conduct telephone or online interviews after 8th June 2020. We had 
previously been advised we needed to develop relationships with the Māori 
community to engage participation in the project and the research team felt this could 
not be done to an acceptable standard without having face-to-face meetings. Because 
of this a real opportunity was missed for valuable insight into Māori perceptions of 
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information given to them about chemotherapy and their thoughts on the use of 
digital technology for this service.  
Further research is therefore necessary to find answers from Māori and other ethnic 
groups being treated with chemotherapy in New Zealand to confirm their medicine 
information needs are met and that inequities are minimised. 
Because of these limitations, the findings are only early markers of New Zealand 
patients’ opinions about the information provided to them about their chemotherapy 
medicines. However, it does provide some answers and feedback for maintenance of 
and improvement on the systems currently in place, and strong support from patients 
to investigate improved solutions for providing information and advice on 
management of their chemotherapy. 
Another limitation of this study is that participants were digitally literate and 
frequently used digital technology in their personal lives so may be more positive 
towards digital solutions. Therefore, more investigation is required to capture 
opinions on the use of digital tools in those who are not as savvy with digital 
technology.  
Furthermore, this study was seeking opinions about a concept rather than an actual 
tool, and this may limit ideas about what perceptions would be if a digital tool was 
implemented in practice. However, this was a useful starting point to gauge 
preliminary feelings about the digital tool concept and glean early ideas for 
optimisation for New Zealand patient requirements. 
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6.6 Chapter conclusion 
This chapter described what people thought about the chemotherapy medicine 
information they received, how they received it, and their perceptions on the use of a 
digital tool for reporting side-effects and giving feedback on the management and 
control of symptoms. 
The amount of information given to people about their chemotherapy and the 
management of their side-effects is overwhelming and can be difficult to digest. 
Information must be tailored to patients’ needs in ways that makes it easier for them 
to find and understand what they are looking for. This is not possible when most 
information is provided in the format of hard-copy pamphlets, information sheets, and 
booklets. At the very least the information needs to be standardised and organised 
into a suitable list with short summaries available for overviews of information. 
Unprompted, participants in this study voiced their preference for having the 
information given to them in a digital format, with some people hoping this would 
enable more personalised and specific information for them. 
People liked the option of having a digital tool to report side-effects, provide them 
with side-effect management advice, and to give them information about their 
treatment. Having a tool in place could promote earlier reporting of side-effects. It 
could also dispel concerns over whether a side-effect warranted a phone call by 
allowing information finding through a reputable and standardised platform. Concerns 
raised over the use of a digital tool are surmountable and could be worked through 
with rigorous co-design in early stages of adoption. However, the service provided at 
the Southern DHB where patients can ring a designated nurse if they are experiencing 
a problem is highly valued by participants and there was a preference for this support 
to be retained. 
More work needs to be done before implementation of the described digital tools to 
gather opinions and requirements of Māori and ethnic minority groups, and of those 
who have limited access and experience with digital technology. 
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Chapter 7: Discussion and conclusions 
7.1 Overview of the thesis 
In New Zealand between 2018–2019 there were over 46,000,000 funded medicines 
dispensed.253 The sheer quantity of these begs the question: ‘Is adequate information 
being given with each instance of prescribing and dispensing of a medicine?’ It is 
possible that barriers experienced at the coalface (lack of provision of information, or 
access to it2, 7, 9, 254) are preventing some patients from receiving the essential 
information required to use their medicines safely and optimally. 
Adequately informing patients about medicines improves satisfaction with their 
treatment and can support adherence to therapy.7 It also supports safer and more 
effective medicine-taking and allows improved patient involvement in treatment 
decisions. 
The overall aim of this research was to investigate how patients are given information 
about their medicines in New Zealand and explore potential solutions to optimise 
quality and provision of medicines information for patients.   
To achieve the aim, several areas for investigation were identified and the work was 
conducted in four stages (listed below; see also Figure 2). Their findings are outlined in 
7.2. 
The four stages of this thesis: 
 A description of what information people want to know about their medicines 
and what good-design principles to follow 
 a survey of current opinions and practice by New Zealand GPs, pharmacists, 
and patients about information provision for low-risk medicines 




 interviews and focus group discussions to determine patients’ opinions on 
current provision of information about chemotherapy and ideas for 
improvement, and their perceptions of the possible use of Patient Reported 
Outcomes (PROs) for optimising information and medicine management.  
7.2 Summary and discussion of findings in the thesis 
7.2.1 Findings of chapter 2 
The findings of each part of the literature review in chapter 2 are outlined below:  
What patients want included in medicine information leaflets 
and how they should be designed for optimal use 
This section described the findings from a literature review about the information that 
patients would like to know about their medicines. A list of required points that need 
to be included in medicine information leaflets was developed (Box 1). Patients 
appreciated this information being included in the leaflets and found that it improved 
their perception of the material.  
Importantly, we found that patients wished for information to be tailored to their 
disease and condition, and wanted unnecessary information to be removed. 
Additionally, patients valued knowing how their medicines work and the benefits of 
taking the treatment. This specific information about medicine benefits can improve 
perceptions of medicine information leaflets and patients’ intention to adhere to 
treatment.  
Other information patients wanted to know included: possible drug/food interactions, 
how to take the medicine, and what to do if a dose is missed. As described in the 
literature, patients want information about the potential harms of their medicines, yet 
healthcare providers can be hesitant in providing this.  
Furthermore, how printed information is designed and presented is important. Our 
review found that optimising the design of leaflets improved patients’ ability to read, 
find, and understand the information that has been given to them.  
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How medicine information leaflets should be designed 
compared to regulatory agencies’ recommendations 
This section described how medicine information leaflets should be designed, 
outlining 20 good-design principles identified in the previous literature search. We 
compared these principles to guidance from an earlier systematic review,2 and to the 
recommendations for written or printed leaflets that are available online from 
regulatory agencies in New Zealand, the UK, the EU, and the USA.  
Some regulatory authorities had very specific guidance about content and 
presentation. Some guidance did not follow the 20 good-design principles and missed 
certain features. New Zealand had very little guidance for manufacturers which is a 
concern. Furthermore, because it is not mandatory to provide leaflets in New Zealand 
at this time, some medicines do not have New Zealand-based information available. 
For the complete picture of medicine information for patients, it is important to 
investigate how medicine information is currently being delivered. Printed information 
about medicines has been common practice for a number of decades, but digital 
information provision is a newer practice. The following section gives an overview of 
innovative concepts of medicine information delivery. 
Digital information about medicines, is there a need? 
Providing information about medicines to patients in a digital format could unlock 
many other opportunities such as information expansion and audio-visual 
accompaniment. However, to ensure accurate, good quality information there would 
need to be regulation of how digital information is provided. It is essential patients are 
pointed in the direction of reputable evidence-based information. Other systems of 
disease-based information provision have shown promise in patient engagement and 
enhancing their knowledge. Therefore, digitally providing medicine information could 
improve patient perceptions of the information. Although many people can access and 
use basic computer programs effectively, the information should be printable for 




Providing information digitally could allow patients to tailor information to their own 
needs. This is important as individuals’ requirements for information vary significantly. 
Those who desire more comprehensive information about the medicine would be able 
to find what they need, and at a time that is convenient for them. 
Patient reported outcomes 
Patient reported outcomes (PROs) enable patients to provide direct accounts of their 
health or treatment to health professionals and allows response to concerns that are 
of greatest importance to them. PROs could therefore be used to provide patients 
with information that helps them use their medicines safely. The type, amount, and 
timing of information collected is hugely variable, and PROs can be designed for a 
multitude of different purposes. 
There are many benefits in using PROs including increasing the information available 
to health professionals for use during consultation, enabling shared-decision making, 
encouraging patients’ self-management of health, and improving documentation and 
observation of improvement or deterioration over time. Disadvantages of using PROs 
include increased burden on health professionals’ time and costs involved. 
PROs are not regularly used in general practice because their effectiveness has not 
been well demonstrated in reviews.73, 122 However, their effectiveness has been 
established when they are used for the reporting of specialised issues such as toxicity 
with chemotherapy124, 135, 136, 255 or progress for psychotherapy patients who are 
predicted to be poor-responders to treatment.137  
Main findings, chapter 2 
Both summary and comprehensive medicine information leaflets should be readily 
available. Leaflet content requirements were identified, and include names of the 
medicine, dose, benefits of treatment, and potential harms of therapy. The guidance 
provided by the New Zealand regulatory agency about how to design written 
consumer medicine information does not align with patients’ stated needs. Innovative 
solutions for providing optimal information about medicines and the management of 
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medicines include adopting digital solutions and facilitating standardised patient 
feedback with Patient Reported Outcomes.  
7.2.2 Findings of chapter 3 
What information is given verbally to patients about their 
medicines? 
This section focused on how frequently GPs and community pharmacists provide 
verbal information about medicines. A cross-sectional survey132 examined their 
reports of (i) providing information in general, (ii) providing information on specific 
counselling points, and (iii) the importance of these counselling points for repeat 
medicines prescribed for chronic conditions. The specific counselling points were 
determined in the literature review as described in chapter 2.  
(i) We found that only three quarters of GPs and fewer than half of pharmacists 
reported they provided patients with verbal information about new medicines all of 
the time. Furthermore, very few of them gave verbalised information about repeated 
medicines all of the time. This supports findings from other research that people may 
not be receiving enough information when they are prescribed new medicines.7-9, 63, 
144, 145 Similar studies investigating counselling provision by pharmacist from self-
reports claim 51–100% pharmacists report to provide counselling to patients63 or that 
information is given all of the time.140  However, from self-reports in our study, only 
43.7% of pharmacists provide verbal counselling all of the time. GPs reported they 
provide verbal counselling 75.3% of the time, and this is supported in observational 
studies that some medication counselling is given most of the time.145, 148(ii) For most 
of the specific counselling points (e.g. what the medicine is for, potential interactions), 
GPs were more likely than pharmacists to report that they discuss these with patients 
all of the time. More than three quarters of respondents from either profession 
reported to discuss all or most of the time: what the medicine is for, the dose and 
duration of treatment, how to administer the medicine, how to monitor treatment 
effectiveness and further monitoring requirements of the medicine, possible side-
effects and what to do if they occurred, and how the medicine helps the condition. 
Furthermore, many points are not frequently discussed by either health professional 
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including: contra-indications and precautions, potential interactions, lifestyle 
information (e.g. drug effect on driving, drinking, sexual activity), and what to do if a 
dose is missed (see Table 5). This is similar to findings from an observational study in 
Sweden where pharmacists generally discussed  ‘non-medical’ counselling points.150 
However, in an Australian study examining pharmacists reported verbal discussions 
covered a variety of clinical topics, using the medicine information leaflet as a 
prompt.26 Our study shows there may be differences in practice between pharmacists 
in New Zealand and Australia. The GP responses from self-reports indicated that most 
clinical information was covered. However, observational studies show that little of 
this information may be covered during consultation, notably that side-effect 
information is often not provided or trivialised.145, 148 
(iii) For most of the specific counselling points for repeat medicines GPs were more 
likely to report they were very important than pharmacists. It has been demonstrated 
that verbal counselling is not as likely to be undertaken for repeat medicines as it is 
with new medicines.63, 140 The findings from this study shows that though counselling 
is less likely, many GPs still think it important that people are informed about most 
aspects of their medicine when they are receiving repeat medicines for chronic 
conditions.  
Main findings, chapter 3 
The findings of this chapter supported the first hypothesis Patient medication 
counselling performed by both general practitioners and pharmacists is of variable 
standard. 
Some GPs and pharmacists will not be adequately discussing their medicines with 
their patients. Furthermore, when medicines are discussed, patients may not be 
receiving all the information they want or need to know.  
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7.2.3 Findings of chapter 4 
Provision of medicine information leaflets and how they are 
perceived by health professionals 
This section described reported provision of medicine information leaflets to patients 
by GPs and community pharmacists. A cross-sectional survey174 examined their (i) self-
reported provision of medicine information leaflets, (ii) views on available leaflets, and 
(iii) support for tailoring information leaflets for patients. 
(i) Very few pharmacists and GPs reported they provided leaflets to patients all of the 
time; slightly more from both groups reported that they gave leaflets more than half 
of the time. Pharmacists were more likely to report providing them, although only 
27.8% would give them more than half the time and 12.7% would give them all of the 
time. Both groups were much less likely to give leaflets for repeat medicines for 
chronic conditions. This differs to findings in a 2014 Australian study173 where 
pharmacists reported providing CMI when dispensing a new medicine most (n = 150, 
43%) or all (n = 168, 48%) of the time. In this same study, GPs reported they provide 
CMI most (n = 56, 31%) or all (n = 18, 10%) of the time with new medicines—this is 
more in line with findings from our study (where 2.1% reported they provided leaflets 
all the time and 11.2% reported providing them most of the time), though the findings 
in Australia are more positive. The situation on provision of leaflets is similar in New 
Zealand and Australia, where CMI is available on an accessible website. However, 
findings in Australia exhibit better leaflet provision. This may be because there have 
been large campaigns to promote the practice of providing leaflets at point-of-care in 
Australia. A 2001 New Zealand survey16 similarly demonstrated that patients may not 
be using leaflets as information resources. In international studies patients report 
receiving leaflets without discussion from their GP or pharmacist.65, 66, 143 However, in 
our study we found that when leaflets are provided, GPs and pharmacists tend to 
discuss leaflets with patients before giving them to take away, which is an improved 
method of providing leaflets to patients.  
(ii) Qualitative analysis identified five themes that GPs and pharmacists liked and/or 
disliked about leaflets: design, content, accessibility, perceived quality, and usefulness 
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and usability. Leaflet design was considered both problematic and valued. The content 
of leaflets was disliked because of a perceived risk that some content could cause 
anxiety for patients and discourage them from taking their medication. Again, GPs and 
pharmacists appreciated well-designed leaflet content that informs patients about the 
benefits of their treatment, how to take it, the potential risk of experiencing side-
effects, and what to do if they occurred. Similar themes have been identified in other 
studies when investigating the likes and dislikes of leaflets.4, 40, 48, 65, 66, 173 However, our 
study also identified that leaflets must be easily accessible at point-of-care and a 
digital format may be well received by health professionals. Leaflets also need to be of 
good quality, and be useful as an aid for educating patients. 
(iii) A summary leaflet is most preferred by GPs and pharmacists and there is some 
support for the tailoring of leaflet information to patient requirements. 
Using websites for medicine information and improving provision of leaflets This 
section discusses whether GPs and community pharmacists recommend websites to 
their patients as a source of information about their medicines. It also describes ways 
GPs and community pharmacists think their provision of medicine information leaflets 
could be improved. A cross-sectional survey184 examined their (i) self-reported use of 
websites for providing medicines information to their patients and (ii) their thoughts 
on what deters or encourages medicine leaflet provision. 
(i) Neither GPs nor pharmacists often recommend websites to their patients for 
medicines information. The Medsafe website, where the manufacturers’ CMIs are 
located, is still the most commonly used website by survey participants, although GPs 
were just as likely to recommend the New Zealand Medicines Formulary which 
provides a summary one-page leaflet. Similar to an Australian study investigating 
provision of leaflets,173 CMI were most likely to be given from the central repository 
(in our study, from the Medsafe website).  However, it is encouraging that the 
summary leaflets available (from the New Zealand Medicines Formulary website) are 
used by almost as many GPs and pharmacists as the manufacturer CMIs. This 
indicates, that where summary leaflets are available, they are being used in practice.  
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(ii) GPs most commonly did not give leaflets to patients because they lacked the time 
to discuss the leaflet, or they thought the patient might have difficulty reading and 
understanding it. Time constraints appear to be a greater restriction in New Zealand 
compared to Australia, where GPs and pharmacists are less likely to identify this as a 
barrier.26 Pharmacists most commonly did not give leaflets because the patient has 
taken the medicine previously, or the medicine was being used for an unlisted 
indication. Both groups commonly did not give leaflets because of concerns that the 
patient will worry about side-effects and refuse their medicine, and they believed that 
patients do not want leaflets. However, internationally it has been shown that 
patients appreciate the leaflets they receive2, 26 and although a common concern, 
knowledge of side-effects does not make people stop taking their medicines without 
consulting a health professional.26, 162, 171, 181  Almost a quarter of GPs thought it was 
the pharmacist’s role to provide medicine information leaflets and so did not provide 
them. This differs from findings of an Australian study26 where over half of GPs 
reported they do not give leaflets because they think the pharmacist will give them. 
However, as mentioned previously, GPs in New Zealand are much less likely to provide 
leaflets to patients than pharmacists and improving provision of leaflets by both 
groups should be encouraged. 
Most commonly, GPs and pharmacists thought leaflet provision might be encouraged 
by having: (i) a summary leaflet available for discussions; (ii) automatic prompts from 
the prescribing system; (iii) personalised leaflets for patients, and (iv) specific 
counselling appointments to discuss medicines with patients. Pharmacists also 
favoured reimbursement for provision of leaflets, increased requests for leaflets from 
patients, and having leaflets available in different languages. 
Patients’ opinions on medicines information leaflet provision 
and usefulness 
This section investigated patients’ experiences and thoughts about receiving 
medicines information leaflets. A cross-sectional survey256 examined (i) patient reports 
of Dunedin GPs’ provision of medicine information leaflets and (ii) patient views on 
the leaflets provided. 
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(i) Most participants had not received leaflets from their GPs in the last six months. 
This finding differed significantly from an Australian study investigating consumers 
reception of leaflets for prescription medicines where 69% reported receiving a leaflet 
in the last six months.26 Almost half of consumers in the Australian study reported 
receiving leaflets every time they received a new medicine. The majority of patients in 
our study thought it was important to receive a leaflet for new medicines, but not for 
repeat medicines, which was in line with our earlier studies investigating perceptions 
of GPs and pharmacists. Most patients would like to receive a leaflet from their GP 
when prescribed a new medicine and over half also wanted one when new 
information is available, when the medicine has serious side-effects, or when there is 
a change in brand. In general a paper-based summary leaflet was the preferred 
option. 
(ii) When they had been given a leaflet by a GP, most patients thought it improved 
their knowledge and helped them take their medicines. This may be because patients 
struggle to remember verbal information once they have left consultations.7, 9, 26, 28, 38, 
39 Almost all participants liked the leaflet they received, even though previous 
investigations of CMI show they may be poorly designed.55 Overall they thought the 
information in the leaflet was readable and easy to find and understand. Almost all 
participants read all or some of the leaflet, which differed to findings in an Australian 
study26 where only two thirds of participants reported reading the CMI.  This may be 
because patients are less likely to be provided leaflets in New Zealand, and because 
they are appreciated, they are used. Other studies show that CMI readership may be 
dependent on participant demographics e.g. age and education level.9 However, the 
participants in our study had lower completed qualification levels than the general 
population and were from a variety of age groups, indicating that people from 
differing literacy levels and age groups still appreciate receiving printed information.  
Nearly half of the participants kept the leaflet for future use. 
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Main findings, chapter 4 
The findings of this chapter supported the second hypothesis Written medicines 
information resources for patients are of differing quality, are under-utilised, and are 
sometimes given without adequate verbal counselling. 
GPs and pharmacists do not routinely provide written medicines information leaflets 
or recommend web-based information sources. To support leaflet provision, they 
need to be well designed, easy to read and understand, and concise because of the 
limited time to discuss leaflets in practice. 
Facilitators to encourage provision of written medicine information included having 
summary and tailored leaflets available, more time with patients, and automatic 
computer prompts. GPs, pharmacists, and patients believe it is important that leaflets 
are given with new medicines. 
Patients’ value having written medicines information leaflets provided to them with 
new medicines. 
7.2.4 Findings of chapter 5 
A Use Case for providing personalised medicines information in 
primary care 
This section described the first of two proposed digital solutions to help medicine 
information provision: the creation of an automated personalised-information builder 
working within current dispensing and prescribing systems in primary care. This would 
provide (i) counselling points for the GP or pharmacist to use at point-of-care, and (ii) 
personalised information for the patient to take away with them.  
A Use Case with summary Use Case diagram and a mock-up example of a personalised 
information leaflet were created to describe the project and goals of the system to 
potential programmers, (see Figures 13 and 14, and Appendices 14 and 15).  
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Feasibility study for providing personalised medicines 
information in primary care 
To determine the feasibility of the project we asked vendors of prescribing and 
dispensing systems in New Zealand to complete a questionnaire about the perceived 
market for the digital tool, technical requirements involved, financial outlay required, 
scheduling feasibility, and potential barriers. Further feedback on the project by 
telephone and email was also gathered. 
Overall, the survey found that the project described in the Use Case is not considered 
a feasible one to pursue and an alternative method of providing patients with 
personalised information should be sought. Barriers to the project identified include 
cost, time, inability to update clinical content, and risk of being unable to complete 
other projects. Vendors did not think the project worthwhile, although they thought 
that users may find it beneficial if such a tool was built.  
Main findings, chapter 5 
The findings of this chapter did not support the third hypothesis It is possible to 
digitally automate the creation and provision of personalised information about 
medicines at point-of-care. 
At this time, it is not feasible to build an automatic leaflet-tailoring and prompting 
system within prescribing and dispensing management software used in New Zealand. 
7.2.5 Findings of chapter 6 
Chapter 6 investigated the current practice of providing information to patients taking 
high-risk medicines (chemotherapy) and also described the second of the two 
proposed digital solutions to help medicine information provision: the use of PROs to 
provide specialised and specific information about how to manage chemotherapy-
induced side-effects on a digital platform. The platform could also provide patients 
with medicines information appropriate for their specific illness any time it is needed.   
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Patient experiences with medicine information about their 
chemotherapy 
This section described the views of people who have had chemotherapy about the 
medicine information they were provided with. This study covered (i) how they were 
given the information about their chemotherapy, (ii) whether they understood this 
information and could act on it, and (iii) whether they thought this information could 
be improved. This information was collected using a questionnaire and then a focus 
group discussion or interview. 
From the questionnaire responses we found that participants agreed the information 
they received was easy to understand and the way it was provided facilitated their 
understanding. However, the quantity was sometimes inappropriate (too great). This 
is similar to findings in other studies that demonstrate that some people want to 
receive plenty of information,238  whilst others show  patients prefer to receive little 
information.236 This is where tailoring of information to patient requirements or 
signposting the most relevant information is important. Furthermore, some 
participants found the information they took home was too complex, or they were too 
ill to understand it or to find the content they were looking for. The use of digital 
resources may improve comprehension,240 by explaining complex terminology and 
providing further descriptions of concepts if necessary. Furthermore, previous 
research of information provision with chemotherapy medicines has demonstrated 
that adequate provision of information can improve adherence, quality of life, and 
satisfaction with treatment.236, 238, 239 So investigating ways to improve information for 
chemotherapy patients is necessary. Importantly, participants in our study reported 
having a good understanding of what they were required to do if they experienced a 
side-effect. 
Four main themes emerged from the thematic analysis: (i) gathering and use of 
information provided with treatment; (ii) problems identified; (iii) other opportunities 
to aid understanding; and (iv) improving information provision. 
(i) Most participants received verbal and written medicine information when they 
started their treatment. As has been mentioned previously with low-risk medicines, 
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verbal information provided to cancer patients might be forgotten following a 
consultation,214, 236 so it is a positive finding that both forms of communication are 
commonly used.  The written information was often used as a reference source for 
future use, which is common practice with chemotherapy medicine information.234, 236 
Not all participants were told which websites to visit for more information; however, 
studies have shown that chemotherapy patients like to receive web-based 
information236, 240 and this practice should be more widely adopted in New Zealand. 
Six participants avoided reading the information given to them. However, as described 
in other studies,237, 241 information was often gathered and used by their support 
people or family members. 
(ii) Some participants actively avoided phoning for help because they did not want to 
have to go to the hospital and would rather try to manage their symptoms themselves 
at home. One participant could not find the information they needed to know. Some 
considered the quantity of reading material provided was overwhelming and 
frightening. Yet, some believed information was missing e.g. some basic information 
(e.g. what are ‘chemotherapy rounds’?) and details about rare side-effects. Lack of 
information has been described in other studies and can result in inferior patient 
experiences.235, 236 Other identified barriers to understanding included: 
communication breakdown with specialists; lack of consistency of information 
between DHBs; and lack of mental capacity due to emotional turmoil or medication-
induced cognitive impairment. 
(iii) Many participants identified that former chemotherapy patients and support 
groups were useful sources of information. The preference to use former 
chemotherapy patients has been described previously236, 241 and using them as a 
sympathetic information source for current patients is common, but not widespread, 
practice. There is progress in New Zealand with the development of web applications 
to connect oncology and haematology patients together, but these are not yet in 
widespread use. 
(iv) Solutions to improving information provision included better structuring of 
information to improve findability, as has been suggested in other studies109 and 
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utilising websites and smart applications to organise and provide information. Three 
participants would also value personalised information.  
Patient views on the use of Patient Reported Outcomes (PROs) 
for providing personalised information in a digital tool for 
chemotherapy medicines 
This section described the views of people from the previous survey about using a 
proposed online tool for capturing Patient Reported Outcomes (PROs) and receiving 
information about their treatment and side-effect management. Any perceived 
advantages/disadvantages of using this tool were also discussed. Information about 
general use of digital technology was gathered by a questionnaire, and then a focus 
group discussion or interview was used to gather opinions on the proposed PROs tool. 
From responses we found that participants frequently accessed the internet, and nine 
of the 11 participants had looked for health information on the internet in the past 
year. This indicates that participants in our study are adept at using the internet as an 
information resource and would be well-suited to digital health solutions. 
From the thematic analysis of the focus groups/interviews, four main themes 
emerged: (i) preference for the proposed digital tool over current system; (ii) inputting 
information and how it is used; (iii) concerns about using the tool; and (iv) preference 
to use both the current system and a digital tool. 
(i) Some participants thought the digital tool could overcome barriers to using the 
current system such as anxiety in phoning the hospital, reluctance to ‘cause a fuss’, 
and being physically unable to talk on the phone. Participants would appreciate the 
perceived ease of use, ability to find more information and share with family/support 
people, and being able to determine if a side-effect was serious enough to warrant 
contacting the hospital. These uses described by participants in our study are similar 
to those currently being described in practice in the international trials.128, 245 
(ii) Most participants felt it important that a digital tool would automatically log side-
effects in their hospital record, as shown in studies of users of the systems,128, 245 but 
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participants in our study also wanted the ability to seek information without this being 
automatically reported. 
(iii) Participants wanted assurance that logged information was reviewed by their 
specialist team and that any lack of access to internet or digital devices would not lead 
to inequities. Reassurance after using web-based reporting systems was demonstrated 
in studies internationally,124, 128, 245  However, these studies were undertaken with 
participants already using the system and equity and access was not discussed. One 
study in Australia investigating perceptions of people who had used the system 
identified issues that did not arise from our discussions, such as trouble inputting data 
and lack of confidence in using the full functionality of the system.124 This may be 
because our group all used the internet for various functions and may be more tech-
savvy than participants in this trial. Assessment of access to the appropriate digital 
requirements (whether hardware or internet) for all potential users of new technology 
is essential before investigation into new digital services for cancer patients. 
(iv) Although there was support for using a digital tool, almost all participants wanted 
the current system to be retained. Some people wanted both because they prefer to 
read paper documents. Some thought it easier to discuss more complex problems 
with a healthcare professional than trying to use the described PRO digital tool.  
Main findings, chapter 6 
The findings of this chapter supported the fourth hypothesis The provision of 
information about high-risk medicines is of variable standard and the use of digital 
technology to provide patients with personalised and relevant medicine information 
might be well-received. 
Oncology/haematology patients consider the way they are given information about 
their treatment does not suit everybody and could be improved. Many thought having 
a digital system available to report side-effects and receive information would be 
beneficial and help support their side-effect management. Using digital technology to 
find information about treatment would also be appreciated. 
279 
 
7.3 Strengths and limitations 
7.3.1 Strengths  
There are a number of strengths in this thesis.  
The investigations undertaken had a multidisciplinary approach and guidance and 
advice was received from many health professionals involved in patient care including 
GPs, hospital pharmacists, oncology/haematology nurses, and oncologists, as well as 
IT consultants and software developers, business advisors, and research study-leads in 
oncology projects involving digital tools in the UK. This required much planning, 
communication, and coordination. It was a worthwhile approach as the 
multidisciplinary collaboration resulted in more comprehensive and effective 
approaches to the investigations. We used different types of research (quantitative to 
answer ‘how’ and qualitative to answer ‘why’) with different stakeholders to seek 
information from different angles. This was to get the full picture of what is happening 
in practice. Using these approaches, with different methodologies and key 
stakeholders, we could determine their needs and opinions on medicine information 
available and how it is provided. By surveying providers of information, those who 
receive the information, those who can support provision of information (i.e. the 
vendors) and users of information in a specific area we could triangulate the outcomes 
to inform the optimal ways of providing medicine information.  
The qualitative data collected from the open ended questions in the surveys with GPs 
and pharmacists provided detailed material on how information on medicines is 
provided to patients in current practice, reasons for providing/not providing this, and 
valuable insight into how this process could be improved in the future.  
A range of views, both positive and negative, were expressed by participants. The 
survey and correspondence with IT vendors in particular provided context to their 
reasoning, and detailed explanations of why they believed the proposed system (tool 
for automated tailoring of medicine information for patients) would not work in the 
current software market. Furthermore, the responses mentioned barriers that had not 
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previously been considered by the research team. This was useful to prevent further 
research being pursued in this area when the industry would be unlikely to support it. 
Further strengths were that the eleven participants of the focus group/interviews in 
chapter 6 were good contributors to their group/interviews and provided rich data. A 
range of views were expressed, saturation of ideas was achieved, and no individual 
dominated the focus group session. 
Another particular strength of this thesis is that a number of peer-reviewed articles 
relating to the investigations were published where the candidate was the first and 
corresponding author. The process of writing, submission, peer review, and revisions 
led to clarifications and improvements in the manuscripts, and to more robust content 
for inclusion in the thesis. 
7.3.2 Limitations and how they were mitigated  
There were some difficulties with recruitment in each of the investigations 
undertaken, but steps were taken to mitigate them.  
Health professionals are known to be difficult to recruit153, 257 and the first 
investigation (questionnaires sent to health professionals) had fewer responses than 
hoped for. An electronic survey was administered, being easier for participants to 
access and use. However, given the likely lower response rates to electronic surveys 
257-259, paper copies were posted to pharmacies who did not initially respond. To 
further encourage participation, email reminders were sent to GPs and pharmacists, 
and a monetary incentive was offered (a ‘prize draw’).260, 261 Lower participation than 
hoped for and possible biases (selection bias, recall bias, and possible socially 
acceptable responses), may limit the generalisability of results. However, because the 
results were not overwhelmingly positive, it is reasonable to assume there is a need 
for improvement in medicine information provision to patients.  
Furthermore, international generalisability may be somewhat limited because policies 
on leaflet provision differ (mandatory in some countries, but not New Zealand). 
However, because we investigated opinions and the use of leaflets in practice, some 
inferences can be made to international experience. Additionally, GPs and pharmacists 
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were not asked to describe their likes or dislikes of a particular type of leaflet, so their 
opinions of specific leaflets cannot be ascertained. We were asking their opinions of 
leaflets in general, although their opinions could change depending on what leaflet 
they were thinking of at the time. However, the majority of respondents would prefer 
to not use CMI so it can be assumed that most of the comments about what they do 
not like about leaflets pertained to the lengthy manufacturer-produced CMI. 
In addition, recruitment of the general public (survey about leaflet provision by GPs) 
may have been impeded by it taking place in a University city (Dunedin), where there 
is the possibility of research fatigue amongst its population.260  
The survey of vendors of software for prescribing and dispensing systems had a small 
number of participants because there are only a few vendors (n=6) in the market in 
New Zealand (see chapter 5). Therefore, the results of chapter 5 may be of limited 
validity and generalisability. Nevertheless, it was felt that the data provided was 
extremely useful in demonstrating the feasibility of the project. 
Recruiting for qualitative research can be especially time-consuming and 
challenging262, and this was found for our qualitative study (interviews and a focus 
group of people who had experienced chemotherapy). Furthermore, our study was 
investigating a sensitive topic, involving experiences at a stressful time of peoples’ 
lives which could have also resulted in lower participation numbers.262 Conversely, 
participation may be encouraged when people believe their experiences are 
important to themselves and to society.262 To encourage recruitment of members of 
the public we built up relationships with support groups and clinical staff,260 used 
mediators and personal contacts,262 and provided a small monetary incentive for 
participants.260 Recruitment activity took place as the COVID-19 epidemic emerged in 
Asia and Europe. As described earlier (chapter 6), recruitment of subjects for this 
investigation was halted soon after by restrictions imposed by the New Zealand 
government and the University of Otago. These prevented travel and face-to-face 
meetings when COVID-19 infections emerged in New Zealand. Unfortunately, as a 
result we were unable to recruit Māori, Pasifika, or rurally-based participants. 
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Further bias may be present from participants who had a troubled relationship with 
their specialist team or a particularly negative experience during their treatment. This 
may make people more inclined to participate and/or be more vocal during focus 
group sessions. We found that there were some negative experiences shared with the 
group, but overall a range of views were expressed. Furthermore, as we were 
attempting to identify areas for improvement and investigate ways of improving 
information provision, a slightly negatively biased group would have provided useful 
data.   
All of the participants in the qualitative study investigating a possible digital solution 
to information provision and medicine management had experience with using the 
internet and many regularly searched for health information online. This may limit the 
findings of this study to those who are digitally literate and who have regular access to 
computers. Further study is required to seek opinions from those who are not 
frequent users of the internet or have restricted, or no, internet access before 
recommendations can be made for the New Zealand population. This, along with 
research with other poorly represented population groups (Māori, Pasifika, and 
people in rural areas) would also need to be addressed before any new system is 
introduced or further work is undertaken. Yet, the findings indicate that some 
improvements can be made and there is a section of the population that would 
appreciate digital solutions. 
A modified investigation  
Chapter 6 of this thesis investigated the opinions of former chemotherapy patients 
about how they received information about their treatment and their views on a 
possible digital tool to help manage their side-effects. This was a modification of an 
investigation that we had hoped to conduct. 
Our original intention was to develop the digital tool described in chapter 6 and 
undertake a feasibility study of the use of this tool in New Zealand, subject to 
successful grant applications. The history behind the postponing/abandoning of these 
plans is as follows:  
283 
 
Video conferences were held with two research leads on similar projects in the UK, 
Professor Galina Velikova at the University of Leeds, and Professor Roma Maguire, 
from the University of Strathclyde. Both Professors gave valuable advice and were 
supportive of our project.  
Six grant applications totalling (NZ$842,376) were submitted to funders between 2018 
and 2019 (see Appendix 22). Unfortunately, none were successful.  
At this point it seemed appropriate to undertake the first phase in a feasibility study 
instead, which was to gauge the opinions of New Zealanders who had experienced 
chemotherapy previously. Therefore, the investigations that were described in 
chapter 6 were conducted.  
The outcomes found from the focus group and interviews in chapter 6 provide some 
evidence of the need for/possible value of a digital tool in New Zealand and further 
work in this area is warranted.  
7.4 Recommendations for practice 
In this section I will describe recommendations for current practice based on the 
outcomes from all areas of investigation. 
The provision of medicine information leaflets either printed or sent digitally should 
be made mandatory in New Zealand by the government. Furthermore, advice being 
provided to those creating medicine information for patients should be adapted to 
incorporate the 20 good-design and content principles for readability. 
Whilst information leaflets cannot be automatically tailored, the information 
discussed and the way written information is provided (via printed leaflet or digitally) 
can be carefully chosen to meet a patient’s requirements. There are different patient 
information leaflets available for many medicines, ranging from short one-page 
summaries to longer manufacturer-produced consumer medicine information leaflets. 
Health professionals could direct patients to the type they think most appropriate for 
them. Some patients want more information for complex conditions in a digital format 
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and the amount of information they desire could be discussed with their GP or 
pharmacist. 
If printed information is being provided, it should be actively discussed with patients 
and important points highlighted to ensure understanding. People who are taking 
medicines for chronic conditions tend to not be provided with repeated and/or 
updated information about their treatment, particularly where provision of leaflets 
with treatment is not mandatory. Ideally, GPs and pharmacists should briefly check 
with patients each time they are having a follow up appointment or collecting a repeat 
prescription about whether they want more information or a leaflet and if they have 
any questions or concerns with their treatment. 
To help with the provision of leaflets, IT systems should be set up to remind GPs and 
pharmacists to provide them, e.g. pop-up alerts within the software. Additionally, 
more should be done to encourage patients to ask for information and the availability 
of leaflets should be actively promoted. This could be achieved by having links for 
health and medicine information on the general practice or pharmacy websites or 
within patient portals, and by displaying lists of sources of information in waiting 
areas. Patients should expect to be provided with written information to take away. 
Furthermore, efforts should be made to ensure patients are comfortable with the 
resources being used and that they are supported to ask questions if they wish. 
Moreover, GPs and pharmacists should familiarise themselves with the different types 
of leaflets available and how to access information efficiently to use at point-of-care. 
Importantly in this digital era, software should enable easy and standardised coding 
for indications and patient characteristics to enable future technologies to automate 
tailoring of resources e.g. using SNOMED coding. Furthermore, giving pharmacists 
access to the indications that medicines are being prescribed for will help them 
provide specific and useful counselling for patients. Not all pharmacists currently have 
access to this level of information. Vendors of patient management systems need to 
engage with the sector to improve the ability to print or digitally send medicine 
information to patients within their current systems. This should be undertaken in a 
manner that suits their users. 
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Patients undergoing chemotherapy can sometimes be overwhelmed with the large 
amount of information provided to them. Printed information should be provided in a 
format that makes it easy to follow, and find, the information that is needed. Some 
suggested changes were that summary leaflets also be given, content of leaflets 
optimally arranged (with most important information is separated from the rest), and 
that all information also be available in digital formats. Many patients valued talking 
to others who had already been through the same treatment, and this information 
sharing should be actively encouraged as a useful way to receive information about 
side-effects of treatment.  
7.5 Recommendations for further research 
First and foremost the voices of Māori, Pasifika, and other ethnic minority groups, and 
those of rurally-located people were not heard in the investigations undertaken in this 
thesis. This needs to be remedied and further research is required to understand their 
medicine information needs and how they manage their side-effects. Often these 
groups are marginalised and experience inequity in the health system so it is essential 
that their views and experiences are gathered and accounted for.  
Further investigation is also needed for people with differing levels of health literacy, 
and in those in whom English is not their first language, and the difficulties they face in 
understanding medicine information in New Zealand. This should lead to the 
production and assessment of leaflets in different languages in New Zealand. 
Investigation into other avenues to automatically tailor information leaflets for patient 
requirements could be undertaken, e.g. in systems that sit outside of patient 
management software. At the least, pop-up alerts within patient management 
systems reminding prescribers and pharmacy staff to print/send medicine information 
leaflets could be assessed for suitability and use in practice. 
Although the research team were unsuccessful in accessing funding to create and 
assess a digital tool for providing chemotherapy medicine and side-effect 
management information, the feasibility of such a system in New Zealand should still 
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be investigated. The evidence of patients’ needs/acceptability (already described in 
chapter 6), when published, could be used in further funding applications. Moreover, 
using PROs for managing the side-effects of other treatments and for general use in 
primary care, requires further consideration. 
7.6 Conclusion 
Health professionals endeavour to provide the best healthcare they can for their 
patients. Unfortunately, providing information about medicines may not be 
considered an essential aspect of the services they provide. Healthcare professionals 
face worsening pressures in primary care with increasingly complex patients living to 
older ages and with limited time to talk with them about their illness, their lifestyle, 
and their medicines; it is understandable that some things may be overlooked. Adding 
another layer to the complexity of providing information about medicines, the type 
and quantity of information that patients want varies depending on numerous factors 
including their age, how long they have had the illness, their health literacy, and the 
severity of the illness they are experiencing. Getting the right amount of information 
about medicines to every patient is difficult. 
This thesis investigated: what information patients want to know about their 
medicines; how written information should be designed; what information is being 
provided in New Zealand practice; the feasibility of adapting New Zealand Patient 
Management Systems to automatically tailor medicine information to patient 
characteristics; experiences of patients’ who received chemotherapy information, and 
their views on using a digital tool to provide them with personalised medicine 
information and side-effect management advice. The individual investigations 
undertaken were investigating ways to improve medicine information provision from 
current practice perspectives, i.e. in community pharmacy, in general practice, and in 
specialist hospital environments. In all instances there were gaps in provision and 
room for improvement. 
Fundamentally the information being given to a person must be understandable to 
them. At this time, it is not mandatory to provide written information in New Zealand, 
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but whether mandatory or not, it is best practice to provide verbal and written 
information. Ideally patients should receive information tailored to them in a way that 
suits them. However, this takes time and effort from the provider, and time is a 
precious and an ever decreasing commodity. Nevertheless, people may not be 
receiving sufficient verbal information about their medicines, and providing complex 
and incomprehensible information leaflets can negatively affect adherence and 
patient satisfaction. Efforts should be made to optimise written medicine information 
for patients; this could improve both healthcare professionals’ willingness to provide 
them and patient understanding.  
Healthcare professionals should promote the use of appropriate online resources for 
medicine information with their patients. People are already using the internet to gain 
information about their illnesses and medicines and would benefit from healthcare 
providers pointing them to reputable websites. Furthermore, with the global rise of 
telehealth due to the COVID-19 epidemic and lessening of face-to-face consultations 
with healthcare professionals, digital resources may soon become a necessary 
requirement for informing patients adequately about their medicines.  
Medicines that can have serious side-effects (e.g. chemotherapy) may be 
accompanied by a multitude of alarming, confusing, and anxiety-producing 
information. There are systems in place to provide people with copious information 
about chemotherapy treatment, but there is still a need to adapt this for individual 
requirements. Digital tools being used internationally might help New Zealand 
patients better understand and manage their medicines. These would be well-
received as an adjunct to current systems. 
Further research is necessary to investigate ways to automate the provision of optimal 
medicine information for patients, and the use of PROs for medicine-management in 
wider practice. Both concepts have the potential to improve medicine information 
provision and patient outcomes. However, research into medicine information needs 
of Māori, Pasifika, and other ethnic minority groups, as well as people living in rural 
locations, those with lower digital literacy, and those with a poor grasp of English 
should also be explored. Changes made will only be a success if they ensure the 
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medicine information requirements for all groups residing in Aotearoa New Zealand 
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Appendix 1. Examples of information leaflets in New 
Zealand 



































Patient information leaflet created by the PILs Committee CDHB  
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Appendix 2. Search strategy and inclusion/exclusion 
criteria of review 
Search strategy of review 
Database Coverage Search string / terms and limits Notes 
Web of 
Science 
1898 (patient* OR consumer* OR public OR "member* of the 
public" OR client* OR customer*) AND TOPIC: (advice 
OR guidance OR recommendation* OR direction* OR 
instruction*) AND TOPIC: (medic* OR drug* OR 
prescription* OR pharmaceutic*) AND TOPIC: ("printed 
information" OR pamphlet* OR leaflet* OR handout* 




Scopus 1823+ (patient* OR consumer* OR public OR "member* of the 
public" OR client* OR customer*) AND TOPIC: (advice 
OR guidance OR recommendation* OR direction* OR 
instruction*) AND TOPIC: (medic* OR drug* OR 
prescription* OR pharmaceutic*) AND TOPIC: ("printed 
information" OR pamphlet* OR leaflet* OR handout* 
OR webpage* OR website* OR app*) AND TOPIC: 
("patient information") 
(due to unmanageable number: LIMIT-TO article, 


















(patient* OR consumer* OR public OR "member* of the 
public" OR client* OR customer*) AND TOPIC: (advice 
OR guidance OR recommendation* OR direction* OR 
instruction*) AND TOPIC: (medic* OR drug* OR 
prescription* OR pharmaceutic*) AND TOPIC: ("printed 
information" OR pamphlet* OR leaflet* OR handout* 





Selected articles from title and abstract (and after removal of duplicates) 207 
Relevant articles from search 5 
Relevant articles from reference lists of the above, and articles citing the above  12 
Total relevant articles 17 
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Inclusion and exclusion criteria of review 
Inclusion criteria Exclusion criteria 
Studies published in English with:  
 Participants using and/or previously 
used medicine information leaflets  
 Optimisation/improvement of 
leaflets by design and/or content 
changes (some studies may not have 
an intervention or comparator e.g. 
interviews, focus groups) 
 Outcomes of  
o Information preferences 
o Improved adherence 
o Increased ability to find and 
comprehend information 
o Increased likelihood for leaflet 
to be read and used 
 Qualitative (seeking patients’ 
opinions, feelings, and experiences 
directly) or quantitative (assessing 
usability, readability, or 
comprehension through 
questionnaires or interviews) 
outcomes 
 Assessing or discussing printed 
medicines information 
Studies: 
 Published before 2008  
 Not involving patients/consumers 
 About the usefulness of using 
printed materials in counselling 
 Focusing on 
o If patients’ received or read 
leaflets 
o If patients’ understand the 
current leaflets available 
o Description of side-effects 
o One aspect of medicine use or 
administration  
o OTC medicines 
 Evaluating the effect of languages in 
a leaflet  
 About pictograms or information in 
booklet form 
 Evaluating leaflet templates or tools 
used to assess written information 
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Appendix 3. Questionnaire sent to GPs and pharmacists, 
chapter 3.3.1 
Survey questions for GPs 
1. How often do you give the following to patients about medicines that are NOT 
considered high-risk (e.g. asthma inhaler)? (Tick the appropriate box in each line) 









Never Never, this 
















      
This question is about the information you give to patients about medicines they have 
never taken before. Please consider what information you would routinely give to 




2. How often do you discuss the following with patients? (Tick the appropriate box in 
each line) 
























names of the 
medicine  
      
What the 
medicine is for 








      





      




      
What to do if a 
dose is missed  














of the drug (if 
applicable) 
      
Potential 
interactions 
      
Side-effects 
and what to do 
if they are 
experienced 








      
General health 




      
Storage and 
disposal of the 
medicine 






















      
Other (please specify) 
 
This question is about what information you give to patients about medicines they 
have taken before (i.e. for a chronic condition). Please consider what information you 
would routinely give to these patients prescribed a medicine that is not considered 
high-risk (such as an asthma inhaler). 








What the medicine is for    
How the medicine helps the condition    
Contra-indications and precautions     
How to take the medicine: dose and length 
of treatment 
   
How to take the medicine: 
administration instructions 
   
What to do if a dose is missed     
How to monitor the treatment’s 
effectiveness (and when to come back if 
necessary) 
   
Monitoring requirements of the drug (if 
applicable) 
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Potential interactions    
Side-effects and what to do if they are 
experienced 
   
Lifestyle information (e.g. drug effect on 
driving, drinking, sexual activity)  
   
General health tips that would improve 
treatment outcomes 
   
Storage and disposal of the medicine    
Ingredients in the medicine (e.g. lactose, 
sugar) 
   
Where patients can access further 
information about the medicine or 
condition 
   
Information about alternative therapies 
and treatment options  
   
Other (please specify) 
 
Please provide the following demographic information 
4. Sex 










6. Please tell us which area this surgery is located in 
⃝ Major City (e.g. Auckland, Wellington, Christchurch) 
⃝ Provincial City (urban area with a population over 30,000 people e.g. Hamilton, 
Dunedin, Nelson, New Plymouth, Napier, Gisborne) 
⃝ Provincial Town (town with a population between 1,000 and 30,000 people e.g. 
Levin, Gore) 





Survey questions for pharmacists 
1. How often do you give the following to patients about medicines that are NOT 
considered high-risk (e.g. asthma inhaler)? (Tick the appropriate box in each line) 



























      
This question is about the information you give to patients about medicines they have 
never taken before. Please consider what information you would routinely give to 
patients prescribed a medicine that is not considered high-risk (such as an asthma 
inhaler).  
2. How often do you discuss the following with patients? (Tick the appropriate box in 
each line) 
 























names of the 
medicine  




medicine is for 








      





      




      
What to do if a 
dose is missed  






when to come 
back if 
necessary) 
      
Monitoring 
requirements 
of the drug (if 
applicable) 
      
Potential 
interactions 
      
Side-effects 
and what to do 
if they are 
experienced 










      
General health 




      
Storage and 
disposal of the 
medicine 




















      
Other (please specify) 
 
This question is about what information you give to patients about medicines they 
have taken before (i.e. for a chronic condition). Please consider what information you 
would routinely give to these patients prescribed a medicine that is not considered 
high-risk (such as an asthma inhaler). 
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The generic and brand names of the medicine     
What the medicine is for    
How the medicine helps the condition    
Contra-indications and precautions     
How to take the medicine: dose and length of 
treatment 
   
How to take the medicine: administration 
instructions 
   
What to do if a dose is missed     
How to monitor the treatment’s effectiveness 
(including when to come back if necessary) 
   
Monitoring requirements of the drug (if 
applicable) 
   
Potential interactions    
Side-effects and what to do if they are 
experienced 
   
Lifestyle information (e.g. drug effect on 
driving, drinking, sexual activity)  
   
General health tips that would improve 
treatment outcomes 
   
Storage and disposal of the medicine    
Ingredients in the medicine (e.g. lactose, 
sugar) 
   
Where patients can access further information 
about the medicine or condition 
   
Information about alternative therapies and 
treatment options  
   




Please provide the following demographic information 
4. Sex 








6. Please tell us which area this surgery is located in 
⃝ Major City (e.g. Auckland, Wellington, Christchurch) 
⃝ Provincial City (urban area with a population over 30,000 people e.g. Hamilton, 
Dunedin, Nelson, New Plymouth, Napier, Gisborne) 
⃝ Provincial Town (town with a population between 1,000 and 30,000 people e.g. 
Levin, Gore) 

















0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Medicine generic and brand names: GP
: Pharmacist
What the medicine is for: GP
: Pharmacist
How the medicine helps the condition: GP
: Pharmacist
Contra-indications and precautions: GP
: Pharmacist
Medicine dose and length of treatment: GP
: Pharmacist
Medicine administration instructions: GP
: Pharmacist
What to do if a dose is missed: GP
: Pharmacist
Monitoring efficacy (e.g. when to come back): GP
: Pharmacist




Side effects and what to do if they occur: GP
: Pharmacist
Lifestyle effects (driving/drinking/sexual): GP
: Pharmacist
General health tips to improve outcomes: GP
: Pharmacist
Medicine storage and disposal: GP
: Pharmacist
Medicine ingredients (e.g. lactose, sugar): GP
: Pharmacist
Where to access further information: GP
: Pharmacist
Alternative therapies and treatment: GP
: Pharmacist
All/Most of the time Some of the time Never Only on patient request
Appendix 5. Figure: Use of counselling points for new, low-risk medicines 
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How to monitor the treatment’s 
effectiveness (including when to come back 








































































Lifestyle information (e.g. drug effect on 






































































Where patients can access further 


















Information about alternative therapies 



















Appendix 7. Questionnaire, chapter 4.3.1 
1. How often do you give patients an information leaflet about their newly 
prescribed medicines?  
⃝ All of the time  
⃝ Most of the time  
⃝ Some of the time  
⃝ Only on patient request* 
⃝ Never* 
2. How often do you give patients an information leaflet about their repeated 
medicines for chronic conditions? 
⃝ All of the time  
⃝ Most of the time 
⃝ Some of the time  
⃝ Only on patient request*  
⃝ Never* 
*If you answered only on patient request or never for questions 1 AND 2, please go to 
question 7 
3. How do you usually use a medicine information leaflet with your patients? 
⃝ Provide a leaflet only with no verbal advice 
⃝ Provide a leaflet only with no verbal advice 
⃝ Provide a leaflet, ask the patient to read it and come back if they have any 
questions 
⃝ Draw attention to specific sections of the leaflet with some verbal advice 
⃝ Verbally discuss the sections of the leaflet that you feel are important 
⃝ Discuss the entire leaflet 
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⃝ Other (please specify) 
4. What are your reasons for providing a medicines information leaflet? (you may 
select more than one option) 
⃝ I want the patient to make an informed choice about their medicine to aid 
adherence 
⃝ I want to check that I did not forget to provide any medicine information 
verbally 
⃝ I want to reinforce the benefits of the medicine and how to take it 
⃝ I have a duty of care to inform the patient about their medicine 
⃝ The patient has a right to information about their medicine  
⃝ The patient requests a medicine information leaflet 
⃝ The patient had a bad experience with a medicine in the past 
⃝ Other (please specify) 
5. What do you like about the medicine information leaflets you use? 
 
6. What don’t you like about the medicine information leaflets you use? 
 
7. When would you like the patient to receive a medicine information leaflet for 
their prescription medicine? (you may select more than one option) 
⃝ Before they are prescribed a medicine to think about the treatment options or 
risks and benefits 
⃝ When they are prescribed/dispensed a new medicine 
⃝ When they are prescribed/dispensed a repeat medicine 
⃝ Every 6-12 months for repeat medicines 




⃝ When new information about the medicine becomes available 
⃝ When they are prescribed/dispensed a medicine that is associated with serious 
side-effects 
⃝ When they ask for it 
⃝ Other (please specify) 
Medicine information for patients is currently available as comprehensive leaflets 
provided by the manufacturer, or as summarised leaflets provided by independent 
providers. Personalised summary leaflets could provide tailored information according 
to patients’ characteristics such as disease, age, and sex, and hence are more relevant 
and patient-centred. 
8. Which one of the following types of medicine information leaflet do you think 
would be most useful to provide to patients? 
⃝ A comprehensive leaflet such as the manufacturer CMI, or similar available 
online, printed, or in the medicine box 
⃝ A personalised summary leaflet printed from prescribing or dispensing 
software tailored to the patient’s characteristics  
⃝ A personalised summary leaflet printed from prescribing or dispensing 
software tailored to the patient’s characteristics, with instructions on how to 
access more comprehensive information if the patient wants it  
⃝ A general summary leaflet printed from prescribing or dispensing software 
⃝ A general summary leaflet printed from prescribing or dispensing software with 
instructions on how to access more comprehensive information if the patient 
wants it  
⃝ None of the above 
⃝ Other 












11. Please tell us which area your pharmacy/ GP practice is located in 
⃝ Major City (e.g. Auckland, Wellington, Christchurch) 
⃝ Provincial City (urban area with a population over 30,000 people e.g. Hamilton, 
Dunedin, Nelson, New Plymouth, Napier, Gisborne) 
⃝ Provincial Town (town with a population between 1,000 and 30,000 people e.g. 
Levin, Gore) 




Appendix 8. Table: Self-reported provision of medicine 
information leaflets 
How often leaflets are provided 




For new medicines 
All/most of the time 19 (13.3%) 51 (40.5%) 
Some of the time 68 (47.6%) 51 (40.5%) 
Never 28 (19.6%) 0 (0%) 
Only on patient request 28 (19.6%) 24 (19.0%) 
No response 0 (0%) 0 (0%) 
For repeat medicines for chronic conditions 
All/most of the time 0 (0%) 2 (1.6%) 
Some of the time 26 (18.2%) 20 (15.9%) 
Never 49 (34.3%) 11 (8.7%) 
Only on patient request 67 (46.9%) 93 (73.8%) 
No response 1 (0.7%) 0 (0%) 
Ways leaflets are provided to patients 




Provided with no verbal advice 1 (1.1%) 5 (5.3%) 
Provided and asked the patient to read 
it and come back if they have questions 
10 (11.2%) 2 (2.1%) 
Draw attention to specific sections with 
some verbal advice or discuss sections 
of the leaflet you feel are important 
73 (82%) 76 (80.9%) 
Discuss the entire leaflet 1 (1.1%) 0 (0%) 
Other  4 (4.5%) 11 (11.7%) 
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Appendix 9. Tables: Likes and dislikes of available 
leaflets 










48 83  
 A4 0 1 “A4 size info with simple language” 
 Big print 0 1 “Big print” 
 Photos/pictures 0 1 “I like the manufacturers pamphlets that 
have photos e.g. efudix as I feel it gives 
the patient a better idea of what to 
expect” 
 Designed for 
patient 
1 5 “Specifically designed for pt” 
 Concise 11 22 “concise and in plain language” 
 Use of tables 0 1 “Contain tables for ease of reading” 
 Simple, clear, 
easy to read 
and understand 
24 46 “Clear, non-technical language” 
 Comprehensive 8 6 “comprehensive and easy to read” 
 
 Consistent (e.g. 
easy to find 
information) 
4 0 “They follow a standard format so that 
when a medication is changed the 
patient can follow the new information 











8 8 “only certain side-effects mentioned” 
 Directions  5 1 “clear info about how to take” 
 Missed dose 0 2 “what to do if miss doses” 
 Excipients 0 1 “tablet excipients” 
 Where to go for 
more 
information 
1 0 “Clear language, concise information and 
directions where to go for further 
information” 
 Indications and 
benefits 
3 0 “details of benefits and side-effects” 
 Mode of action 1 0 “They explain mode of action, address 
how best to take” 
 When to seek 
advice 
1 0 “common side-effects and side-effects 




13 11  
 Easy to access 
and produce 





18 22  
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 Informative 4 3 “Informative at patient level” 
 Give more 
information 
that can be 
covered in 
consultation 
2 4 “Can provide more information about 
the medicine than can be provided (or 
remembered by patient) in the short 
time available with current funding 
structure, and gives them the 
opportunity to come back to me with 
further questions” 
 Information to 
refer back to 
5 4 “Information is provided and the patient 





3 7 “it reinforces what you have said and it 
gives the patient a reference in case they 
forget or get confused about information 
given verbally” 
 Awareness of 
issues with OTC 
products 
0 1 “OTC awareness” 
 Guide to 
discussions 





1 2 “Save time, informed consent, thorough” 
 Useful 1 0 “Useful” 
Quality 
 
8 5  
 Up to date 0 1 “Direct from the manufacturer or 











2 1 “Direct from the manufacturer or 
medsafe” 
 From a reliable 
source 
2 3 “trusted source (CDHB). Concise. 
Readable” 
 Accurate 3 0 “accurate easy to print off” 
 Not from drug 
company 
1 0 “I am familiar with them , not from drug 
company so unbiased” 
 










65 44  
 No colour 0 1 “black and white, no colour” 
 Too long 13 14 “can be lengthy” 
 Can be 
misunderstood/ 
misinterpreted 
13 1 “Can be miss interpreted, if taken the 
wrong way can actually act as a barrier to 
compliance and/or lead the patient to make 
a missinformed choice leading to a negative 
health outcome” 
 Too much 
information or 










difficult for those 
with low literacy) 
5 3 “they are wordy, confusing and not written 
easily for patient consumption” 
 Too technical 3 4 “may be too technical for the patient - 
verbal advice can overcome this” 
 Too simplistic 3 1 “My experience with patient info sheets is 
that they tend to be too simplistic, eg 'keep 
medicines safely away from children blah 
blah' or pages of irrelevant stuff” 
 No pictures 0 1 “Ones printed off TONIQ i feel are too 
wordy, no pictures, just text after text - 
makes it hard to read, not direct and to the 
point, not addressing main issues but are 
just covering manufacturers” 
 Small font 0 2 “sometimes too long and small that old 
patients cannot read” 
 Not easy to find 
information 
0 1 “sometimes contain irrelevant information 
and it's hard to distinguish the main points” 
 Does not print 
pharmacy details 
0 1 “Small writing. Not pre-printed with our 
details (considering the come via our 
dispensing programme)” 
 Badly written 3 1 “The content can be too generic and not 
practically helpful, or worded badly” 
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 Bad format and 
not user friendly 
2 0 “I don't like the format, not very user 
friendly, they don't seem to have different 
ones for different uses of the medications” 
Content 
 
27 36  
 Adverse effect 
list 
18 17 “side-effect list can scare patients” 
 No 'off-label' 
information or 
wrong indication 
1 4 “drug use not always accurate e.g. tricyclics 
for depression yet almost always used for 
nerve pain. This may stop patients from 
taking medicines” 
 No dosing guide 0 1 “no doses guide so will sometimes use 
prescriber ones. Not all meds have leaflets” 
 No benefits of 
taking medicine 
0 1 “no motivation for the patients regarding 
the benefits of the medicine 
None” 
 Too generic and 
not specific 
enough 
1 6 “some are very generic and not specific” 
 Not personalised 5 1 “Not personalised and use medical English” 
 No storage 
information 
0 1 “Sometimes a little more information 
regarding storage and use of the medicine 
would be helpful” 
 Inadequate 
directions on use 
1 1 “special instructions e.g. cytotoxics, best 
time to take, not always more prominent” 
 Does not contain 
the desired 
information 
0 4 “sometimes does not have all the 
information I would like to pass on” 
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 Too many 
interactions 
1 0 “Sometimes too much is written- such as 
listing all potential side-effects or 
interactions even if very remote possibility” 
Accessibility 
 
15 8  






8 6 “Not all medicines have an information 
leaflet on medsafe website” 
 Patient sign up 
to program 
necessary 
0 1 “Not enough of them or can be too 
technical for patient. Don't like when they 
ask patient to sign up to a program to 
receive info as I believe this makes them 
less likely to use resource” 
 High cost 0 1 “The cost to subscribe to them!” 
 Have to print off  5 0 “a lot of my patients don't have computers 
or the internet, so have to print things off” 
 Too many 
options 
2 0 “Printing is time consuming, too many 
leaflets available so hard to select and stay 




10 13  
 Only available in 
English 
0 3 “Need more languages other than English 
available” 
 Not relevant 0 2 “Possibly lacks relevance” 
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 Lacks patient 
perspectives 
2 0 “they are made as "one size fits all" - 
information is usually only about treating a 
"disease" not treating illness or a persons 
experience of their disease - including 
socioeconomic issues” 
 Cause anxiety 3 4 “may cause patient anxiety” 
 Relies on 
patients to find 
information or 
want to read it 
1 0 “Puts the responsibility on the patient to 
access the info, which can be good and 
bad” 
 Require a lot of 
explanation 
1 4 “some of them esp consumer info sheets 
show so much - it deters many patients and 
have to be used with quite lot of 
explanation” 
 Not enough time 
to print and use 
them 
3 0 “Time issue” 
Quality 
 
4 4  
 Sometimes out 
of date 
0 1 “Sometimes the tablet/capsule description 
is out of date/incorrect but this gets fixed 
when we contact the company” 
 Contain 
advertising 
1 1 “I dont hand out the ones I do not like for 
example advert focused ones” 
 Written by 
Manufacturer 
3 1 “Often produced by the manufacturer of 
the medication” 
 Variable quality 0 1 “quality varies considerably. Not concise” 
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Appendix 10. Questionnaire, chapter 4.4.1 
These first two questions are about the information you give to patients to read about 
medicines that are NOT considered high-risk (e.g. asthma inhaler). [NB. most of the 
time was defined as more than half of the time, and some of the time defined as less 
than half of the time.] 
1. How often do you give patients an address for a website containing information 
about medicines?  
⃝ All of the time  
⃝ Most of the time  
⃝ Some of the time  
⃝ Only on patient request 
⃝ Never 
2. What is your preferred source for supplying medicine information leaflets to 
patients? (select the most commonly used option) 
⃝ Medsafe website 
⃝ Patient.info website 
⃝ UpToDate website 
⃝ Healthinfo website  
⃝ New Zealand Formulary website 
⃝ Other:    1. Website (please specify); or 
2. Computer program (please specify); or 
3. Loose leaflets (please specify); or 
4. Unmentioned source (please specify) 
3. What are the main reasons you would not provide a medicine information 
leaflet to patients? (please select up to 5) 
⃝ The patient receives all the information they need verbally 
⃝ The patient should trust the doctor to prescribe a medicine that is suitable for 
them 
⃝ The patient has taken the medicine previously 
⃝ Patients are not interested in receiving medicine information leaflets 
⃝ The medicine is for short term treatment (less than 2 weeks) 
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⃝ It is the role of the doctor/pharmacist to provide medicine information 
leaflets 
⃝ I am concerned the patient will worry about the possible side-effects and not 
take the medicine 
⃝ I do not believe the medicine information leaflet is useful to the patient 
⃝ I do not think to use them when talking with patients 
⃝ Other (please specify) 
 
4. Do any of the following prevent you from providing a leaflet to patients? (you may 
select more than one option) 
⃝ The leaflet is not available in other languages 
⃝ The medicine is being used for a purpose other than indicated (including ‘off-
label’ use) 
⃝ The patient has difficulty with understanding or reading the medicine 
information leaflets 
⃝ I do not always have time to spend discussing a medicine information leaflet 
with the patient 
⃝ The leaflet is too long to print off 
⃝ There is no available printer 
⃝ There is no reimbursement for printing costs 
⃝ It is not the policy of the pharmacy or pharmacist/ individual GP or GP 
practice to provide information leaflets 
⃝ Other (please specify) 
 
5. What might help you or other pharmacists to provide leaflets to patients? (you 
may select more than one option) 
⃝ More frequent requests from patients for information leaflets 
⃝ More time to provide and explain information leaflets 
⃝ Specific counselling appointments to discuss a patient’s medicines 
⃝ A leaflet that gives a summary of the medicine, making it easier to cover 
salient points 
⃝ Personalised leaflets tailored to patients’ disease or condition, and 
characteristics 
⃝ Having leaflets available in different languages 
⃝ Having a self-serve computer in the pharmacy/GP surgery for patients to 
print the medicine information they want 
⃝ Reimbursement for provision of leaflets. 
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⃝ Dispensing/prescribing software prompts to provide, and record the 
provision of the leaflet automatically 
⃝ Other (please specify) 
 
6. When do you think a personalised summary leaflet could be provided for 
medicines considered LOW risk (e.g. asthma inhaler)? (Tick the appropriate box in 
each line) 
 
 All of the 
time  
Some of 
the time  
None of 
the time  
Not applicable, 
a summary 
leaflet is not 
suitable  
By the doctor at the time of 
prescribing a new medicine 
    
By the doctor at the time of 
prescribing a repeat 
medicine 
    
By the pharmacist on 
dispensing a new medicine 
    
By the pharmacist on 
dispensing a repeat 
medicine 
    
When patients ask for it     
⃝ Other (please specify) 
 
Note, Most of the time is considered more than half of the time and Some of the time 
is considered less than half of the time. 
 
 
7. When do you think a personalised summary leaflet could be provided for 




 All of the 
time  
Some of 
the time  
None of 
the time  
Not applicable, a 
summary leaflet is 
not suitable  
By the doctor at the 
time of prescribing a 
new medicine 
    
By the doctor at the 
time of prescribing a 
repeat medicine 
    
By the pharmacist on 
dispensing a new 
medicine 
    
By the pharmacist on 
dispensing a repeat 
medicine 
    
When patients ask for 
it 
    
⃝ Other (please specify) 
 
Note, Most of the time is considered more than half of the time and Some of the time 
is considered less than half of the time. 
 
Please provide the following demographic information 












10. Please tell us which area your pharmacy/GP practice is located in 
⃝ Major City (e.g. Auckland, Wellington, Christchurch) 
⃝ Provincial City (urban area with a population over 30,000 people e.g. 
Hamilton, Dunedin, Nelson, New Plymouth, Napier, Gisborne) 
⃝ Provincial Town (town with a population between 1,000 and 30,000 people 
e.g. Levin, Gore) 




Appendix 11. Table: Why General Practitioners (GPs) 
and pharmacists do not provide medicine information 
leaflets 








Reasons with similar response rates from GPs and pharmacists 
The patient has difficulty with understanding or 































The patient should trust the doctor to prescribe a 






Reasons more commonly selected by pharmacists (p<0.05) 






The medicine is being used for a purpose other 






I am concerned the patient will worry about the 





















I do not believe the medicine information leaflet is 






Reasons more commonly selected by GPs (p<0.05) 
I do not always have time to spend discussing a 













It is the role of the doctor/pharmacist to provide 






The medicine is for short term treatment (less 






It is not the policy of the pharmacy or 
pharmacist/practice or individual doctor to 








Appendix 12. Questionnaire, chapter 4.5.1 
1. Are you currently taking any prescription medicines? 
⃝ Yes 
⃝ No (thank you for your time, we have no more questions) 
2. Have you received any information leaflets about your medicines from your 
doctor in the last 6 months? 
⃝ Yes 
⃝ No (go to question 11) 
If there has been more than one information leaflet about your medicines given to 
you, please think about the most recent example when answering the following 
questions 
3. How did they use this leaflet with you?  
⃝ Provide a leaflet only, without talking to you about it 
⃝ Provide a leaflet, ask you to read it and come back if you had any questions 
⃝ Draw attention to specific sections of the leaflet and spoke to you about these 
sections 
⃝ Talked about the sections of the leaflet that you felt were important (for example, 
possibly answering a question you may have had) 
⃝ Discussed the entire leaflet 
⃝ Other (please specify in box below) 
 
4. Did you feel that this leaflet was helpful because: (you may select more than one 
option) 




⃝ It helped you take your medicines correctly  
⃝ It encouraged you to take your medicines as instructed (for example, you did not 
stop the medicine before it was supposed to stop, or you did not miss doses) 
⃝ None of the above, the leaflet was not helpful 
⃝ Other (please specify in box below) 
 
5. For the following question, we are wanting to know what you thought about the 
style of the leaflet 
 
6. Overall, would you say you liked the leaflet? 
⃝ Yes 
⃝ No  
⃝ Don’t know 
7. Did you read this leaflet? 
⃝ Yes I read the leaflet fully (go to question 10) 
⃝ Yes, I partially read or skim read the leaflet (go to question 10) 
⃝ No  
 Yes No Don’t 
know 
Did you like how the leaflet looked (the 
leaflets design)?  
   
Could you find the information you were 
looking for? 
   
Do you think the leaflet had relevant 
information in it? 
   
Could you read and understand the 
information in the leaflet? 
   




8. Why did you not read the leaflet? (you may select more than one option) 
⃝ I didn’t need to, the doctor told me all I needed to know  
⃝ I have taken this medicine before  
⃝ I am only taking the medicine for a short time (less than 2 weeks) 
⃝ It was too difficult to read and understand 
⃝ The leaflet was too long 
⃝ I didn’t think it was important 
⃝ Other (please specify in box below) 
 
9. Did you keep this leaflet? 
⃝ Yes  
⃝ No  
10. How important is it for you to receive medicine information leaflets from your 
doctor about the following: (tick the appropriate option in each line) 
 
11. When would you like to receive a medicine information leaflet from your doctor? 
(you may select more than one option) 
⃝ Before you are prescribed a medicine - to get information about the benefits of the 
medicine and its possible side-effects before you decide to take it 







New medicines     
Repeat long-term 
medicines 




⃝ When you are prescribed a repeat medicine 
⃝ Every 6–12 months for repeat medicines 
⃝ When there is a change in the brand of your medicine 
⃝ When new information about the medicine becomes available 
⃝ When you are prescribed a medicine that is associated with serious side-effects 
⃝ I would prefer to receive the leaflet at the pharmacy  
⃝ I’d prefer not to be given medicine leaflets  
⃝ Other (please specify in box below) 
 
12. How would you like to receive information about your medicines? (you may 
select more than one option) 
⃝ A paper copy printed by doctor or pharmacist 
⃝ A digital (printable) copy emailed to you 
⃝ A digital (printable) copy in a patient portal (patient portals are online websites 
provided by GPs, where patients can access their health information and interact with 
their general practice) 
⃝ A digital (printable) copy on a website 
⃝ Other (please specify in the box below) 
 
13. What would you prefer: 





⃝ A short 1–2 page summary leaflet about your medicines, with the option to choose 
more information to be included in your leaflet 
⃝ A comprehensive leaflet containing all the information about a medicine 
14. How often do you seek additional information about your medicines, other than 
that given to you by your doctor or pharmacist?  
⃝ All of the time 
⃝ More than half of the time 
⃝ Half of the time 
⃝ Less than half of the time 
⃝ None of the time 
⃝ Not applicable 
15. What is your gender 
⃝ Male 
⃝ Female 
16. What is your highest level of formal education? 
⃝ No qualification 
⃝ Secondary school (high school) 
⃝ Postgraduate diploma (for example nursing or teaching diplomas, or advanced 
trade certificates) 
⃝ Bachelor’s degree 
⃝ Postgraduate degree 










18. Is English your first language? 
⃝ Yes 
⃝ No my first language is………………………………..
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Appendix 13. Ethical approval D17/007 
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Appendix 14. Use Case [1]: Using an integrated 
information tool in prescribing systems to create 
personalised medicines information for patients 
1. Description 
The prescriber decides to create patient-specific information about medicines for use 
at point-of-care. The medicine information tool uses the information about the 
patient held within the Patient Management System (PMS), and information about the 
medicine to present information to the prescriber that is personalised for their patient 
at the time of consultation. It will also provide an individualised medicines information 
leaflet for the patients to read and take away, and/or be sent to the patient’s portal 
for future reference. 
2. Justification 
Prescribers have little time to talk to patients about medicines, let alone seek out 
relevant medicine information. Easily accessed personalised information could help 
GPs fulfil their ethical obligations to ensure patients are fully informed about their 
medicines. 
 In a recent study174 we determined that more than:  
 70% of GPs want their patient management system to display key counselling 
points about medicines automatically tailored to their patient for use during 
consultation.  
 50% of GPs would like patients to receive a medicine information leaflet when 
they are prescribed a new medicine yet 30% of GPs report they do not think to 
use them at point-of-care.  
 50% of GPs think that prescribing software that prompts to provide and record 
the provision of the leaflet automatically, would help them in providing leaflets 
to patients.  
  50% of GPs think the most beneficial leaflets would be a personalised 
summary leaflet tailored to patient requirements.  
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2.1. Information for patients 
Patients do not always find leaflets useful and they often discard leaflets without 
reading them. Many studies over the last few decades have led to some improvement 
in medicine information for patients, however there is still much room for 
improvement; patients are often dissatisfied, considering leaflets to be poorly 
designed and difficult to understand. In a recent review article109 we determined the 
information that patients want included in their information leaflets: 
Box 1 Recommendations for content of medicine information leaflets 
Recommendation Comments 
Name of the medicine  The name people are most familiar with (i.e. the 
brand of the dispensed drug) should also be 
included 
Tailored information  Tailored information to indication a definite 
requirement. Age and gender are less important 
to patients but worth considering if possible  
How a medicine works and the 
benefits of treatment  
Include: 
 why it is important to treat the disease and 
what would happen without treatment 
 whether the medicine is curative, 
preventative, or provides symptomatic relief 
 how long treatment will be required for 
Dose This information should only be included if it can 
be tailored to the patients specific regimen – i.e. 
personalised 
How to take the medicine  Also include what to do if a dose is missed 
How long to take the medicine 
for 
For certain medicines also include what would 
happen if stopping medicines e.g. withdrawal 
symptoms from antiepileptic medicines, return of 
infection for antibiotics etc. 
How to monitor the treatment’s 
effectiveness  
Include when to return to the doctor if no benefit 
seen – i.e. antibiotics should start to show benefit 
within days compared to antidepressants which 
take weeks  
Comprehensive list of risks Important to include the action required if side-
effects are experienced. Duration of risk would 
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 be helpful to include. Note design of side effect 
list is mentioned below 
Numeric description of side-
effects  
As well as describing these numerically, e.g. as 
natural frequencies (e.g. three in 100 people), 
side-effects should be categorised by how likely 
they are to occur and how serious they are with 
details of what action is required if a side effect is 
experienced. Boxes or tables should be utilised 
for clarity with side-effects requiring immediate 
cessation of therapy or medical treatment listed 
first. 
Long-term effects  Where applicable e.g. corticosteroids, 
benzodiazepines (addictive) 
Monitoring requirements  Such as blood monitoring and usual frequency 
Interactions  Focus should be on over-the-counter medicines 
and foodstuffs. 
Allergies and excipients  Evidence-based cross-reactivity should be 
included as well as excipients and any particular 
allergy concern  
How to store a medicine  The general recommendation of keeping out of 
reach of children as well as specific requirements. 
Also should include how to dispose of medicines 
(e.g. fentanyl patches—ensure nobody can 
accidentally be exposed to remaining active 
ingredient) 
Lifestyle information and 
general health tips  
Lifestyle information about medicine or disease 
effects including driving, drinking, sexual activity 
etc. General health tips cover how to best self-
manage disease e.g. healthy diet and exercise in 
diabetes 
Details for more information  Where to see more detailed information leaflets, 
patient organisations, helpline numbers, and 
website addresses  
Comparative information for 
alternative drug therapies and 
treatment options including 
non-pharmacological and 
natural medicine  
This may be problematic as it could confuse some 
people and lead to anxiety in some cases. It 
would be necessary to tailor this information 
following discussion with patients and before 
treatment decisions are made to aid 
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concordance. Information should be succinct and 
evidence-based only and may not be available for 
a number of medicines 
Date  Date of last update of leaflet 
Young, A., Tordoff, J., & Smith, A. ‘What do patients want?’ Tailoring medicines 
information to meet patients' needs. Research in Social and Administrative 
Pharmacy. 2017;13(6):1186-1190. 
A new type of Medicine information leaflet 
Much of the information listed above is either missing from current leaflets available 
(such as those available via New Zealand Formulary, Canterbury District Health Board, 
or some manufacturer produced information), or is written in such a way as to make 
leaflets too long and difficult to navigate and understand (e.g. some manufacturer 
produced information). 
New information for patients will be created by the research team with review and 
input from practicing healthcare professionals. Information will be sourced from 
validated resources including the Medsafe approved Data Sheets and Consumer 
Medicine Information, New Zealand Formulary, and SafeRx. Our project will be a 
“proof of concept study” where we will develop and test one customisable leaflet for 
one condition. At a later date, we anticipate that we will work with collaborators to 
widen the number of medicines included.  
2.2. Expected benefits 
There will be written point-of-care information for GPs to use when speaking to 
patients in the form of key practice points particularly relevant for each patient. 
Patients would have a relevant personalised medicine information leaflet to take 
away, or a digital copy through their patient portal, for them to refer back to if 
needed. 
The following benefits can be measured via user surveys: 
 For prescribers 
o Improvement in prescriber-patient communications. 
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o Improved confidence in information communicated during consultation 
with support of information tool.  
o Less time wasted searching for appropriate information to give to 
patient. 
 For patients 
o The personalised nature of these leaflets will improve patients’ 
perceptions of the information leaflet and willingness to read it.  
o Increased patient knowledge about their medicines. 
o Improved intent to adhere to medicines. 
o Increased satisfaction with consultation. 
3. Level 
Summary (this Use Case occurs as part of a broader context of receiving information 
about medicines). 
4. Trigger 
The Prescriber writes a prescription for a medicine for the patient and the medicine 
information is automatically created. 
5. Primary Actor 
The Primary Actor is the prescriber who is discussing and prescribing a patient’s 
medicines. 
6. Additional/Supporting Actors 
Secondary Actors:  
 Patients 
 Research team creating medicine information for patients 
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7. Stakeholders  
Stakeholders: 
 Pharmacists/their staff dispensing the medicines 
 Other health care professionals involved in care 
 Patients’ carers (if applicable) 
8. Preconditions 
1. The prescriber must be logged into and have entered patient details into the 
Patient Management System correctly.  
2. The patient must be prescribed a recognisable medicine in the database.  
3. If the patient wants to receive information digitally, they must have access to the 
internet. 
4. The patient must be able to read and understand English (other languages could 
be created too).  
5. Information must be stored within the system to allow the information to be 
tailored to patients’: 
a. name 
b. gender 
c. age and date of birth 
d. indication medicine is being taken for [an option for including this is 
required] 
e. dose of the medicine and directions for taking it 
6. The tool needs to be aligned with e-health standards already in place in New 




9. Main Success Scenario 
1. Prescriber and patient choose a medicine for treating condition. 
2. Prescriber enters patient details and medicine details into PMS. 
3. Using information from the electronic health record, the medicine information 
tool will auto populate key counselling points for the prescriber to use during a 
consultation. 
4. The prescriber can then create a leaflet by clicking a button. Using information 
from the electronic health record, the medicine information tool will auto-
populate a personalised information leaflet for the patient. 
5. Prescriber discusses key counselling points and relevant sections of leaflet. 
6. Prescriber gives the patient the leaflet to take away. 
7. The system notes that information about medicine given to patient. 
8. Patient leaves consultation with prescription and information. 
10. Extensions 
4. Alternative: Patient wants digital information: 
1. Prescriber sends digital leaflet to patient either via email, or sends to patient 
portal. 
2. Patient receives digital leaflet. 
3. Confirmation of receipt stored in PMS and the system notes that information 
about medicine given to patient. 
4. Patient leaves consultation with prescription. 
4. Alternative: Prescriber wants to give more or less information to patient: 
1. Prescriber can review all stored information about the medicine and can cut 
and paste leaflet sections in a ‘drag and drop’ format allowing creation of 
updated information leaflet. 
2. If wanted, the prescriber can tick a box to indicate if these sections are to be 




3. Prescriber discusses key counselling points and relevant sections of leaflet. 
4. Prescriber gives the patient the leaflet to take away or sends digitally as 
described above. 
5. The system notes that information about medicine has been given to the 
patient. 
6. Patient leaves consultation with prescription and information. 
5. Alternative: Patient wants further information via their patient portal: 
1. Prescriber sends digital leaflet to patient via patient portal. 
2. Patient receives digital leaflet. 
3. Confirmation of receipt stored in PMS. 
4. Once patient opens digital leaflet, the leaflet icon will change to indicate it 
has been opened (e.g. as emails have a closed envelope for unread and an 
open envelope for read mail). 
5. Patient can review all stored information about the medicine and can cut 
and paste leaflet sections in a ‘drag and drop’ format allowing creation of 
own information to refer to. 
6. Patient portal stores information for patient. 
3. Exception: Insufficient information in electronic health record: 
1. Prescriber includes required information in patient record via medicine 
information tool. 
2. The medicine information tool can then carry on usual processing. 
3. Personalised medicine information can be given. 
3. Exception: Medicine indication not included in stored medicine information: 
1. Prescriber prompted to enter the indication. They can select from the 
patient’s current condition list or another condition searched and selected 
(this also adds to the patient’s condition list in the PMS automatically). 
There will be the option to include more than one indication for the 
medicine.  
2. The medicine information tool can then carry on usual processing. 
3. Personalised medicine information can be given. 
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5. Exception: Patient does not want information about medicines: 
1. Prescriber does not print leaflet. 
2. The system notes a leaflet not given. 
6. Exception: digital information not sent/received: 
1. The system notes a leaflet not given due to system error. 
2. Prescriber has option to send again.  
11. Post Conditions 
11.1. Success End Condition 
The PMS notes that medicine information has been given.  
The patient receives relevant and instructive information about their medicines.  
The prescriber is confident the required information has been passed on to patient in 
order for them to take their prescribed medicines safely and effectively.  
11.2. Minimal Guarantees 
The prescriber is able to prescribe and manage patient information as per usual 
workflow if medicine information tool not in place.  
11.3. Failure End Condition 
The prescriber will not have information about medicines at their fingertips, assisting 
effective and personalised consultation with patients and enabling fulfilment of ethical 
obligations for informing patients. Their patient will have not have the access to well-
designed information (i.e. as a personalised summary medicine information ‘leaflet’).  
12. Frequency 
Prescribers will see patients and prescribe medicines approx. 4 times per hour. At this 
time it is unknown how many times a leaflet will be created. Once the test medicine 
has been confirmed, more accurate frequencies can be calculated. 
374 
 
13. Special Requirements 
13.1 Performance 
The prescriber should have the relevant medicines information within 1 second 
(maximum 3 seconds) of entering the PMS. Leaflets should also be created within 1 
second (maximum 3 seconds) of pushing the button. 
13.2 Privacy 
Patient details will not be available for review to any third party not involved in direct 
patient care.  
13.3 Unmodifiable information 
13.3.1 Patient specific information 
The patient information details included in the leaflet will be obtained directly from 
the PMS. These details will not be able to be changed unless they are updated within 
the PMS. The details include: 
a. patient name 
b. patient sex 
c. patient age and date of birth 
d. indication medicine is being taken for [an option for including this is 
required] 
e. dose of the medicine and directions for taking it. 
13.3.2. Medicine specific information 
The information contained in the system will be obtained via an information ‘pool’ and 
is dragged and dropped from a Source template. The information sections contained 
in the ‘pool’ are not modifiable. The only changes able to be made will be if the 
information sections are to be included in the information leaflet or not. The 
information will be created by the research team and owned and hosted by the 
University of Otago.  
375 
 
13.4. Usability / Accessibility 
Prescribers and patients must be able to view page in English. Prescribers will need 
access to the internet; patients wanting digital information will also require internet 
access. 
13.5. Other 
Once the program has been developed the research team will provide medicine 
information on a group of medicines (e.g. those for gout or hypertension), for initial 
piloting and analysis. Researchers are flexible as to whether piloting will be 
undertaken in a small subset of practitioners or will have a national roll out.  
The project/trial will be deployed and available for use by general practitioners. In 
order to determine the usability, usefulness, and effectiveness of the alerts the 
solution will need to: 
1. Record each time consultation points have been produced. 
2. Record the prescriber’s interaction with an alert (i.e. engagement with the 
program). 
3. Record the creation of the medicine information leaflet. 
14. Next Steps and future extensions 
14.1. Next Steps 
Next Steps: 
 Finalise requirements with system developers 
 Create medicine information for use in practice 
 Decide on medicines and conditions to for pilot  
14.2. Future extensions 
Many enhancements can be made to the medicine information tool once initial 
development, user testing, and piloting have been completed. User feedback is 




Examples of possible future extensions for consideration: 
 Further tailoring to health literacy levels 
 Translation into different languages 




Appendix 15. Use Case [2]: Using an integrated 
information tool in dispensing systems to create 
personalised medicines information for patients 
1. Description 
The pharmacist decides to create patient-specific information about medicines for use 
at point-of-care. The medicine information tool uses the information about the 
patient held within the dispensing system, and information about the medicine to 
present information to the pharmacist that is personalised for their patient at the time 
of consultation. It will also provide an individualised medicines information leaflet for 
the patients to read and take away, and/or be sent to the patient’s portal for future 
reference. 
2. Justification 
Pharmacists have little time to talk to patients about medicines, let alone seek out 
relevant medicine information. Easily accessed personalised information could help 
pharmacists fulfil their ethical obligations to ensure patients are fully informed about 
their medicines. 
 In a recent study 174 we determined that more than:  
60% of pharmacists want their dispensing system to display key counselling points 
about medicines automatically tailored to their patient for use during consultation.  
70% of pharmacists would like patients to receive a medicine information leaflet when 
they are dispensed a new medicine.  
40% of pharmacists think that dispensing software that prompts to provide, and 
record the provision of the leaflet automatically would help them in providing leaflets 
to patients.  
 60% of pharmacists think the most beneficial leaflets would be a personalised 
summary leaflet tailored to patient requirements.  
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2.1. Information for patients 
Patients do not always find leaflets useful and they often discard leaflets without 
reading them. Many studies over the last few decades have led to some improvement 
in medicine information for patients, however there is still much room for 
improvement; patients are often dissatisfied, considering leaflets to be poorly 
designed and difficult to understand. In a recent review article109 we determined the 
information that patients want included in their information leaflets: 
Box 1 Recommendations for content of medicine information leaflets 
Recommendation Comments 
Name of the medicine  The name people are most familiar with (i.e. the 
brand of the dispensed drug) should also be 
included 
Tailored information  Tailored information to indication a definite 
requirement. Age and gender are less important 
to patients but worth considering if possible  
How a medicine works and the 
benefits of treatment  
Include: 
why it is important to treat the disease and what 
would happen without treatment 
whether the medicine is curative, preventative, 
or provides symptomatic relief 
how long treatment will be required for 
Dose This information should only be included if it can 




How to take the medicine  Also include what to do if a dose is missed 
How long to take the medicine 
for 
For certain medicines also include what would 
happen if stopping medicines e.g. withdrawal 
symptoms from antiepileptic medicines, return of 
infection for antibiotics etc. 
How to monitor the treatment’s 
effectiveness  
Include when to return to the doctor if no benefit 
seen – i.e. antibiotics should start to show benefit 
within days compared to antidepressants which 
take weeks  
Comprehensive list of risks 
 
Important to include the action required if side-
effects are experienced. Duration of risk would 
be helpful to include. Note design of side effect 
list is mentioned below 
Numeric description of side-
effects  
As well as describing these numerically, e.g. as 
natural frequencies (e.g. three in 100 people), 
side-effects should be categorised by how likely 
they are to occur and how serious they are with 
details of what action is required if a side effect is 
experienced. Boxes or tables should be utilised 
for clarity with side-effects requiring immediate 
cessation of therapy or medical treatment listed 
first. 
Long-term effects  Where applicable e.g. corticosteroids, 
benzodiazepines (addictive) 
Monitoring requirements  Such as blood monitoring and usual frequency 
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Interactions  Focus should be on over-the-counter medicines 
and foodstuffs. 
Allergies and excipients  Evidence-based cross-reactivity should be 
included as well as excipients and any particular 
allergy concern  
How to store a medicine  The general recommendation of keeping out of 
reach of children as well as specific requirements. 
Also should include how to dispose of medicines 
(e.g. fentanyl patches—ensure nobody can 
accidentally be exposed to remaining active 
ingredient) 
Lifestyle information and 
general health tips  
Lifestyle information about medicine or disease 
effects including driving, drinking, sexual activity 
etc. General health tips cover how to best self-
manage disease e.g. healthy diet and exercise in 
diabetes 
Details for more information  Where to see more detailed information leaflets, 
patient organisations, helpline numbers, and 
website addresses  
Comparative information for 
alternative drug therapies and 
treatment options including 
non-pharmacological and 
natural medicine  
This may be problematic as it could confuse some 
people and lead to anxiety in some cases. It 
would be necessary to tailor this information 
following discussion with patients and before 
treatment decisions are made to aid 
concordance. Information should be succinct and 
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evidence-based only and may not be available for 
a number of medicines 
Date  Date of last update of leaflet 
Young, A., Tordoff, J., & Smith, A. ‘What do patients want?’ Tailoring medicines 
information to meet patients' needs. Research in Social and Administrative 
Pharmacy. 2017;13(6):1186-1190. 
A new type of Medicine information leaflet 
Much of the information listed above is either missing from current leaflets available 
(such as those available via New Zealand Formulary, Canterbury District Health Board, 
or some manufacturer produced information), or is written in such a way as to make 
leaflets too long and difficult to navigate and understand (e.g. some manufacturer 
produced information). 
New information for patients will be created by the research team with review and 
input from practicing healthcare professionals. Information will be sourced from 
validated resources including the Medsafe approved Data Sheets and Consumer 
Medicine Information, New Zealand Formulary, and SafeRx. Our project will be a 
“proof of concept study” where we will develop and test one customisable leaflet for 
one condition. At a later date, we anticipate that we will work with collaborators to 
widen the number of medicines included.  
2.2. Expected benefits 
There will be written point-of-care information for pharmacists to use when speaking 
to patients in the form of key practice points particularly relevant for each patient. 
Patients would have a relevant personalised medicine information leaflet to take 
away, or a digital copy through their patient portal, for them to refer back to if 
needed. 
The following benefits can be measured via user surveys: 
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 For pharmacists 
o Improvement in pharmacist-patient communications. 
o Improved confidence in information communicated during consultation 
with support of information tool.  
o Less time wasted searching for appropriate information to give to 
patient. 
 For patients 
o The personalised nature of these leaflets will improve patients’ 
perceptions of the information leaflet and willingness to read it.  
o Increased patient knowledge about their medicines. 
o Improved intent to adhere to medicines. 
o Increased satisfaction with consultation. 
3. Level 
Summary (this Use Case occurs as part of a broader context of receiving information 
about medicines). 
4. Trigger 
The pharmacist dispenses a prescription for a medicine for the patient and the 
medicine information is automatically created. 
5. Primary Actor 
The Primary Actor is the pharmacist who is discussing a patient’s medicines. 
6. Additional/Supporting Actors 
Secondary Actors:  
 Patients 
 Research team creating medicine information for patients 
7. Stakeholders  
Stakeholders: 




 Other health care professionals involved in care 
 Patients’ carers (if applicable) 
8. Preconditions 
1. The pharmacist must be logged into and have entered patient details into the 
dispensing system correctly.  
2. The patient must be prescribed a recognisable medicine in the database.  
3. If the patient wants to receive information digitally, they must have access to the 
internet. 
4. The patient must be able to read and understand English (other languages could 
be created too).  
5. Information must be stored within the system to allow the information to be 
tailored to patients’: 
a. name 
b. gender 
c. age and date of birth 
d. indication medicine is being taken for [an option for including this is 
required] 
e. dose of the medicine and directions for taking it 
6. The tool needs to be aligned with e-health standards already in place in New 
Zealand e.g. SNOMED CT and the NZULM, be user friendly, and be automated 
and editable. 
9. Main Success Scenario 
1. Pharmacist receives prescription from patient or directly from prescriber. 
2. Pharmacist enters patient details and medicine details into dispensing system. 
3. Using information from the electronic health record or, if unavailable, from their 
own system (with prompting for inserting further information if necessary), the 
medicine information tool will auto populate key counselling points for the 
pharmacist to use during a consultation. 
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4. The pharmacist can then create a leaflet by clicking a button. Using information 
from the electronic health record or, if unavailable, from their own system (with 
prompting for inserting further information if necessary), the medicine 
information tool will auto-populate a personalised information leaflet for the 
patient. 
5. Pharmacist discusses key counselling points and relevant sections of leaflet. 
6. Pharmacist gives the patient the leaflet to take away. 
7. The system notes that information about medicine given to patient. 
8. Patient leaves pharmacy with medicines and information. 
10. Extensions 
4. Alternative: Patient want’s digital information: 
1. Pharmacist sends digital leaflet to patient either via email, or sends to 
patient portal. 
2. Patient receives digital leaflet. 
3. Confirmation of receipt stored in dispensing system and the system notes 
that information about medicine given to patient. 
4. Patient leaves pharmacy with medicines. 
4. Alternative: Pharmacist wants to give more or less information to patient: 
1. Pharmacist can review all stored information about the medicine and can cut 
and paste leaflet sections in a ‘drag and drop’ format allowing creation of 
updated information leaflet. 
2. If wanted, the pharmacist can tick a box to indicate if these sections are to 
be included for all future leaflets for patients, or for all leaflets for this 
specific medicine. 
3. Pharmacist discusses key counselling points and relevant sections of leaflet. 
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4. Pharmacist gives the patient the leaflet to take away or sends digitally as 
described above. 
5. The system notes that information about medicine has been given to the 
patient. 
6. Patient leaves pharmacy with medicines and information. 
6. Alternative: Patient wants further information via their patient portal: 
1. Pharmacist sends digital leaflet to patient via patient portal. 
2. Patient receives digital leaflet. 
3. Confirmation of receipt stored in dispensing system. 
4. Once patient opens digital leaflet, the leaflet icon will change to indicate it 
has been opened (e.g. as emails have a closed envelope for unread and an 
open envelope for read mail). 
6. Patient can review all stored information about the medicine and can cut 
and paste leaflet sections in a ‘drag and drop’ format allowing creation of 
own information to refer to. 
7. Patient portal stores information for patient. 
2. Exception: Pharmacy technician is entering patient details into system: 
1. Pharmacy technician confirms with pharmacist if a medicine information 
leaflet is required and details to be included. 
2. The medicine information tool can then carry on usual processing. 
3. Personalised medicine information can be given. 
3. Exception: Insufficient information in electronic health record: 
1. Pharmacist includes required information in patient record via medicine 
information tool. 
2. The medicine information tool can then carry on usual processing. 
3. Personalised medicine information can be given. 
3. Exception: Medicine indication not included in stored medicine information: 
386 
 
1. Pharmacist prompted to enter the indication. They can select from the 
patient’s current condition list or another condition searched and selected 
(this also adds to the patient’s condition list in the dispensing system 
automatically). There will be the option to include more than one indication 
for the medicine. If not able to include indication, the leaflet will contain a 
general overview about how the medicine works with the following 
statement “please ask your prescriber to enter the reason your medicine 
has been prescribed the next time you visit”. 
2. The medicine information tool then carries on with usual processing. 
3. Personalised medicine information can be given. 
5. Exception: Patient does not want information about medicines: 
1. Pharmacist does not print leaflet. 
2. The system notes a leaflet not given. 
6. Exception: digital information not sent/received: 
1. The system notes a leaflet not given due to system error. 
2. Pharmacist has option to send again.  
11. Post Conditions 
11.1. Success End Condition 
The dispensing system notes that medicine information has been given.  
The patient receives relevant and instructive information about their medicines.  
The pharmacist is confident the required information has been passed on to the 
patient in order for them to take their prescribed medicines safely and effectively.  
11.2. Minimal Guarantees 
The pharmacist is able to provide and manage patient information as per usual 
workflow if medicine information tool not in place.  
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11.3. Failure End Condition 
The pharmacist will not have information about medicines at their fingertips, assisting 
effective and personalised consultation with patients and enabling fulfilment of ethical 
obligations for informing patients. Their patient will have not have access to well-
designed information (i.e. as a personalised summary medicine information ‘leaflet’).  
12. Frequency 
Pharmacists will see patients and dispense medicines to an exceedingly variable 
extent. At this time it is unknown how many times a leaflet will be created. Once the 
test medicine has been confirmed, more accurate frequencies can be calculated. 
13. Special Requirements 
13.1. Performance 
The pharmacist should have the relevant medicines information within 1 second 
(maximum 3 seconds) of entering the dispensing system. Leaflets should also be 
created within 1 second (maximum 3 seconds) of pushing the button. 
13.2. Privacy 
Patient details will not be available for review to any third party not involved in direct 
patient care.  
13.3. Unmodifiable information 
13.3.1. Patient specific information 
The patient information details included in the leaflet will be obtained directly from 
the dispensing system. These details will not be able to be changed unless they are 
updated within the dispensing system. The details include: 
a. patient name 
b. patient sex 
c. patient age and date of birth 
d. indication medicine is being taken for [an option for including this is required] 
e. dose of the medicine and directions for taking it. 
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13.3.2. Medicine specific information 
The information contained in the system will be obtained via an information ‘pool’ and 
is dragged and dropped from a Source template. The information sections contained 
in the ‘pool’ are not modifiable. The only changes able to be made will be if the 
information sections are to be included in the information leaflet or not. The 
information will be created by the research team and owned and hosted by the 
University of Otago.  
13.4. Usability / Accessibility 
Pharmacists and patients must be able to view page in English. Pharmacists will need 
access to the internet; patients wanting digital information will also require internet 
access. 
13.5. Other 
Once the program has been developed the research team will provide medicine 
information on a group of medicines (e.g. those for gout or hypertension), for initial 
piloting and analysis. Researchers are flexible as to whether piloting will be 
undertaken in a small subset of practitioners or will have a national roll out.  
The project/trial will be deployed and available for use by pharmacists. In order to 
determine the usability, usefulness, and effectiveness of the alerts the solution will 
need to: 
1. Record each time consultation points have been produced. 
2. Record the pharmacist’s interaction with an alert (i.e. engagement with the 
program). 
3. Record the creation of the medicine information leaflet.
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14. Next Steps and future extensions 
14.1. Next Steps 
Next Steps: 
 Finalise requirements with system developers 
 Create medicine information for use in practice 
 Decide on medicines and conditions to for pilot  
14.2. Future extensions 
Many enhancements can be made to the medicine information tool once initial 
development, user testing, and piloting have been completed. User feedback is 
essential before future extensions can be developed. 
Examples of possible future extensions for consideration: 
 Further tailoring to health literacy levels 
 Translation into different languages 




Appendix 16. Questionnaires sent to vendors of GP 
patient management software 
Questionnaire introduction 
Prescribers have limited time to talk to patients about medicines, let alone seek out 
relevant medicine information. Providing patients with accessible personalised 
information could help General Practitioners (GPs) fulfil their ethical obligations to 
ensure patients are fully informed about their medicines. 
 In a recent study174 we found that more than:  
 70% of GPs want their patient management system to display key counselling 
points about medicines automatically tailored to their patient for use during 
consultation.  
 50% of GPs would like patients to receive a medicine information leaflet when 
they are prescribed a new medicine yet 30% of GPs report they do not think to 
use them at point-of-care.  
 50% of GPs think that prescribing software that prompts to provide and record 
the provision of the leaflet automatically, would help them in providing leaflets 
to patients.  
 50% of GPs think the most beneficial leaflets would be a personalised summary 
leaflet tailored to patient requirements.  
 
We are undertaking a feasibility study to understand the viability of our proposed 
project (to develop systems for personalised patient information) and require 
information from New Zealand vendors to assist our planning. The questions in this 
study are related to the document Use case for personalised medicine, sent as a 
separate attachment.  
Please read Use case for personalised medicine and the summary below before 
answering the questions.  
Please note that the information you provide will be used in an anonymised manner. 
Summary description of the project 
The proposal is for a medicine information tool to be built into existing Patient 
Management Systems (PMS) in use in medical centres. This will allow fast and simple 
391 
 
information retrieval by the healthcare providers during consultation. The medicine 
information tool will use the information contained within the PMS about the patient 
along with details about the medicine to present information to the prescriber that is 
personalised for each patient. The information will be presented as key practice points 
particularly relevant for each patient, accessible at point-of-care. The tool will also 
provide an individualised medicines information leaflet that can be printed during 
consultation for the patients to read and take away; alternatively it could be emailed 
to the patient or sent to the patient’s portal for future reference. 
Questionnaire  
Possible benefits to users 
1. Do you believe there is a need for a tool that could provide individualised 
medicines information to the prescriber? (please select one option) 
No, a tool is not necessary  
No, most prescribers do not need a tool  
There is some need for a tool providing 
individualised medicines information for 
patients 
 
Yes, many prescribers would find this tool 
necessary 
 






2. Do you believe that this tool would be used by prescribers? (please select one 
option) 
No, prescribers would not use this tool  





Some prescribers would use this tool   
Yes, most prescribers would use this tool  




3. Do you agree with the following statement: 
Patients would like to be given personalised information as described in the Use 
Case? (please select one option) 
Strongly agree  
Agree  
Neither agree nor disagree   
Disagree  
Strongly disagree  






4. Does your software currently allow prescribers to print medicines information 
leaflets? 
⃝ Yes 
⃝ No  





b. Do you know if this functionality is used? If so, can you give us any figures for 




1. Do you anticipate this project has future market potential?  
⃝ Yes 




2. Do you anticipate the addition of the medicine information tool would influence 
potential buyers of your software? 
⃝ Yes 
⃝ No  
3. If you were to develop the software, would it be (please select one option):  
⃝ a. Included in your current software package for prescribers  
⃝ b. Available as a subscription for purchase on top of current package 
⃝ c. Other (please specify) 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
4. Do you think the addition of the medicine information tool would increase sales 
of your product? 
⃝ Yes 
⃝ No  





5. Do you think the medicine information tool would give you a market advantage 
over your competitors? 
⃝ Yes 
⃝ No  




1. What additional materials or resources would be required to undertake this 
project? Please list the materials and quantity you estimate will be required 
(some examples included) 
Type of resource Expected number 
Additional Servers  
Computer Hardware and Software  
Additional office space for 
employee(s) 
 




2. Please indicate current or additional employees that would be required to 
undertake this project. Assume the research team would be providing the 
clinical information required for the medicine information tool. 
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Type of employee Number of Full Time 
Equivalents (FTEs, 1 FTE 
= 40 hours/week)  
Time employee to 
be dedicated to 
project (e.g. in 
weeks or months) 
Senior Management   
Project Management   
Software Developer   
Additional clinical support   
Other (please specify)   
   
3. Are there any other technology requirements not previously mentioned, needed 
to undertake this project? 
⃝ Yes 
⃝ No  




1. What would you estimate the total start-up cost of this project to be? 




2. If this was a project that was being undertaken by your company, would 
external investment be required? 
⃝ Yes 
⃝ No  
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3. Does your company currently set aside funding for new projects? 
⃝ Yes 
⃝ No  
4. Overall, do you believe this project would provide return on investment? 
⃝ Yes 
⃝ No  
Scheduling feasibility 
1. How long do you estimate it would take to create the software for this project? 
(please select one option) 
⃝ 3–6 months 
⃝ 7 months–1 year 
⃝ Other (please specify)  
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
2. Would this project be disruptive to your current work schedules? 
⃝ Yes 
⃝ No  
Barriers 
1. Aside from the time and cost, what other barriers to this project would you 
consider there are? 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
2. Would you foresee any concerns about data protection with the 
implementation of this project? 
⃝ Yes 
⃝ No  
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If so, what could these be? 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 





1. Do you think this project is one that would be worth pursuing for your 
company? 
⃝ Yes 
⃝ No  
 (NB this is not a commitment to being involved in the project, however if this of 
interest to you, please contact the research team) 




3. Would this project help your company meet this philosophy or goal? 
⃝ Yes 
⃝ No  





Appendix 17. Questionnaires sent to vendors of 
pharmacy dispensing software 
Questionnaire introduction 
Pharmacists have limited time to talk to patients about medicines, let alone seek out 
relevant medicine information. Providing patients with accessible personalised 
information could help pharmacists fulfil their ethical obligations to ensure patients 
are fully informed about their medicines. 
 In a recent study174 we found that more than:  
 60% of pharmacists want their patient management system to display key 
counselling points about medicines automatically tailored to their patient for 
use during consultation.  
 70% of pharmacists would like patients to receive a medicine information 
leaflet when they are dispensed a new medicine.  
 40% of pharmacists think that dispensing software that prompts to provide, 
and record the provision of the leaflet automatically would help them in 
providing leaflets to patients.  
  60% of pharmacists think the most beneficial leaflets would be a personalised 
summary leaflet tailored to patient requirements.  
 
We are undertaking a feasibility study to understand the viability of our proposed 
project (to develop systems for personalised patient information) and require 
information from New Zealand vendors to assist our planning. The questions in this 
study are related to the document Use case for personalised medicine, sent as a 
separate attachment.  
Please read Use case for personalised medicine and the summary below before 
answering the questions.  
Please note that the information you provide will be used in an anonymised manner. 
Summary description of the project 
The proposal is for a medicine information tool to be built into existing dispensing 
software in use in pharmacies. This will allow fast and simple information retrieval by 
the healthcare providers during consultation. The medicine information tool will use 
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the information contained within the dispensing software about the patient along 
with details about the medicine to present information to the pharmacist that is 
personalised for each patient. The information will be presented as key practice points 
particularly relevant for each patient, accessible at point-of-care. The tool will also 
provide an individualised medicines information leaflet that can be printed during 
consultation for the patients to read and take away; alternatively it could be emailed 
to the patient or sent to the patient’s portal for future reference. 
Questionnaire 
Possible benefits to users 
1. Do you believe there is a need for a tool that could provide individualised 
medicines information to the pharmacist? (please select one option) 
No, a tool is not necessary  
No, most pharmacists do not need a tool  
There is some need for a tool providing 
individualised medicines information for 
patients 
 
Yes, many pharmacists would find this tool 
necessary 
 






2. Do you believe that this tool would be used by pharmacists? (please select one 
option) 
No, pharmacists would not use this tool  
No, most pharmacists would not use this 
tool 
 
Some pharmacists would use this tool   
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Yes, most pharmacists would use this tool  





3. Do you agree with the following statement: 
Patients would like to be given personalised information as described in the Use 
Case? (please select one option) 
Strongly agree  
Agree  
Neither agree nor disagree   
Disagree  
Strongly disagree  





4. Does your software currently allow prescribers to print medicines information 
leaflets? 
⃝ Yes 
⃝ No  
a. If yes, where are these leaflets sourced from (e.g. NZF, Med+info)? 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
b. Do you know if this functionality is used? If so, can you give us any figures for 






1. Do you anticipate this project has future market potential?  
⃝ Yes 




2. Do you anticipate the addition of the medicine information tool would influence 
potential buyers of your software? 
⃝ Yes 
⃝ No  
3. If you were to develop the software, would it be (please select one option):  
⃝ a. Included in your current software package for pharmacists  
⃝ b. Available as a subscription for purchase on top of current package 
⃝ c. Other (please specify) 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
4. Do you think the addition of the medicine information tool would increase sales 
of your product? 
⃝ Yes 
⃝ No  





5. Do you think the medicine information tool would give you a market advantage 
over your competitors? 
⃝ Yes 
⃝ No  




1. What additional materials or resources would be required to undertake this 
project? Please list the materials and quantity you estimate will be required 
(some examples included) 
Type of resource Expected number 
Additional Servers  
Computer Hardware and Software  
Additional office space for 
employee(s) 
 





2. Please indicate current or additional employees that would be required to 
undertake this project. Assume the research team would be providing the 




Type of employee Number of Full Time 
Equivalents (FTEs, 1 FTE 
= 40 hours/week)  
Time employee to 
be dedicated to 
project (e.g. in 
weeks or months) 
Senior Management   
Project Management   
Software Developer   
Additional clinical support   
Other (please specify)   
   
 
3. Are there any other technology requirements not previously mentioned, needed 
to undertake this project? 
⃝ Yes 
⃝ No  




1. What would you estimate the total start-up cost of this project to be? 






2. If this was a project that was being undertaken by your company, would 
external investment be required? 
⃝ Yes 
⃝ No  
3. Does your company currently set aside funding for new projects? 
⃝ Yes 
⃝ No  
4. Overall, do you believe this project would provide return on investment? 
⃝ Yes 
⃝ No  
Scheduling feasibility 
1. How long do you estimate it would take to create the software for this project? 
(please select one option) 
⃝ 3–6 months 
⃝ 7 months–1 year 
⃝ Other (please specify)  
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
2. Would this project be disruptive to your current work schedules? 
⃝ Yes 
⃝ No  
Barriers 
1. Aside from the time and cost, what other barriers to this project would you 





2. Would you foresee any concerns about data protection with the 
implementation of this project? 
⃝ Yes 
⃝ No  
If so, what could these be? 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 





1. Do you think this project is one that would be worth pursuing for your 
company? 
⃝ Yes 
⃝ No  
 (NB this is not a commitment to being involved in the project, however if this of 
interest to you, please contact the research team) 
2. What is your company’s overall philosophy and/or goal? 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
3. Would this project help your company meet this philosophy or goal? 
⃝ Yes 
⃝ No  









Appendix 19. Study protocol 
Background 
In New Zealand, more than 25,000 patients are diagnosed with new cancer each year and over 
69,000 are receiving oral chemotherapy in the community. There are also over 1000 hospital 
admissions each year because of adverse events from community-dispensed chemotherapies. 
Toxicity can often be avoided or minimised through early identification and management. 
Currently, community-based patients phone either the oncology nurse or the ward if they 
experience a side-effect. This system relies on patients’ willingness to ring for help or advice. 
Aims of project: 
1. To explore participants’ perceptions of how they were given information about their 
chemotherapy, whether they understood this information and could act on it, and 
whether or not they think this process could be improved. 
2. To ascertain participants’ thoughts on using a possible online tool/system that could 
convey information about chemotherapy medicines  
Methods 
Participation 
We will be holding four focus groups sessions, each with between 6-8 people who meet the 
selection criteria: 
 18 years of age and over. 
 Have previously had chemotherapy and are in remission 
 Can read and speak English. 
Those who are under 18 years of age, who are currently using chemotherapy medicines, or 
cannot read or speak English, will be unable to participate in these focus groups. We will not 
be asking for specific information about participants’ cancer or their treatment. 
The first focus group will be a group from the general population from in and around Dunedin. 
The second will be Māori participants from the local population in and around Dunedin. The 
third will be Māori participants from a different area of New Zealand (recruitment will be from 
Northland). The fourth will be with the general population from a more rural/remote location 
(e.g. Southland). 
Recruitment 
The recruitment process for people who have been through chemotherapy will be through a 
number of avenues including local support groups (e.g. the Otago-Southland division of the 
Cancer Society, EXPINKTTM the University of Otago Physical Education School’s exercise 
programme for women who have had breast cancer surgery), through contacts in oncology 
organisations in Northland, and through local Māori contacts. We will ask the leaders of these 
organisations to advertise the project to their members/patients through posters and/or 
email (if appropriate). Members can contact the research team if they are interested in 
participating. They will then be provided with a participant information sheet either by post or 
by email (according to their preference). The participant information sheet has the contact 
details for the study team for if they have any questions about the study before participating.  
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Consultation with Māori advisors has been undertaken about recruitment for this study. 
Through this consultation we have been given valuable contacts to aid our recruitment 
process. We will also ensure that kai will be provided during the focus group sessions and 
whānau can accompany participants if they would like them to attend. 
The informed consent form will be completed at the beginning of the focus group sessions. 
Location of the focus group sessions 
The focus groups in Dunedin and Invercargill will be conducted at University of Otago facilities. 
The focus group in Northland will be conducted at a location such as a community centre or 
the Cancer society.  
Structure of focus group session 
The structure of the meeting will be outlined at the start of the meeting. Each focus group will 
have four parts:  
 Questionnaire;  
 Focus group discussion about items from questionnaire;  
 Capturing Patient Reported Outcomes (PROs) using an online tool;  
 Participants’ thoughts on the online tool for capturing Patient Reported Outcomes 
(PROs).  
The first part will be a questionnaire that the focus group members will be asked to complete 
on their own in the first 5-10 minutes of the meeting. The second part will be a group 
discussion of the questionnaire and with wider discussion of the topics covered in the 
questionnaire. 
The third part will involve introducing the group to the concept of using an online tool to 
capture Patient Reported Outcomes (PROs) and how this could be used to provide patients 
with personalised medicine-management advice. 
The fourth part will be discussion of the possibility of using an online tool to determine 
participants’ ideas about the use of this tool and participants’ thoughts about the 
advantages/disadvantages of using this for people undergoing chemotherapy. 
See below for the focus group outline for more detailed information including the 
questionnaire to be provided to participants, further questions for discussion, and for 
information about the online tool. 
Consultation with Māori advisors has been undertaken regarding the content of the 
questionnaire. Following their review, adjustments were made to improve cultural 
appropriateness. 
Those who indicated that they are interested in participating will be provided with a paper or 
digital version of a Participant Information Sheet (PIS) (attached to ethics application) to read 
and they can then ask the researcher questions if needed. A consent form will be provided at 
the beginning of the focus group session. 
Upon completion of the survey, participants will receive a $20 supermarket voucher. 
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Focus group outline  
The focus group meeting will involve four parts: i) the individual questionnaire; ii) the 
discussion about items from questionnaire; iii) capturing Patient Reported Outcomes (PROs) 
using an online tool (i.e. the introduction of the online tool); and iv) participants’ thoughts on 
the online tool for capturing PROs. 
Part one: Individual questionnaire  
The first part consists of a questionnaire. The participants will be asked to complete the 
questionnaire on their own in the first 5-10 minutes of the meeting. The questionnaire will be 
provided to participants on a separate standalone document. 
 
Questionnaire for participants 
Thank you for showing an interest in this project. We are wanting to know about how 
you were given information about your chemotherapy before it was started and if this 
information was suited to you. 
This part is about the information on possible side-effects that you were given before 
you started chemotherapy  
1. Thinking about the information you were told about possible side-effects, please 




Disagree  Neutral Agree Strongly 
agree 
1a) The information was easy to 
understand 
 
     
1b) The information was given to 
me in a way that helped me to 
understand it 
 
     
1c) There was too much 
information given 
 
     
1d) There was not enough 
information given 
 
     
1e) I was told how to get more 
information if I wanted it 
 








2. Were you given useful information to take away with you about what to do if you 
experienced a side-effect with your chemotherapy treatment?  
⃝ Yes 
⃝ No (go to question 8) 
 
3. Thinking about the information you were given to take away with you, please tick 











Disagree  Neutral Agree Strongly 
agree 
3a) The information was easy to 
understand 
 
     
3b) There was too much 
information given 
 
     
3c) There was not enough 
information given 
 
     
3d) I read this information at home 
 
     
3e) The information was useful to 
me at a later time 
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4. Did you share and discuss this information with anyone else? 
⃝ Yes 
⃝ No (go to question 6) 
5. Who did you share this information with? 
…………………………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………………………… 
6. Did you follow the information given to you if you experienced a side-effect?  
⃝ Yes (go to question 8) 
⃝ No  
⃝ Sometimes 
7. Why did you not follow this information all of the time? You can tick all the boxes 
that apply to you 
⃝ Couldn’t find it 
⃝ Couldn’t remember it 
⃝ It wasn’t relevant to my symptom/s 




8. Did you feel prepared about what to do and who to contact if you had a side-effect 
from your medicine?  
⃝ Yes 
⃝ No  






Some information about you 
This part is about your background and use of technology 
9. Are You 
⃝ Male  
⃝ Female  
⃝ Gender diverse 
 
10. What year were you born? 
 
11. Which ethnic group do you belong to? 
⃝ New Zealand European 
⃝ Māori 
⃝ Samoan 





⃝ Other (Please state: e.g. Dutch, Japanese, Tokelauan) 
 




13. How often do you usually use the internet on a computer and/or smart device 
(tablet or smart phone)?  
⃝ Never (go to question 14) 
⃝ A couple of times in the last year 
⃝ About once or twice a month 
⃝ About once or twice a week 
⃝ Often/daily 
 
14. If you use a computer and/or smart device (tablet or smart phone), what are your 
typical activities on these? You can tick all the boxes that apply to you 
⃝ Buy or make a reservation for travel 
⃝ Email or instant messaging/chat 
⃝ Look up a recipe 
⃝ Look for health/medical info 
⃝ Look for info on a hobby or interest 
⃝ Read the news/weather/sports/blog 
⃝ Online banking or bill paying 
⃝ Shopping 
⃝ Web searches 
⃝ Playing games  
⃝ Watch videos 
15 In the last year, how often have you visited a web site to locate health information? 
⃝ A couple of times in the last year  
⃝ About once or twice a month  
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Part two: Focus group discussion about items from questionnaire 
The second part of the meeting will consist of a group discussion of the questionnaire 
facilitated by Amber Young and/or Alesha Smith. This will involve a wider discussion of the 
topics covered in the questionnaire in part one. 
In this part we will start off by discussing what the participants think might be good for 
improving the medicine information services for oncology patients. 
a. How were they given the information about their treatment and the possible 
side-effects (e.g. verbal only, written, web addresses)? 
b. Could this process of receiving information have been easier? 
c. Do participants think the information and how it is given is appropriate for 
someone from their culture? E.g. Māori or other culture  
d. Do they feel this could be improved in any way? 
We will also discuss 
e. If the information helped them feel well-prepared for any possible side-effects? 
f. What they did if they experienced a side-effect and needed help  
g. If they looked for information themselves from other sources? 
Part three: Capturing Patient Reported Outcomes (PROs) using an online 
tool 
In this part we will describe the use of an online tool to capture Patient Reported Outcomes 
(PROs) and how this could electronically provide patients with personalised medicine-
management advice. We will give a brief summary of what is happening internationally. We 
will provide participants with the information below. The information for participants will be 
provided on a separate standalone document. 
 
Information provided to participants 
Many oncology services in New Zealand use the UK oncology nursing society traffic light tool 
when talking to patients about the chemotherapy side-effects they have experienced. The 
common side-effects that can cause severe problems for patients are contained in the traffic 
light tool e.g. nausea and vomiting, diarrhoea, pain, and fatigue. By following the questions in 
the traffic light tool, oncology staff (usually ward nurses) can classify the severity of patients’ 
symptoms into traffic light colours: 
 Green is considered mild, the side-effect can be managed at home; the nurses can 
provide advice on self-management. 
 Amber is considered moderate, the side-effect that may be managed at home; if more 
than one Amber side-effect occur then consideration is given to bringing the patient 
to hospital for review. 
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 Red is considered severe, the patient requires prompt management by oncology 
team.  
There are a number of hospitals in the UK and Europe who are trialling an online tool or 
application that has taken the traffic light tool and turned it into a questionnaire that patients 
can complete themselves on the internet. Depending on how patients answer the questions, 
the tool will provide them with information on how to manage their side-effects at home or 
will inform them that they need to visit the hospital. (This is similar to the advice a nurse 
would provide if a patient were to contact them over the phone). The information that 
patients put into the system will also be automatically logged in their hospital record and will 
alert the ward staff when the patient requires a review with a hospital staff member. The tool 
is a secure portal that only patients and the hospital can access. 
 
This tool is designed to help provide patients with appropriate information quickly that is easy 
to follow. The other potential benefit is that the patient’s hospital records are up to date with 
how they are tolerating their chemotherapy. 
 
Requirements for this tool are: ready access to a computer, laptop, or smart device (such as 
tablet or smartphone) and access to the internet. 
 
What we are wanting to know is if this tool would be suitable for use in New Zealand. That is 
why we are wanting to discuss this with you today. 
Part four: Participants’ thoughts on the online tool for capturing Patient 
Reported Outcomes (PROs)  
The fourth part will be discussion of the online tool for capturing Patient Reported Outcomes 
to determine participants’ ideas about the use of this tool and their thoughts about the 
benefits of this for patients undergoing chemotherapy. 
 
The following discussion points will be used: 
a. Do you think this online tool that we discussed would be something you would be 
able to use or like to use? 
b. What would you like about using the tool for a side-effect you experience?  
Would you also like to use this to look for other information about your treatment? 
c. What concerns would you have about using the tool to report a side-effect or to 
receive information?  
d. What would be useful about using this tool?  
e. Would you prefer to use the tool or to telephone the hospital?  
Analysis of data 
The data from the questionnaire will be entered into data management software and basic 
descriptive analysis will be undertaken. The focus group data will be transcribed verbatim and 
a thematic analysis will be completed by Amber Young.  
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Dissemination of information 
The data gathered in this study will be used to form a chapter of Amber Young’s thesis for PhD 
candidature. Other uses of the data to be used by the research team include an article for 
publication and conference proceedings. 
If the participants indicate they are wanting to be informed of the results, we can record their 
details independently of the study recordings and create a list of those who want to be 
informed. We will then send out the documentation once the study review has been 
completed e.g. once an article has been accepted for publication. 
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Appendix 21. Participant Information Sheet 
 
 
Participant Information Sheet 




Dr Alesha Smith 




03 479 5052 
Introduction 
If you decide to participate we thank you. If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request.  
This study is being carried out by researchers at the School of Pharmacy, University of Otago. 
This project is being undertaken by Amber Young as part of her PhD. 
What is the aim of this research project? 
The Aim of project is to find out the views of people who have had chemotherapy about: 
 How they were given the information about their chemotherapy, whether they 
understood this and could act on the information given, and whether or not they 
think this could be improved. 
 Using a possible online tool/system that could convey information about 
chemotherapy medicines.  
Who is funding this project? 
This project is funded by the University of Otago. 
Who are we seeking to participate in the project? 
We are seeking participants 18 years of age and over who have taken chemotherapy 
medicines for cancer but are not currently on these medicines. We will be holding four focus 
group discussions with 6-8 people in each group. 
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Two groups will involve the general population; one will be urban-based and one will be rural-
based. The other two groups will involve the Māori population; one will be urban-based and 
one will be rural-based. 
We are seeking participants through local support groups and oncology services who meet the 
selection criteria: 
 18 years of age and over. 
 Have previously had chemotherapy. 
 Can read and speak English. 
Those who are under 18 years of age, who are currently using chemotherapy medicines, or 
cannot read or speak English, will be unable to participate in these focus groups. 
If you participate, what will you be asked to do? 
Should you agree to take part in this project, you will be asked to attend a focus group 
discussion. This will involve answering a short questionnaire in the first 5-10 minutes, then 
participating in further discussion in a group about the medicine information you received 
concerning your chemotherapy, and possible ways this information could be provided 
differently. 
We expect the focus group session to last approximately one hour. 
Please be aware that you may decide not to take part in the project without any disadvantage 
to yourself. 
As a thank you for participating, you will receive a $20 supermarket voucher. 
Is there any risk of discomfort or harm from participation? 
No, you will be asked to share your experiences and opinions about receiving information 
about medicines. 
What specimens, data or information will be collected, and 
how will they be used?  
The discussions will be recorded and then transcribed by a member of the research team. This 
project involves an open-questioning technique. The general line of questioning includes how 
you were given information about your medicines, if this information was easy to understand, 
how you think information provision could be improved, and your views on possibly using an 
online tool to report side-effects and receive self-management information. The precise 
nature of the questions that will be asked have not been determined in advance, but will 
depend on the way in which the interview develops. Consequently, although the University of 
Otago ethics committee is aware of the general areas to be explored in the interview, the 
Committee has not been able to review the precise questions to be used. 
In the event that the line of questioning does develop in such a way that you feel hesitant or 
uncomfortable you are reminded of your right to decline to answer any particular question(s). 
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The results of the project may be published and will be available in the University of Otago 
Library (Dunedin, New Zealand) but every attempt will be made to preserve your anonymity. 
You are most welcome to request a copy of the results of the project should you wish. If so, 
your name and contact details will be kept on a separate list, and not linked to your 
questionnaire responses. 
What about anonymity and confidentiality? 
The written information provided in the questionnaires will be retained at the University in a 
locked storage unit with access only by the research team. We will ask questions about your 
age, sex, ethnicity, and computer use but will not be requiring any identifiable information. 
The recording and transcription will be retained on a password protected computer. The data 
collected will be securely stored in such a way that only the members of the research team 
will be able to gain access to it. Data obtained as a result of the research will be retained for at 
least 10 years in secure storage. Any personal information held on the participants (such as 
name and contact details following recruitment) may be destroyed at the completion of the 
research even although the data derived from the research will, in most cases, be kept for 
much longer or possibly indefinitely. 
No material that could personally identify you will be used in any reports on this study. Results 
of this research may be published. The data from this project will be publicly archived so that 
it may be used by other researchers. 
If you agree to participate, can you withdraw later? 
You may withdraw from participation in the project at any time before or during the focus 
group meeting without any disadvantage to yourself. After the focus group meeting, 
withdrawal will not be possible because de-identified information will already be integrated 
into the study. 
Any questions? 
If you have any questions now or in the future, please feel free to contact either: 
Amber Young 
PhD candidate 
School of Pharmacy 
Contact phone number: 
03 479 7321 
Contact email: 
amber.young@postgrad.otago.ac.nz 
Dr Alesha Smith 
Senior Lecturer 
School of Pharmacy 
Contact phone number: 






This study has been approved by the University of Otago Human Ethics Committee (Health). If 
you have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (phone +64 3 479 8256 or 
email gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and 
investigated and you will be informed of the outcome
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Appendix 22. Research Grants applied for during 
candidature 
Date Title Name of Grant Amount of 
grant 
14 May 2018 Self-monitoring and reporting 
of medicine adverse effects in 
oncology patients 
Otago Innovation Proof of 
Concept Grant, Otago 





Self-monitoring and reporting 
of medicine adverse effects in 
oncology patients 
Lottery Health Research 
2018/19 grants, New 





Do lifestyle factors influence 
chemotherapy toxicities 
Regular Grant Programme 
2018/2019 Seed Grants 





Self-monitoring and reporting 
of medicine  adverse effects in 
oncology patient 
National Research Grant 
Round 2019, Cancer 




On-line advice for self-
monitoring adverse effects of 
chemotherapy in breast 
cancer patients 
Innovation and Technology 
in Breast Cancer, Breast 
Cancer Foundation New 






treatments by predicting 
adverse effects and optimising 
care 
National Science Challenge 
Seed Projects 2019, 
Science for Technological 
Innovation (SfTI) 
NZ$230,000 
 
